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Abstract 
 
Preclinical studies indicating that conjugated isomers of linoleic acid suppress mitosis, 
restore apoptosis, induce differentiation and suppress angiogenesis in animal models of 
cancer formed the rationale for an in vitro investigation of their potential benefits in 
targeting drug-resistant cancer cells.  Additionally, several lines of evidence implicate a 
role for sphingolipids in multiple drug resistance.  The objective of this study was to 
evaluate the effects of conjugated linoleic acids (CLA) and various anticancer drugs on 
growth of MCF-7 and MCF-7/cis cell lines and to evaluate the effects of co-treatments 
of CLA and doxorubicin (Dox) on cell growth, intracellular drug accumulation, 
sphingolipid content and cellular lipid composition in a drug-resistant melanoma model.  
Initially an investigation of the potential of co-treatment with a commercial mixture of 
CLA isomers (CLA-mix) and two single isomers c9,t11-CLA and t10,c12-CLA to 
enhance the cytotoxic effects of Doxorubicin (Dox) on a drug naive MDA-MB435-S-F 
(MDA) cancer cell line was carried out.  It was found that each preparation of CLA 
enhanced cytotoxicity of Dox in a dose dependant manner with an increase of over 3-
fold with 6 µg/ml CLA-mix.  Similarly, both c9,t11- and t10,c12-CLA purified isomers 
yielded an increase in doxorubicin cytotoxicity of up to 3 fold.  Toxicity assays carried 
out on a Dox-pulsed MDA cell line, MDA-MB435-S-F/Adr10p10p (A10p10p), 
demonstrated a similar pattern of enhanced toxicity with up to 5, 7 and 12-fold increase 
when co-treated with CLA-mix, c9,t11-CLA and t10,c12-CLA respectively.  Dox 
retention as determined by liquid chromatography tandem mass spectrometry (LCMS) 
was significantly enhanced by the CLA-mix in A10p10p cells and by c9,t11-CLA in 
MDA and A10p10p cells.  Analysis of sphingomyelin metabolites by High Performance 
Liquid Chromatography (HPLC) revealed that CLA treatments in combination with Dox 
increased ceramide levels in both cell lines compared with Dox alone.  Treatment of 
both MDA and A10p10p cells with CLA-mix resulted in down-regulation of Her2/neu 
coded p185 c-erbB2/c-neu oncoprotein expression.  Eicosapentanoic acid (EPA) and 
docosahexanoic acid (DHA) resulted in similar down-regulation of this protein in the 
A10p10p cell line.  Fatty acid composition of MDA and A10p10p cells was analysed by 
gas chromatography (GC).  There was a marked increase in the unsaturation index of 
both cell lines following all fatty acid treatments, suggesting inhibition of fatty acid 
synthase (FAS) activity, a key enzyme in the de novo synthesis of fatty acids.  With the 
exception of the CLA-mix in the resistant line, all fatty acids in both cell lines caused a 
decrease in the ratio of C18:1/18:0 suggesting the ∆ 9 desaturase enzyme stearoyl-CoA 
desaturase (SCD) as a potential target for inhibition by fatty acid treatments.  The data 
suggest that CLA-induced changes in ceramide status, intracellular drug accumulation 
and lipid profiles may underlie the enhanced chemosensitivity of the resistant cell line 
and represent a new avenue to develop chemotherapy regimes for patients with drug-
resistant tumours leading to improved response and survival rates in these patients. 
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1.1 Cancer 
 
Cancer is a group of diseases characterised by uncontrolled growth and spread of 
genetically abnormal cells.  If spread is not controlled it can lead to death.  The word 
“cancer” is synonymous with malignant tumours.  It is a Latin term, literally translated 
from the Greek “Karkinos” meaning crab, which refers to the metaphorical claws 
reaching out to invade surrounding tissues.  In the ancient Hippocratic school of 
medicine “Karkinos” was also used to describe a non-healing ulcer, whereas 
“Karkinoma” referred to a malignant tumour. 
 
 In Ireland there were over 19000 new cases of cancer reported each year up to 2001, 
with 7627 cancer deaths (Campo et al, 2004).  Figures for the years 2000-2004 show 
that incidence rates rose to over 29000 (21500 cases excluding non-melanoma skin 
cancer) with the average number of cancer deaths at 11261 (National Cancer Registry, 
2007; Donnelly et al., 2009).  This shows that while cancer incidence is rising sharply in 
Ireland, death rates are slower indicating an improvement in cancer survival, either 
through early detection, improved treatment or both. 
 
Age-specific rates of incidence for men and women aged between 80 to 84 y are two to 
three times higher than rates for those aged 60 to 64 y, and rates for men and women 
aged 60-64 y are roughly four to ten times higher than for the 40-44 y age group.  Given 
the fact that more and more people are living well past 65 y, the number of cancer cases 
is sure to continue to rise.  However, risk factors other than age are modifiable.  It is 
known that, approximately one third of all cancers are caused by tobacco; one third by 
diet (high fat/ low fruit and vegetables); and most of the remaining third by other 
lifestyle choices such as excessive drinking, lack of regular exercise, sexual and 
reproductive patterns and frequent sunburns.  Occupational exposures account for the 
remaining cancer risk, while the final –and very small-outstanding proportion of risk 
relates to toxins in the environment (Campo et al, 2004).  
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A few worrying trends have been identified in a relatively recent report by the Irish 
Cancer Registry.  Mortality rates are higher for both men and women in Ireland than in 
the US even though the incidence is lower.  Men have higher incidence (20 %) and 
mortality (40 %) rates than women in Ireland.  However, while the rates for men are 
equivalent to those in the EU, the incidence and mortality rates for women in Ireland are 
significantly higher than in the EU (Campo et al., 2004; Donnelly et al., 2009).  This 
highlights the scope for interdisciplinary and inter-institutional collaboration and 
communication promoting a free-flow of information to aid translation of new 
treatments from the laboratory bench to the patient’s bedside. 
 
1.1.1 Cancer Development 
 
Cancer represents a large group of diseases characterised by uncontrolled growth of an 
abnormal cell to produce a population of cells that have acquired the ability to multiply 
and invade surrounding and distant tissues.  In terms of nomenclature most adult cancers 
are carcinomas that are derived from epithelial cells (breast, colon, skin, lung, etc.).  
Sarcomas are derived from mesenchymal tissues while leukaemias and lymphomas are 
derived from bone marrow cells and lymphoid tissue.  Cancer is essentially a genetic 
disease because it can be traced to activation of specific genes (oncogenes) that promote 
cell proliferation and to inactivation of specific genes (tumour suppressor genes) that 
normally restrain cell proliferation.  The latter act as brakes in preventing cells from 
becoming malignant whereas the former function like an accelerator speeding up cell 
proliferation and producing malignant tumours that invade surrounding healthy tissue.  
Human cancers develop by stepwise accumulation of mutations involving oncogenes 
and tumour suppressor genes.  Epidemiologists have interpreted the age-related 
exponential increase in cancer incidence to denote a small number (three to seven) of 
critical mutations or ‘hits’ within a single somatic cell during an individual’s lifetime 
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(Lodish et al., 2004).  
 
Oncogenes arise as a result of critical mutations in proto-oncogenes that are involved in 
the positive regulation of cell growth in normal cells.  Oncogenes encode proteins that 
belong to one of seven basic functional groups involved in growth factor signalling: 
growth factors, growth factor receptors, plasma membrane G proteins, protein kinases, 
transcription factors, cdk-cyclins and apoptotic proteins.  Tumour suppressor genes 
encode proteins involved in DNA repair or chromosome sorting.  When mutated they 
encode proteins that are mainly inactive.  Most cancers are monoclonal in origin, being 
derived from a single cell.  Initially a somatic mutation occurs in a critical gene and this 
provides a growth advantage to the cell and results in expansion of the mutant clone.   
Each additional critical mutation provides a further selective growth advantage resulting 
in clonal expansion of cells with mutations in critical genes.  Under normal conditions 
DNA repair may revert the cell back to a normal cell.  In other cases programmed cell 
death or apoptosis is initiated.  Failure in each case results in carcinogenesis (Lodish et 
al., 2004).  These stages are illustrated in Figure 1.1.1 below.   
 
 
 
Figure 1.1.1 Schematic showing development of cancer cells (adapted from McGrath, 2003) 
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Apoptosis is characterised by cell shrinkage, chromatin condensation, membrane 
blebbing and DNA fragmentation (Arends and Wylie, 1991).  A cascade of cysteine 
proteases (caspases) are activated in the final stages of apoptosis, which act on key 
proteins including poly (ADP-ribose) polymerase (PARP) (Alnemri, 1997).  This is 
followed by endonuclease cleavage of DNA (DNA laddering) into small fragments 
typically 180-200 bp and subsequent absorption of apoptotic bodies into macrophages 
(Raff et al., 1993).  Activation of caspases occurs as a result of exposure to 
chemotherapeutic agents, radiation or growth factor withdrawal.  Mechanisms of action 
of chemotherapeutic agents will be discussed in greater detail in later sections. 
 
Figure 1.1.2 takes the example of breast cancer and shows a schematic of the probable 
stages in breast cancer development.  Mutations in BRCA1 and BRCA2 tumour 
suppressor genes have been implicated in the majority of hereditary forms of breast 
cancer, which in turn constitute approximately 10 % of breast cancers (Polyak, 2001).   
 
 
 
Figure 1.1.2 Hypothetical model depicting the multi-step process of breast tumourigenesis 
(Polyak, 2002) 
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They (BRCA1 and BRCA2) normally repair breaks in double stranded DNA.   If DNA 
damage is not repaired, a checkpoint is activated that leads to an increase in p53 
transcription factor.  Mutations in TP53, the tumour suppressing gene encoding p53, are 
found in 15-34 % of sporadic breast cancers.  P53 normally acts as a “molecular 
policeman” in monitoring genome integrity (Voet et al., 1999).  It accumulates in the 
cell following DNA damage, directing the cell to halt in G1 phase of the cell cycle until 
the damage is repaired or to apoptosis if the damage is extensive (Ingvarsson, 1999).  
Excessive activity of certain proteins and genes in breast cancer cells can switch on 
molecular signalling pathways that stimulate cell proliferation and survival.  Her2, for 
example is a member of the epidermal growth factor receptor family which when 
activated dimerises with a neighbouring EGFR (HER1, 3 or 4) causing activation of 
tyrosine kinase activity that initiates a signal cascade to the cell nucleus (Franklin et al., 
2004).  Activation of growth factor receptors essentially switches on ras and/or PI3K 
activity which lead to a cascade of protein interactions that lead to cell growth and 
suppression of cell death by apoptosis.  Mutations in any gene along these signalling 
pathways can promote cell growth and survival making these genes and their encoded 
proteins important targets for anti tumour therapies (Lodish et al., 2004).  
 
 
1.1.2 Breast Cancer 
 
Despite the major advances that have been made in the past 25 years in understanding 
the biological and clinical nature of breast cancer it still is the most prevalent type of 
cancer among women in the developed world and its incidence has shown a continuous 
rise in recent decades (Hanklin, 1993).  The National Cancer Institute (NCI) in America 
estimates that more than one in eight women born today will develop breast cancer at 
some point in their lifetime, based on statistics for the years 2000 to 2002.  This means 
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that estimated lifetime risk of breast cancer has gone up gradually over the past several 
decades, from one in ten women in the 1970’s.  Breast cancer also occurs in men but the 
probability is about one hundred times less than for women (Ries, 2005).   
 
In Ireland, the incidence rate for breast cancer in women is higher than the average rate 
for women in the EU.  Also, the mortality rate for women with breast cancer is 
significantly higher than in both the EU and US.  Mortality rates in Northern Ireland, 
where nationally sponsored screening programs are well-established, have fallen by 
more than 20 % between 1994 and 2000.  However, in the Republic of Ireland, the 
breast cancer mortality rate was the same in 2000 as in 1994.  This suggests the need for 
improved mammography screening services in the Republic (Campo et al., 2004).   
 
Among the numerous histological types of breast carcinomas, the majority (nearly 90 %) 
arise in the ducts and are referred to as ductal carcinomas.  They are further classified 
according to cell types e.g. medullary, tubular, mucinous and "NOS" (not otherwise 
specified), the most common of the ductal carcinomas.  Approximately 5 % of breast 
cancers arise in the lobules and are referred to as lobular carcinomas.  The remainder are 
classified as Paget's disease, which involve the nipple and the inflammatory carcinomas 
(Cooper, 1992). 
 
Stages of breast cancer range from Stage 0 to IV.   Stage 0 is used to describe non-
invasive breast cancers, such as ductal carcinoma in situ (DCIS) and lobular carcinoma 
in situ (LCIS).  In stage 0, there is no evidence of cancer cells or non-cancerous 
abnormal cells breaking out of the part of the breast in which they started, or of getting 
through to or invading neighbouring normal tissue.  Stages I to IV describe degrees of 
advanced invasive breast cancer (cancer cells are breaking through to or invading 
neighbouring normal tissue).  Stage IV describes invasive breast cancer in which the 
cancer has spread to other organs of the body, usually the lungs, liver, bone or brain.  
"Metastatic at presentation" means that the breast cancer has spread beyond the breast 
and nearby lymph nodes, even though this is the first diagnosis of breast cancer.  The 
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reason for this is that the primary breast cancer was not found when it was only inside 
the breast.  Metastatic cancer is considered stage IV (www.breastcancer.org). 
 
The statistics listed above and in section 1.1 highlight the need for continued 
advancement in both the early diagnosis and treatment of breast cancer.  It is clear from 
the comparison of incidence and mortality rates between Ireland and the UK (including 
Northern Ireland), that many women would benefit from an early diagnosis as facilitated 
by well-organised screening programs (Campo et al., 2004; Allgar and Neal, 2005; 
Donnelly et al., 2009).  To complement this, continued fervour in the research and 
development of new and improved cancer treatment schedules is also of vital 
importance. 
 
1.2 Cancer Treatment 
 
There are four treatment options available when a patient presents with a tumour, 
surgery, radiation, chemotherapy and molecular-based therapy.  If the tumour is 
confined to its initial location surgery almost always results in a cure.  If cancer cells 
have broken away from the parent mass and have entered the lymphatic or vascular 
circulation so as to have spread to other parts of the body and established lethal 
secondary tumours (metastases) surgical removal of primary tumour is insufficient.  
Radiation treatment destroys actively proliferating cells that have metasatasised to 
distant locations.  Chemotherapy uses drugs that, like radiation treatment, selectively 
destroys dividing cells (Smith et al., 2007).  There are a range of classes of 
chemotherapy drugs in current use including cytotoxic antibiotics (e.g. Doxorubicin), 
mitotic inhibitors (e.g. Taxol), antimetabolites (e.g. 5-Fluorouracil) and alkylating agents 
(e.g. Cisplatin) (Smith et al., 2000; Serin et al., 2005; Sparreboom et al., 2005; Wright et 
al., 2005; Smith et al., 2007).  These drugs enter the bloodstream and travel throughout 
the body, killing cancer cells wherever they reside. The problem with both radiation and 
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chemotherapy is that they kill normal dividing cells as well as cancer cells, resulting in 
toxic side effects (susceptibility to infections as a result of destruction of bone marrow 
cells).  Because of this shortcoming scientists are currently developing other less toxic 
ways to treat metastatic cancer (Smith et al., 2007).  The field of cancer chemotherapy, 
as with other areas of cancer detection and treatment, is ever evolving.  Breast cancer 
was the first solid tumour cancer to be treated with the monoclonal antibody trastuzumab 
(herceptin) when it was approved for human use in 1998.  It is a humanised antibody 
that targets a specific cell surface receptor protein on tumour cells called Her2, blocking 
its growth factor binding site, preventing it from being activated and stimulating its 
internalisation.  HER2 is a member of the erbB family of receptor tyrosine kinases, all of 
which bind extracellular growth factor ligands initiating intracellular signalling 
pathways regulating diverse biological responses including proliferation, differentiation, 
cell motility and survival (Marmor et al., 2004).  In 30 % of patients with breast cancer 
the ERBB2 receptor gene has been found to be significantly overexpressed.  
Amplifications of the gene have also been reported in other cancers including ovarian 
(reviewed in Sahin and Wiemann, 2009).  Overexpression of the HER2 oncogene has 
been shown to confer resistance to chemotherapeutic drugs and to be indicative of poor 
prognosis in patients with advanced breast cancer (Colomer et al., 2000).  However, the 
use of targeted drugs such as the monoclonal antibody, trastuzumab (herceptin), has led 
to improved treatment results in this subset of patients (Smith et al., 2007).   
 
A massive research effort over the last decade to understand the cellular and molecular 
basis of cancer by clinicians and researchers alike looks set to yield promising results in 
the war against cancer.  
 
1.2.1 Targeted Cancer Therapy 
 
Conventional approaches to combating cancer (surgery, chemotherapy, radiation) often 
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cannot rid a patient of all cancer cells.  Advances in the disciplines of genetics and 
biochemistry in the last decade have revolutionised our understanding of cancer cell 
biology, so much so as to provide new insights into how cancer may be treated.  DNA 
microarray analysis is a powerful chip technology that has impacted on the way cancer 
is diagnosed and treated.  The expression of tens of thousands of genes may be 
determined simultaneously, permitting complex tumour phenotypes to be defined at the 
molecular genetics level.  Analysis of expression patterns has revealed subtle differences 
between tumour cells and has potential to distinguish between primary tumours and 
metastatic tumours, thereby providing cancer researchers with a list of genes to look at 
more closely as potential targets for therapeutic drugs.  Indeed, variations in the genes 
that are altered may lead to differences in how breast cancers of individual patients 
behave.  The development of proteomics tools to determine the protein profile of a 
patient’s tumour has greatly enhanced the potential for identifying differences between 
cancer cells and normal cells and has provided potential new leads for drug 
development.   
 
Basic biology research has led to the rational design of treatments for selectively 
destroying cancer cells.  At the present time a large number of clinical trials are being 
conducted to test a variety of new anticancer strategies that may be divided into 4 
groups: those that depend on antibodies or immune cells to attack tumour cells, those 
that introduce a gene that either kills tumour cells or causes them to regain normal 
properties, those that inhibit the activity of cancer-promoting proteins and those that 
prevent the growth of blood vessels that nourish tumours.  The success of trastuzumab 
has led to development of other antibody-based therapies that target different sites on 
Her2, preventing dimerisation (eg pertuzumab) or that have the potential to deliver a 
toxin to cancer cells (Agus et al., 2002).  Other examples of monoclonal antibodies 
include cetuximab (Erbitux), which is used in the treatment of metastatic colorectal 
cancer and advanced head and neck squamous cell carcinoma (Vincenzi et al., 2008).   
 
Growth factor receptors are also being targeted by small molecule tyrosine kinase 
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inhibitors that prevent the transmission of growth signals into a cell.  Lapatinib is a dual 
EGFR/Her2 tyrosine kinase inhibitor that has shown promise in inducing growth arrest 
and cell death in breast cancer cell lines that overproduce Her2.  Other kinase inhibitors 
target insulin like growth factor receptor 1 protein and vascular endothelial growth 
factor (VEGF) receptor protein involved in forming blood vessels for tumours.  Small 
molecular weight chemical inhibitors such as erlotinib (Tarceva) and gefitinib (Iressa) 
have been developed which compete for the ATP binding sites of the receptors’ tyrosine 
kinase domain.  These are in current use for the treatment of non-small cell lung 
carcinoma (NSCLC) (Sahin and Wiemann, 2009).  Since angiogenesis, or the ability to 
develop new blood vessels to supply nutrients and oxygen and to remove waste 
products, is a key step in the progression of tumour development, this represents another 
ideal drug target to treat such tumours.  Bevacizumab (Avastin), also a monoclonal 
antibody, was developed by Genentech as a VEGF inhibitor and is in use in the 
treatment of metastatic colorectal cancer and more recently breast cancer (Calfa et al., 
2006; Cameron and Bell, 2008).  Other VEGF inhibitors such as sunitinib (Sutent) are 
undergoing clinical trials (Eichelberg et al., 2008).   
 
Hormonal therapy includes the agonist Tamoxifen which binds ERβ and blocks 
oestrogen-dependent transcription and cell proliferation (Lazo and Larner, 1998).  When 
a cancer arises in a tissue whose growth requires a certain hormone, it may be treated 
using drugs that block the action of that hormone.  Degarelix (Firmagon) is an example 
of a luteinising-hormone releasing-hormone (LHRH or gonadotropin-releasing 
hormone/GnRH) antagonist which suppresses testosterone in prostate cancer cells –in 
effect causing chemical castration (Gittleman et al., 2008).  Anti-androgens such as 
Flutamide (Eulexin) on the other hand, block androgen receptors in prostate cancer cells 
inhibiting growth (Labrie et al., 1988). 
 
The remainder of this review will focus on three conventional chemotherapeutic drugs in 
particular; Doxorubicin, Taxol and 5-Fluorouracil and their related families.  All three 
drugs have been used extensively, either as single agents or in combinations with other 
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drugs, for decades in the treatment of various types of cancer including breast cancer and 
continue to form part of standard therapies to this day (Smith et al., 2000; Serin et al., 
2005; Sparreboom et al., 2005; Wright et al., 2005). 
 
 
1.2.2 Doxorubicin 
 
Doxorubicin (or Adriamycin) is a member of the anthracycline drug family, which is in 
turn a member of the rhodomycin group of antibiotics isolated from different strains of 
Streptomyces (Woodruff and Waksman, 1960) (Figure 1.2.2.1).   
 
 
 
 
Figure 1.2.2.1 Structure of Doxorubicin (Smith et al., 2000) 
 
 
Epirubicin is another example of an anthracycline (Figure 1.2.2.2).  Both drugs consist 
of a flat anthraquinone linked by a glycosidic bond to an amino sugar (Robert, 1994). 
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Figure 1.2.2.2 Structure of Epirubicin (Smith et al., 2000) 
 
 
The bulk of doxorubicin (Dox) administered to sensitive tumour cells is known to 
rapidly localise in the nucleus and its high affinity for DNA provides the driving force 
for further nuclear uptake (Gigli et al, 1988).  Dox first binds to DNA by intercalation –
inserting between the stacked paired bases of the super-coiled double helix.  This results 
in uncoiling of the helix followed by impairment of topoisomerase II activity (Liu, 1989) 
an essential enzyme in controlling the supercoiling of DNA, allowing it to function 
normally in replication and transcription.  This enzyme creates and repairs nicks in two 
adjacent parent DNA strands (Epstein, 1988).  These nicks permit the release of the 
daughter DNA strand following replication and therefore prevent the parent and 
daughter DNA strands from becoming inextricably entangled.  Inhibition of 
topoisomerase results in permanent DNA cleavage (D’Arpa and Liu, 1989). 
 
Anthracyclines are among the most efficient drugs used in cancer chemotherapy, but a 
significant risk of cardiotoxicity limits their use (Olson and Mushlin, 1990; Singal et al., 
1997).  Other common side effects associated with the drug are anorexia, nausea, 
vomiting, thinning and ulceration of mucous membranes, bone marrow suppression, 
leukopenia and alopecia (Abraham et al., 1996).  Despite these side effects, there is a 
general consensus that the most efficacious chemotherapy regimens for the treatment of 
breast cancer are those that contain one member of the anthracycline drug family (Smith 
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et al., 2000).   
 
1.2.3 Taxanes 
 
Following the isolation of Taxol (or Paclitaxel) from the stem bark of the Pacific yew 
tree Taxus brevifolia and its discovery as an antileukemic agent by Wani et al. in 1971, 
the taxanes have garnered considerable attention.  Taxanes have been used with success 
in the clinical treatment of a range of human cancers including ovarian, metastatic breast 
and non-small cell lung carcinomas (Rowinski et al., 1992).  Unfortunately, Taxus bark 
is not a renewable source and a 100-year-old tree can only provide approximately one 
gram of taxol.  And so, attention turned to the development of semisynthetic derivatives.  
The production of these derivatives followed the discovery that the taxol molecule 
(Figure 1.2.3.1, Smith et al., 2000) consisted of two parts, a complex central core (a 
diterpene with a taxane ring system linked to a four-membered oxetane ring at positions 
C-4 and C-5) connected to a structurally simpler ester side chain at the C-13 position.  
 
 
 
Figure 1.2.3.1 Structure of TaxolTM (paclitaxel) (Smith et al., 2000) 
 
 
It was found that the central core of the taxol molecule could be obtained from the 
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needles of the European yew tree, Taxus braccata (Figure 1.2.3.2) and that the side 
chain could be synthesised de novo and attached to the core (Nicolaou et al., 1996).  
Paclitaxel (TaxolTM; Bristol-Myers Squibb Oncology, Princeton, NJ) was the first 
semisynthetic taxane produced.  The second clinically used taxane, docetaxel 
(TaxotereTM; Rhone-Poulenc Rorer, Antony, France) (Figure 1.2.3.3) differs from 
paclitaxel by the composition of the ester side chain, which accounts for the different 
activities, potencies and toxicity profiles of the two agents (Smith et al., 2000). 
 
 
 
Figure 1.2.3.2 Taxus braccata 
 
 
Following the discovery by Horwitz and her team that the cellular target was tubulin 
(Schiff et al., 1979), it has been established that taxanes share a unique mechanism of 
action, altering the function of cellular microtubules.  The dynamic polymerisation and 
de-polymerisation of microtubules is essential for normal cellular function.  This is 
because these structures compose the mitotic spindle apparatus and are involved in a 
number of essential interphase functions, for example, maintenance of shape, motility, 
anchorage, mediation of signals between cell surface receptors and the nucleus and 
intracellular transport (Rowinski et al., 1992; reviewed in Smith et al., 2000).   
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Figure 1.2.3.3 Structure of TaxotereTM (docetaxel) (Smith et al., 2000) 
 
 
Upon binding to the β-subunit of tubulin, Taxol promotes the formation of structurally 
abnormal microtubules that consist of only 12 subunits that are relatively resistant to de-
polymerisation i.e. they are abnormally stable.  Taxotere exerts a similar influence, the 
resulting microtubules consisting of 13 subunits that are structurally normal, but also 
abnormally stable.  This explains the comparative effects of the two agents; taxotere has 
a greater affinity for the microtubule binding site (Diaz and Andreu, 1993) and double 
the activity as a microtubule stabiliser (Gueritte-Voegelein et al., 1991).   
 
Adverse events associated with taxane therapy include myelosuppression, mucositis, 
alopecia, asthenia, arthralgia and paraesthesia.  However, there are also adverse events 
that are specific to taxane therapy.  Hypersensitivity reactions, ranging from mild 
erythematous skin rashes to anaphylaxis have been observed with both taxol and 
taxotere.  These reactions are more frequently associated with the administration of 
taxol, thought to be due to the use of Cremophor EL to solubilise the drug (Smith et al., 
2000). 
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1.2.4 5-Fluorouracil 
 
The anti-metabolite 5-Fluorouracil (5-FU) (Figure 1.2.4.1) was first synthesised in 1957 
and has been used widely in the treatment of various cancers, including breast cancer, 
for over 40 years (Ansfield et al., 1969; Pinedo and Peters, 1988; Smith et al., 2000).  5-
FU an analogue of uracil, the naturally occurring pyrmidine, inhibits the enzyme 
thymidylate synthase.  After delivery to cells it is metabolised to nucleoside forms by the 
addition of ribose or deoxyribose by enzymes that normally act on uracil and thymine.  
Phosphorylation then leads to the active fluorinated nucleotides 5-FUTP and 5-FdUMP.  
One of the pathways responsible for the cytotoxic events associated with 5-FU occurs 
upon the catabolism of the false deoxyribotide –FdUMP.  This competes with the 
naturally occurring molecule dUMP, resulting in inhibition of thymidylate synthase 
therefore depleting dTMP required for DNA synthesis through mis-incorporation of 
uracil leading to DNA strand breaks (Ladner et al., 2000).   
 
Another major mechanism of action is through the incorporation of the nucleotide FUTP 
into RNA, particularly nuclear RNA.  This apparently disturbs the normal maturing of 
nuclear, ribosomal and messenger RNA and may cause other errors of base pairing 
during transcription (Siu and Moore, 2005).   
 
 
 
 
Figure 1.2.4.1 Structure of 5-Fluorouracil (Smith et al., 2000) 
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5-FU is usually administered as a single dose by intravenous bolus injection because of 
its erratic bioavailability following oral treatment.  Adverse events associated with 5-FU 
are significant and varied and a major problem in treating patients due to its lack of 
tumour specificity.  They include myelosuppression, megaloblastic anaemia, 
leucopoenia, thrombocytopenia, alopecia and gastro-intestinal toxicities.  To try to 
circumvent these problems, analogues of 5-FU have been developed, e.g. Capecitabine 
(Figure. 1.2.4.2).  This can be administered orally and has better tumour specificity 
leading to a lower toxicity profile (Smith et al., 2000).   
 
 
 
Figure 1.2.4.2. Structure of Capecitabine 
 
 
1.3 Multidrug Resistance 
 
The ability of tumour cells to develop cross resistance to many chemotherapeutic drugs 
(termed multidrug resistance or MDR) poses a major obstacle to successful 
chemotherapy.  Its development relates to either inadequate drug exposure and or 
changes in cancer cells themselves.  Poor drug bioavailability and distribution, 
insufficient dosage and poor tumour vascularisation account for why cells may not be 
exposed to effective doses of drugs during chemotherapy.  An increase in drug efflux or 
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a decrease in drug uptake by cancer cells, increased drug metabolism and excretion, 
changes in drug metabolising enzymes and altered apoptotic genes in tumour cells may 
all contribute to reduced intracellular concentrations of anticancer drugs in tumour cells 
(Gaudiano et al., 2000).  Although chemotherapy drugs (anthracyclins, taxanes, vinca 
alkaloids) may have entirely different structures and mechanisms of cytotoxicity they 
share a common transport mechanism; they are actively pumped out of the cell as a 
consequence of expression of ABC transporter proteins.  The ABC superfamily 
comprises several hundred different transport proteins specific for either single 
substrates or groups of related substrates (Moscow and Cowan, 1988; Gottesman, 1993).  
The genetic basis for the phenotypic expression of drug resistance has been elucidated in 
tumour cell lines for many drugs.  Amplification of the mdr1 gene in multidrug resistant 
tumour cells leads to a large overproduction of MDR1 protein, more commonly known 
as P-gp.  It was the first eukaryotic ABC protein identified in 1976 and is a significant 
component of anthracycline resistance in tumour cells that showed resistance to tumour 
drugs.  It uses the energy of ATP hydrolysis to export drugs from the cytosol to the 
extracellular medium.  It is also involved in physiological functions, for example lipid 
transport and cholesterol trafficking (Johnstone et al., 2000; Moscow and Cowan, 1988; 
Gottesman, 1993).  Its expression on gut epithelia, liver cells, kidney tubules and at 
blood tissue barriers is consistent with drug removal role, but its selective expression in 
the adrenal gland, haematopoietic stem cells, natural killer cells, dendritic cells, T and B 
lymphocytes  suggest P-gp also has important functions in immunology and apoptosis.  
Evidence suggests that P-gp can cause drug resistance by inhibiting caspases, 
downstream effectors of apoptosis (Moscow and Cowan, 1988; Gottesman, 1993).   
 
Other ABC transporter proteins include MRP-1, a multidrug resistance associated 
protein (Schrenk et al., 2001), Lung resistance-related protein (LRP) (Scheper et al., 
1993) and BCRP, breast cancer resistance protein Mao and Unadkat, 2005.   MRP-1 
shares homology with P-gp, although it has a more limited substrate specificity (Seelig 
et al., 2000).  Lung resistance-related protein (LRP) is a major vault protein widely 
distributed in normal tissues, and over-expressed in multidrug-resistant cancer cells.  
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LRP was originally found to be over-expressed in a non small cell lung cancer cell line 
selected for doxorubicin resistance that did not express P-gp (Scheper et al., 1993).  The 
LRP gene encodes a 110 kDa multi-subunit with a barrel-like structure thought to be 
involved in nucleo-cytoplasmic transport.  Substrates for LRP include doxorubicin, 
cisplatin, etoposide and mitoxantrone, although transport of such substrates is also 
dependent on expression of associated minor vault proteins such as vault poly-(ADP-
ribose) polymerase (VPARP) and telomerase-associated protein (TEP1) (Mossink et al., 
2003).  Breast cancer resistance protein (BCRP or ABCG-2) is an ABC transporter 
protein that is expressed and functionally active in the mitochondria of MDR-positive 
cancer cells (Solazzo et al., 2009).  As the name suggests, this 72 kDa protein was first 
discovered in breast cancer cells, specifically the MCF-7 cell line, and has since been 
reported in colon, gastric and ovarian carcinoma and fibrosarcoma cells.  Its substrates 
include anthracyclins, mitoxantrone, camptothecins and methotrexate (Mao and 
Unadkat, 2005).  
 
Glutathione upregulation represents another common mechanism of resistance in tumour 
cells.  This endogenous antioxidant is believed to cause resistance by providing 
protection against free radical damage (Lutzky et al., 1989).  A related mechanism relies 
on the ability of resistant tumour cells to efficiently promote glutathione S-transferase 
(GST)-catalyzed GSH conjugation of antitumour drugs (O’ Brien and Tew, 1996; Tew, 
1994).  Although Gaudiano et al. (2000) failed to demonstrate GSH conjugation in 
doxorubicin-resistant human breast cancer MCF-7/DOX cells, there was however a 14-
fold increase of the GST P1–1 activity in resistant cells relative to the sensitive MCF-7 
cells suggesting that the overexpression of GST P1–1 in MCF-7/DOX cells may be an 
endogenous defense against oxidative stress induced by anthracyclines.  Liu and 
colleagues (2001) suggested that GST P1–1 functions together with drug efflux pumps 
such as MRP-1, MRP-2 and/or P-gp to reduce cellular cytotoxic drug accumulation.  
Similar observations were reported by Harbottle and coworkers (2001) in HEp2 human 
cancer cells.   
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Other mechanisms for chemoresistance relate to changes in topoisomerase II activity, to 
expression of important apoptosis-associated proteins such as bcl-2 family of proteins 
(Reed, 1995; Clynes et al., 1998), the tumour suppressor protein p53 (Mueller and 
Eppenberger, 1996), the synthesis of vaults (Kickhoefer et al., 1998), overexpression of 
caveolae (Lavie et al., 1998) and dysfunctional metabolism of ceramide (Senchenkov et 
al., 2001). 
 
Many attempts have been made to use current knowledge of drug resistance mechanisms 
to reverse MDR in cancer and to extend patient survival.  Agents which inhibit cancer 
resistance mechanisms are termed resistance modulators or chemosensitising agents.  
These include pump inhibitors (e.g. cyclosporin A, verapamil, resveratrol, quercetin), 
pump bypass agents (inclusive drugs) i.e. drugs that are not substrates of drug 
transporters (e.g. flavopridol, epothilone, inhibitors of MAPK and PI3K signalling 
pathways) and exclusive protectors (a protective agent that is a substrate of drug 
transporters and therefore retained at a higher level in normal cells; e.g. caspase inhibitor 
Z-DEVD-fmk, low dose anthracyclines) (Blagosklonny, 2003).  Specifications for an 
agent that would be therapeutically most useful to modulate MDR were listed by Clynes 
et al. (1998) and include i) it should inhibit at a low and physiologically relevant 
concentration, ii) be selectively toxic for tumour tissue, iii) irreversibly inhibit the 
resistance mechanism, iv) permeate through all cells in a tumour at an effective 
concentration, v) have no significant effect on the pharmacokinetics of chemotherapy 
drugs, vi) be non toxic on its own, vii) be available as a pure chemical with well 
described consistent pharmacokinetics and viii) it should not increase the toxicity of the 
chemotherapy in other parts of the body.     
 
 
1.4 Improving Chemotherapy 
 
While cancer continues to be a leading cause of morbidity and mortality, there will 
                                  
 
22 
 
 
 
 
 
always be room for improvement in cancer chemotherapy; the need is obvious and has 
been stated at length in previous sections.  Numerous studies have focused on trying to 
improve the efficacy of the anti-cancer drugs in present use.  One such study tested the 
potential of a number of non steroidal anti-inflammatory drugs (NSAIDs) 
(indomethacin, sulindac, tolmetin, acemetacin, zomepirac, mefenamic acid, 
meclofenamic acid, diclofenac, naproxen, fenoprofen, phenylbutazone, flufenamic acid, 
flurbiprofen, ibuprofen and ketoprofen) to enhance the cytotoxic effect of a catalogue of 
chemotherapeutic agents.  Specific NSAIDs (including indomethacin and sulindac) 
enhanced the efficacy of the anthracycline group and structurally related anti-cancer 
drugs.  These drugs are substrates for MRP-1 (multidrug resistance related protein).  The 
synergistic combination was effective in cell lines in which the multi-drug resistance 
(MDR) was due to MRP-1 over-expression and in drug sensitive cell lines that were 
shown to express MRP (Duffy et al., 1998).  Other groups have more recently directed 
their attention toward various polyunsaturated fatty acids (PUFA). 
 
 
1.5 Polyunsaturated Fatty Acids (PUFA) 
1.5.1 Enhancement of chemotherapy cytotoxicity by PUFA 
 
Experimental studies in animal models of chemical carcinogenesis, animals bearing 
transplanted tumours and in animals representing genetic models of tumourigenesis have 
indicated that dietary treatments with omega-3 (n-3) polyunsaturated fatty acids (PUFA) 
exert anti-tumoural effects.  Similarly, research has shown that n-3 PUFA inhibited the 
growth of various cancer cells in culture (Guthrie and Carroll, 1999).   
 
Numerous studies have shown that n-3 PUFA protect against carcinogenesis, help 
prevent formation and growth of aberrant crypt foci in the colon, and inhibit tumour 
metastasis including that of mammary tumours (Bougnoux, 1999).  While the growth of 
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tumors is inhibited in animals fed diets rich in omega-3 fish oils, it is often reported that 
tumour growth is stimulated by diets rich in n-6 vegetable oils, particularly Linoleic 
acid.  However, exceptions exist in the n-6 family of PUFA’s that show great promise as 
antitumour agents, two of which are γ-linolenic acid (GLA) and an isomer of linoleic 
acid (LA) known as conjugated linoleic acid (CLA) (Burns and Spector, 1993).   
 
The fact that certain essential fatty acids (EFA’s) and their derivatives, of both the n-3 
and n-6 series show selective cytotoxicity without harming normal cells, makes them 
ideal candidates for further research as possible chemo-sensitisers (Burns and Spector, 
1994).  For example, Das et al. (1998) found that not only did various EFA’s (γ-
linolenic acid (GLA), eicosapentanoic acid (EPA), arachidonic acid (AA) and 
docosahexanoic acid (DHA)) enhance chemotherapy drug efficacy in cancer cell lines, 
they also increased the sensitivity of drug-resistant cells (KB-ChR-8-5 (HeLa variant) 
human cervical carcinoma cells) to the cytotoxic action of vincristine in vitro.  Further, it 
was found that these fatty acids and DGLA (dihomo gamma-linolenic acid) also 
increased the uptake and decreased the efflux of radiolabelled vincristine in KB-3-1 
(HeLa variant), KB-ChR-8-5 and HeLa cell lines. 
 
Tsai et al. (1997) found EPA increased the sensitivity of the tumourigenic cell line 
derived from immune mouse fibroblastic NIH3T3 cells to Mitomycin C; also that EPA 
demonstrated a protective function against Mitomycin C in the non-malignant variant of 
the NIH3T3 cell line.  DHA was shown to enhance doxorubicin cytotoxicity in MDA-
MB-231 breast cancer cells by Germain et al. (1998).  This effect was nullified by 
Vitamin E, indicating the role of lipid oxidation pathways.  It has also been shown by 
Bougnoux et al. (1999) that an increased level of DHA in breast adipose tissue directly 
correlated with increased responses (both partial and complete) to chemotherapy. 
 
Animal studies have also corroborated these findings.  In one such study, human A549 
lung cancer cells were implanted subcutaneously on the backs of nude mice.  Following 
an incubation period to allow the tumours to develop and grow, the mice were divided 
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into groups fed on diets containing 20 % corn oil, or 19 % fish oil/1 % corn oil.  They 
were then sub-divided into those treated with/without doxorubicin.  It was found that 
there was significant tumour regression in the mice that consumed fish oil diets before 
and during Dox treatment, but not in the mice that consumed corn oil diets before and 
during Dox treatment (Hardman et al., 2000).  Subsequent studies by this group showed 
that fish oil concentrate increased efficacy of Dox against MDA-MB-231 human breast 
cancer xenografts in athymic mice (Hardman et al., 2001) and that the cytotoxic action 
of these fatty acids is through mechanisms including lipid peroxidation, although 
suppression of glutathione peroxidase (GPX) was found to be a more important factor in 
increasing sensitivity to Dox (Hardman et al., 2005). 
 
Furthermore, Hardman et al. (2002) demonstrated that a concentrated omega-3 product 
containing 55 % EPA at 2 % in the diet ameliorated the harmful side-effects of CPT-11 
chemotherapy in mice.  Beneficial effects were obtained with a volume of concentrate 
that was lower than a 6 % fish oil diet that contained the same amount of EPA and DHA.  
The ability of fish oils to enhance the antitumour activity of CPT-11 in breast carcinoma 
xenografts was confirmed in a separate study in rats bearing the Ward colon tumour (Xu 
et al., 2007).  Colas et al. (2006) also showed that dietary DHA supplementation turned 
a malignant tumour from being anthracycline-resistant to anthracycline-sensitive. 
 
In experiments conducted by Davies et al. (1999) it was found that cellular uptake of 
various anthracyclines including doxorubicin increased following a 24 h incubation of 
multidrug resistant MGH-U1/R bladder and MCF-7/R breast cancer cells with GLA.  
GLA was administered as the clinical formulation Lithium-GLA (LiGLA) at 20 µg/ml, 
which was a sub-lethal dose.  These results demonstrate that one of the mechanisms of 
action in enhancement of drug cytotoxicity is by increasing drug uptake into the cells 
thereby increasing intracellular concentrations of the drug.  Menendez et al. (2002), 
found that co-incubation with GLA in various combinations enhanced the cytotoxic 
action of vinorelbine in breast cancer cell lines.  Potential synergy was evaluated 
following exposure of cells simultaneously to vinorelbine and GLA, or sequentially to 
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GLA followed by vinorelbine.  The cell lines used were MDA-MB231, T47D and SK-
Br3 breast cancer cells.  In all cell lines it was found that the level of synergism was 
independent of treatment schedule and exposure time. 
 
More recently, a soluble fatty acid formulation (meglumine EPA,) was demonstrated to 
enhance the efficacy of both epirubicin and mitomycin in bladder cancer cells in vitro 
(Mackie et al., 2006).  It is apparent that conjugation of fatty acid with glutamine to 
form soluble quaternary amine complexes has potential to improve treatment regimes 
based on unstable highly oxidisable PUFA like EPA. 
 
 
1.5.2 Mechanisms of Action of PUFA 
 
Several studies have implicated lipid peroxidation as one mechanism by which n-3 
PUFA potentiate the cytotoxic action of chemotherapy drugs.  In the study by Germain 
and colleagues (1998), described above it was concluded that the increased cytotoxicity 
of doxorubicin by DHA in human breast cancer cells in vitro was due to oxidative stress 
which was reduced by the addition of α-tocopherol.  Similarly the increased 
sensitisation by DHA of chemically induced mammary carcinoma to epirubicin in 
Sprague-Dawley rats was cancelled out by the addition of α-tocopherol to the diet 
(Colas et al., 2006). 
 
n-3 PUFA have been shown to cause a reduction in the production of eicosanoids from 
arachidonic acid (AA) (Rose et al., 1995).  Production of such eicosanoids (e.g. 
prostaglandin E2) has been shown to be up-regulated in cancer cells (Karmali, 1987).  
EPA has the ability to compete with AA for the enzymes cyclooxygenase (COX) and 
lipooxygenase (LOX) which are involved in the production of these eicosanoids, 
resulting in the production of compounds which are less biologically active and in some 
cases antiproliferative in cancer cells (Yang et al., 2004). 
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PUFA are the basic constituents of membrane phospholipids and their alterations in 
membranes may modify cellular membrane fluidity and consequently modulate enzyme 
activities, carriers and membrane receptors (Calviello et al., 2006).  DHA incorporation 
into the plasma membrane of T27A murine leukaemia cells has been shown to enhance 
membrane permeability (Stillwell et al., 1993) and alter membrane structure, increasing 
susceptibility of the cells to destruction by the immune system (Pascale et al., 1993).  
Supplementing the diet of mice with fish oil markedly altered the lipid composition of 
colonic caveolae/lipid rafts and EPA and DHA were incorporated in the fatty acyl 
groups of caveola phospholipids and decreased the caveolar content of cholesterol and 
caveolin-1, an important structural component.  Perturbation of these lipid micro-
domains was found to displace resident proteins H-Ras but not K-Ras in colonic 
caveolae both in vitro and in vivo, altering their functionality and subsequent 
downstream signalling (Ma et al., 2004).   
 
Several transcription factors such as NFκB have been shown to be modulated by n-3 
fatty acids.  Constitutive activation of NFκB has been implicated in the progression of 
cancer in humans having roles in the regulation of cell proliferation, migration and 
apoptosis (Calviello et al., 2006).  EPA and DHA have been shown to down-regulate 
NFκB activity in various cell lines including human T-cells, colon and prostate cancer 
cells (Denys et al., 2005; Narayanan et al., 2003; Ross et al., 2003) and in kidney cells 
of transgenic rats (Theuer et al., 2005).  Several studies now indicate that inhibition of 
NFκB can sensitise tumour cells to chemotherapeutic drugs (Reviewed in Biondo et al., 
2008).  n-3 PUFA have also been reported to modulate the activity of other transcription 
factors such as peroxisome proliferator activated receptors (PPAR), p53, c-myc AP-1, 
HIF-1 and retinoid X receptors (RXR) (Calviello et al., 2006).   
 
Recent evidence suggests that the phosphoinositol 3-kinase (PI3K)/Akt signalling 
pathway is constitutively active in many types of human cancer and overexpression has 
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been linked to development of multi-drug resistance.  EPA and DHA have been 
demonstrated to inhibit Akt phosphorylation and activation in various types of cancer 
cells, thereby explaining in part the increased chemotherapeutic response by these fatty 
acids in tumour cells (Biondo et al., 2008).  Another protein kinase overexpressed in 
various mammary cancers is mitogen activated protein kinase (MAPK).  n-3 PUFA are 
reported to decrease phosphorylation and activity of the MAPK extracellularly regulated 
kinases (ERK) in tumour cells (Calviello et al., 2006).   
 
It is widely accepted that human cancer cells have the ability to synthesise their own 
supply of fatty acids, seemingly independent of the regulatory signals that down-regulate 
fatty acid synthesis in normal cells (Kuhajda, 2000).  Fatty acid synthase (FAS), 
previously known as oncogenic antigen 519 (OA-519), is a key enzyme in the de novo 
synthesis of fatty acids and has been identified as a tumour marker in breast cancer 
indicating a poor prognosis (Kuhajada et al., 1989; 1994).  FAS is down-regulated in 
normal human cells by the intake of small amounts of fat in the diet, but is highly 
expressed in human cancers and is probably one of the most common molecular changes 
in cancer cells (Kuhajda, 2000; Menendez et al., 2005).  In fact it has recently been 
discovered that elevated FAS expression contributes to increased drug resistance in 
breast cancer cells (Liu et al., 2008).  DHA and alpha-linolenic acid (ALA) have been 
found to inhibit FAS activity in human breast cancer cells (Menendez et al., 2004).   
 
Other modulatory effects of DHA and EPA which explain an increased sensitivity to 
chemotherapy drugs in tumour cells include an increase in the induction of apoptosis 
through reduction in expression of the anti-apoptotic protein bcl-2 (Chiu et al., 1999; 
2004).  In addition, DHA treatment increased expression of the pro-apoptotic protein 
Bax in HL-60 human leukaemia cells (Chiu et al., 2004) while EPA induced apoptosis 
and increased caspase 3 activation in human pancreatic cell lines (Shirota et al., 2005).  
Work by Calviello and colleagues (2005), supports the hypothesis that n-3 PUFA 
enhance the pro-apoptotic effect of anticancer drugs.  DHA was shown to increase the 
cytotoxicity of 5-FU in a colon cancer cell line by decreased expression of anti-apoptotic 
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proteins bcl-2 and bcl-XL.  An understanding of the mechanisms of action of n-3 PUFA 
in combination therapy will drive translational research towards developing their use as 
dietary adjuvants to chemotherapy for patients. 
 
 
1.6 Conjugated Linoleic Acids (CLA) 
1.6.1 CLA Structure and Origin 
 
Conjugated linoleic acid (CLA) refers to a group of polyunsaturated fatty acids that exist 
as positional and geometric isomers of the n-6 essential fatty acid linoleic acid (LA) 
(c9,c12; octadecadienoic acid), which contain a conjugated double bond system and 
occur naturally in edible fats derived from ruminant animals.  Several isomers of CLA 
exist depending on which double bonds are relocated to either cis or trans 
configurations.  The c9,t11 and t10,c12-CLA isomers account for up to 90 % of 
synthetic CLA mixtures combined (Lin et al., 1995).   
 
c9,t11-CLA is the predominant isomer naturally occurring in dairy products constituting 
up to 90 % of the total CLA present, with t10,c12-CLA making up the majority of the 
remainder.  CLA content in food varies from 0.2 mg/g in corn and peanut oils, 17 mg/g 
in beef and 30 mg/g in milk fat (O’Shea et al., 1998).  The CLA content of milk can be 
improved greatly when dairy cows are fed supplemental fish and vegetable (safflower) 
oils (Murphy et al., 2008). 
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Figure 1.6.1.1 Structure of c9,t11 and t10,c12-CLA and Linoleic acid (LA) (Pariza, 2001). 
 
 
c9,t11-CLA is formed in the rumen as an intermediate product in the biohydrogenation 
of LA by linoleic acid isomerase enzyme of the anaerobic bacteria Butyrivibrio 
fibrisolvens (Kepler et al., 1970).  More recently it has also been found to be produced in 
tissues by the desaturation of trans-vaccenic acid (t-VA) by ∆9 desaturase (Yurawecz et 
al., 1998).  This was confirmed by Miller and co-workers in breast and colon cancer 
cells (2003) and more recently by Reynolds et al. (2008), in Caco2 colon cancer cells.   
 
Other isomers are formed at much lower amounts, such as the t10,c12-CLA isomer 
which is produced when the pH in the rumen drops with a low fibre diet (Griinari et al., 
1998).  A second pathway involving the bacterium Megasphaera elsdenii YJ-4 is 
responsible for producing the t10,c12-CLA isomer from LA (Kim et al., 2002).  Figure 
1.6.1.2 illustrates the production of c9,t11-CLA from LA in the rumen and vaccenic acid 
in the tissues and the role of ∆9-desaturase (Bauman and Griinari, 2000). 
 
t10,c12-CLA 
c9,t11-CLA 
Linoleic acid 
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Figure 1.6.1.2 Production of c9,t11-CLA from LA in the rumen and vaccenic acid in the tissues.  
Also showing the role of ∆9-desaturase.  (Adapted from Bauman and Griinari, 2000) 
 
 
A dairy diet represents the main source of CLA in humans (McGuire et al., 1999), 
although CLA, principally c9,t11-CLA, has recently been reported to be produced by 
intestinal Bifidobacteria from free linoleic acid (Coakley et al., 2006).  This was 
postulated to account for the beneficial effects of bifidobacteria present in the human 
gastrointestinal tract.  Dietary intake of CLA has been estimated to range between 52-
350 mg CLA/day in women and 137-430 mg CLA/day in men (Ritzenthaler et al., 1998; 
Fritsche and Steinhart, 1998; Ens et al., 2001).  However, one study in Australia 
estimated a daily intake of up to 1500 mg CLA by its participants (Parodi et al., 2003). 
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C18:0  Stearic Acid 
 
Rumen 
 Tissues 
c9,c12  C18:2 
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C18:0                   c-9  C18:1 
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1.6.3 Biological Effects of CLA and Mechanisms of Action 
 
CLA was first found to have anticarcinogenic properties when extracted from cooked 
minced beef (Ha et al., 1987).  Since then CLA has been shown to exhibit a number of 
physiological effects in animal models, having activity as an anti-adipogenic agent (Park 
et al., 1997), an anti-atherogenic agent (Lee et al., 1994; Navarro et al., 2007) and 
having immuno modulatory effects (Cook et al., 1993; Miller et al., 1994; Loscher et al., 
2005; Reynolds et al., 2008).  Clement and Margot Ip and co-workers have reported 
extensively on the anticancer effects of CLA in various rat and murine mammary cancer 
models in vitro and in vivo (Ip et al., 1991, 1994, 1995, 1996, 1997ab, 1999ab, 2000 and 
2001).  Dietary supplementation with 1 % CLA in the diet has been shown to inhibit 
chemically induced cancer development in mammary glands of rats.  When CLA was 
administered to pre-pubescent animals, i.e. during active morphogenesis of the 
mammary gland from weaning at 21 days to 50 d there was persistent protection against 
subsequent tumour development following withdrawal of CLA from the diet (Ip et al., 
1995).  However, when they administered CLA to a more mature rat model at 55 d, it 
was found that a continuous intake of CLA was necessary to inhibit tumour development 
(Thompson et al., 1997).  More recently they reported that the t10,c12-CLA isomer 
induced apoptosis and G1 arrest of p53 mutant TM4t murine mammary tumour cells (Ou 
et al., 2007).  Chemically-induced cancer in the mammary glands of rodents has proved 
to be a good model to replicate breast cancer tumourigenesis in humans as both occur 
primarily in the undifferentiated, rapidly proliferating epithelium at the distal end of the 
terminal end buds and terminal ducts of breast tissue (Medina, 1996).   
 
CLA induced apoptosis of murine mammary tumour cells via release of cytochrome c 
from the mitochondria to the cytosol, decreased expression of anti-apoptotic protein Bcl-
2 and activation of the caspase-9/caspase-3 proteolytic cascade (Ou et al., 2007).  Other 
studies have also demonstrated a similar reduction in Bcl-2 levels in colon (Miller et al., 
2002), prostate (Ochoa et al., 2004) and breast cancer cell lines (Majumder et al., 2002).  
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In MDA-MB-231 breast cancer cells the anti-proliferative effect of CLA was associated 
with up-regulation of the pro-apoptotic protein Bak, reduced levels of anti-apoptotic 
Bcl-xL, release of cytochrome c from the mitochondria, cleavage of pro-caspase-9 and 
pro-caspase-3 and finally a reduction in ERK1/2 leading to interruption of ERK/MAPK 
signalling (Miglietta et al., 2006). 
 
Dietary CLA has been shown to inhibit angiogenesis in vivo and in vitro, and to decrease 
vascular endothelial growth factor (VEGF) and its receptor, Flk-1 concentrations in the 
mouse mammary gland.  The t10,c12-CLA isomer was demonstrated to have the 
additional ability to decrease serum leptin, a proangiogenic growth factor in CD2F1Cr 
mice.  It is widely accepted that the ability of CLA isomers to inhibit angiogenesis in 
vivo may contribute to their ability to inhibit carcinogenesis (Masso-Welch et al., 2004). 
 
ErbB2 (HER2) and ErbB3 have been implicated in the development of various cancers.  
In a study in the HT-29 colon cancer cell line, CLA decreased ErbB2 and ErbB3 mRNA 
and protein levels in a dose-dependent manner.  Cho et al. (2003) concluded that CLA 
inhibits cell proliferation and stimulates apoptosis in HT-29 cells by its ability to 
downregulate ErbB3 signalling and the PI3-kinase/Akt pathway.   
 
Tanmahasamut and colleagues (2004) demonstrated that CLA inhibited growth of the 
oestrogen receptor (ER)-positive breast cancer cell line MCF-7, but not ER- negative 
MDA-MB-231 breast cancer cells.  This was attributed to the ability of CLA to directly 
affect oestrogenic activity in the ER positive cells, down regulating ERα expression at 
both mRNA and protein levels and interfering with binding of a nuclear protein to the 
oestrogen response element. 
 
In addition to the anticarcinogenic effects, CLA has demonstrated other positive health 
benefits.  CLA was first found to have immune modulatory effects in chickens and rats 
(Cook et al., 1993).  Since then, Loscher and colleagues demonstrated that c9,t11-CLA 
suppressed NF-κB activation and enhanced transcription and production of the anti-
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inflammatory cytokine IL-10 in dendritic cells, while inhibiting the Th1-promoting 
cytokine IL-12 (Loscher et al., 2005).  As described above constitutive activation of 
NFκB has been implicated in the progression of cancer in humans having roles in the 
regulation of cell proliferation, migration and apoptosis, therefore suppression of NFκB 
activity may explain in part the anticarcinogenic effects of CLA.  This was supported by 
Hwang and co-workers (2007), in a study which found that CLA inhibited NF-κB 
driven-COX-2 expression by blocking the IκK and PI3K-Akt signalling in hairless 
mouse skin in vivo. 
 
It has also been shown that inhibition of lipid accumulation induced by t10,c12-CLA 
treatment during adipocyte differentiation is associated with a tight regulatory cross-talk 
between early (PPARγ and CCAAT/enhancer binding protein a (C/EBPa)) and late 
(liver X receptor a; a fatty acid binding protein, aP2; CD36, a fatty acid translocase; 
adipogenic marker genes (Granlund et al., 2005).  Activation of PPAR gamma and delta 
by conjugated linoleic acid was also found to have a protective effect in experimental 
inflammatory bowel disease in mice (Bassaganya-Riera et al., 2004). 
 
In a study of the effect of CLA on atherosclerosis in cholesterol-fed rabbits, the LDL 
cholesterol to HDL cholesterol ratio and total cholesterol to HDL cholesterol ratio were 
significantly reduced in CLA-fed rabbits.  Also, examination of the aortas of CLA-fed 
rabbits showed less atherosclerosis than controls (Lee et al., 1994).  t10,c12-CLA 
feeding in hypercholesterolaemic hamsters was demonstrated to reduce cholesterol 
esterification in liver and decrease serum VLDL-cholesterol, but did not result in a 
hypocholesterolaemic effect (Navarro et al., 2007). 
 
It has been suggested that CLA competes with LA for desaturation and elongation 
enzymes involved in the conversion of long chain metabolites.  These same enzymes are 
involved in the metabolism of n-3 fatty α-linolenic acid, ALA.  Elongation and 
desaturase metabolites of CLA, notable for their conservation of the conjugated diene 
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structure, have been detected and identified by Banni and coworkers in various tissues 
including mammary tissue, rat liver and lamb tissue (1996, 1999 and 2001).  In rat liver 
and adipose tissue c9,t11-CLA was found to be mainly converted into a C20:3 
conjugated fatty acid, while the t10,c12-CLA isomer was metabolised into a conjugated 
C18:3 or C16:3 fatty acid (Sebedio et al., 2001).  The presence of these metabolites in 
different lipid fractions of tissues (Banni et al., 2004) may account for some of the 
differing and sometimes conflicting physiological effects of the different CLA isomers. 
 
These diverse physiological actions of CLA make it an ideal candidate for further study 
of the anticancer potential of CLA in multi-drug resistant tumours.  The work described 
in this thesis is the first study to test the efficacy of CLA alone or in combination with 
chemotherapeutic drugs in drug-resistant cancer cell lines.  Following an evaluation of 
the cytotoxic effects of PUFA and doxorubicin (Dox) as single agents, the overall 
objective of this project was to characterise the effects of co-administering PUFA 
including CLA with the anticancer drug Dox in a cellular model of multi-drug resistant 
cancer and to determine mechanisms by which fatty acids may modulate drug resistance 
or sensitivity.   
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1.7 Thesis Objectives 
 
 To characterise the cytotoxic effects of single treatments of various PUFA including 
CLA and three chemotherapeutic agents (Doxorubicin, Taxotere and 5-Fluorouracil) 
in drug sensitive and resistant cancer cell lines using a cost effective high through-
put cytotoxicity assay. 
 
 To evaluate the potential of co-treatment with a commercial mixture of CLA isomers 
(CLA-mix) and two single isomers c9,t11-CLA and t10,c12-CLA to enhance the 
cytotoxic effects of Doxorubicin (Dox) on a drug naive MDA-MB435-S-F (MDA) 
melanoma cell line and a multidrug resistant variant MDA-MB435-S-F/Adr10p10p 
(A10p10p). 
 
 To determine the effect of CLA-mix, c9,t11 and t10,c12-CLA on net 
uptake/accumulation of Dox in cells and retention after efflux by liquid 
chromatography tandem mass spectrometry (LC-MS) methods. 
 
 To determine differences if any between ceramide and basal sphingosine levels in 
untreated MDA and A10p10p cells and investigate the effects of CLA, EPA and 
DHA, alone and in combination with Dox, on basal sphingosine and ceramide levels 
in both cell lines. 
 
 To measure and compare the expression of her2/neu expression in untreated MDA 
and A10p10p cells and elucidate the effects of CLA, EPA and DHA treatments on 
her2/neu expression in both cell lines. 
 
 To determine the differences if any between the lipid profiles of untreated MDA and 
A10p10p cells and investigate the effects of CLA, EPA and DHA, on the total 
cellular lipid fatty acid profiles of both MDA and A10p10p cell lines. 
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Chapter 2 
 
A comparative study of effects of conjugated linoleic 
acid and three chemotherapeutic drugs on proliferation 
of human cancer cells. 
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2.0 Abstract 
 
Conjugated linoleic acid (CLA) has been shown to reduce tumour incidence and 
progression in vivo and to be cytotoxic toward a broad range of tumour cells in vitro 
including breast, colon, prostate and skin cancer cell lines.  The effect of CLA on drug 
resistant tumour cells however, has yet to be characterised.  The aim of this work was to 
characterise the effects of three preparations of CLA (c9,t11 and t10,c12-CLA isomers 
and a synthetic mixture of CLA isomers) complexed with BSA or as free fatty acids and 
three common chemotherapy drugs (taxotere, doxorubicin and 5-fluorouracil) in cellular 
models of clinically significant drug-resistant cancer.  Cytotoxicity was determined by 
MTS and acid phosphatase assays and expressed as percentage inhibition relative to 
control.  Significant inhibition (p<0.05) of cell growth was observed after 5 and 7 days 
of treatments with each CLA preparation.  Cytotoxicity of CLA was dependent on 
isomer composition, concentration and duration of exposure.  MCF-7 cisplatin resistant 
cells were more sensitive to inhibition by t10,c12-CLA and the CLA mixture than 
parental MCF-7 cells.  Drug resistance of MDA-MB435S-F/Tax10p (Tax10p) and 
MDA-MB435S-F/Tax10p4p (Tax10p4p) was demonstrated only when cells were treated 
with taxotere, doxorubicin and 5-fluorouracil in a short term exposure assay; negligible 
differences were observed following long term drug exposure.  There was no significant 
difference in sensitivities of the drug naïve MDA-MB435S-F (MDA) cancer cell line 
and two taxol pulsed, drug resistant variants Tax10p and Tax10p4p to the CLA mixture 
of isomers.  MDA cells however, were more sensitive to inhibition by c9,t11 and 
t10,c12-CLA at concentrations exceeding 12 µg/mL than the Tax10p or Tax10p4p cell 
lines.  Toxicity data obtained in this chapter will be used in the design of an experiment 
using sub-optimal concentrations of both fatty acids and drug to investigate synergistic 
interactions in melanoma cells. 
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2.1 Introduction 
 
Several isomers of CLA both in pure form and as a mixture have been shown to be 
cytotoxic at micromolar concentrations for a variety of breast, colon, prostate and skin 
tumour cell lines (Belury, 2002).  Cytotoxicity of CLA was found to be concentration-
dependent and isomer specific in the MCF-7 human breast cancer cell line (O’Shea et 
al., 2000).  Cell numbers were significantly reduced following treatment for 8 days with 
synthetic preparations of a mixture of CLA isomers and the single isomer c9,t11 -CLA; 
and CLA enriched milk fat.  Interestingly, while the c9,t11-CLA isomer, mixture of 
CLA isomers and CLA enriched milk fat were found to significantly reduce cell 
numbers, treatment with the t10,c12-CLA isomer resulted in no significant difference 
relative to untreated controls.  Linoleic acid (LA) was also tested in this study and found 
to increase cell numbers.  The same authors found in another study that CLA-induced 
cytotoxicity against MCF-7 and the colon cancer cell line SW480 was related to the 
extent of lipid peroxidation of CLA treated cells; CLA-induced antioxidant enzymes 
failed to protect these cells from cytotoxic lipid peroxidation products (O’Shea et al., 
1999).   
 
The overall objective of the work described in this chapter was to assess in a pilot study 
the antiproliferative effects of various preparations of CLA in two in vitro models of 
drug-resistant cancer, MCF-7 and a cisplatin-resistant variant MCF-7/cis and MDA-MB-
435S-F (MDA) and two taxol-resistant variants MDA-MB-435S-F/Taxol-10p (Tax10p) 
and MDA-MB-435S-F/Taxol-10p4p (Tax10p4p).  MCF-7 and MDA cell lines and 
variants have been shown previously to be ER positive cell lines (Tanmahasamut et al., 
2004; Glynn et al., 2004).  There is a consensus in current scientific literature that the 
MDA cell line has been mis-identified as a metastatic breast cancer line for over 25 
years.  It is now known to express several genes commonly transcribed in melanocytes 
but not in commonly used breast cancer cell lines (Rae et al., 2004; 2007).  For this 
reason, the MDA-MB-435 cell line is designated a melanoma cell line in this thesis. 
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This is the first study to examine the effects of CLA in drug-resistant cancer cell lines.  
The growth inhibitory effects of three common chemotherapeutic drugs taxotere, 5-
fluorouracil and doxorubicin were also evaluated in the three MDA derived cell lines.  
Toxicity data obtained in this chapter was used in the design of an experiment using sub-
optimal concentrations of both fatty acids and drug to investigate synergistic interactions 
in human cancer cells. 
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2.1.1 Specific Objectives 
 
• To compare the effects of three preparations of CLA (c9,t11 and t10,c12-CLA 
isomers and a synthetic mixture of CLA isomers) and LA, delivered as sodium 
salts complexed with bovine serum albumin (BSA) in a 2:1 w/w ratio, on an 
MCF-7 breast cancer cell line and the cisplatin resistant variant, MCF-7/cis using 
the MTS microplate assay. 
 
• To establish and optimise a more cost effective high through-put cytotoxicity 
assay and to investigate an alternative cancer cell line whose drug resistance is 
better characterised. 
 
• To determine the cytotoxic effects of single treatments of five fatty acids (three 
preparations of CLA, LA and GLA) complexed with bovine serum albumin 
(BSA) in a 2:1 molar ratio and three chemotherapeutic agents (Doxorubicin, 
Taxotere and 5-Fluorouracil) on three MDA melanoma cell lines (MDA, Tax10p 
and Tax10p4p) using the Acid Phosphatase assay. 
 
• To determine the cytotoxic effects of the above fatty acids without BSA i.e. as 
free fatty acid solutions to eliminate a source of variation in the system.  
 
• To determine the cytotoxic effects of the above anticancer drugs in a more 
clinically relevant assay i.e. to run the assays with a short term exposure (4 h 
exposure to the drug, with a 7 day recovery) in place of long term (7 day) 
exposure. 
 
• To design an experimental model based on IC50 values, to elucidate the possible 
synergistic interactions between CLA and Dox in combination treatments. 
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2.2 Materials and Methods 
2.2.1 Materials 
 
Cell culture media, supplements and related solutions were purchased from Sigma-
Aldrich, Dublin, Ireland, unless otherwise stated.  The MCF-7 human breast cancer cell 
line was obtained from the American Type Culture Collection (ATCC) (Manassas, VA, 
USA).  MCF-7/cis a cisplatin-resistant variant of MCF-7 was developed and gifted by 
Dr. Yizheng Liang (formerly of National Institute of Cellular Biotechnology (NICB), 
Dublin, Ireland).   The MDA-MB-435-S-F (MDA) human cancer cell line and its taxol-
resistant variants MDA-MB-435-S-F/ Taxol 10p (Tax10p) and MDA-MB-435-S-F/ 
Taxol 10p4p (Tax10p4p) were developed and kindly donated by Dr. Sharon Glynn 
(formerly of NICB, Dublin).  Chemotherapy agents Doxorubicin (Dox), 5-Fluorouracil 
(5-FU) [Farmitalia Carlo Erba, Milton Keynes, UK] and Taxotere (Tax) [Aventis, 
France] were kindly donated by Dr. O’Connor (NICB, Dublin). 
 
Conjugated Linoleic Acid (CLA) mixture of isomers (99% pure, approximately 
comprising: 44 % t10,c12-CLA; 41 % c9,t11/t9,c11-CLA; 10 % c10,c12-CLA and 
minor amounts of t9,t11; t10,t12 & c9,c11-CLA) (Cat: UC-59A) and single preparations 
(90 % pure) of isomers c9,t11- and t10,c12-CLA (Cat: UC-60A, UC-61A) were from 
NuChek-Prep, Elysian, MN, USA.  Linoleic Acid (LA) and γ-Linolenic Acid (GLA) 
were purchased from Sigma-Aldrich, Dublin (Cat: L1012; L2378).  All fatty acid 
preparations were dissolved in sterile filtered ethanol: 1 g fatty acid in 10 mL ethanol to 
yield solutions of 99 mg/mL CLA mixture, LA and GLA; and 90 mg/mL c9,t11- and 
t10,c12- CLA.  These were then divided into 1 mL aliquots and stored at -20 oC.   
 
Fatty acids used in the cytotoxicity tests on the MCF-7 and MCF-7/cis cell lines, were 
delivered as sodium salts in bovine serum albumin (BSA) (Cat: A8918) (in a 2:1 w/w 
ratio, equivalent to 473:1 molar ratio) containing medium and were prepared as follows:  
Equimolar amounts of CLA and NaOH (1 mL CLA stock at 0.1 g/mL or 0.35 M and 1 
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mL 0.35 M NaOH) were mixed.  This was diluted to 20 mg/mL CLA with 3 mL DMEM 
containing BSA to yield a BSA concentration of 10 mg/mL.  The solution was incubated 
for 15 minutes at 37 oC, then at 50 oC for a further 15 min.  These stocks were stored at -
20 oC (Ip, et al, 1999).  Working stock solutions of these fatty acid sodium salts were 
prepared in medium at concentrations of 142 µM fatty acid: 0.32 µM BSA and were 
stored for up to two weeks at -20 oC if necessary.   
 
For the first phase of the single treatment cytotoxicity testing on the MDA cell lines 
(MDA, Tax10p and Tax10p4p), stock solutions of fatty acids were prepared in RPMI 
medium containing bovine albumin (BSA) (Cat: A1595) in a 2:1 molar ratio.  A fatty 
acid free formulation of BSA was sourced and used for this stage to reduce variation in 
the assays.  In the second phase of single treatments, fatty acids were made up as free 
fatty acid solutions in RPMI medium fresh for each experiment.   
 
Chemotherapy drug treatments were also prepared in basal medium, fresh for each 
experiment.  Drugs were first diluted 1:1000 (e.g. 10 µL in 10 mL) in medium, then 
diluted further to 2X the final desired concentration.  The three drugs were supplied in 
liquid form (at concentrations of 2 mg/mL Dox, 6 mg/mL Tax and 25 mg/ml 5-FU) 
aliquoted into 1.5 mL screwcap vials (by Dr. Glynn, NICB); this eliminated the dangers 
involved in handling the powdered forms and the use of syringes.  All work using the 
drugs was carried out in a class II laminar air-flow cabinet (Gelaire 85, BSB4 laminar 
air-flow cabinet).  Safety measures included wearing lab coats that fastened covering the 
neck, which also had elasticated cuffs.  Nitrile disposable gloves were worn stretched to 
overlap the elasticated cuffs of the lab coat and safety goggles were worn at all times 
when working with the drugs.  Tax and 5-FU were stored at room temperature and Dox 
at 4 oC, all in locked compartments. 
 
All sterile disposable plastic-ware was from Sarstedt Ltd., Wexford, Ireland.  Phosphate 
buffered saline (PBS) (Lennox, Cat: BR14) was prepared by dissolving five tablets in 
500 mL ultra-distilled water (dH2O).  This was then autoclaved at 115 oC for 20 min.  
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All water used in cleaning or for maintaining humidity in the incubator was also dH2O 
autoclaved.  PBS and sterile water were both stored at room temperature.  
Trypsin/EDTA solution (T/E) was made up as follows: 50 mL of 10X Trypsin (Sigma, 
Cat: T4549) and 10 mL of 1% w/v EDTA (Cat: E6511) were added to 440 mL PBS.  
This was aliquoted into sterile universal containers and stored at -20 oC.  A stock 
solution of 1% EDTA can be made up in advance and stored at 4 oC. 
 
 
2.2.2 Cell Culture 
2.2.2.1 Media Preparation 
 
Cell culture media was prepared as follows: For MCF-7 and MCF-7/cis, 25 mL (5 % 
v/v) Foetal calf serum (FCS) (Sigma, Cat: F7524); 5 mL (1 unit/ml) 
Penicillin/Streptomycin (Pen/Strep) (Cat: P0781); 5 mL (10 mM) Sodium Pyruvate (Cat: 
S8636) and 0.5 mL (1 mM) HEPES (Cat: H0887) were added to Dulbecco’s Minimum 
Essential Medium (DMEM) (Cat: D5796).  Basal medium for the MDA, Tax10p and 
Tax10p4p cell lines was RPMI-1640 (Cat: R7388) to which supplements 50 mL (10 % 
v/v) FCS, 5 mL Pen/Strep and 5 mL sodium pyruvate were added.  Complete media was 
stored at 4 oC for up to two weeks. 
 
2.2.2.2 Feeding 
 
All cell lines were grown in a ShelLab, IR2424 model CO2 humidified Incubator at 
37oC.  Cell culture work was carried out in a class II laminar airflow cabinet (Gelaire 85, 
BSB4 laminar air-flow cabinet).  Protocol for maintenance of cell lines was adapted 
from O’Shea et al, 1999.  The relevant complete media was incubated at 37 oC for 20 
min in a water-bath prior to use.  Industrial methylated spirits (IMS) (Lennox, Cat: 
                                  
 
44 
 
 
 
 
 
1170) diluted to 70 % with dH2O was used to spray all internal surfaces of the laminar 
prior to use.  All bottles, plastics etc brought into the laminar, as well as gloves were 
also sprayed with IMS.  Waste media was drawn off from the flask with a pipette and 
transferred to a waste bottle.  The flask was then rinsed with PBS (Lennox, Cat: BR14), 
3 mL for T25 flask, 7 mL for T75 flask and again transferred to the waste bottle.  The 
appropriate fresh complete media was then added, 3-5 mL for T25 or 10-15 mL for T75 
flasks.  The flask was then sprayed with IMS and replaced in the incubator.  When 
finished working in the laminar all surfaces were washed down with Virkon solution 
(Lennox, Cat: 222/0154/01).  This was then rinsed using tissue paper damped with 
sterile water.  Once dry all surfaces were then sprayed down with IMS and allowed to 
dry again.  This cleaning operation was also performed between any work involving 
different cell lines. 
 
2.2.2.3 Subculturing 
 
Media and trypsin/EDTA (T/E) solution were incubated at 37 oC for 20 min in a water-
bath.  Waste media was drawn off and the flask rinsed with PBS as per feeding method.  
T/E was then added, 2 mL for T25’s or 4 mL for T75’s and incubated until all the cells 
were detached from the base of the flask (2-5 min).  This solution was then transferred to 
a universal tube.  The flask was then rinsed with PBS, 8 mL for T25’s or 6 mL for T75’s 
and added to the universal.  This cell suspension along with a counter balance of another 
universal containing 10 mL was centrifuged at 1000 rpm for 5 min using a Labofuge 400 
centrifuge, Heraeus Instruments (supplied by Foss Electric, Dublin).  The supernatant 
was removed and the pellet resuspended in 15 mL complete media or appropriate 
amount.  Following a cell count the appropriate amount of this cell suspension or stock 
was then used to re-seed a new flask at the required cell density.   
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2.2.3 Cell Counting and Viability Assays 
2.2.3.1 Cell Counting with Trypan Blue 
 
A cell suspension was made as per Subculturing method i.e. a flask of cells was 
trypsinised, spun and resuspended.  1 mL of this suspension was then transferred to a 
microtube, into which 200 µL trypan blue (Sigma, Cat: T8154) was added.  This was 
then mixed and 10 µL of this mixture was pipetted to the side of the chamber of the 
haemocytometer enclosed by a cover slip and was drawn in by capillary motion.   
 
 
 
 
 
 
 
 
                                                                                                                                                                                           
Figure 2.3.1.1.  Diagram of Haemocytometer with coverslip. 
 
 
Cells were counted from the four large corner quadrants and the centre square as 
observed under the 10X objective.  This total number was divided by 5 to give the 
average cell number per square.  This was multiplied by the dilution factor of 1.2 and 
then by 104, which results in the total cell number per mL.  Viable cells appear clear and 
do not stain, whereas non-viable cells stain blue from the influx of trypan blue across 
breached membranes.  % viability can thus be determined. 
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Figure 2.3.1.2.  Illustration of squares on a haemocytometer, showing one of the corner 
quadrants shaded.  The volume underneath the coverslip of this area (or one square) is 0.1 mm3 
or 10-4 ml. 
 
 
2.2.3.2 MTS Microplate Assay 
 
The MTS microplate assay (CellTiter 96R Aqueous One Solution Cell Proliferation Assay, 
Promega, distributed by Medical Supply Company (MSc), Dublin, Ireland, Cat: G3581) 
is a modification of the original tetrazolium assay, the MTT assay, involving fewer steps 
because the formazan product is soluble in culture medium unlike the product of MTT 
reduction, which is a crystalline precipitate that requires the addition of a solubilisation 
solution and incubation overnight before the spectrophotometric absorbance can be 
measured on a microplate reader.  This method is therefore also safer, eliminating the 
need for handling volatile organic solvents.  The MTS assay is a colourimetric non-
radioactive assay system, which is used widely to quantify cell proliferation and 
viability.  The MTS assay solution contains a tetrazolium compound, 3-(4,5-
diamethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) -2H-tetrazolium, 
inner salt (MTS) and the electron coupling reagent phenazine ethosulfate (PES) 
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(Promega Technical Bulletins; No’s 169 and 245). 
 
 
 
Figure 2.3.2.1.  Conversion and structures of MTS tetrazolium to the formazan product 
(Promega, Technical Bulletin No.245) 
 
 
The assay is based on the cleavage or bio-reduction of the yellow tetrazolium salt (MTS) 
into a soluble form of the purple formazan product by mitochondrial dehydrogenases in 
metabolically active cells.  This bio-reduction involves the pyridine nucleotide co-
factors NADH and NADPH produced by those enzymes.  The absorbance of the 
formazan product read at 490 nm is directly proportional to the number of living cells in 
the well/culture (Promega, Technical Bulletin No.245). 
 
A confluent flask was trypsinised and cell suspension made as per Subculturing method.  
A cell count was performed using trypan blue according to the Cell Counting method 
and stocks were calculated and made up at the required cell density i.e. 5x104 cells/mL 
for 1 and 3 day assay time points and 1x104 cells/mL for 5 and 7 day assays.  Sterile 96-
well microplates were seeded as follows; using a multi-channel micropipette, 100 µL of 
the appropriate cell stock was pipetted into each well.  Wells to be used as blanks were 
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left empty.  Plates were then cultured for 24 h to allow cells to attach to the substratum 
before addition of 100 µL fatty acid treatment/media.  Control and blank wells were 
supplemented with medium containing the vehicle -BSA at the same concentration as 
the maximum in the experimental wells.  All treatments were set up in triplicate.  Plates 
were incubated for the required time period i.e. 1, 3, 5 and 7 days after which 
cytotoxicity was assessed.   
 
20 µL of One Solution Cell Proliferation Assay (Promega, distributed by the Medical 
Supply Company –MSC, Dublin; Cat: G3581) was added to each well and incubated for 
4 h.  Following this the plates were read on a Rosys Anthos 2010 microplate reader 
(Anthos Labtec Instruments, Austria) at 492nm.  Cytotoxicity was expressed as 
percentage inhibition compared to control.  Data was obtained from at least five 
experiments in which treatments and time points were set up in triplicate.  Statistical 
analysis was carried out using the Student’s t-test. 
 
 
2.2.3.3 Acid Phosphatase Assay 
 
A confluent flask was trypsinised and cell suspension made as per Subculturing method.  
A cell count was performed using trypan blue according to the Cell Counting method 
and a stock was made up at a cell density of 1x104 cells/ mL.  Plates were seeded with 
100 µL of cell stock in each well.  These were then cultured for 24 h following which 
100 µL of treatments/media was added to corresponding wells.  Cytotoxicity was 
assessed after 7 days.   
 
All assay reagents were pre-prepared in advance.  PBS was made up as previously listed, 
as was a 1 M NaOH solution and both were stored at room temperature.  Sodium acetate 
buffer was prepared at a concentration of 0.1 M, containing 0.1 % Triton X-100 and 
adjusted to pH 5.5 using glacial Acetic acid.  This was stored at 4 oC in the dark for up 
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to one month.  The p-nitrophenyl phosphate (pNPP) (Sigma-Aldrich, Cat: P5869) was 
added immediately prior to performing the assay to yield a 10 mM solution. 
 
After the required incubation time (7 days) all media was removed from the plates by 
flicking the plates upside-down over a waste container.  They were then rinsed with 100 
µL PBS per well, which was also removed by flicking plates upside-down and 100 µL 
sodium acetate buffer containing the substrate (pNPP) was added.  This was gently 
mixed, then incubated for 2 h.  After this period 50 µL 1M NaOH was added to each 
well.  This causes an electrophilic shift in the pNP chromophore thus producing the 
yellow colour.  NaOH also kills the cells upon addition, therefore stopping the reaction 
and preserving the results. Plates were usually left at least one day at 4 oC before reading 
absorbance; this allows any bubbles that may have formed in the wells through pipetting 
solutions to die down, allowing a more accurate result.  Absorbance was read at 405 nm 
on a Tecan A-5082 Sunrise microplate reader (Tecan, Austria) (O’Connor, 1998; Martin 
and Clynes, 1991).  Statistical analysis was carried out using the Student’s t-test. 
 
   
2.2.4 Cytotoxicity Testing 
2.2.4.1 Fatty Acids (as sodium salts with BSA 2:1 w/w ratio) on MCF-
7 and MCF-7/cis 
 
MCF-7 and MCF-7/cis cells were seeded as listed in Section 2.2.3.2 MTS Microplate 
Assay.  Fatty acid stock solutions were prepared as sodium salts complexed with BSA in 
a 2:1 w/w ratio (equivalent to 473:1 molar ratio) as described above.  After 24 h, 100 µL 
of medium containing fatty acids was added in increments to yield final concentrations 
in the range 2 µg/mL to 20 µg/mL (or 7.1 µM to 71 µM) and a maximum BSA 
concentration of 0.16 µM.  Fatty acids tested at this stage were Linoleic Acid (LA), CLA 
mixture of isomers (CLA-mix) and pure isomers c9,t11- and t10,c12-CLA.  Control and 
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blank wells were supplemented with medium containing BSA at a final concentration of 
0.16 µM as in experimental wells.  All treatments were set up in triplicate.  Plates were 
incubated for the required time period i.e. 1, 3, 5 and 7 days after which cytotoxicity was 
assessed using the MTS assay as listed in Section 2.3.2 MTS Microplate Assay.   
 
 
2.2.4.2 Fatty Acids (with BSA 2:1 molar ratio) on MDA cell lines 
 
MDA-MB-435-S-F (MDA), MDA-MB-435-S-F/ Taxol 10p (Tax10p) and MDA-MB-
435-S-F/ Taxol 10p4p (Tax10p4p) cells were seeded as listed in Section 2.3.3 Acid 
Phosphatase Assay.  Stock solutions of fatty acids were prepared in medium containing 
bovine albumin in a 2:1 molar ratio.  After 24 h 100 µL of medium containing 
treatments was added to corresponding wells in 10 % increments to a maximum 
concentration of 40 µg/mL for CLA mix, c9,t11 and t10,c12-CLA; 50 µg/mL for LA 
and GLA.  10 concentrations of each treatment were examined per plate with 6 
replicates for each concentration and each plate was set up in duplicate.  Cells treated 
with medium containing an equivalent concentration of bovine albumin served as 
controls in this experiment.  Cytotoxicity was assessed after 7 days using the Acid 
Phosphatase Assay listed in section 2.3.3.  Data was obtained from at least three 
experiments.  
 
 
2.2.4.3  Free Fatty Acids on MDA cell lines 
 
MDA, Tax10p and Tax10p4p cells were seeded at a density of 1x104 cells/mL as 
previously listed.  Stock solutions of free fatty acids were prepared in medium without 
BSA and made fresh for each experiment.  As above treatments were added after 24 h in 
10 % increments with maximum final concentrations for CLA mix, c9,t11 and t10,c12-
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CLA at 40 µg/mL and LA and GLA at 50 µg/mL.  10 concentrations of each treatment 
were examined per plate with 8 replicates for each concentration and each plate was set 
up in duplicate.  Cells treated with medium containing an equivalent concentration of 
ethanol served as controls in this experiment.  Cytotoxicity was assessed after 7 days 
using the Acid Phosphatase Assay described above.  Data was obtained from at least 
three experiments.  
 
 
2.2.4.4 Chemotherapy drugs Dox, Tax and 5-FU on MDA cell lines in 
long term exposure assays 
 
MDA, Tax10p and Tax10p4p cells were seeded at a density of 1x104 cells/mL.  Drug 
treatments were made up in basal medium and were prepared fresh for each experiment.  
After 24 h 100 µL of medium containing treatments was added to corresponding wells in 
10 % increments to a maximum concentration of 50 ng/mL, 10 ng/ml and 400 ng/mL for 
Doxorubicin (Dox), Taxotere (Tax) and 5-Fluorouracil (5-FU) respectively.  10 
concentrations of each treatment were examined per plate with 6 replicates for each 
concentration and each plate was set up in duplicate.  Cells treated with basal medium 
served as controls for this experiment.  Cytotoxicity was assessed after 7 days using the 
Acid Phosphatase Assay listed in section 2.3.3.  Data was obtained from at least three 
experiments.  
 
 
2.2.4.5 Chemotherapy Drugs on MDA cell lines in short term 
exposure assay 
 
MDA, Tax10p and Tax10p4p cells were seeded at a density of 1x104 cells/mL as 
previously listed.  Drug Treatments were made up in basal medium and prepared fresh 
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for each experiment.  Treatments were added after 24 h in 10 % increments with 
maximum final concentrations up to 500 ng/mL, 50 ng/mL and 10 µg/mL for Dox, Tax 
and 5-FU respectively.  In this assay, drug treatments were left on for a 4 h exposure 
following which media/treatments were removed.  Plates were then rinsed with PBS and 
200 µL fresh media added to each well for a 7 day recovery period.  10 concentrations of 
each treatment were examined per plate with 8 replicates for each concentration and 
each plate was set up in duplicate.  Cells treated with basal medium were controls for 
this experiment.  Cytotoxicity was assessed after 7 days using the Acid Phosphatase 
Assay listed in section 2.2.3.3 Acid Phosphatase Assay.  Data was obtained from at least 
three experiments.  
 
2.3 Results 
2.3.1 Fatty acid single treatments on MCF-7 and MCF-7/cis cell 
lines 
 
Fatty acids used in the cytotoxicity tests on the MCF-7 and MCF-7/cis cell lines, were 
delivered as sodium salts in BSA in a 2:1 w/w ratio (equivalent to 473:1 molar ratio) and 
incubated for 1, 3, 5 and 7 days after which cytotoxicity was assessed using the MTS 
assay as listed above.  Fatty acids tested at this stage were Linoleic Acid (LA), CLA 
mixture of isomers (CLA-mix) and pure isomers c9,t11- and t10,c12-CLA.  MCF-7 
cisplatin resistant cells (MCF-7/cis) were more sensitive to inhibition by the CLA-mix 
than the MCF-7 parental cell line after the 7 day incubation, illustrated in Figure 2.3.1.1.  
These differences were found to be significant with p<0.05, as determined by the 
Student’s t-test.   IC70 values for MCF-7/cis and MCF-7 were 9.6 + 0.5 and 13.4 + 0.5 
µg/mL, while IC50 values were 6.8 + 0.9 and 10.1 + 1.0 µg/mL.  Linoleic acid (LA) 
treatment caused no significant inhibition relative to control in MCF-7 cells.  However, 
significant inhibition of 41.8 + 10.0 % relative to control was seen at the maximum dose 
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of 20 µg/mL in MCF-7/cis cells (p=0.025) after 7 days (Figure 2.3.1.2).  c9,t11-CLA 
was similarly effective in inhibiting cell growth in both cell lines after a 7 day treatment.  
IC50 values for MCF-7/cis and MCF-7 were 11.1 + 1.3 and 13.5 + 1.7 µg/mL c9,t11-
CLA respectively as seen in Figure 2.3.1.3.  MCF-7/cis cells were more sensitive to 
inhibition by t10,c12-CLA than the MCF-7 parental cell line.  IC50 values for MCF-7/cis 
and MCF-7 were 5.1 + 1.2 and 13.2 + 2.0 µg/mL t10,c12-CLA (Figure 2.3.1.4).   
 
All fatty acids in both cell lines followed a similar pattern of toxicity with a 5 day 
incubation to that seen after 7 days.  In MCF-7 cells, significant inhibition was seen with 
the CLA-mix at as low as 6 µg/mL (p=0.032) and at 16 and 14 µg/mL (p=0.01 and 
0.048) for c9,t11 and t10,c12-CLA respectively.  LA caused no significant inhibition in 
MCF-7 cells for the concentrations used (Figure 2.3.1.5).  In MCF-7/cis cells, growth 
inhibition by t10,c12-CLA was significant for all treatments in the range 0-20 µg/mL 
(p<0.05).  Inhibition by CLA-mix and c9,t11-CLA were found to be significant for 
treatments of and above 4 and 8 µg/mL respectively (p<0.05).  LA showed significant 
inhibition at 18 and 20 µg/mL (p=0.02 and 0.0004), but at a maximum of 40.5 + 3.6 % 
inhibition (Figure 2.3.1.6). 
 
In the MCF-7 parental line, 3 days incubation resulted in significant inhibition for 
c9,t11-CLA at 20 µg/mL and t10,c12-CLA at 16 to 20 µg/mL.  LA and CLA-mix 
caused no significant inhibition after 3 days in range tested (Figure 2.3.1.7).  In the 
MCF-7/cis cell line, incubation of the CLA mixture and both isomers c9,t11 and 
t10,c12-CLA for 3 days resulted in significant inhibition at the highest concentration, 20 
µg/mL only and did not reach 50 % inhibition in any case.  LA did not result in 
significant inhibition at any concentration in MCF-7/cis cells (Figure 2.3.1.8).   
 
Following the 1 day incubation significant inhibition was observed in the MCF-7 
parental line with the CLA mixture and c9,t11-CLA for the 1 day incubation at 18 and 
20 µg/mL, whereas t10,c12-CLA and LA caused no significant inhibition (Figure 
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2.3.1.9).  In the MCF-7/cis cell line no significant inhibition was seen with any fatty acid 
for the 1 day incubation (Figure 2.3.1.10).   
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Figure 2.3.1.1 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells incubated 
with CLA mixture (0-20 µg/mL) for 7 days.  Cytotoxicity was assessed following the 7 
day incubation using the MTS microplate assay as described in Section 2.3.2.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Each concentration was set up with 6 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from at least three experiments in which treatments and 
time points were set up in triplicate.  Error bars represent standard error of the mean.  
Cells without treatment served as controls for this experiment.   
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Figure 2.3.1.2 Effects of LA (0-20 µg/mL) on growth of MCF-7 and MCF-7/cis drug 
resistant cells for 7 days.  Growth was assessed following the 7 day incubation using the 
MTS microplate assay as described in Section 2.3.2 and expressed as a percentage 
relative to control, which was taken to be 0 %.  Data was obtained from five experiments 
in which treatments and time points were set up in triplicate.  Error bars represent 
standard error of the mean.  Cells without treatment served as controls for this 
experiment.   
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Figure 2.3.1.3 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells incubated 
with c9,t11-CLA (0-20 µg/mL) for 7 days.  Cytotoxicity was assessed following the 7 
day incubation using the MTS microplate assay as described in Section 2.3.2.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %. 
Data was obtained from at least three experiments in which treatments and time points 
were set up in triplicate.  Error bars represent standard error of the mean.  Cells without 
treatment served as controls for this experiment.   
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Figure 2.3.1.4 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells incubated 
with t10,c12-CLA (0-20 µg/mL) for 7 days. Cytotoxicity was assessed following the 7 
day incubation using the MTS microplate assay as described in Section 2.3.2.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Cells without treatment served as controls for this experiment.   Data was obtained from 
at least three experiments in which treatments and time points were set up in triplicate.  
Error bars represent standard error of the mean.   
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Figure 2.3.1.5 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells incubated 
with CLA mixture (0-20 µg/mL) for 5 days.  Cytotoxicity was assessed following the 5 
day incubation using the MTS microplate assay as described in Section 2.3.2.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Each concentration was set up with 6 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from at least three experiments in which treatments and 
time points were set up in triplicate.  Cells without treatment served as controls for this 
experiment.  Error bars represent standard error of the mean.   
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Figure 2.3.1.6 Effects of LA (0-20 µg/mL) on growth of MCF-7 and MCF-7/cis drug 
resistant cells for 5 days.  Growth was assessed following the 5 day incubation using the 
MTS microplate assay as described in Section 2.3.2 and expressed as a percentage 
relative to control, which was taken to be 0 %.  Each concentration was set up with 6 
replicates per plate and each plate was set up in duplicate.  Data was obtained from at 
least three experiments in which treatments and time points were set up in triplicate.  
Cells without treatment served as controls for this experiment.  Error bars represent 
standard error of the mean.   
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Figure 2.3.1.7 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells incubated 
with c9,t11-CLA (0-20 µg/mL) for 5 days.  Cytotoxicity was assessed following the 5 
day incubation using the MTS microplate assay as described in Section 2.3.2.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Each concentration was set up with 6 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from at least three experiments in which treatments and 
time points were set up in triplicate.  Cells without treatment served as controls for this 
experiment.  Error bars represent standard error of the mean.   
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Figure 2.3.1.8 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells incubated 
with t10,c12-CLA (0-20 µg/mL) for 5 days.  Cytotoxicity was assessed following the 5 
day incubation using the MTS microplate assay as described in Section 2.3.2.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Each concentration was set up with 6 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from at least three experiments in which treatments and 
time points were set up in triplicate.  Cells without treatment served as controls for this 
experiment.  Error bars represent standard error of the mean.   
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Figure 2.3.1.9 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells incubated 
with CLA-mix (0-20 µg/mL) for 3 days.  Cytotoxicity was assessed following the 3 day 
incubation using the MTS microplate assay as described in Section 2.3.2.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Each concentration was set up with 6 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from at least three experiments in which treatments and 
time points were set up in triplicate.  Cells without treatment served as controls for this 
experiment.  Error bars represent standard error of the mean.   
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Figure 2.3.1.10 Effects of LA (0-20 µg/mL) on growth of MCF-7 and MCF-7/cis drug 
resistant cells for 3 days.  Growth was assessed following the 3 day incubation using the 
MTS microplate assay as described in Section 2.3.2 and expressed as a percentage 
relative to control, which was taken to be 0 %.  Each concentration was set up with 6 
replicates per plate and each plate was set up in duplicate.  Data was obtained from at 
least three experiments in which treatments and time points were set up in triplicate.  
Cells without treatment served as controls for this experiment.  Error bars represent 
standard error of the mean.    
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Figure 2.3.1.11 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells 
incubated with c9,t11-CLA (0-20 µg/mL) for 3 days.  Cytotoxicity was assessed 
following the 3 day incubation using the MTS microplate assay as described in Section 
2.3.2.  Growth inhibition was expressed as a percentage relative to control, which was 
taken to be 0 %.  Each concentration was set up with 6 replicates per plate and each plate 
was set up in duplicate.  Data was obtained from at least three experiments in which 
treatments and time points were set up in triplicate.  Cells without treatment served as 
controls for this experiment.  Error bars represent standard error of the mean.    
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Figure 2.3.1.12 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells 
incubated with t10,c12-CLA (0-20 µg/mL) for 3 days.  Cytotoxicity was assessed 
following the 3 day incubation using the MTS microplate assay as described in Section 
2.3.2.  Growth inhibition was expressed as a percentage relative to control, which was 
taken to be 0 %.  Each concentration was set up with 6 replicates per plate and each plate 
was set up in duplicate.  Data was obtained from at least three experiments in which 
treatments and time points were set up in triplicate.  Cells without treatment served as 
controls for this experiment.  Error bars represent standard error of the mean.    
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Figure 2.3.1.13 Growth inhibition in MCF-7 and MCF-7/cis drug resistant cells 
incubated with CLA-mix (0-20 µg/mL) for 1 day.  Cytotoxicity was assessed following 
the 1 day incubation using the MTS microplate assay as described in Section 2.3.2.  
Growth inhibition was expressed as a percentage relative to control, which was taken to 
be 0 %.  Each concentration was set up with 6 replicates per plate and each plate was set 
up in duplicate.  Data was obtained from at least three experiments in which treatments 
and time points were set up in triplicate.  Cells without treatment served as controls for 
this experiment.  Error bars represent standard error of the mean.    
                                  
 
68 
 
 
 
 
 
 
 
-80
-70
-60
-50
-40
-30
-20
-10
0
10
20
0 5 10 15 20
LA  µg/mL
%
 
 
In
hi
bi
tio
n
MCF-7
MCF-7/cis
 
 
Figure 2.3.1.14 Effects of LA (0-20 µg/mL) on growth of MCF-7 and MCF-7/cis drug 
resistant cells for for 1 day.  Growth was assessed following the 1 day incubation using 
the MTS microplate assay as described in Section 2.3.2 and expressed as a percentage 
relative to control, which was taken to be 0 %.  Each concentration was set up with 6 
replicates per plate and each plate was set up in duplicate.  Data was obtained from at 
least three experiments in which treatments and time points were set up in triplicate.  
Cells without treatment served as controls for this experiment.  Error bars represent 
standard error of the mean.    
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Figure 2.3.1.15 Effects of c9,t11-CLA (0-20 µg/mL) on growth of MCF-7 and MCF-
7/cis drug resistant cells for 1 day.  Growth was assessed following the 1 day incubation 
using the MTS microplate assay as described in Section 2.3.2 and expressed as a 
percentage relative to control, which was taken to be 0 %.  Each concentration was set 
up with 6 replicates per plate and each plate was set up in duplicate.  Data was obtained 
from at least three experiments in which treatments and time points were set up in 
triplicate.  Cells without treatment served as controls for this experiment.  Error bars 
represent standard error of the mean.    
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Figure 2.3.1.16 Effects of t10,c12-CLA (0-20 µg/mL) on growth of MCF-7 and MCF-
7/cis drug resistant cells for 1 day.  Growth was assessed following the 1 day incubation 
using the MTS microplate assay as described in Section 2.3.2 and expressed as a 
percentage relative to control, which was taken to be 0 %.  Each concentration was set 
up with 6 replicates per plate and each plate was set up in duplicate.  Data was obtained 
from at least three experiments in which treatments and time points were set up in 
triplicate.  Cells without treatment served as controls for this experiment.  Error bars 
represent standard error of the mean.    
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2.3.2 Single Treatments of Fatty Acids (with BSA 2:1 molar 
ratio) on MDA, Tax10p and Tax10p4p cell lines 
 
With a view to addressing the synergistic potential of fatty acid treatments with 
chemotherapy drugs, it was decided that it would be more beneficial to use a cellular 
model where the resistance and other qualities of the cell lines in question were better 
characterised to gain a better understanding of the interactions.  For this reason it was 
decided to repeat the single treatments of fatty acids on a new range of cell lines and to 
use the 7 day exposure only.  This proved the most effective time point for delivering 
accurate significant inhibition results.  MDA-MB435S-F (MDA) melanoma cell line and 
its taxol resistant variants MDA-MB435S-F/Taxol 10p (Tax10p) and MDA-MB435S-
F/Taxol 10p4p (Tax10p4p) were developed and kindly donated by Dr. Sharon Glynn 
(NICB, Dublin) (Glynn et al., 2004).   
 
In this experimental design, stock solutions of fatty acids were prepared in RPMI 
medium containing bovine serum albumin (BSA) in a 2:1 molar ratio.  After seeding for 
24 h, MDA, Tax10p and Tax10p4p cells were treated up to a maximum concentration of 
40 µg/mL for CLA-mix, c9,t11 and t10,c12-CLA; 50 µg/mL for LA and GLA; and 50 
ng/mL, for a 7 day exposure.  Cytotoxicity was assessed after 7 days using the Acid 
Phosphatase Assay.  Data was obtained from at least three experiments.  
 
While the Tax10p cell line appears to be more sensitive to inhibition by the CLA 
mixture than the MDA and Tax10p4p lines, this difference was only statistically 
significant with the 36 & 40 µg/mL treatments (p <0.05), illustrated in Figure 2.3.2.1.  
IC50 values for MDA, Tax10p and Tax10p4p were 26.7, 21.2 & 26.2 µg/mL 
respectively.  LA showed no significant inhibition with respect to control in any cell line 
at the concentrations used (0-50 µg/mL), illustrated in Figure 2.3.2.2.  Furthermore, 
significant growth stimulation by LA was found at 5 and 45 µg/mL in the Tax10p4p cell 
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line and at 5 µg/mL in the Tax10p cell line. 
 
Tax10p cells were more sensitive to inhibition by c9,t11-CLA than the MDA and 
Tax10p4p lines, this difference was statistically significant with treatments above 20 
µg/mL (p <0.005) (Figure 2.3.2.3).  IC50 values for MDA, Tax10p and Tax10p4p were 
31, 19.5 & 27 µg/mL respectively.  t10,c12-CLA was equally effective at inhibiting cell 
growth in MDA, Tax10p and Tax10p4p lines at the concentrations used (Figure 2.3.2.4).  
IC50 values for MDA, Tax10p and Tax10p4p were 28.3, 24.5 & 27.5 µg/mL 
respectively.   
 
GLA treatment on the three cell lines (Figure 2.3.2.5) yielded generally lower inhibition 
values than the three CLA preparations even though a higher concentration range was 
used (0-50 µg/mL).  The treatment was most effective on the MDA parental line 
reaching a maximum inhibition of 50.6 % at 50 µg/mL.  Maximum inhibition values on 
Tax10p and Tax10p4p were 25.1 & 40.1 µg/mL respectively.   
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Figure 2.3.2.1 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
CLA-mix in the range 0-40 µg/mL, for 7 days. CLA was prepared in medium containing 
bovine albumin in a 2:1 molar ratio.  Cytotoxicity was assessed following the 7 day 
incubation using the Acid Phosphatase assay as described in Section 2.3.3.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Each concentration was set up with 6 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from three experiments.  Cells without treatment served as 
controls for this experiment.  Error bars depict standard error of the mean. 
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Figure 2.3.2.2 Effects of LA (0-50 µg/mL) on growth of MCF-7 and MCF-7/cis drug 
resistant cells for 7 days.  LA was prepared in medium containing bovine albumin in a 
2:1 molar ratio.  Growth was assessed following the 7 day incubation using the Acid 
Phosphatase assay as described in Section 2.3.3.  Growth inhibition was expressed as a 
percentage relative to control, which was taken to be 0 %.  Each concentration was set 
up with 6 replicates per plate and each plate was set up in duplicate.  Data was obtained 
from three experiments.  Cells without treatment served as controls for this experiment.  
Error bars depict standard error of the mean. 
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Figure 2.3.2.3 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
c9,t11-CLA in the range 0-40 µg/mL, for 7 days.  CLA was prepared in medium 
containing bovine albumin in a 2:1 molar ratio.  Cytotoxicity was assessed following the 
7 day incubation using the Acid Phosphatase assay as described in Section 2.3.3.  
Growth inhibition was expressed as a percentage relative to control, which was taken to 
be 0 %.  Each concentration was set up with 6 replicates per plate and each plate was set 
up in duplicate.  Data was obtained from three experiments.  Cells without treatment 
served as controls for this experiment.  Error bars depict standard error of the mean. 
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Figure 2.3.2.4 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
t10,c12-CLA in the range 0-40 µg/mL, for 7 days.  CLA was prepared in medium 
containing bovine albumin in a 2:1 molar ratio.  Cytotoxicity was assessed following the 
7 day incubation using the Acid Phosphatase assay as described in Section 2.3.3.  
Growth inhibition was expressed as a percentage relative to control, which was taken to 
be 0 %.  Each concentration was set up with 6 replicates per plate and each plate was set 
up in duplicate.  Data was obtained from three experiments.  Cells without treatment 
served as controls for this experiment.  Error bars depict standard error of the mean. 
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Figure 2.3.2.5 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
GLA in the range 0-50 µg/mL, for 7 days.  GLA was prepared in medium containing 
bovine albumin in a 2:1 molar ratio.  Cytotoxicity was assessed following the 7 day 
incubation using the Acid Phosphatase assay as described in Section 2.3.3.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Each concentration was set up with 6 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from three experiments.  Cells without treatment served as 
controls for this experiment.  Error bars depict standard error of the mean. 
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2.3.3  Single Treatments of Free Fatty Acids on MDA, Tax10p 
and Tax10p4p cell lines 
 
One of the problems encountered when using bovine serum albumin (BSA) as the 
vehicle for delivery of fatty acids was that it was observed that BSA introduced 
considerable variation to the system which was made manifest in high standard 
deviations and % co-efficient of variations (% CV).  For this reason it was decided to 
repeat the fatty acid assays using free fatty acids instead of that complexed with BSA. 
 
After seeding for 24 h, MDA, Tax10p and Tax10p4p cells were treated in 10 % 
increments up to a maximum concentration for CLA-mix, c9,t11 and t10,c12-CLA at 40 
µg/mL and LA and GLA at 50 µg/mL, for a 7 day exposure.  Stock solutions of free 
fatty acids were prepared in basal medium without BSA.  Cytotoxicity was assessed 
after 7 days using the Acid Phosphatase Assay.  Data was obtained from at least three 
experiments.  
 
The free fatty acid CLA treatment resulted in a similar pattern of toxicity in each of the 
three cell lines (Figure 2.3.3.1).  Growth was significantly inhibited in each cell line, but 
IC50 values were not statistically different relative to each other as determined by the 
Student’s t-test.  IC50 values for MDA, Tax10p and Tax10p4p were 15.2, 21.7 & 19.7 
µg/mL respectively.  Treatment with LA yielded IC50 values of 44.0 µg/mL for the 
MDA cell line and 44.0 and 46.5 µg/mL for Tax10p and Tax10p4p (Figure 2.3.3.2).   
 
Both c9,t11 and t10,c12-CLA resulted in a similar pattern of toxicity on the three cell 
lines, with both the parental MDA cell line and Tax10p4p being more susceptible to 
inhibition than Tax10p.  IC50 values for c9,t11 and t10,c12-CLA on MDA cells were 
12.8 and 10.0 µg/mL; 23.5 and 17.0 µg/mL on Tax10p; and 10.4 and 4.3 µg/mL on 
Tax10p4p respectively (Figures 2.3.3.3 and 2.3.3.4).  Treatment with GLA on the other 
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hand, resulted in IC50 values of 35, 34.3 and 32 µg/mL for MDA, Tax10p and 
respectively (Figure 2.3.3.5).   
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Figure 2.3.3.1 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
CLA in the range 0-40 µg/mL, for 7 days.  CLA was prepared fresh for each experiment 
in basal medium without BSA.  Cytotoxicity was assessed following the 7 day 
incubation using the Acid Phosphatase assay as described in Section 2.3.3.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Each concentration was set up with 8 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from at least three experiments.  Cells without treatment 
served as controls for this experiment.  All datapoints for the MDA cell line were 
significant (p<0.005) with respect to control and all above 4 and 8 µg/mL were 
significant for Tax10p (p<0.005) and Tax10p4p (p<0.01) respectively, as determined by 
the Student’s t-test.  Error bars depict standard error of the mean. 
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Figure 2.3.3.2. Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
LA in the range 0-50 µg/mL, for 7 days. LA was prepared fresh for each experiment in 
basal medium without BSA.  Cytotoxicity was assessed following the 7 day incubation 
using the Acid Phosphatase assay as described in Section 2.3.3.  Growth inhibition was 
expressed as a percentage relative to control, which was taken to be 0 %.  Each 
concentration was set up with 8 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from three experiments.  Cells without treatment served as 
controls for this experiment.  All datapoints for the MDA cell line above 15 µg/mL were 
significant with respect to control and all above 25 µg/mL were significant for Tax10p 
and Tax10p4p, as determined by the Student’s t-test (p<0.05).  Error bars depict 
standard error of the mean. 
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Figure 2.3.3.3 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
c9, t11-CLA in the range 0-40 µg/mL, for 7 days.  c9,t11-CLA was prepared fresh for 
each experiment in basal medium without BSA.  Cytotoxicity was assessed following 
the 7 day incubation using the Acid Phosphatase assay as described in Section 2.3.3.  
Growth inhibition was expressed as a percentage relative to control, which was taken to 
be 0 %.  Each concentration was set up with 8 replicates per plate and each plate was set 
up in duplicate.  Data was obtained from four experiments for the MDA cell line, three 
in the case of Tax10p and Tax10p4p.  Cells without treatment served as controls for this 
experiment.  All datapoints above 4 µg/mL were significant with respect to control for 
the MDA cell line and Tax10p and all were significant for Tax10p4p cells (p<0.05), as 
determined by the Student’s t-test.  Error bars depict standard error of the mean. 
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Figure 2.3.3.4 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
t10, c12-CLA in the range 0-40 µg/mL, for 7 days.  t10,c12-CLA was prepared fresh for 
each experiment in basal medium without BSA.  Cytotoxicity was assessed following 
the 7 day incubation using the Acid Phosphatase assay as described in Section 2.3.3.  
Growth inhibition was expressed as a percentage relative to control, which was taken to 
be 0 %.  Each concentration was set up with 8 replicates per plate and each plate was set 
up in duplicate.  Data was obtained from three experiments for the MDA cell line and 
two in the case of Tax10p and Tax10p4p.  Cells without treatment served as controls for 
this experiment.  All datapoints were significant with respect to control for the MDA cell 
line (p< 0.001); all except 8 µg/mL for Tax10p (p<0.05) and all above 8 µg/mL for 
Tax10p4p (p<0.005), as determined by the Student’s t-test.  Error bars depict standard 
error of the mean. 
                                  
 
83 
 
 
 
 
 
-50
0
50
100
0 10 20 30 40 50
GLA µg/mL
%
 
G
ro
w
th
 
In
hi
bi
tio
n
MDA  
Tax10p  
Tax10p4p
 
 
Figure 2.3.3.5 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with γ-
Linolenic Acid (GLA) in the range 0-40 µg/mL, for 7 days.  GLA was prepared fresh for 
each experiment in basal medium without BSA.  Cytotoxicity was assessed following 
the 7 day incubation using the Acid Phosphatase assay as described in Section 2.3.3.  
Growth inhibition was expressed as a percentage relative to control, which was taken to 
be 0 %.  Each concentration was set up with 8 replicates per plate and each plate was set 
up in duplicate.  Data was obtained from three experiments for the MDA cell line and 
two in the case of Tax10p and Tax10p4p.  Cells without treatment served as controls for 
this experiment.  All datapoints were significant with respect to control for the MDA cell 
line (p< 0.001) and all above 5 µg/mL and 10 µg/mL for Tax10p (p<0.01) and Tax10p4p 
(p<0.05) respectively, as determined by the Student’s t-test.  Error bars depict standard 
error of the mean. 
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2.3.4 Single Treatments of Chemotherapy Drugs on MDA, 
Tax10p and Tax10p4p cell lines in long term exposure assays 
 
After seeding for 24 h, MDA, Tax10p and Tax10p4p cells were treated in 10 % 
increments up to a maximum concentration of 50 ng/mL, 10 ng/ml and 400 ng/mL for 
doxorubicin (Dox), taxotere (Tax) and 5-fluorouracil (5-FU) respectively for a 7 day 
exposure.  Stock solutions of drug treatments were prepared in basal medium.  
Cytotoxicity was assessed after 7 days using the Acid Phosphatase Assay.  Data was 
obtained from at least three experiments.  
 
Doxorubicin was equally effective at inhibiting growth in the parental MDA and Tax10p 
and Tax10p4p lines (Figure 2.3.4.1).  IC50 values for MDA, Tax10p and Tax10p4p were 
12.3, 12.4 & 12.7 ng/mL respectively.  All points above 5 ng/mL were significant with 
p<0.005.  Taxotere was also found to be similarly effective at inhibiting growth in the 
MDA, Tax10p and Tax10p4p lines.  IC50 values for MDA, Tax10p and Tax10p4p were 
0.65, 0.64 & 0.94 ng/mL respectively (Figure 2.3.4.2).  All points were significant with 
p<0.005.  Response to 5-Fluorouracil treatment followed a similar pattern in all three 
cell lines.  IC50 values for MDA, Tax10p and Tax10p4p were 109.9, 119.3 and 117 
ng/mL respectively (Figure 2.3.4.3).  All points were significant with p<0.05.   
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Figure 2.3.4.1 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
Doxorubicin (Dox) in the range 0-50 ng/mL, for 7 days.  Dox was prepared fresh for 
each experiment in basal medium.  Cytotoxicity was assessed following the 7 day 
incubation using the Acid Phosphatase assay as described in Section 2.3.3.  Growth 
inhibition was expressed as a percentage relative to control, which was taken to be 0 %.  
Each concentration was set up with 6 replicates per plate and each plate was set up in 
duplicate.  Data was obtained from three experiments.  Cells without treatment served as 
controls for this experiment.  Error bars depict standard error of the mean. 
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Figure 2.3.4.2 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
Tax in the range 0-10 ng/mL, for 7 days.  Tax was prepared fresh for each experiment in 
basal medium.  Cytotoxicity was assessed following the 7 day incubation using the Acid 
Phosphatase assay as described in Section 2.3.3.  Growth inhibition was expressed as a 
percentage relative to control, which was taken to be 0 %.  Each concentration was set 
up with 6 replicates per plate and each plate was set up in duplicate.  Data was obtained 
from three experiments.  Cells without treatment served as controls for this experiment.  
Error bars depict standard error of the mean. 
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Figure 2.3.4.3 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 5-
FU in the range 0-400 ng/mL, for 7 days.  5-FU was prepared fresh for each experiment 
in basal medium.  Cytotoxicity was assessed following the 7 day incubation using the 
Acid Phosphatase assay as described in Section 2.3.3.  Growth inhibition was expressed 
as a percentage relative to control, which was taken to be 0 %.  Each concentration was 
set up with 6 replicates per plate and each plate was set up in duplicate.  Data was 
obtained from three experiments.  Cells without treatment served as controls for this 
experiment.  Error bars depict standard error of the mean. 
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2.3.5 Single Treatments of Chemotherapy Drugs on MDA, 
Tax10p and Tax10p4p cell lines in short term exposure assays 
 
In the previous section, no significant difference was observed in the sensitivity of the 
three cell lines to taxotere (Tax), doxorubicin (Dox) and 5-fluorouracil (5-FU) –
suggesting that resistance of the Tax10p and Tax10p4p lines to the drugs would be 
better observed in short term assays.  To this end it was decided to run the drug assays as 
4 h exposure, 7 day recovery in place of long term (7 day) exposure –with a view to 
mimicking the clinical situation more closely (Glynn et al, 2004).   
 
After seeding for 24 h, MDA, Tax10p and Tax10p4p cells were treated in 10 % 
increments up to a maximum concentration for 500 ng/mL, 50 ng/mL and 10 µg/mL for 
Dox, Tax and 5-FU respectively for 4 h exposure followed by a 7 day recovery period.  
Stock solutions of drug treatments were prepared in basal medium.  Cytotoxicity was 
assessed after 7 days using the Acid Phosphatase Assay.   Data was obtained from at 
least three experiments.  
 
Doxorubicin treatment for the 4 h exposure, 7 day recovery resulted in IC50 values of 
228, 274 and 334 ng/mL for the MDA, Tax10p and Tax10p4p cell lines respectively.  
All Dox treatments above 50 ng/mL were significant relative to control with p<0.0001 
for the MDA cell line and p<0.05 for Tax10p4p and Tax10p as determined by the 
Student’s t-test (Figure 2.3.5.1).  Treatment with Taxotere showed that the parental 
MDA was more susceptible to drug cytotoxicity than the Tax10p and Tax10p4p cell 
lines with IC50 values of 13.0, 40.0 and 50.5 ng/mL respectively.  All concentrations of 
Tax resulted in significant inhibition for the MDA cell line, whereas all above 5 and 25 
ng/mL were significant for Tax10p and Tax10p4p cells respectively (p<0.05) (Figure 
2.3.5.2).  Finally, with 5-Fluorouracil exposure there was a similar order of susceptibility 
with IC50 values on MDA, Tax10p and Tax10p4p being 6, 9.75 and 9.9 µg/mL 
respectively.  All concentrations above 1 µg/mL 5-FU yielded significant inhibition 
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relative to control for the MDA cell line, whereas 4 and 7-10 µg/mL 5-FU resulted in 
significant inhibition for Tax10p and all above 3 µg/mL were significant for Tax10p4p 
cells, with p<0.05 (Figure 2.3.5.3). 
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Figure 2.3.5.1 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 
Doxorubicin (Dox) in the range 0-500 ng/mL for 4 h followed by a 7 day recovery.  Dox 
was prepared fresh for each experiment in basal medium.  Cytotoxicity was assessed 
following the 7 day incubation using the Acid Phosphatase assay as described in Section 
2.3.3.  Growth inhibition was expressed as a percentage relative to control, which was 
taken to be 0 %.   Each concentration was set up with 8 replicates per plate and each 
plate was set up in duplicate.  Data was obtained from three experiments.  Cells without 
treatment served as controls for this experiment.  Error bars depict standard error of the 
mean. 
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Figure 2.3.5.2 Growth inhibition for MDA, Tax10p and Tax10p4p cells incubated with 
Taxotere (Tax) in the range 0-50 ng/mL for 4 h followed by a 7 day recovery.  Tax was 
prepared fresh for each experiment in basal medium.  Cytotoxicity was assessed 
following the 7 day incubation using the Acid Phosphatase assay as described in Section 
2.3.3.  Growth inhibition was expressed as a percentage relative to control, which was 
taken to be 0 %.   Each concentration was set up with 8 replicates per plate and each 
plate was set up in duplicate.  Data was obtained from three experiments.  Cells without 
treatment served as controls for this experiment.  Error bars depict standard error of the 
mean. 
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Figure 2.3.5.3 Growth inhibition in MDA, Tax10p and Tax10p4p cells incubated with 5-
Fluorouracil (5-FU) in the range 0-10 µg/mL for 4 h, followed by a 7 day recovery.  5-
FU was prepared fresh for each experiment in basal medium.  Cytotoxicity was assessed 
following the 7 day incubation using the Acid Phosphatase assay as described in Section 
2.3.3.  Growth inhibition was expressed as a percentage relative to control, which was 
taken to be 0 %.   Each concentration was set up with 8 replicates per plate and each 
plate was set up in duplicate.  Data was obtained from three experiments.  Cells without 
treatment served as controls for this experiment.  Error bars depict standard error of the 
mean. 
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2.4 Discussion 
 
In the first set of single treatments, MCF-7 and MCF-7/cis cells were treated with fatty 
acids (conjugated linoleic acid mixture (CLA-mix), LA, c9,t11 and t10,c12-CLA) 
delivered as sodium salts in medium containing BSA in a 2:1 w/w ratio (473:1 molar 
ratio).  Cytotoxic effects of CLA-mix, c9,t11 and t10,c12-CLA were time and dose-
dependent in both MCF-7 and MCF-7/cis cell lines.  Cytotoxicity of CLA was found to 
be dependent on isomer composition, concentration and duration of exposure.  This is in 
agreement with findings by O’Shea et al. (2000) that the cytotoxic effects of CLA were 
concentration dependant in the MCF-7 cell line.  However little is known about the 
action of CLA on a drug-resistant cell line.  Here we found MCF-7 cisplatin resistant 
cells were more sensitive to inhibition by t10,c12-CLA and the CLA mixture than 
parental MCF-7 cells.  Linoleic acid (LA) displayed a much lower cytotoxicity profile 
than the three CLA preparations as expected, with negligible effects on growth 
following exposure of both cell lines to linoleic acid at concentrations less than 18 
µg/mL.   
 
With a view to moving on to investigate the synergistic potential of fatty acid treatments 
with chemotherapy drugs, it was decided that it would be more beneficial to use a model 
where the resistance and other qualities of the cell lines in question were better 
characterised to gain a better understanding of the interactions.  MDA-MB435S-F 
(MDA) human melanoma cell line and taxol resistant variants MDA-MB435S-F/Taxol 
10p (Tax10p) and MDA-MB435S-F/Taxol 10p4p (Tax10p4p) were developed and 
kindly donated by Dr. Sharon Glynn (NICB, Dublin) (Glynn et al, 2004).  The single 
treatments of fatty acids were tested on the new range of cell lines in the 7 day exposure 
only.  This proved the most effective time point for delivering accurate significant 
inhibition results.   
 
In this experimental design, stock solutions of fatty acids were prepared in RPMI 
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medium containing BSA in a 2:1 molar ratio.  Of the fatty acid treatments, CLA-mix and 
t10,c12-CLA were similarly effective at inhibiting growth in all three cell lines.  c9,t11-
CLA however, at the higher concentrations (36 & 40 µg/mL) appeared to be more 
effective at inhibiting cell growth in Tax10p cells than in the MDA or Tax10p4p cell 
lines.  LA showed no significant inhibition in any cell line at the concentrations used (0-
50 µg/mL).  GLA on the other hand, while the resulting inhibition was significant 
relative to control, the inhibition observed was much lower than that of all three CLA 
preparations.   
 
It was also decided to repeat the fatty acid assays using free fatty acids instead of that 
complexed with bovine serum albumin (BSA).  One of the problems encountered when 
using BSA as the vehicle for delivery was that it introduced considerable variation to the 
system which was made manifest in high standard deviations and % co-efficient of 
variations (% CV).  Fatty acids were made up as free fatty acid solutions in basal RPMI 
medium, fresh for each experiment.  Delivery of the fatty acids as free fatty acid 
solutions eliminated one source of variation in the experiments, resulting in statistically 
significant inhibition at lower concentrations –including with LA, which was showing 
negligible effects complexed with BSA.  The IC50 values of all fatty acid treatments 
were reduced compared to the treatments containing BSA in a 2:1 molar ratio, 
suggesting that BSA conferred a protective effect on the cells.  The MDA cell line 
appeared to be more susceptible to inhibition by the three CLA preparations (CLA-mix, 
c9,t11 and t10,c12-CLA) than Tax10p4p, which was in turn more susceptible than, 
Tax10p although these differences were not statistically significant. 
 
The chemotherapeutic agents doxorubicin (Dox), taxotere (Tax) and 5-fluorouracil (5-
FU) were also tested on MDA, Tax10p and Tax10p4p cells in a 7 day exposure.  Drug 
treatments were made up in medium and were prepared fresh for each experiment.  
Cytotoxicity was assessed after a 7 day incubation.  No significant difference was 
observed in the sensitivity of the three cell lines to Tax, Dox or 5-FU –suggesting that 
resistance of the Tax10p and Tax10p4p lines to Tax and other drugs would be better 
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observed in short term assays.  To this end it was decided to run the drug assays as 4 h 
exposure, 7 day recovery in place of long term (7 day) exposure –also with a view to 
mimicking the clinical situation more closely (Glynn et al, 2004).  Drug treatments were 
again prepared fresh for each experiment in basal medium.    
 
With Dox, Tax and 5-FU, the change in design from treatments for a 7 day exposure to 
the 4 h exposure, 7 day recovery resulted in a dramatic increase in IC50 values as 
expected.  Differences emerged between the cell lines in terms of drug sensitivities.  
When comparing IC50 values, Tax10p and Tax10p4p cells were 1.6 and 1.7 fold more 
resistant to 5-FU treatment than MDA cells respectively.  Similarly, Tax10p and 
Tax10p4p were 1.2 and 1.5 fold more resistant to Dox treatment and 3.1 and 3.9 fold 
more resistant to Tax treatment than the MDA cell line.  Not surprisingly, of the two cell 
lines that had previously been taxol pulsed; Tax10p4p, which had four extra rounds of 
pulses of Tax, displayed higher resistance to each of the three drugs than Tax10p.  This 
finding supports data from the original characterisation of these cell lines (Glynn et al, 
2004).  IC50 values obtained in this section will be used in the design of an experiment 
using sub-optimal concentrations of both fatty acids and drugs to investigate synergistic 
interactions in melanoma cells. 
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Chapter 3 
 
Enhancement of Doxorubicin Cytotoxicity by 
Conjugated Linoleic Acid (CLA) in a cellular model of 
Drug-Resistant Cancer 
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3.0 Abstract 
 
The effects of two isomers of conjugated linoleic acid (CLA) and a mixture of isomers 
on doxorubicin (Dox) cytotoxicity and intracellular drug accumulation were evaluated in 
a human melanoma cell line MDA-MB435S-F (MDA) and a Dox resistant variant 
MDA-MB435S-F/A10p10p (A10p10p).  CLA enhanced cytotoxicity of Dox in a dose 
dependant manner in MDA cells and enhanced the toxicity with greater effect in the 
resistant A10p10p cells.  The c9,t11-CLA isomer significantly increased uptake of Dox 
(p<0.05) in both MDA and A10p10p cell lines.  CLA mixture of isomers also resulted in 
significantly greater retention of Dox in A10p10p cells (p<0.05) after 3 h of efflux, 
while c9,t11-CLA again significantly increased Dox retention in both cell lines after 3 h 
(p<0.05).  These data demonstrate the potential of CLA for further use in modulating 
tumour drug-sensitivity in pre-clinical trials. 
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3.1 Introduction  
 
Multidrug resistant (MDR) cancer cells accumulate chemotherapeutic drugs to a lesser 
degree than sensitive cells.  It is believed that ability to keep intracellular drug levels 
below a cell killing threshold is principally the result of pumping out of cytotoxic drugs 
by transport proteins resident in the lipid bilayer of cells.  Targeting multidrug resistance 
(by co-administering pump inhibitors, pump bypass agents or membrane active agents) 
has been a goal of cancer biologists during the past 35 years.  However recent studies 
(reviewed in Hendrich and Michalak 2003) have shown that acquisition of the MDR 
phenotype in general is accompanied by up-regulation of specific membrane lipids 
notably glucosylceramide, cholesterol and phospholipids containing saturated fatty 
acids.  The development of doxorubicin resistance in breast and colon cancer cells has 
been associated with decreased fluidity of lipid bilayers and increased degree of fatty 
acid saturation of cholesteryl esters (Santini et al, 2001).  These lipids constitute liquid-
ordered membrane micro-domains which house members of the ABC (ATP binding 
cassette) transporter superfamily (Pgp, MRP1) responsible for drug efflux.   
 
Considering the importance of lipid phase in modulating membrane structure and 
function in tumour cells, it is not surprising that many studies have been carried out to 
elucidate the role of polyunsaturated fatty acids in modulating tumour drug sensitivity.  
Several in vitro studies and limited in vivo investigations have shown that select 
polyunsaturated fatty acids enhance the cytotoxicity of several anticancer agents.  
Gamma linolenic acid was shown to synergistically enhance the cytotoxicity of 
lipophilic taxane drugs against human breast cancer cells (Menendez et al., 2001, 2002, 
2004).  Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were found to 
enhance taxol and taxotere efficacy in various breast cancer cell lines including MDA-
MB-231 (Germain et al., 1998; Menendez et al., 2002 & 2005), T47D and SK-Br3 
(Menendez et al., 2002 & 2005).  DHA has also been reported to reverse taxane (taxol 
and taxotere) resistance in BT-474 taxane resistant breast cancer cell lines (Menendez et 
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al., 2005).  Supplementation of diet with fish oil containing EPA and DHA potentiated 
efficacy of doxorubicin against lung and breast cancer xenografts (Hardman et al., 1999, 
2000, 2001).  A pro-drug formed by covalent linkage of DHA with paclitaxel 
(Taxoprexin; Protarga, Inc), improved safety and efficacy of paclitaxel in a Phase 1 
study (Wolff et al., 2003).    
 
All of the fatty acids that enhance sensitivity of drug-resistant human tumour cell lines 
cited above contain double bonds in the cis configuration.  Current evidence suggests 
that susceptibility of PUFA’s to oxidation and generation of cytotoxic hydroperoxides in 
drug resistant cancer cells may reverse the antioxidant tone that characterises drug 
resistant cells in which glutathione and antioxidant enzyme activities are elevated to 
protect the cell against drug-induced free radical aggression (Mahéo et al., 2005).   
 
Interestingly a wealth of literature now exists to support a role for conjugated isomers of 
these fatty acids also being metabolised and active in cancer cell models (Cesano et al., 
1996; Ha et al., 1987 & 1990; Hubbard et al., 2000, 2003, 2006; Ip et al., 1999; Liew et 
al., 1995; Miglietta et al., 2006; Tsujita-Kyutoku et al., 2004; Tsuzuki et al., 2004; 
Visonneau et al., 1998)   Conjugated linoleic acid (CLA) refers to a group of positional 
and geometric isomers of octadecadienoic acids (C18:2) with two conjugated double 
bonds.  The double bonds of CLA can be located at the 9,11 or 10,12 positions of C18:2 
and in cis and/or trans spatial configurations (Lin et al., 1995).  CLA has been shown to 
be an anticancer agent in a number of rodent and human tumour model systems, 
including carcinogen-induced and transplantable mammary tumour models.  Several 
isomers of CLA (c9t11-, t10c12- and t9t11-CLA) both in pure form and as a mixture 
have been shown to be cytotoxic at micromolar concentrations for a variety of breast, 
colon, prostate and skin tumour cell lines (Belury, 2002a).  c9t11- and t10c12-CLA have 
been shown to alter a wide array of targets involved in regulation of cell proliferation, 
apoptosis, angiogenesis, tumour invasion and differentiation (proteins of BCL-2 family, 
cyclins and cyclin dependent kinase inhibitors, protein-kinases and phosphatases 
(Miglietta et al., 2006), COX-2 (Nugent et al., 2005), 5-LOX (Ochoa et al., 2004), 
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VEGF and matrix-metalloproteinases (Wang et al., 2005; Hubbard et al., 2007) and 
alkaline phosphatase (Lampen et al., 2005)).  In addition they have been shown to act as 
transcription regulators, being able to modulate the activity of different transcription 
factors, including NFkB (Goua et al., 2008); peroxisome proliferator-activated receptors 
(Belury et al., 2007), retinoid X receptors (Lee et al., 2008/9) and SREBP (Ecker et al., 
2007; Purushotham et al., 2008).  Enzymes regulating lipid metabolism, such as fatty 
acid synthase and stearoyl-CoA desaturase (SCD), are further molecular targets critical 
in the growth and survival of cancer cells which have been modulated by CLA (Choi et 
al., 2000, 2002; Ntambi et al., 2004).   
 
Previous work in this lab showed a concentration dependent cytotoxic effect of CLA in 
human breast cancer (MCF-7) and colon cell lines (SW480, HT29) which was 
associated with peroxidative damage (O’Shea et al., 2000), alterations in antioxidant 
enzymes (O’Shea et al., 1999), rapid cellular uptake and modulation of membrane 
phospholipid composition (Miller et al., 2001; 2003) and induction of apoptosis (Miller 
et al., 2002).  The discovery by Fite et al. (2007) that CLA isomers (40 µM) can 
significantly potentiate the cytotoxicity of docetaxel in breast cancer cells is of 
considerable importance as it was the first study to show the potential role of CLA to 
improve chemotherapy effects when drug treatments are accompanied by CLA isomers.  
The effective cytotoxic concentration of docetaxel was reduced by up to 70 % when the 
t10,c12-CLA isomer was present and by 59 % when a 50:50 isomer mix of t10,c12-CLA 
and c9,t11-CLA was present.  CLA’s similarity to docetaxel in terms of modulating 
similar key oncogenes involved in the apoptotic pathway suggests CLA may be a new 
adjuvant agent for chemotherapy.  The effect of CLA on the process of intracellular drug 
accumulation (uptake, retention, distribution and efflux) in breast cancer cells remains to 
be determined. 
 
The cytotoxic activity of a CLA mixture of isomers (CLA-mix) and two single isomers, 
c9t11 and t10c12-CLA (all present at 1 and 6 µg/ml equivalent to 3.6 and 21.4 µM) in 
combination with doxorubicin (37.5-115 ng/mL or 65-200 nM), in the MDA-MB-435S-
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F human melanoma cell line and a doxorubicin-pulsed variant was assessed.  Net 
uptake/accumulation of Dox in cells following 2 h treatment and retention after 3 h of 
efflux were determined by liquid chromatography tandem mass spectrometry (LC-MS) 
methods.  The study provided evidence that the co-administration of CLA at as low a 
concentration as 21.4 µM and doxorubicin (65 nM) can result in better chemosensitivity 
and enhanced drug retention in resistant cells than higher concentrations of drug alone 
and may represent novel approach for improving therapeutic management of cancer. 
 
 
3.1.1 Specific Objectives 
 
 To evaluate the potential of co-treatment with a commercial mixture of CLA 
isomers (CLA-mix) and two single isomers c9,t11-CLA and t10,c12-CLA to 
enhance the cytotoxic effects of Doxorubicin (Dox) on a drug naive MDA-
MB435-S-F (MDA) human melanoma cell line and a multidrug resistant variant 
MDA-MB435-S-F/Adr10p10p (A10p10p) 
 
 To determine the effect of CLA-mix, c9,t11 and t10,c12-CLA on net 
uptake/accumulation of Dox in cells and retention after efflux by liquid 
chromatography tandem mass spectrometry (LC-MS) methods 
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3.2 Materials and Methods 
3.2.1 Materials 
 
Cell culture media, supplements and related products were purchased from Sigma-
Aldrich, Dublin, Ireland, unless otherwise stated.  MDA-MB-435S-F (MDA) human 
melanoma cell line and its doxorubicin resistant variant MDA-MB-435S-F/Adr10p10p 
(A10p10p) were developed and donated by Dr. Sharon Glynn (NICB, Dublin).  
Chemotherapy agents, doxorubicin (Dox) and daunorubicin were kindly gifted by Dr. 
Robert O’Connor (NICB, Dublin) (sourced originally from Farmitalia Carlo Erba 
(Milton Keynes, UK)).  All solvents used were of LC-MS grade and purchased from 
Sigma-Aldrich, Dublin, Ireland.   
 
Conjugated Linoleic Acid (CLA-mix) mixture of isomers (99 % pure, approximately 
comprising: 44 % trans 10, cis 12 (t10c12)-CLA; 41 % cis 9, trans 11 (c9t11)/ trans 9, 
cis 11 (t9c11)-CLA; 10 % cis 10, cis 12 and minor amounts of trans 9, trans 11; trans 
10, trans 12; cis 9, cis 11-CLA) (Cat: UC-59A) and single preparations of isomers 
c9t11-CLA and t10c12-CLA (90 % pure, Cat: UC-60A, UC-61A) were from NuChek-
Prep, Elysian, MN, USA.   Eicosapentaenoic acid (EPA) and Docosahexaenoic acid 
(DHA) were purchased from Sigma-Aldrich, Dublin (purity: 99 and 98 %, Cat: E2011 
and D2534 respectively).  All fatty acid preparations were dissolved in sterile filtered 
ethanol and stored at -20 oC.   
 
 
3.2.2 Cytotoxicity assays  
 
Cells were grown and maintained in RPMI-1640 culture medium, supplemented with 10 
% (v/v) foetal calf serum, penicillin/streptomycin (1 unit/mL) and 10 mM sodium 
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pyruvate.  96-well plates were seeded at a cell density of 1x104 cells/mL in each well.  
These were then cultured for 24 h following which 100 µL of treatments/serum-free 
media was added to corresponding wells.  Fatty acids (FA) examined were CLA mixture 
of isomers (CLA-mix), purified isomers c9t11-CLA and t10c12-CLA and omega-3 fatty 
acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  Three 
concentrations of Dox (37.5, 57.5 and 115 ng/mL, equivalent to 65, 100 and 200 nM) 
and two concentrations of CLA (1 and 6 µg/mL or 3.6 and 21.4 µM) were examined per 
plate with 8 replicates for each treatment combination and each plate was set up in 
duplicate.  The concentrations of EPA and DHA used in this study were 1 & 6 µg/mL 
(corresponding to 3.3 and 19.8 µM EPA and 3 and 18.2 µM DHA).  Each experiment 
was divided into three treatment regimes: Dox and fatty acid (FA) for 4 h exposure, 
followed by a 7 day recovery [4 h], Dox and FA for 4 h, followed by 7 day FA exposure 
[7 day] and finally cells treated as in the 7 day group but pre-treated with FA for 24 h 
[pre-treat].  Cytotoxicity was assessed after 7 days using the acid phosphatase assay 
[25].  Data was obtained from at least three experiments and expressed as mean + 
standard error from the mean.  
 
 
3.2.3 Cellular Doxorubicin Content: Sample Preparation 
 
The flasks were seeded at 6x105 cells/flask with or without FA pre-treatment, and then 
cultured for 24 h to allow cells to attach to the substratum.  Following this, flasks were 
treated in triplicate with combinations of Dox (2 µM) and fatty acid (6 µg/mL) for 2 h 
and divided into two groups for influx and retention measurements.  To measure the 
influx of Dox into cells, treatment/media was removed after the 2 h incubation and 
centrifuged at 1000 g for 5 min using a Labofuge 400 centrifuge, Heraeus Instruments 
(supplied by Foss Electric, Dublin) to collect the floating dead cells.  The flasks were 
then rinsed with basal media and the attached live cells were harvested, combined with 
floating cells, counted and spun to form a pellet for later extraction.  To measure 
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retention after efflux the second group of flasks were rinsed with basal media following 
the 2 h treatment and incubated with fatty acid/control media for a further 3 h after 
which flasks were harvested, counted and pelleted as above.  Cells treated with Dox and 
ethanol (at the same concentration as in the fatty acid stock) and Dox alone were used as 
controls for this experiment. 
 
 
3.2.4 Cellular Doxorubicin Content: Extraction and Analysis 
 
Pellets were extracted and analysed by LC-MS according to Wall et al., 2007.  Briefly, 
pellets were re-suspended in 200 µL ultrapure water, transferred to labelled plastic 
extraction tubes (Sarstedt, Cat: 60.551) making sure that all cells were removed and 20 
µL of 33 % (w/v) silver nitrate added.  A range of doxorubicin standards were prepared 
in microtubes at 10X concentrations of 50, 100, 500, 1000, 5000 ng/mL.  100 µL of each 
standard was added in duplicate to extraction tubes containing the untreated cells.  
Control (cells, no treatment) and blank (cells, no treatment, no IS) samples were also 
prepared in extraction tubes containing untreated cell pellets.  Following this 100 µL 
internal standard daunorubicin (excluding blank), 700 µL ice cold isopropanol and 100 
µL 1 M ammonium formate buffer were added and mixed.  After careful addition of 
1400 µL chloroform, tubes were mixed by inverting for 5 min and centrifuged at 4000 
rpm for 5 min in a Heraeus Labofuge 400 (Foss Electric, Dublin).  The bottom layer 
containing the drug was removed (1.1 mL) using a glass Pasteur pipette (Lennox, 
Dublin, Cat: APP490.33) and placed in an autosampler vial (AGB, Dublin, Cat: 
11090417).  The samples were then dried in a vacuum rotary evaporator at -80 0C.   
 
Samples were reconstituted in 50 µL of LC mobile phase and 20 µL was injected 
automatically using the instrument autosampler.  The LC-MS system used was a GE 
Healthcare (Amersham Biosciences) EttanTM Multi-dimensional liquid chromatographic 
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system (MDLC) interfaced to Thermo FinniganTM PDA detector and LTQTM mass 
spectrometer.  The chromatographic separation was performed on a PhenomenexR  
Prodigy ODS(3) 100 Ǻ, 5 µm, 150 mm x 2.1 mm column with a mobile phase of water, 
acetonitrile and formic acid in the ratio 72:28:0.1 (v/v/v), delivered isocratically at a 
flow-rate of 200 µL/min.  The monitoring wavelength was 254 nm and mass spectral 
data were collected in the scan range 200-700 m/z.  Selected reaction monitoring (SRM) 
mode was used for quantitation using the transition ion: m/z 544-397 for the [M + H+] 
doxorubicin adduct and 528-363 for the [M + H+] daunorubicin adduct. 
 
3.2.5 Statistical analysis 
 
Differences between means were analysed for significance using the Student’s two-
tailed, paired t-test, unless otherwise stated.   
 
 
3.3. Results   
3.3.1 Cytotoxicity Assays: Single Treatments 
 
Tables 3.3.1- 3.3.3 summarise data obtained from the [4 h], [7 day] and [pre-treat] 
treatment regimes respectively.  Each table presents percentage growth inhibition of five 
fatty acids (CLA-mix, c9t11 and t10c12-CLA, EPA and DHA) alone and in combination 
with Dox in the MDA parental cell line and the drug resistant variant, A10p10p.  In the 
[4 h] treatment regime (Table 3.3.1), CLA-mix, t10c12-CLA and DHA at 1 µg/mL 
significantly inhibited growth (p < 0.05) of the MDA cell line by 16.8 + 3.2, 12.6 + 1.5 
and 20.5 + 3.3 % respectively.  In A10p10p cells, only c9t11-CLA at 1 µg/mL caused 
significant inhibition (17.0 + 2.7 %).  At 6 µg/mL however, the CLA mixture, c9t11- & 
t10c12-CLA and EPA significantly inhibited growth (p < 0.05) of the MDA cell line by 
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23.1 + 3.2, 12.3 + 3.0, 25.1 + 7.7 and 25.6 + 2.3 % respectively.  In A10p10p cells, only 
c9t11-CLA at 6 µg/mL caused significant inhibition (26.5 + 5.6 %).   
 
In the [7 day] treatment regime (Table 3.3.2), t10c12-CLA and DHA at 1 µg/mL 
significantly inhibited growth (p < 0.05) of the MDA cell line.  Growth inhibition was 
13.4 + 2.9 and 34.0 + 5.9 % relative to ethanol control.  Only the CLA-mix at 1 µg/mL 
resulted in significant inhibition of 26.8 + 6.4 % in the A10p10p cell line.  At 6 µg/mL 
however, c9t11- and t10c12-CLA and DHA yielded significant inhibition alone in MDA 
cells.  Percentage growth inhibition relative to control for c9t11- and t10c12-CLA and 
DHA was 18.1 + 5.6 %, 25.8 + 4.4 % and 38.9 + 6.9 % respectively.  Again, the CLA 
mixture, at 6 µg/mL was the only fatty acid to cause significant inhibition of 34.6 + 5.1 
% (p < 0.05) in A10p10p cells.  Treatment for 7 days with either of the two single 
isomers of CLA, EPA or DHA had no significant effect on growth in the resistant cell 
line.  
 
As in the 7 day treatment regime t10c12-CLA (1 µg/mL) significantly inhibited growth 
(p < 0.05) of the MDA cell line in the [pre-treat] group with 9.9 + 0.4 % inhibition 
(Table 3.3.3).  None of the fatty acid treatments at 1 µg/mL inhibited growth in 
A10p10p cells.  At 6 µg/mL, only the CLA mixture (21.7 + 3.6 %) yielded significant 
inhibition (p < 0.05) in MDA cells.  In A10p10p cells, only inhibition by EPA and DHA 
at 6 µg/ml reached statistical significance (p < 0.05).  Percentage growth inhibition 
relative to control for EPA and DHA was 72.7 + 10.4 % and 79.4 + 7.7 % respectively.   
 
The effects of Dox on growth of MDA and A10p10p cells are also listed in Tables 3.3.1- 
3.3.3.  There was no difference in exposure time of Dox across the three treatment 
regimes.  Growth inhibition by Dox alone is shown to be dose dependent across the 
three concentrations (65, 100 and 200 nM) used.  As expected, there was higher growth 
inhibition at each drug concentration across all treatments regimes in the parental MDA 
cell line than in the A10p10p cells.  % inhibition was 7.6 + 1.1, 18.6 + 1.1 and 40.9 + 0.9 
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% for 65, 100 and 200 nM Dox respectively in the MDA cell line.  Corresponding 
values for 65, 100 and 200 nM Dox in A10p10p were 4.1 + 1.8, 12.5 + 1.7 and 28.9 + 
1.2 % respectively, thus confirming doxorubicin resistance in the A10p10p cell line 
(Glynn et al., 2004). 
 
In summary, the effects of the CLA mixture, c9t11-CLA, t10c12-CLA, EPA and DHA 
on cell growth were dose dependent in both cell lines.  The effects of the CLA mixture, 
t10c12-CLA, EPA and DHA were time dependent only in the A10p10p cell line.  
Growth inhibition by Dox was also dose dependant in both cell lines. 
 
 
3.3.2 Cytotoxicity Assays: Combination Treatments during [4 h] 
regime 
CLA at 1 µg/mL enhanced by a factor of 2.3 the toxicity of Dox (65 nM) in the [4 h] 
regime in MDA cells, from 9.2 + 3.4 to 21.3 + 4.8 % inhibition (Table 3.3.1).  At higher 
drug concentrations CLA at 1 µg/mL had no significant effect on Dox toxicity.  The 
CLA mixture (1 µg/mL) had negligible effect on Dox toxicity in the A10p10p cell line.  
At the higher concentration (6 µg/mL), CLA mixture enhanced by factors of 2.8 and 1.4 
the toxicity of Dox at 65 and 100 nM in the MDA cell line but had no effect at the 
higher drug concentration of 200 nM.  Interestingly, while the CLA mixture apparently 
enhanced the toxicity of Dox from -9.6 + 1.5 to 23.9 + 14.6 %, 5.8 + 7.0 to 32.3 + 17.1 
% and 23.0 + 9.4 to 41.1 + 15.5 % at 65, 100 and 200 nM respectively in A10p10p cell 
line, the differences did not reach statistical significance according to the Student’s t-
test.   
 
Treatment with the c9t11-CLA isomer (1 µg/mL) for 4 h enhanced Dox toxicity in MDA 
cells by factors of 1.3 and 1.2 at 100 and 200 nM respectively.  Similarly, 1 µg/mL 
c9t11-CLA increased the toxicity of Dox by a factor of 1.6 at 100 nM in A10p10p cells.  
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At the higher concentration (6 µg/mL) the c9t11-CLA isomer had no effect on Dox 
toxicity in MDA cells but did enhance (p < 0.05) toxicity of Dox at 100 nM in A10p10p 
cells.  Inhibition of growth in the resistant cell line increased from 21.1 + 7.2 % in the 
presence of drug alone to 40.0 + 11.6 % (sensitivity factor of 1.9) in the presence of 
drug/fatty acid combination (Table 3.3.1).   
 
Treatment with the t10c12-CLA isomer at 1 µg/mL did not significantly affect Dox 
toxicity in MDA cells.  Treatment with t10c12-CLA at 6 µg/mL significantly enhanced 
the toxicity of 65, 100 and 200 nM Dox by factors of 2.4, 1.8 and 1.4 respectively.  In 
A10p10p cells, t10c12-CLA at 1 µg/mL enhanced toxicity of Dox at 65 nM by a factor 
of 2.6.  6 µg/mL t10c12-CLA did not significantly affect Dox toxicity at any 
concentration in this cell line. 
 
Treatment with EPA at 1 µg/mL for 4 h significantly enhanced toxicity of Dox at 200 
nM by a factor of 1.1 in MDA cells.  6 µg/mL EPA did not significantly affect Dox 
toxicity at any concentration in this cell line.  In A10p10p cells, neither 1 nor 6 µg/mL 
EPA caused significant enhancement of Dox toxicity at any concentration.  DHA at 1 or 
6 µg/mL did not significantly enhance Dox toxicity at any concentration in either MDA 
or A10p10p cells.   
 
 
3.3.3 Cytotoxicity Assays: Combination Treatments [7 day] 
regime 
Increasing the duration of treatment with CLA mixture of isomers (6 µg/mL) from 4 h to 
7 days significantly enhanced the toxicity of Dox at 100 nM in MDA cells by a factor of 
2.2 (Table 3.3.2).  However CLA-mix at 1 µg/mL did not yield a significant increase in 
Dox toxicity in the MDA cell line.  In A10p10p cells, 1 µg/mL CLA-mix did yield 
significant increased Dox toxicity at 65, 100 and 200 nM by factors of 2.5, 1.9 and 1.5 
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respectively.  At 6 µg/mL CLA-mix significantly enhanced the toxicity of Dox at 100 
and 200 nM by factors of 3.1 and 2.2 respectively.   
 
Interestingly, a concentration as low as 1 µg/mL c9t11-CLA caused significant 
enhancement of toxicity of Dox at 65, 100 and 200 nM in the MDA cell line in the [7 
day] regime, by factors of 2.1, 1.7 and 1.3 respectively.  At 6 µg/mL, c9t11-CLA 
resulted in significant enhancement of toxicity of Dox at all three concentrations, by 
factors of 2.5, 1.8 and 1.4 respectively.  In A10p10p cells, only 6 µg/mL c9t11-CLA 
significantly enhanced the toxicity of Dox at 200 nM by a factor of 2.2.   
 
Combination of t10c12-CLA at 6 µg/mL significantly enhanced (p<0.05) toxicity of 
Dox at 100 nM by a factor of 1.5 in the MDA cell line.  No other combination of t10c12-
CLA with drug significantly enhanced Dox toxicity in MDA cells.  In A10p10p cells, 1 
µg/mL t10c12-CLA resulted in significant enhancement of toxicity of Dox at 65 and 200 
nM, from -1.5 + 12.3 to 20.6 + 6.5 % and 23.6 + 16.6 to 45.4 + 19.1 % inhibition 
respectively.  6 µg/mL t10c12-CLA resulted in significant enhancement of toxicity of 
Dox at all three concentrations, by factors of 2.5, 1.8 and 1.4 respectively.   
 
EPA at 1 µg/mL significantly enhanced (p<0.05) toxicity of 65 and 200 nM Dox in 
MDA cells (by factors of 3.3 and 1.1) and that of 100 and 200 nM Dox at 6 µg/mL EPA 
(by factors of 2.2 and 1.5).  In A10p10p cells, treatments of 1 µg/mL EPA did not yield 
a significant increase in Dox toxicity at any concentration of Dox.  6 µg/mL EPA 
significantly enhanced (p<0.05) the toxicity of Dox at concentrations of 65, 100 and 200 
nM (by factors of 10.7, 7.4 and 2.2 respectively).   
 
Combination of 1 µg/mL DHA significantly enhanced (p<0.05) Dox toxicity at 100 and 
200 nM Dox in the MDA cell line (by factors of 1.6 and 1.2 respectively), while 6 
µg/mL DHA significantly enhanced Dox toxicity at all three concentrations of Dox (by 
factors of 5.4, 2.0 and 1.3 respectively).  However, in A10p10p cells, neither 1 nor 6 
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µg/mL DHA significantly enhanced toxicity of Dox at any concentration of Dox. 
 
 
3.3.4 Cytotoxicity Assays: Combination Treatments [pre-treat] 
regime 
Pre-treatment of cells with the mixture of CLA isomers (CLA-mix) at 1 µg/mL for 24 h 
prior to 4 h drug treatment and recovery in the presence of CLA-mix for 7 days did not 
significantly affect the toxicity of Dox in MDA cells (Table 3.3.3).  At 6 µg/mL 
however, the CLA-mix significantly enhanced Dox toxicity at 65 and 100 nM Dox (by 
factors of 4.6 and 1.9 respectively).  In the A10p10p cell line, 1 µg/mL CLA-mix 
yielded significant increased Dox toxicity at all three Dox concentrations (by factors of 
2.8, 2.0 and 1.7), while 6 µg/mL CLA-mix yielded significant increased Dox toxicity at 
100 and 200 nM Dox (by factors of 2.8 and 2.1 respectively). 
 
c9t11-CLA at 1 µg/mL did not significantly affect the toxicity of Dox in MDA or 
A10p10p cells.  6 µg/mL c9t11-CLA significantly enhanced (p<0.05) Dox toxicity of 
200 nM in MDA cells by a factor of 1.3, while the same combination in A10p10p 
significantly enhanced (p<0.05) Dox toxicity by a factor of 2.6.  Similarly, t10c12-CLA 
at 1 µg/mL did not significantly affect the toxicity of Dox in MDA or A10p10p cells.  6 
µg/mL t10c12-CLA significantly enhanced (p<0.05) toxicity of Dox at 65 and 200 nM 
in MDA cells only, by factors of 3.3 and 1.5 respectively. 
 
EPA at 1 µg/mL did not significantly affect the toxicity of Dox in MDA or A10p10p 
cells.  6 µg/mL EPA significantly enhanced (p<0.05) toxicity of 100 and 200 nM Dox in 
MDA cells (by factors of 6.8 and 1.7) and that of all Dox concentrations in A10p10p 
cells (by factors of 10.2, 5.3 and 2.9).  DHA treatments did not significantly affect the 
toxicity of Dox in MDA cells.  In A10p10p cells, 1 µg/mL DHA significantly enhanced 
(p<0.05) toxicity of Dox at 65 nM in A10p10p cells (by a factor of 5.6), while 6 µg/mL 
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DHA significantly enhanced (p<0.05) toxicity of Dox at all concentrations (by factors of 
9.0, 5.6 and 2.6).   
 
In summary, it was apparent that across all three treatment regimes that the CLA mixture 
of isomers and the two single pure isomers were as potent as EPA and DHA in 
enhancing sensitivity of both cell lines to Dox. 
 
 
 Table 3.3.1 Relative growth inhibition values following exposure to Dox with various fatty acids in the [4 h] treatment regime on the MDA and A10p10p 
melanoma cell lines. 
 
CLA-mix 
 
c9,t11-CLA 
 
t10,c12-CLA 
 
EPA 
 
DHA 
 
FA 
µg/ml 
 
Dox 
nM 
 
MDA 
 
A10p10p 
 
MDA 
 
A10p10p 
 
MDA 
 
A10p10p 
 
MDA 
 
A10p10p 
 
MDA 
 
A10p10p 
0 
1 
6 
 
0 
0 
0 
 
 
0.0 
16.8 (3.2)* 
23.1 (3.2)* 
 
0.0 
3.3 (5.8) 
19.0 (12.5) 
 
0.0 
6.8 (4.7) 
12.3 (3.0)* 
 
0.0 
17.0 (2.7)* 
26.5 (5.6)* 
 
0.0 
12.6 (1.5) * 
25.1 (7.7) * 
 
0.0 
23.1 (9.3) 
34.5 (15.3) 
 
0.0 
10.7 (7.9) 
25.6 (2.3)* 
 
0.0 
10.1 (6.0) 
17.3 (7.5) 
 
0.0 
20.5 (3.3)* 
25.7 (12.7) 
 
0.0 
8.9 (9.5) 
20.3 (19.6) 
 
0 
1 
6 
 
65 
65 
65 
 
 
9.2 (3.4) 
21.3 (4.8)+ 
25.9 (3.7)+ 
 
-9.6 (1.5) 
9.8 (10.8) 
23.9 (14.6)  
 
7.6 (5.3) 
16.1 (0.5) 
19.1 (3.6) 
 
7.2  (4.1) 
21.1 (5.6)  
33.2 (14.1) 
 
7.1 (5.0) 
16.9 (6.0)  
16.9 (4.1) + 
 
7.9 (13.1) 
20.2 (14.6) + 
33.4 (21.5)  
 
6.2 (6.7) 
11.2 (2.9) 
21.5 (5.0) 
 
-3.9 (5.4) 
10.3 (11.3) 
21.8 (21.6) 
 
3.0 (6.9) 
10.0 (6.8) 
13.0 (4.7) 
 
4.7 (7.3) 
17.6 (19.4) 
39.7 (19.7) 
 
0 
1 
6 
 
100 
100 
100 
 
 
22.6 (5.4) 
26.2 (4.1) 
30.6 (4.6)+ 
 
5.8 (7.0) 
18.0 (9.1) 
32.3 (17.1)  
 
21.3 (3.4) 
27.5 (2.6)+ 
25.8 (1.9) 
 
21.1 (7.2) 
33.0 (7.5) + 
40.0 (11.6)+ 
 
15.9 (1.9) 
25.4 (4.4) 
28.1 (3.2) + 
 
20.7 (16.8) 
31.0 (20.2) 
41.7 (22.8)  
 
17.9 (2.5) 
15.3 (1.9) 
29.3 (6.5) 
 
4.7 (9.3) 
23.9 (14.2) 
32.1 (19.7) 
 
13.9 (10.3) 
18.2 (10.8)  
21.8 (6.4) 
 
10.7 (10.3) 
30.3 (15.9) 
43.5 (19.9) 
 
0 
1 
6 
 
200 
200 
200 
 
41.7 (8.6) 
47.9 (7.2) 
48.7 (4.7) 
 
23.0 (9.4) 
32.1 (7.9) 
41.1 (15.5)  
 
43.4 (8.8) 
50.6 (7.7)+ 
48.2 (8.5) 
 
36.4 (9.0) 
45.8 (8.5) 
51.0 (13.7) 
 
34.7 (5.9) 
46.3 (8.7) 
49.3 (6.6) + 
 
31.7 (16.4) 
42.8 (20.6) 
45.7 (25.2) 
 
36.2 (7.5) 
41.9 (8.0)+ 
50.4 (4.6)+ 
 
22.0 (8.7) 
34.5 (13.9) 
38.8 (18.4) 
 
39.4 (20.8) 
43.9 (21.7) 
43.3 (15.7) 
 
28.7 (10.1) 
43.6 (16.9) 
47.3 (22.2) 
 
       Growth inhibition expressed as a percentage relative to control, which was taken to be 0 %.  Data was obtained from at least three experiments (Standard Error of 
Mean).   
       * denotes significant inhibition by fatty acids relative to control with p < 0.05   
           +
 denotes significant inhibition by fatty acid-drug combination relative to corresponding treatment of Dox alone with p < 0.05 
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Table 3.3.2 Relative growth inhibition values following exposure to Dox with various fatty acids in the [7 d] treatment regime on the MDA and 
A10p10p melanoma cell lines. 
 
CLA-mix 
 
c9,t11-CLA 
 
t10,c12-CLA 
 
EPA 
 
DHA 
 
FA 
µg/ml 
 
Dox 
ng/ml MDA A10p10p MDA A10p10p MDA A10p10p MDA A10p10p MDA A10p10p 
0 
1 
6 
 
0 
0 
0 
 
 
0.0 
13.4 (6.9) 
13.6 (4.8) 
 
0.0 
26.8 (6.4)* 
34.6 (5.1)* 
 
0.0 
10.0  (4.6) 
18.1 (5.6)* 
 
0.0 
11.0 (5.6) 
37.2 (13.2) 
 
0.0 
13.4 (2.9)* 
25.8 (4.4)* 
 
0.0 
25.8 (9.4) 
41.2 (11.4) 
 
0.0 
17.5 (10.1) 
46.1 (16.8) 
 
0.0 
25.3 (17.7) 
44.3 (18.1) 
 
0.0 
34.0 (5.9)* 
38.9 (6.9)* 
 
0.0 
23.9 (23.3) 
56.3 (20.7)* 
 
0 
1 
6 
 
65 
65 
65 
 
 
13.1 (5.4) 
26.4 (2.7) 
28.4 (4.8) 
 
9.3 (1.7) 
23.1 (3.6)+ 
47.1 (14.1) 
 
14.1 (7.5) 
30.0  (6.6)+ 
34.8  (2.9)+  
 
-6.6 (4.2) 
15.7 (13.1) 
41.7 (21.8) 
 
7.9 (2.1) 
20.6 (6.5) 
30.0 (6.3) 
 
-1.5 (12.3) 
20.6 (16.1)+ 
43.6 (19.2)+ 
 
6.3 (2.8) 
20.5 (4.5)+ 
42.0 (12.2) 
 
5.4 (9.0) 
31.0 (16.8) 
57.8 (16.3)+ 
 
5.1 (2.0) 
19.6 (4.5) 
27.4 (3.9)+ 
 
3.4 (4.1) 
31.4 (16.3) 
55.0 (19.7) 
 
0 
1 
6 
 
100 
100 
100 
 
 
19.0 (3.7) 
28.0 (4.6) 
41.8 (4.0)+ 
 
17.0 (6.5) 
32.9 (6.5)+ 
53.4 (14.1)+ 
 
19.4  (8.1) 
32.1  (8.9)+ 
35.8  (7.6)+ 
 
4.6 (5.3) 
19.4 (12.8) 
42.5 (23.2) 
 
18.9 (3.5) 
28.9 (2.9)+ 
38.2 (5.8) 
 
8.9 (12.5) 
30.0 (19.2) 
48.4 (20.5) + 
 
24.1 (6.2) 
29.6 (7.3) 
52.5 (13.5)+ 
 
8.3 (9.3) 
32.4 (14.4) 
61.7 (14.6)+ 
 
19.5 (4.5) 
31.9 (2.7)+ 
39.7 (1.2)+ 
 
10.1 (10.7) 
39.1 (16.8) 
58.0 (21.1) 
 
0 
1 
6 
 
200 
200 
200 
 
43.2 (8.8) 
51.9 (8.8) 
57.6 (7.1)  
 
30.5 (7.7) 
46.3 (8.4)+ 
66.8 (13.0)+ 
 
37.1  (10.2) 
50.0  (10.1)+ 
51.8  (9.6)+ 
 
27.3 (11.6) 
38.5 (14.2) 
59.5 (17.0)+ 
 
34.6 (9.2) 
44.8 (5.9) 
55.4 (4.9) 
 
23.6 (16.6) 
45.4 (19.1)+ 
57.2 (20.1)+ 
 
44.2 (10.9) 
50.1 (10.4)+ 
64.4 (11.8)+ 
 
30.4 (7.8) 
48.0 (14.0) 
67.7 (14.2)+ 
 
44.8 (8.6) 
54.7 (7.1)+ 
59.7 (5.0)+ 
 
28.1 (6.6) 
47.9 (17.9) 
61.1 (21.4) 
 
          Growth inhibition expressed as a percentage relative to control, which was taken to be 0 %.  Data was obtained from at least three experiments (Standard Error of 
Mean).   
          * denotes significant inhibition by fatty acids relative to control with p < 0.05   
           +
 denotes significant inhibition by fatty acid-drug combination relative to corresponding treatment of Dox alone with p < 0.05 
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Table 3.3.3 Relative growth inhibition values following exposure to Dox with various fatty acids in the [pre-treat] treatment regime on the MDA 
and A10p10p melanoma cell lines. 
 
CLA-mix 
 
c9,t11-CLA 
 
t10,c12-CLA 
 
EPA 
 
               DHA 
 
FA 
µg/ml 
 
Dox 
ng/ml 
 
MDA 
 
A10p10p 
 
MDA 
 
A10p10p 
 
MDA 
 
A10p10p 
 
MDA 
 
A10p10p 
 
MDA 
 
A10p10p 
0 
1 
6 
 
0 
0 
0 
 
 
0.0 
18.8 (6.7) 
21.7 (3.6)* 
 
0.0 
28.5 (7.9) 
49.4 (17.0) 
 
0.0 
8.1 (7.8) 
16.8 (7.2) 
 
0.0 
-23.6 (35.6) 
16.3 (24.6) 
 
0.0 
9.9 (0.4)* 
23.3 (2.7) 
 
0.0 
25.0 (14.4) 
47.0 (12.3) 
 
0.0 
7.9 (8.5) 
44.5 (20.1) 
 
0.0 
44.6 (16.4) 
72.7 (10.4)* 
 
0.0 
7.1 (5.1) 
24.9 (9.4) 
 
0.0 
38.7 (14.9) 
79.4 (7.7)* 
 
0 
1 
6 
 
65 
65 
65 
 
 
8.3 (5.2) 
19.5 (7.4) 
38.2 (6.2)+ 
 
16.6 (6.1) 
45.7 (10.4)+ 
64.7 (12.2) 
 
12.0 (5.2) 
15.7 (7.5) 
27.2 (7.2)+ 
 
8.4 (2.9) 
33.7 (11.1) 
46.4 (27.2) 
 
12.7 (1.0) 
9.9 (11.5) 
42.3 (3.8)+ 
 
4.5 (5.9) 
43.2 (13.5) 
56.6 (13.7) 
 
0.2 (3.8) 
11.6 (5.4) 
49.8 (17.0) 
 
6.7 (2.4) 
57.8 (20.3) 
68.5 (13.6) + 
 
-0.5 (6.4) 
-5.8 (13.7) 
0.3 (20.8) 
 
8.8 (7.3) 
49.1 (12.8)+ 
79.6 (8.8)+ 
 
0 
1 
6 
 
100 
100 
100 
 
 
23.3 (4.4) 
32.3 (5.6) 
43.6 (3.5)+ 
 
25.7 (8.4) 
51.8 (10.4)+ 
71.4 (10.9)+ 
 
18.0 (5.4) 
20.4 (6.7) 
31.2 (6.8)+ 
 
7.5 (5.3) 
38.7 (9.8) 
53.5 (24.3) 
 
15.9 (9.8) 
14.0 (6.0) 
36.6 (7.1) 
 
14.9 (5.0) 
52.0 (14.9) 
64.3 (13.8) 
 
8.6 (3.2) 
14.3 (5.5) 
58.6 (17.0)+ 
 
13.7 (3.3) 
63.9 (17.5) 
72.1 (12.5)+ 
 
9.8 (5.0) 
1.4 (13.6) 
21.9 (14.0) 
 
14.1 (4.0) 
55.1 (13.3) 
81.1 (8.7)+ 
 
0 
1 
6 
 
200 
200 
200 
 
42.5 (8.1) 
46.3 (6.1) 
63.2 (7.5) 
 
38.7 (6.5) 
65.8 (3.7) 
81.1 (6.9) 
 
44.0 (5.8) 
46.9 (7.9) 
55.3 (9.0)+ 
 
28.0 (11.6) 
54.8 (9.0) 
73.9 (13.7)+ 
 
38.2 (9.9) 
40.8 (8.5) 
55.5 (10.2)+ 
 
28.3 (5.3) 
62.6 (8.3) 
77.0 (7.3) 
 
37.0 (7.5) 
41.1 (10.5) 
61.9 (14.0)+ 
 
26.3 (7.1) 
73.5 (13.5) 
77.3 (10.2)+ 
 
35.9 (11.4) 
42.5 (7.3) 
47.2 (6.1) 
 
31.0 (2.6) 
62.2 (9.8) 
81.9 (7.9)+ 
 
         Growth inhibition expressed as a percentage relative to control, which was taken to be 0 %.  Data was obtained from at least three experiments (Standard Error of 
Mean).   
         * denotes significant inhibition by fatty acids relative to control with p < 0.05   
           +
 denotes significant inhibition by fatty acid-drug combination relative to corresponding treatment of Dox alone with p < 0.05 
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3.3.5 Calculation of Intracellular Dox levels 
 
LC-MS detection results in chromatogram peaks, the area of which are given in peak 
area counts and are proportional to the amount of Dox/daunorubicin in the sample.  
Standard solutions of doxorubicin (Dox) in the range 0-500 ng were run with each 
set of samples extracted.  The peak area ratio (PAR) was calculated by dividing the 
peak area of a given concentration of Dox by the corresponding IS peak area in the 
same sample.  The PAR calculation is used to correct for any variation that may 
occur as a result of the extraction process.  Graphs were plotted of Dox concentration 
over PAR in the MDA and A10p10p cell lines, illustrated in Figure 3.3.5.1.  This 
reverse plot for each extraction was used to generate the equation of the line.  The 
equation is used in Excel to calculate from the PAR data the mass in nanograms (ng) 
of Dox in each experimental sample.  From these values percentage Dox per million 
cells relative to control, which was taken to be 100 %, was calculated. 
 
 
3.3.6 Analysis of Intracellular Drug levels 
 
Figure 3.3.6.1 represents the proportion of intracellular Dox concentrations 
remaining in MDA and A10p10p cells after pulsing with drug (2 µM Dox) in the 
absence and presence of CLA preparations (6 µg/mL) for 2 h and after a 3 h recovery 
from drug treatment.   It is apparent that irrespective of fatty acid treatments, the 
A10p10p variant exhibited an increase in Dox efflux compared with the parental cell 
line.  % cellular Dox in control MDA cells was reduced from 100 + 1.1 % Dox at 0 h 
to 77.5 + 34.7 % at 3 h and from 100 + 0.5 % at 0 h to 44.8 + 19.4 % in A10p10p 
cells at 3 h.   
 
When drug was combined with c9t11-CLA, there was a significant increase (p < 
0.001) in Dox accumulation in MDA cells relative to Dox alone at time 0 h and 
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retention after 3 h in presence of the fatty acid (Figure 3.3.6.1 a).  Both the CLA 
mixture of isomers and t10c12-CLA also increased Dox accumulation in MDA cells 
but this did not reach statistical significance (p = 0.260 and 0.088 respectively).  
 
c9t11-CLA also significantly increased (p < 0.05) % cellular drug level (178.1 + 16.7 
% relative to control) in resistant A10p10p cells at time 0 h (Figure 3.3.6.1 b).  
Following 3 h recovery in the presence of c9t11-CLA, % Dox was retained at a 
higher level (69.7 + 20.5 %) relative to control (44.8 + 19.4 %) (p = 0.008).  The 
CLA mixture significantly increased Dox retention to 58.0 + 21.9 % (p = 0.04) after 
3 h relative to control.  Both the CLA mixture of isomers and t10c12-CLA also 
increased Dox accumulation at time 0 h in A10p10p cells from 100.31 + 0.5 to 144.5 
+ 32.7 and 177.4 + 28.4 % respectively, but this did not reach statistical significance 
(p = 0.305 and 0.110 respectively).  The t10c12-CLA isomer also increased drug 
retention in A10p10 cells from 44.8 + 19.4 to 91.3 + 35.9 %, but again did not reach 
statistical significance (p = 0.148). 
 
In summary, untreated MDA cells retain more Dox after 3 h efflux following drug 
treatment than A10p10p cells.  When drug was combined with c9t11-CLA there was 
a significant increase in cellular Dox accumulation at 0 h and retention after 3 h in 
both MDA and A10p10p cell lines.  Also, the CLA mixture significantly increased 
the intracellular Dox retention after 3 h in A10p10p cells. 
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b) 
Figure 3.3.5.1.  Standard curves of Dox over peak area ratio (PAR) in the MDA (a) 
and A10p10p (b) cell lines.  PAR was calculated by dividing the peak area of a given 
concentration of Dox by the corresponding internal standard (IS) peak area in the 
same sample. 
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b)  
Figure 3.3.6.1.  Effect of fatty acid preparations on doxorubicin influx and retention 
after efflux in a) MDA and b) A10p10p melanoma cells.  Following 24 h fatty acid 
pre-treatment, cells were treated in triplicate with combinations of Dox (2 µM) and 
fatty acid (6 µg/mL) for 2 h.  Half were harvested (0 h) and half were washed and re-
incubated with fatty acid/control media for a further 3 h.  Data represent the mean + 
SEM of three experiments. * denotes significance relative to control with p < 0.05. 
                                  
 118 
3.4 Discussion  
 
Drug resistance and toxicity are significant factors that limit the effectiveness of 
current chemotherapeutic drugs.  Despite a significant risk of cardiotoxicity (Olson 
and Mushlin, 1990; Singal et al., 1997) and multiple side effects including cachexia, 
nausea, vomiting, thinning and ulceration of mucous membranes, bone suppression 
and alopecia (Abraham et al., 1996),  doxorubicin (or Adriamycin), a member of the 
anthracycline drug family of antibiotics, is a chemotherapeutic agent that has been 
used extensively, either as a single agent or in combinations with other drugs for 
decades in the treatment of various types of cancer including breast cancer  (Smith et 
al., 2000; Serin, et al., 2005; Sparreboom et al., 2005; Wright et al., 2005).  Several 
mechanisms have been proposed to explain the antitumor property of doxorubicin 
which include intercalation into DNA and inhibition of topoisomerase II (Liu, 1989; 
D’Arpa and Liu, 1989), lipid peroxidation and bioreductive activation leading to the 
formation of drug and oxygen free radicals and alkylating species (reviewed in 
Quiles et al., 2002).  Pre-clinical nutritional intervention studies with DHA (Ohira et 
al., 1996) have provided valuable new insights into how to address the problem of 
attenuating side effects while enhancing tumour drug responses and reversing 
inherent or acquired multiple drug resistance.   
 
Emerging mechanisms of action of bioactive CLA isomers in cancer cells (affecting 
cell proliferation, apoptosis, angiogenesis, tumour invasion and differentiation 
(Miglietta et al., 2006; Nugent et al., 2005; Ochoa et al., 2004; Wang et al., 2005; 
Hubbard et al., 2007; Lampen et al., 2005)) provided the impetus in this study to 
investigate the potential of CLA to predispose resistant cancer cells to increased drug 
sensitivity.  Apart from work published by Fite et al. (2007) this is the only other 
study showing CLA to augment the response of human cancer cell lines to 
chemotherapy drugs and the only to report CLA reversing drug resistance in a drug-
resistant cancer cell line. 
 
In this report we provide evidence that the three preparations of CLA used (CLA 
mixture of isomers and purified isomers c9t11- and t10c12-CLA) were similarly 
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effective to two omega-3 polyunsaturated fatty acids EPA and DHA at enhancing the 
cytotoxicity of doxorubicin in MDA-MB435S-F (MDA) melanoma cells.  Data show 
that CLA enhanced cytotoxicity of Dox on the MDA cell line in a dose dependant 
manner in each of the three treatment groups with significant enhancement (p<0.05) 
seen with as low as 1 µg/mL of each of the fatty acids in combination with Dox.  The 
most effective regime over all was found to be pre-exposure to fatty acid followed by 
concurrent treatment with Dox and a 7 day fatty acid exposure in the [pre-treat] 
group.  All fatty acids enhanced the efficacy of Dox in the Dox resistant cell line 
MDA-MB435S-F/Adr10p10p (A10p10p) to a greater extent than the corresponding 
treatments in the MDA cell line.  Further, all five fatty acids in combination with 
Dox rendered the A10p10p cells more sensitive to the drug than the parental drug 
sensitive MDA cells with higher levels of percentage inhibition for corresponding 
combination treatments.  The fatty acids are therefore in effect reversing the Dox-
resistance in the A10p10p cells.   The c9t11-CLA isomer was found to enhance the 
uptake of Dox into the cells in both cell lines possibly by increasing the fluidity of 
the membrane allowing more passive diffusion and/or flip flop of the drug across the 
membrane (Hendrich and Michalak 2003).  Also, the mixture of CLA isomers (CLA-
mix) enhanced drug retention after treatment in the A10p10p line, while the c9t11-
CLA isomer enhanced retention in both cell lines. 
 
The mechanism of action of CLA may relate to an altered rate of cellular lipid 
synthesis. Previous work in the lab has shown that CLA isomers and its precursor t-
VA are rapidly taken up into cancer cells (O’Shea et al., 2000; Miller et al., 2003b,).  
Agatha et al. (2004) reported that CLA modulated membrane FA composition and 
PUFA metabolism (FA desaturation and elongation), in four cultured human 
leukemia cell lines representing a profile of possible variations of leukemic tumor 
differentiation.  The increased membrane unsaturation index as a result of CLA 
incorporation would likely provide more abundant targets for reactive oxygen 
species (ROS) generated by Dox metabolism.  Products of lipid peroxidation such as 
hydroperoxides, hydroxynonenal, malondialdehyde and other aldehydes modulate 
signalling cascades involved in cell replication and cell death and thus may account 
for increased drug efficacy.   
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The ability to enhance chemosensitivity of drug resistant tumour cells by 
administering CLA prior to or simultaneously with chemotherapeutics is of potential 
benefit for treatment of cancer.  Although multiple sources of CLA exist (O’Shea et 
al., 1998); a mixture of the c9t11 and t10c12-CLA isomers is widely available as 
dietary supplement in health food shops.  The c9t11 isomer of CLA is the major form 
of naturally occurring CLA and is found in milk fat, cheese and ruminant meats.  
c9t11 isomer of CLA is also synthesised endogenously in humans after 
supplementation with its precursor vaccenic acid through the stearoyl CoA 
desaturase (SCD)/Delta 9 desaturase pathway (Miller et al., 2003b).  Blood levels of 
CLA isomers are reported to be in range 20-70 µM, of which c9t11-CLA and 
t10c12-CLA make up approximately 80 % and 10 % respectively (Salminen et al., 
1998).  Studies to determine the extent to which physiological levels of CLA alter 
composition of lipid rafts, functionality of ABC transporters and prooxidant activity 
of drugs may provide an explanation for the enhanced chemosensitivity in drug 
resistant cells.  Optimal drug treatment reflects a compromise between effects on the 
cancer and toxicity to normal tissues.  Hence, it is of critical importance to 
demonstrate that such treatments do not enhance the chemosensitivity of normal non 
malignant cells.  Long term supplementation with a commercial 50:50 mixture of the 
two main CLA isomers showed it was well tolerated in healthy, overweight and 
obese human subjects and did not adversely affect blood safety parameters including 
inflammatory and diabetogenic markers (Gaullier et al., 2007).  This bodes 
favourably for undertaking translational research as suggested by Fite et al. (2007) to 
determine if CLA may be capable of reversing multiple drug resistance in vivo.  To 
address the problem of MDR cancer, the role of CLA in modulating the efficacy of 
other anticancer drugs in drug resistant models of cancer deserves further study. 
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Chapter 4 
 
Effects of conjugated linoleic acid (CLA) on cellular 
ceramide levels and expression of Her2/neu in drug-
resistant and sensitive melanoma cells. 
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4.0 Abstract 
 
Growth factor receptors and proteins that activate apoptosis are amongst several 
types of proteins encoded by protooncogenes, which if selectively blocked could stop 
the uncontrolled growth of cancer cells.  Polyunsaturated fatty acids are known to 
exert important regulatory effects on genes controlling apoptotic proteins and growth 
factor receptors.  Such effects may be mediated either by binding directly to 
transcription factors or indirectly through effects on specific enzyme-mediated 
pathways.  Amongst the latter is the sphingomyelinase signal transduction pathway 
that generates ceramide, a pro-apoptotic lipid whose rapid conversion to 
glucosylceramide is a hallmark of drug-resistant cancer.  Direct effects on gene 
transcription have recently been reported to explain the down-regulation by DHA 
and GLA of the HER2/neu oncoprotein, a growth factor receptor that is over-
expressed in approximately 30 % of breast cancer cases.  The aim of this study was 
to determine if anticancer activity of CLA and n-3 PUFA in drug-resistant cells is 
mediated by modulating levels of ceramide and/or HER2/neu.   MDA and A10p10p 
cells were treated in the presence or absence of Dox at 115 ng/mL with CLA-mix; 
c9,t11-CLA; t10,c12-CLA; EPA or DHA at 6 µg/mL.  Ceramide levels, as 
determined by HPLC were lower in untreated A10p10p cells than in the MDA cell 
line, suggesting that dysfunctional metabolism of ceramide may protect drug-
resistant cells from cytotoxic effects of doxorubicin (Dox).  Of the fatty acids 
studied, only c9,t11- and t10,c12-CLA in the presence of Dox significantly increased 
ceramide in A10p10p.  HER2/neu expression as determined by ELISA was elevated 
in A10p10p cells compared with MDA cells and was down-regulated by CLA-mix in 
both MDA and A10p10p cells and by EPA and DHA in the A10p10p cell line.  
These data suggest that the cytotoxic action of Dox and c9,t11-CLA combination and 
the Dox and t10,c12-CLA combination in A10p10p cells is related in part to an 
increase in cellular ceramide-mediated apoptosis levels and that the cytotoxic action 
of the Dox and CLA-mix is related in part to a decrease in HER2/neu-mediated 
proliferation. 
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4.1 Introduction 
 
Despite the major advances that have been made in the past 25 years in 
understanding the biological and clinical nature of breast cancer it still is the most 
prevalent type of cancer among women in the developed world and its incidence has 
shown a continuous rise in recent decades (Hanklin, 1993).  Nutrition is a key factor 
in breast cancer development and a relationship between incidence of breast cancer 
and diet has been revealed by numerous epidemiological and experimental studies 
(Miglietta et al., 2006).  In chapter 2 and 3 the cytotoxic effect of CLA both as a 
single treatment and in combination with doxorubicin (Dox) on the multidrug 
resistant and sensitive melanoma cell lines (originally derived from a patient with 
metastatic ductal adenoma of the breast) was reported.  However, the precise cellular 
mechanisms by which CLA exert these anticancer effects remains to be fully 
elucidated. 
 
Ip and colleagues reported that CLA induced apoptosis in various rodent mammary 
cancer cell lines via reduction in expression of the antiapoptotic, proto-oncogene bcl-
2 (Ip et al., 1999; 2007; Banni et al., 1999).  CLA also induced apoptosis and 
increased the expression of the tumour suppressive proteins in the p53-dependent 
apoptotic pathway (p53, p21WAF1/CIP1) whilst inhibiting the expression of the 
anti-apoptotic bcl-2 in MCF-7 (oestrogen-positive cells) in this pathway (Wahle and 
Heys, 2004).  Miglietta and co-workers (2006) demonstrated that CLA induced 
apoptosis in oestrogen unresponsive breast cancer cells (MDA-MB-231) via a 
mitochondrial dependent pathway involving ERK/MAPK signalling and the release 
of cytochrome c from the mitochondrial intramembrane space to the cytoplasm.  It 
has also been shown previously that various anti-cancer drugs including doxorubicin 
induce apoptosis via this same mitochondrial dependent pathway (Wang et al., 
2001). 
 
Other endogenous biological factors associated with fatty acid-induced apoptosis and 
differentiation are sphingolipid metabolites such as ceramide and sphingosine.  
Sphingomyelinase is an enzyme that catalyzes the hydrolysis of sphingomyelin (SM) 
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to ceramide.  A variety of studies have shown that ceramide is ubiquitously produced 
during cellular stress and is associated with apoptosis.  Furthermore, treating cells 
with synthetic short-chain ceramide has been shown to induce cell-cycle arrest and 
apoptosis.  Ceramide levels also changed during progression through the cell cycle 
and have been shown to enhance expression of p21, a cellular inhibitor of cdk2 
kinase that is involved in cell-cycle arrest via hypophosphorylation of retinoblastoma 
protein (pRb) (Wu et al., 2005).  Direct evidence for an involvement of sphingolipid 
signalling in growth arrest by polyunsaturated fatty acids was provided recently 
when omega-3 polyunsaturated fatty acids attenuated breast cancer growth through 
activation of a neutral sphingomyelinase-mediated pathway (Wu et al., 2005).  
However data in the literature is not conclusive; while some reports have indicated 
that n-3 PUFA such as DHA and EPA result in increased ceramide production in 
cancer cells (Siddiqui et al., 2003; Wu et al., 2005), others have reported decreases in 
ceramide levels in response to n-3 PUFA treatment (Jolly et al., 1997; McMurray et 
al., 2000).  Whether sphingolipid signalling plays an important role in CLA-
mediated induction of apoptosis of MDA and A10p10p breast cancer cells has yet to 
be assessed.   
 
Other significant effects induced by CLA include downregulation of target genes of 
the APC-β-catenin-TCF-4 and PPAR δ signalling pathways in CaCo2 cells.  
Expression of c-myc, c-jun, β-catenin, PPARδ, cyclin D1 and promoter activities of 
c-myc and AP1 were decreased in a concentration-dependent manner (Lampen et al., 
2005).  Interestingly, the t10,c12-CLA isomer was found to stimulate tumourigenesis 
in transgenic mice over-expressing erbB2 oncogene in the mammary epithelium (Ip 
et al., 2007; Meng et al., 2008), while DHA was found by Menendez and colleagues 
(2005c) to downregulate c-erbB2 (her2/neu) oncogene expression in human breast 
cancer cells.  HER2 is a member of the erbB family of receptor tyrosine kinases all 
of which bind extracellular growth factor ligands initiating intracellular signalling 
pathways regulating diverse biological responses including, proliferation, 
differentiation, cell motility and survival (Reviewed in Marmor et al., 2004).  The 
effects of the various fatty acids on expression of her2/neu in MDA and A10p10p 
cells remains to be elucidated. 
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One objective of this chapter was to determine the effects of various preparations of 
CLA alone and in combination with doxorubicin on ceramide levels in MDA and 
A10p10p cells, thus identifying a potential mechanism of apoptosis induction.  
Another objective was to elucidate the effects of the various fatty acids on expression 
of her2/neu in MDA and A10p10p cells. 
 
4.2 Specific Objectives 
 
 
 To validate a high performance liquid chromatography (HPLC) procedure for 
the analysis of basal sphingosine and ceramide levels in MDA and A10p10p 
cells. 
 
 To determine differences if any between basal sphingosine and ceramide 
levels in untreated MDA and A10p10p cells. 
 
 To investigate the effects of CLA mixture of isomers (CLA-mix), two single 
isomers (c9,t11 and t10,c12-CLA) and two omega-3 fatty acids (EPA and 
DHA), alone and in combination with doxorubicin (Dox), on basal 
sphingosine and ceramide levels in the MDA cell line. 
 
 To investigate the effects of CLA-mix, c9,t11 and t10,c12-CLA, EPA and 
DHA, alone and in combination with Dox, on basal sphingosine and ceramide 
levels in the A10p10p cell line. 
 
 To measure and compare the expression of her2/neu oncoprotein in untreated 
MDA and A10p10p cells. 
 
 To elucidate the effects of the various fatty acid treatments on her2/neu 
oncoprotein expression in both cell lines. 
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4.3 Materials & Methods 
4.3.1 Materials 
 
MDA-MB-435-S-F (MDA) human melanoma cell line and its Doxorubicin resistant 
variant MDA-MB-435-S-F/Adr10p10p (A10p10p) were developed and kindly 
donated by Dr. Sharon Glynn (NICB, Dublin).  Chemotherapy agent Doxorubicin 
(Dox) was kindly donated by Dr. Robert O’Connor (NICB, Dublin) (sourced 
originally from Farmitalia Carlo Erba (Milton Keynes, UK)).  Conjugated Linoleic 
Acid (CLA) mixture of isomers (99 % pure, approximately comprising: 44 % 
t10,c12-CLA; 41 % c9,t11/t9,c11-CLA; 10 % c10,c12-CLA and minor amounts of 
t9,t11; t10,t12 and c9,c11-CLA) (Cat: UC-59A) and single preparations (90 % pure) 
of isomers c9,t11- and t10,c12- CLA (Cat: UC-60A, UC-61A) as listed previously 
were from NuChek-Prep, Elysian, MN, USA.  All sterile disposable plastic-ware was 
from Sarstedt Ltd., Wexford, Ireland.  Cell culture media, supplements and reagents 
were purchased from Sigma-Aldrich.  Sphingosine, N-acetyl-D-sphingosine 
(ceramide) and O-phthaldehyde (OPA) were also purchased from Sigma, as were all 
other chemicals and solvents listed in this section unless otherwise specified.  The 
Calbiochem c-erbB2/c-neu (HER2/neu) Rapid Format ELISA kit (Cat # QIA10) was 
purchased from Merck Chemistry Ltd, Nottingham, UK.  Pepstatin (# 516481) was 
also purchased from Merck.  Leupeptin(# L-2884), ethylenediamine-tetraacetic acid 
(EDTA) (#E-6511) and phenylmethylsulfonyl fluoride (PMSF) (#P-7626) were 
purchased from Sigma. 
 
 
4.3.2 Ceramide Analysis 
4.3.2.1 Reagent preparation 
 
Solvents were HPLC grade or higher.  All solutions were prepared in advance unless 
otherwise stated and stored in the solvent press or refrigerator as appropriate. 
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 Chloroform: methanol: 1 N HCl solution; 100: 100: 1 v/v/v 
 Balanced salt solution (BSS) (135 mM NaCl, 4.5 mM KCl, 1.5 mM CaCl2, 0.5 
mM MgCl2, 5.6 mM glucose, 10 mM HEPES, pH 7.2)   
 100 mM solution of EDTA sodium salt at pH 7.5 was prepared and mixed with 
the BSS in a ratio of 9: 1 BSS: EDTA   
 0.1 and 1 N KOH and 1 N HCl in 100 % methanol  
 1 M NaCl in water  
 Mobile phase consisted of 90 % methanol and 10 % 5 mM K2HPO4 (to pH 7.0 
using KOH)   
 OPA reagent was prepared fresh each day by mixing 24.86 mL 3 % boric acid in 
water (pH 10.5 with KOH), 125 µL ethanol containing 100 mg/mL OPA (o-
phthalaldehyde, Cat: H5030, Sigma) and 12.5 µL 2-mercaptoethanol (Cat: 
M6250, Sigma).  
 
 
4.3.2.2 Cell Culture 
4.3.2.2.1 Single treatment Fatty Acids on MDA and A10p10p 
 
Cell lines were grown and maintained as listed previously in a ShelLab, IR2424 
model CO2 humidified Incubator at 37oC.  Cell culture work was carried out in a 
class II laminar airflow cabinet (Gelaire 85, BSB4 laminar air-flow cabinet).  T-75 
flasks were seeded with MDA or A10p10p cells at a density of 3x106 cells/flask and 
pre-treated in triplicate with CLA mixture of isomers (CLA-mix); c9,t11-CLA; 
t10,c12-CLA; EPA or DHA at a final concentration of 6 µg/mL.  The flasks were 
then cultured for 24 h to allow the cells to attach.  Following 24 h, flasks were rinsed 
with PBS and 12 mL fresh media containing fatty acid/control was added for a 3 day 
exposure period.  For controls, flasks were treated with media containing ethanol at 
the same concentration as in experimental flasks (< 0.01 %).  After 3 days, floating 
cells were collected by centrifuging the media in the flasks at 1000 g for 5 min using 
a Labofuge 400 centrifuge, Heraeus Instruments (supplied by Foss Electric, Dublin) 
and adherent cells were trypsinised as listed previously.  Floating and adherent cells 
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were pooled and a cell count performed using the Trypan Blue exclusion method.  
Cells were centrifuged as above and the pellets frozen until extraction at a later date. 
 
4.3.2.2.2 Combinations of Fatty Acids and Dox on MDA and A10p10p 
 
T-75 flasks were seeded with MDA or A10p10p cells at a density of 3x106 cells/flask 
and pre-treated in triplicate with CLA mixture of isomers (CLA-mix); c9,t11-CLA; 
t10,c12-CLA; EPA or DHA at a final concentration of 6 µg/mL.  The flasks were 
then cultured for 24 h to allow the cells to attach, following which media was 
removed and replaced with fresh media containing fatty acid/control plus Dox at 115 
ng/mL for 4h.  Flasks were then rinsed with PBS and 12 mL fresh media containing 
fatty acid/control added for a 3 day recovery period.  For controls, flasks were treated 
with Dox plus media containing ethanol at the same concentration as in experimental 
flasks (<0.01%).  After 3 days, floating cells were collected by spinning down the 
media in the flasks and adherent cells were trypsinised as listed previously.  These 
were pooled and a cell count performed using the Trypan Blue exclusion method.  
Cells were centrifuged at 1000 g for 5 min using a Labofuge 400 centrifuge, Heraeus 
Instruments (supplied by Foss Electric, Dublin) and the pellets frozen until extraction 
at a later date. 
 
 
4.3.2.3 Cellular Lipid Extraction 
 
Frozen cell pellets were removed from the freezer and 2 mL Chloroform: methanol: 
1 N HCl solution was added followed by 0.6 mL of BSS/EDTA.  The solution was 
then vortexed and centrifuged at 800 g for 5 min using a Labofuge 400 centrifuge, 
Heraeus Instruments (supplied by Foss Electric, Dublin).  The lower organic phase 
was transferred to two different sets of tubes; marked ‘basal’, on which an alkaline 
hydrolysis step was carried out to detect the basal level of sphingosine and ‘total’, on 
which the cellular ceramide was deacylated converting it to sphingosine.  ‘Basal’ 
represents the normal level of sphingosine in the cells.  ‘Total’ represents ceramide 
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levels plus ‘basal’ sphingosine levels.  Both sets of samples were dried down under a 
stream of nitrogen gas.  At this point it was possible to freeze the samples at -20oC 
until a later date as required (Santana et al., 1996). 
 
 
4.3.2.4 Sphingosine extraction by alkaline hydrolysis 
 
Sphingosine (SP1) standards (0-2000 pmol) were made up in chloroform: methanol 
(1:1, v/v) and dried down under nitrogen.  500 µL of 0.1 M KOH was added to the 
lipid film of each standard and basal sample tube.  These tubes were then vortexed 
and incubated for 1 h in a 37 ºC water-bath (Grant Instruments, Cambridge, UK). 
Following this, 500 µL of chloroform and 300 µL BSS/EDTA solution were added to 
all tubes to extract the sphingolipids.  The tubes were then vortexed and centrifuged 
at 800 g for 5 min using a Labofuge 400 centrifuge, Heraeus Instruments (supplied 
by Foss Electric, Dublin).  The lower organic phase was transferred to a new set of 
tubes and dried down under nitrogen.  At this point it was possible to freeze the 
samples until a later date as required (Santana et al., 1996). 
 
 
4.3.3.5 Deacylation of ceramide 
 
Sphingosine (SP2) and ceramide standards (0-2000 pmol) were dissolved in 
chloroform: methanol (1:1, v/v) and dried down under nitrogen.  These were used 
later to calculate the overall recovery of sphingolipids and the efficiency of the 
deacylation procedure.  500 µL of 1 M KOH in methanol was added to the lipid film 
of each standard and ‘total’ sample tubes to deacylate the ceramide.  The tubes were 
then capped, vortexed and incubated at 100ºC for 1.5 h.  At this point the tubes were 
allowed to cool and then neutralized with 500 µL 1 M HCl in methanol.  The 
sphingoid base was extracted by addition of 1 mL chloroform and 900 µL 1 M NaCl, 
vortexed and centrifuged at 800 g for 5 min using a Labofuge 400 centrifuge, 
Heraeus Instruments (supplied by Foss Electric, Dublin).  The upper phase was 
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removed and the remaining lower phase dried down under nitrogen.  At this point it 
was possible to freeze the samples until a later date as required (Santana et al., 1996). 
 
 
4.3.3.6 Derivatisation with O-Phthalaldehyde (OPA) 
 
Neat sphingosine (SPN, in the range 0-2000 pmol) was dissolved in chloroform: 
methanol (1:1, v/v) and dried down under nitrogen.  All standards and samples were 
derivatised at this stage with OPA reagent.  The sphingoid base in each tube was 
redissolved in 50 µL of methanol, to which 50 µL of OPA reagent (prepared as 
above) was added and incubated at room temperature for 10 min.  500 µL of 
methanol: 5 mM potassium phosphate (9:1, v/v), pH 7.0 was added to the tubes, 
which were then centrifuged at 1500 g for 30 s using a Labofuge 400 centrifuge, 
Heraeus Instruments (supplied by Foss Electric, Dublin) to clarify the samples.  Of 
this 500 µL was transferred to HPLC vials.  This derivatisation step converts the 
sphingosine to a fluorescent compound which can be detected and quantitated by 
HPLC (Santana et al., 1996). 
 
4.3.3.7 HPLC separation and Quantitation 
 
The derivatised sphingosine was separated by HPLC (Varian 9012) fitted with a 
Dynamix® AI-200 automatic sample injector with a 20 µL injection loop and 
quantitated using a Varian 9075 fluorescence detector.  A Nova Pack® C18 column 
(Waters, Milford, MA, USA) was used for the separation.  A mobile phase of 
methanol: 5 mM potassium phosphate, pH 7.0 (9:1, v/v) and flow rate of 0.6 mL/min 
were used to elute the samples.  An excitation wavelength of 340 nm and an 
emission wavelength of 455 nm were used (Santana et al., 1996). 
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4.3.3.8 Calculation of cellular ceramide content 
 
Calculations for ceramide cellular content were adapted from Santana et al., (1996) 
and were carried out as follows: 
 
pmol ceramide/ 106 cells  =  [(pmol total x recovery 1 x  recovery 2) – pmol 
basal] / million cells in each pellet 
 
pmol total = pmol in the total sample (deacylated) read against the ceramide 
standard curve. 
Recovery 1 = averaged peak areas of each point in ceramide standard curve / peak 
areas of SPN.  This is a measure of the efficiency of deacylation. 
Recovery 2 = averaged peak areas of each point in SP2 standard curve/peak areas of 
SP1.  This is a measure of the efficiency of sphingolipid recovery. 
pmol basal = pmol in the basal sample (alkaline hydrolysis) read against the SP1 
standard curve. 
 
 
4.3.4 HER2/neu Assay 
4.3.4.1 Cell Culture 
 
Cell lines were grown and maintained as listed previously in a ShelLab, IR2424 
model CO2 humidified Incubator at 37oC.  Cell culture work was carried out in a 
class II laminar airflow cabinet (Gelaire 85, BSB4 laminar air-flow cabinet).  T-25 
flasks were seeded with MDA or A10p10p cells at a density of 1x106 cells/flask.  
The flasks were then cultured for 24 h to allow the cells to attach.  Following 24 h 
flasks were treated with fresh media containing fatty acid/control in triplicate for a 3 
day exposure period.  Fatty acids used in this experiment were CLA mixture of 
isomers (CLA-mix); c9,t11-CLA; t10,c12-CLA; EPA and DHA at a final 
concentration of 6 µg/mL.  For controls, flasks were treated in triplicate with media 
containing ethanol at the same concentration as in experimental flasks (<0.01%).  
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After 3 days, floating cells were collected by centifuging the media in the flasks at 
800 g for 5 min using a Labofuge 400 centrifuge, Heraeus Instruments (supplied by 
Foss Electric, Dublin) and adherent cells were trypsinised as listed previously.  
Floating and adherent cells were pooled and a cell count performed using the Trypan 
Blue exclusion method.  Cells were centrifuged as above and the pellets frozen until 
extraction at a later date. 
 
 
4.3.4.2 Reagent preparation  
 
Immediately prior to extracting the cell lysates, the following reagents were 
prepared. 
 
 Resuspension buffer provided in the assay kit was adjusted to contain 5 mM 
EDTA, 0.2 mM PMSF, 1 µg/mL pepstatin and 0.5 µg/mL leupeptin.   
 Wash buffer was prepared by addition of 25 mL of 20X concentrated solution 
(provided in the kit) to 475 mL dH20.  This was mixed and transferred to a wash 
bottle. 
 A lyophilised c-erbB2/c-neu standard (provided in the kit) was re-constituted in 
dH20 and allowed to sit at room temperature for 15 min. 
 Serial dilutions of this standard were made in labelled tubes to contain 3, 1.5, 
0.75, 0.375, 0.188, 0.094 and 0 ng/mL c-erbB2/c-neu using sample diluent 
(provided in the kit). 
 The 500X Conjugate was diluted 1:500 with conjugate diluent (both provided); 
i.e. 24 µL in 12 mL.  This was gently mixed and filtered using a 0.2 µm syringe 
filter. 
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4.3.4.3 Cell Lysate Extraction 
 
Frozen cell pellets were removed from the freezer and allowed to thaw.  
Resuspension buffer prepared above was added to each pellet at approximately 1 
mL/1x106 cells.  For every 100 µL of cell suspension, 20 µL of antigen extraction 
agent (AEA) (provided in the kit) was added. These were mixed and placed on ice 
for 30 min with occasion vortexing throughout.  The extracts were transferred to 
microcentrifuge tubes and centrifuged for 5 min at 1000 g using a Labofuge 400 
centrifuge, Heraeus Instruments (Foss Electric, Dublin).  The resulting clear lysates 
were transferred to clean tubes.  An aliquot of each was set aside and frozen for a 
protein assay to be done at a later date (Calbiochem user protocol QIA10 Rev. 16).   
 
 
4.3.4.4 c-erbB2/c-neu ELISA protocol 
 
The appropriate number of wells were removed from the foil pouch (provided in the 
kit).  Unused wells were returned to the pouch, re-sealed and stored at 4oC.  100 µL 
of each standard in duplicate and each sample (already in triplicate) was pipetted into 
the appropriate wells.  The plate was covered with a plate-sealer and incubated at 
room temperature for 2 h, after which the wells were washed three times with the 
wash buffer prepared above.  100 µL of detector antibody (provided in the kit) was 
pipetted into each well, covered with a plate-sealer and incubated at room 
temperature for 1 h.  Again the wells were washed three times with wash buffer, 
following which 100 µL of conjugate (prepared above) was added.  The plate was 
covered with a plate-sealer and incubated at room temperature for 30 min.  Wells 
were washed three times with wash buffer, after which the entire plate was flooded 
with dH20.  The water was removed by inverting over the sink and tapping the plate 
on paper towels.  100 µL of substrate solution (provided) was added to each well and 
incubated in the dark at room temperature for 30 min.  100 µL of stop solution 
(provided) was added to the wells in the same order as previous additions.  The 
absorbance of each well was measured using a Tecan A-5082 Sunrise microplate 
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reader (Tecan, Austria) at dual wavelengths of 450/595 nm within 30 min of adding 
the stop solution.  The c-erbB2/c-neu content of each sample was calculated using 
the equation of the line from the standard curve which was linear in the range used.  
This yielded values in ng/mL; these were multiplied by a conversion factor of 400 to 
yield values of c-erbB2/c-neu in human neu units (HNU) (Calbiochem user protocol 
QIA10 Rev. 16). 
 
 
4.3.4.5 Bio-rad Protein Assay 
 
Bio-Rad protein assay dye reagent was prepared by addition of 4 mL dye reagent 
concentrate to 16 mL dH20.  This was mixed by inverting.  A protein standard 
solution was prepared using BSA and diluted using dH20 to yield a range of (0-2100 
µg/mL) standards of BSA.  10 µL of each sample (aliquots of cell lysate for each 
sample set aside earlier) and standard was pipetted in triplicate into appropriate wells 
of a 96-well plate.  200 µL of dye reagent was added to each well and mixed gently.  
The plate was incubated at room temperature for 5 min (max 1 h).  Absorbance was 
read on a Tecan A-5082 Sunrise microplate reader (Tecan, Austria) at a wavelength 
of 620 nm.  The protein content of each sample was calculated by extrapolation from 
the standard curve.  These values were then used to adjust the p185 c-erbB2/c-neu 
HNU values to p 185 c-erbB2/c-neu HNU/mg protein. 
 
4.3.5 Statistical Analysis 
 
Differences between means were analysed for significance using the Student’s two-
tailed, paired t-test, unless otherwise stated.   
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4.4 Results 
4.4.1 Ceramide Analysis  
4.4.1.1 Standard curves  
 
Four standard curves were set up as per “Materials and Methods” section.  All 
standard curves were prepared in the range 0- 2000 pmol.  Each standard was 
prepared and analysed for sphingosine and ceramide (converted to sphingosine) 
content using HPLC to obtain reliable linear correlations between sphingosine 
concentration and peak area.  A sphingosine standard curve (SP1) was set up and 
subjected to an alkaline hydrolysis step in addition to derivatisation and was 
quantified using HPLC, illustrated in Figure 4.4.1.1.1 (b).  A second sphingosine 
standard curve (SP2) was set up and subjected to the steps involved in deacylation 
and derivatisation, and then quantified using HPLC (Figure 4.4.1.1.2 (a)).  The 
purpose of these two steps was to calculate the overall recovery of sphingosine 
(Recovery 2) from the extraction procedure, which would then be used when 
quantifying basal sphingosine levels in the MDA and A10p10p cell extracts.  The 
Recovery 2 value was calculated to be 81.9 % (n= 4).   
 
Figure 4.4.1.1.2 (b) illustrates a standard curve in which ceramide standards were 
deacylated to form sphingosine, derivatised and quantified using HPLC.  Finally, a 
sphingosine standard curve (SPN) was set up and subjected to derivatisation with 
OPA and was quantified using HPLC (Figure 4.4.1.1.1 (a)).  By comparing the SPN 
standard curve with the ceramide standard curve, it is possible to calculate the 
efficiency of the deacylation procedure (Recovery 1).  The Recovery 1 value was 
calculated to be 89.9 % (n= 4).  The ceramide is converted to sphingosine via the 
deacylation procedure and thus a ceramide standard curve allows for quantification 
of total sphingosine (basal sphingosine levels plus deacylated ceramide levels) in the 
cell samples.  A simple subtraction of basal sphingosine levels from total sphingosine 
levels will subsequently yield cellular ceramide levels.  Figure 4.4.1.1.3 depicts a 
typical HPLC chromatogram of (a) SPNEAT at a concentration of 1000 pmol and (b) 
ceramide standard at a concentration of 500 pmol having undergone deacylation, 
where ceramide is converted to sphingosine, and derivatised with OPA.  It can be 
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seen here that the retention time of the resultant sphingosine was 8.094 min in (a) 
and 7.919 min in (b) and the OPA reagent eluted between 1.5- 2.5 min in both. 
 
 
4.4.1.2 Basal sphingosine levels in untreated MDA and A10p10p 
cells 
 
T-75 flasks were seeded with MDA or A10p10p cells at a density of 3x106 
cells/flask.  Following 24 h flasks were rinsed with PBS and 12 mL fresh media was 
added for a 3 day incubation period.  After 3 days, floating and adherent cells were 
collected and pooled as described in Materials and Methods.  Lipids were extracted 
and subjected to alkaline hydrolysis and derivatisation steps and quantitated by 
HPLC as described in above sections.   
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Figure 4.4.1.1.1 Standard curves of (a) SPNEAT (neat sphingosine in the range 0-2000 pmol) 
which was derivatised with OPA and (b) SP1 sphingosine standard (0-2000 pmol) which was 
hydrolysed and derivatised with OPA.  All were separated by HPLC on a Nova Pack® C18 
column and quantitated using a Varian 9075 fluorescence detector at an excitation 
wavelength of 340 nm and an emission wavelength of 455 nm (n = 4). 
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Figure 4.4.1.1.2.  Standard curves of (a) SP2 sphingosine standard (0-2000 pmol) and (b) 
Ceramide (0-2000 pmol) both of which were deacylated (to convert ceramide to 
sphingosine), derivatised and derivatised with OPA.  All were separated by HPLC on a Nova 
Pack® C18 column and quantitated using a Varian 9075 fluorescence detector at an 
excitation wavelength of 340 nm and an emission wavelength of 455 nm (n = 4). 
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 (a) 
 
 (b) 
    
 
Figure 4.4.1.1.3.  Typical HPLC chromatogram of (a) SPNEAT at a concentration of 1000 
pmol and (b) ceramide standard at a concentration of 500 pmol having undergone 
deacylation, where ceramide is converted to sphingosine, and derivatised with OPA.  The 
retention time of the sphingosine was 8.094 in (a) and 7.919 min in (b) and the OPA reagent 
eluted between 1.5- 2.5 min in both. 
 
 
 
 
Levels of basal sphingosine in MDA and A10p10p cells were compared and 
illustrated in Figure 4.4.1.2.  There was no trace of basal sphingosine detected in the 
untreated MDA cells and while it was detected in some A10p10p samples 0.56 + 0.4 
pmol, the variation was such that the levels were not deemed statistically significant 
with respect to the MDA cells.  The fact that sphingosine was only detected in the 
A10p10p cells twice out of three experiments suggests that the levels of sphingosine 
found in A10p10p cells are close to the limit of detection for this method. 
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Figure 4.4.1.2. Basal Sphingosine in the MDA and A10p10p cell lines.  T-75 flasks were 
seeded with MDA or A10p10p cells at a density of 3x106 cells/flask.  Following 24 h the 
flasks were washed with PBS, treated with control media for 72 h, extracted and analysed as 
above.  Data represents results from three experiments.  Error bar depicts SEM. 
 
  
4.4.1.3 Ceramide levels in untreated MDA and A10p10p cells 
 
T-75 flasks were seeded with MDA or A10p10p cells at a density of 3x106 
cells/flask.  Following 24 h flasks were rinsed with PBS and 12 mL fresh media was 
added for a 3 day incubation period.  After 3 days, floating and adherent cells were 
collected and pooled as described in Materials and Methods.  Lipids were extracted 
and subjected to deacylation and derivatisation steps and quantitated by HPLC as 
described in above sections.  Levels of ceramide in MDA and A10p10p cells were 
compared and illustrated in Figure 4.4.1.3.  While there was a clear apparent 
difference in the levels of ceramide in MDA and A10p10p cells at 253.1 + 40.4 and 
91.0 + 32.8 pmol respectively, the difference was not found to be statistically 
significant. 
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Figure 4.4.1.3 Ceramide levels in the MDA and A10p10p cell lines.  T-75 flasks were 
seeded with MDA or A10p10p cells at a density of 3x106 cells/flask.  Following 24 h the 
flasks were washed with PBS and treated with control media for 72 h.  Data represents 
results from three experiments.  Error bars depict SEM. 
 
 
4.4.1.4 Effects of fatty acid treatments alone or in combination 
with Dox on basal sphingosine levels in MDA cells 
 
T-75 flasks were seeded with MDA cells at a density of 3x106 cells/flask and pre-
treated in triplicate with CLA-mix; c9,t11-CLA; t10,c12-CLA; EPA or DHA at a 
final concentration of 6 µg/mL as listed in above sections.  Following 24 h, media 
containing fatty acid alone/control or fatty acid/control plus Dox at 115 ng/mL was 
added.  After 3 days, floating and adherent cells were pooled and a cell count 
performed as listed previously.  Lipids were extracted and subjected to alkaline 
hydrolysis and derivatisation steps and quantitated by HPLC as described in above 
sections.  The effects of fatty acids/control alone or in combination with Dox on 
cellular basal sphingosine levels in the MDA cell line are illustrated in Figure 4.4.1.4 
(a) and (b) respectively.   
 
Each of the five fatty acid treatments alone caused an increase in basal sphingosine 
levels at 1.0 + 1.0, 2.5 + 2.5, 1.4 + 1.4, 1.1 + 1.1, 1.2 + 1.2 pmol with CLA mix, 
                                  
 142 
c9,t11 and t10,c12-CLA, EPA and DHA respectively.  However, none were deemed 
significantly different from control cells in which sphingosine was undetectable.  
Sphingosine was only detected following fatty acid alone treatments in one out of 
three experiments, hence Mean = SEM in each case.  When Dox was combined with 
CLA mix, c9,t11 and t10,c12-CLA there was a significant increase in basal 
sphingosine levels (22.4 + 5.0, 20.6 + 7.5 and 15.3 + 5.5 pmol sphingosine 
respectively) relative to respective fatty acid alone treatments listed above.  These 
combinations were also found to be significantly different relative to untreated 
control.  However, relative to Dox alone which yielded 32.4 + 13.7 pmol 
sphingosine, the combination of Dox plus any of the five fatty acids was not found to 
be significantly different. 
 
4.4.1.5 Effects of fatty acid treatments alone or in combination 
with Dox on ceramide levels in MDA cells 
 
T-75 flasks were seeded with MDA cells at a density of 3x106 cells/flask and pre-
treated in triplicate with CLA-mix; c9,t11-CLA; t10,c12-CLA; EPA or DHA at a 
final concentration of 6 µg/mL as listed in above sections.  Following 24 h, media 
containing fatty acid alone/control or fatty acid/control plus Dox at 115 ng/mL was 
added.  After 3 days, floating and adherent cells were pooled and a cell count 
performed as listed previously.  Lipids were extracted and subjected to deacylation 
and derivatisation steps and quantitated by HPLC as described in above sections.  
The effects of fatty acids/control alone or in combination with Dox on ceramide 
levels in the MDA cell line are illustrated in Figure 4.4.1.5 (a) and (b) respectively.   
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Figure 4.4.1.4 Effects of fatty acids/control alone or in combination with Dox on cellular basal sphingosine levels 
in the MDA cell line.  T-75 flasks were seeded with MDA cells and pre-treated in triplicate with CLA, c9,t11, 
t10,c12, EPA or DHA at a final concentration of 6 µg/ mL.  Following 24 h the flasks (FA alone) were washed 
with PBS and treated with fatty acid for 72 h.  Flasks (Dox + FA) were treated with fatty acid/control plus Dox at 
115 ng/mL for 4h, followed by 72 h with fatty acid/control.  Data represents results from at least three 
experiments.  Error bars depict SEM. 
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Figure 4.4.1.5 Effects of fatty acids/control (a) alone or (b) in combination with Dox on total cellular ceramide 
levels in the MDA cell line.  T-75 flasks were seeded with MDA cells at a density of 3x106 cells/flask and pre-
treated in triplicate with CLA, c9,t11, t10,c12, EPA or DHA at a final concentration of 6 µg/ mL.  Following 24 h 
the flasks (a) were washed with PBS and treated with fatty acid for 72 h.  Flasks (b) were treated with fatty 
acid/control plus Dox at 115 ng/mL for 4h followed by 72 h with fatty acid/control.  Data represents results from 
at least three experiments.  Error bars depict SEM.  *Denotes results which are significantly different to 
control/Dox control cells (p<0.05).   
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The levels of cellular ceramide were found to be 169.7 + 33.9, 192.0 + 50.2, 117.1 + 
4.3, 73.3 + 31.1 and 174.6 + 118.6 pmol in MDA cells treated with CLA mix, c9,t11 
and t10,c12-CLA, EPA and DHA respectively.  With the exception of EPA, these 
values were not deemed to be significant relative to untreated controls at 253.1 + 
40.4 pmol.  In cells treated with combinations of Dox plus fatty acid, corresponding 
values were 168.6 + 14.2, 175.2 + 37.9, 170.5 + 32.4, 163.6 + 22.1 and 193.6 + 60.4 
pmol respectively.  Again, these values were not deemed to be significant relative to 
Dox alone at 126.6 + 40.9 pmol or to untreated controls and respective fatty acid 
alone treatments (listed above). 
 
 
4.4.1.6 Effects of fatty acid treatments alone or in combination 
with Dox on basal sphingosine levels of A10p10p cells 
 
T-75 flasks were seeded with A10p10p cells at a density of 3x106 cells/flask and pre-
treated in triplicate with CLA-mix; c9,t11-CLA; t10,c12-CLA; EPA or DHA at a 
final concentration of 6 µg/mL as listed in above sections.  Following 24 h, media 
containing fatty acid alone/control or fatty acid/control plus Dox at 115 ng/mL was 
added.  After 3 days, floating and adherent cells were pooled and a cell count 
performed as listed previously.  Lipids were extracted and subjected to alkaline 
hydrolysis and derivatisation steps and quantitated by HPLC as described in above 
sections.  The effects of fatty acids/control alone or in combination with Dox on 
basal sphingosine levels in the A10p10p cell line are illustrated in Figure 4.4.1.6 (a) 
and (b) respectively.   
 
While all five fatty acids appeared to cause an increase in basal sphingosine from 0.6 
+ 0.4 pmol in the untreated control to 0.7 + 0.4 pmol with CLA mix, 1.9 + 1.3 pmol 
with c9,t11-CLA, 1.0 + 0.8 pmol with t10,c12-CLA, 3.3 + 1.7 pmol with EPA and 
2.2 + 1.2 pmol sphingosine with DHA, none were found to be statistically 
significant.   
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Figure 4.4.1.6 Effects of fatty acids/control (a) alone or (b) in combination with Dox on 
cellular basal sphingosine levels in the A10p10p cell line.  T-75 flasks were seeded with 
A10p10p cells at a density of 3x106 cells/flask and pre-treated in triplicate with CLA, c9,t11, 
t10,c12, EPA or DHA at a final concentration of 6 µg/ mL.  Following 24 h the flasks (a) 
were washed with PBS and treated with fatty acid for 72 h.  Flasks (b) were treated with fatty 
acid/control plus Dox at 115 ng/mL for 4 h followed by 72 h with fatty acid/control.  Data 
represents results from at least three experiments.  Error bars depict SEM. 
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There was a similar trend in the combinations with Dox relative to Dox alone with 
increases in basal sphingosine from 10.9 + 7.4 pmol in the Dox control to 18.1 + 9.7 
pmol in combination with CLA mix, 18.3 + 11.8 pmol with c9,t11-CLA, 23.0 + 19.0 
pmol with t10,c12-CLA, 19.3 + 15.0 pmol with EPA and 27.1 + 19.1 pmol with 
DHA, although again not statistically significant (Figure 4.4.1.6 (a)).    
 
4.4.1.7 Effects of fatty acid treatments alone or in combination 
with Dox on ceramide levels of A10p10p cells 
 
T-75 flasks were seeded with A10p10p cells at a density of 3x106 cells/flask and pre-
treated in triplicate with CLA-mix; c9,t11-CLA; t10,c12-CLA; EPA or DHA at a 
final concentration of 6 µg/mL as listed in above sections.  Following 24 h, media 
containing fatty acid alone/control or fatty acid/control plus Dox at 115 ng/mL was 
added.  After 3 days, floating and adherent cells were pooled and a cell count 
performed as listed previously.  Lipids were extracted and subjected to deacylation 
and derivatisation steps and quantitated by HPLC as described in above sections.  
The effects of fatty acids/control alone or in combination with Dox on basal 
sphingosine levels in the A10p10p cell line are illustrated in Figure 4.4.1.7 (a) and 
(b) respectively.   
 
Treatments of fatty acids alone caused no significant effect on the cellular ceramide 
in A10p10p cells.  The combination of Dox plus t10,c12-CLA yielded a significant 
increase in ceramide levels from 100.30 + 0.08 pmol in the Dox control to 276.49 + 
17.16 pmol following combination treatment.  This was found to be significant 
relative to untreated control listed above.  Similarly, the combination of Dox plus 
c9,t11-CLA yielded a significant increase in ceramide levels to 226.8 + 55.0 pmol 
following treatment.  Combinations with the remaining three fatty acids, CLA-mix, 
EPA and DHA, caused an apparent but not significant increase in ceramide levels to 
221.2 + 106.4, 138.4 + 55.2 and 116.6 + 22.9 pmol ceramide respectively following 
treatments.  
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Figure 4.4.1.7 Effects of fatty acids/control (a) alone or (b) in combination with Dox on total 
cellular ceramide levels in the A10p10p cell line.  T-75 flasks were seeded with A10p10p 
cells at a density of 3x106 cells/flask and pre-treated in triplicate with CLA, c9,t11, t10,c12, 
EPA or DHA at a final concentration of 6 µg/ mL.  Following 24 h the flasks (a) were 
washed with PBS and treated with fatty acid for 72 h.  Flasks (b) were treated with fatty 
acid/control plus Dox at 115 ng/mL for 4h followed by 72 h with fatty acid/control.  Data 
represents results from at least three experiments.  *Denotes results which are significantly 
different to control/Dox control cells (p<0.01).  Error bars depict SEM. 
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4.4.2 HER2/neu Assay 
4.4.2.1 Bio-Rad Protein Assay 
 
A bovine serum albumin (BSA) standard curve in the range 0-2100 µg/mL was set 
up as per “Materials and Methods” section.  By extrapolation from this standard 
curve, the protein content of fatty acid/control treated MDA and A10p10p cells was 
calculated (Table 4.4.2.1). 
 
 
Table 4.4.2.1 Protein levels in MDA and A10p10p cells following various fatty acid 
treatments 
Treatment MDA cells 
µg/mL 
A10p10p cells 
µg/mL 
Control 1450 1550 
CLA-mix 1500 1500 
c9,t11-CLA 1200 800 
t10,c12-CLA 1350 1450 
DHA 1725 1775 
EPA 700 1550 
 
 
 
4.4.2.2 c-erbB2/c-neu ELISA  
 
T-25 flasks were seeded with MDA or A10p10p cells at a density of 1x106 
cells/flask.  Following 24 h flasks were treated with fresh media containing fatty 
acid/control in triplicate for a 3 day exposure period.  Fatty acids used in this 
experiment were CLA mixture of isomers (CLA-mix); c9,t11-CLA; t10,c12-CLA; 
EPA and DHA at a final concentration of 6 µg/mL.  Floating and adherent cells were 
pooled, the cell lysate extracted and an aliquot of each sample was assayed for 
protein content as described above.  The p185 c-erbB2/c-neu Calbiochem ELISA 
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was performed as listed in Methods.  A standard curve of c-erbB2/c-neu in range 0-3 
ng/mL was performed and illustrated in Figure 4.4.2.2.1.   
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Figure 4.4.2.2.1 Standard Curve of p185 c-erbB2/c-neu in the range 0-3 ng/mL.  The p185 c-
erbB2/c-neu Calbiochem ELISA was performed as listed in Methods.  Error bars depict 
SEM. 
 
 
 
The effects of fatty acids/control on the expression of c-erbB2/c-neu in MDA and 
A10p10p cells were determined using the equation of the line obtained from the 
standard curve and is illustrated in Figure 4.4.2.2.2.    In MDA cells CLA-mix 
treatment resulted in a significant reduction in c-erbB2/c-neu expression relative to 
untreated MDA control from 30.9 + 6.0 HNU/mg protein in control MDA cells to 
8.4 + 1.7 HNU/mg protein following CLA-mix treatment.  Conversely, c-erbB2/c-
neu expression was significantly upregulated to 64.1 + 8.6 and 56.8 + 7.3 HNU/mg 
protein following treatment with c9,t11 and t10,c12-CLA respectively.  DHA and 
EPA treatment did not result in a significant change in c-erbB2/c-neu expression in 
MDA cells at levels of 36.5 + 3.0 and 13.1 + 1.2 HNU/mg protein respectively.   
 
                                  
 151 
CLA-mix also resulted in significant down-regulation of c-erbB2/c-neu expression in 
A10p10p cells relative to untreated A10p10p control from 82.9 + 4.3 to 36.6 + 1.0 
HNU/mg protein following treatment.  As in MDA cells, c9,t11-CLA caused a 
significant  upregulation of c-erbB2/c-neu expression in A10p10p cells relative to 
control with a level of 145.6 + 5.3 HNU/mg protein following treatment.  Both DHA 
and EPA treatment resulted in significant down-regulation of c-erbB2/c-neu 
expression in A10p10p cells relative to untreated A10p10p control at levels of 71.6 + 
4.2 and 67.2 + 2.8 HNU/mg protein respectively.  t10,c12-CLA treatment did not 
result in significant change at 79.0 + 3.9 HNU/mg protein following treatment. 
 
In untreated samples of MDA and A10p10p, there was a significant up-regulation c-
erbB2/c-neu expression in the multidrug resistant A10p10p cells relative to MDA 
cells.  Also, this difference between the cell lines remained following treatments of 
CLA-mix, c9,t11-CLA, EPA and DHA with a significant increase in c-erbB2/c-neu 
levels relative to corresponding treatments in the MDA cell line. 
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Figure 4.4.2.2 (a) Standard Curve of p185 c-erbB2/c-neu in the range 0-3 ng/mL and (b) 
level of p185 c-erbB2/c-neu (HNU/mg protein) in MDA and A10p10p cells treated with 
fatty acid/control.  Fatty acids used were CLA-mix; c9,t11-CLA; t10,c12-CLA; EPA and 
DHA at 6 µg/mL for 3 days.  The p185 c-erbB2/c-neu Calbiochem ELISA was performed as 
listed in Methods.  *Denotes samples statistically different relative to control MDA or 
A10p10p cells as determined by the Student’s t-test with p<0.05. +Denotes A10p10p samples 
statistically different relative to corresponding MDA samples with p<0.05.   Error bars depict 
SEM. 
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4.5 Discussion 
 
One hypothesis being tested in this work is that fatty acids including CLA induce 
toxicity in MDA and A10p10p melanoma cells by mechanisms involving an increase 
in ceramide production in the cells.  Ceramide belongs to highly bioactive class of 
molecules known as sphingolipids that are used by cells to regulate growth, 
differentiation, apoptosis and other cellular functions.  They are located in lipid-rich 
structures such as the extracellular leaflet of the cell membrane and are critical for 
the maintenance of membrane structure, especially that of “microdomains” (such as 
caveolae) (Harder and Simons, 1997); they modulate the behaviour of growth factor 
receptors and extracellular matrix proteins (Hakomori, 1991).  Sphingolipids 
function as “second messengers” for growth factors, cytokines, differentiation factors 
and growing list of agonists and toxins (Kolesnick, 1998; Merrill et al., 1997; Riboni 
et al., 1997; Spiegel and Merrill, 1996).  Sphingolipid turnover into different 
bioactive metabolites depends on activation of sphingomyelin hydrolysis to ceramide 
by sphingomyelinase, which is further metabolized by ceramidase and sphingosine 
kinase to sphingosine and sphingosine-1-phosphate.  Agents that activate only 
sphingomyelinase (which results in ceramide accumulation) have profound effects on 
the behaviour of cells because sphingosine-1-phosphate is a potent mitogen and an 
inhibitor of apoptosis (Cuvillier et al., 1998; Olivera and Spiegel, 1993), whereas 
sphingosine and ceramide inhibit growth and/or induce apoptosis (Hannun, 1994; 
Sweeney et al., 1998). 
 
In this study an in vitro model of drug sensitive and resistant melanoma cells 
characterised by Glynn et al., (2004) was used.  MDA and A10p10p cells were 
treated in the presence or absence of Dox, with CLA-mix; c9,t11-CLA; t10,c12-
CLA; EPA or DHA.  Ceramide and basal sphingosine were analysed and quantitated 
by HPLC as described in above sections.  Ceramide levels were found to be lower in 
A10p10p cells than in the MDA cell line, which points to one mechanism by which 
the drug resistant A10p10p cells protect themselves from anticancer drugs.  It has 
been shown that decreased levels of endogenous ceramide by over-expression of 
glucosylceramide synthase, which clears ceramide levels by incorporating it into 
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glucosylceramide, results in the development of a multidrug resistant phenotype in 
human cancer cells (Ogretmen and Hannun, 2001). 
 
EPA single treatments caused a significant reduction in ceramide levels in both cell 
lines, suggesting that the cytotoxic action of EPA is not through a pathway initiated 
by ceramide production.  In contrast, all fatty acids plus Dox resulted in an increase 
in ceramide levels relative to Dox alone in both cell lines although this was only 
significant in the case of c9,t11 and t10,c12-CLA plus Dox in A10p10p cells.  This 
points to a trend indicating that perhaps ceramide production is one of many 
pathways by which these fatty acids enhance the cytotoxic action of anticancer drugs. 
 
Interestingly, Dox treatments alone and in combination with fatty acids caused an 
increase in sphingosine levels relative to respective single treatments of fatty acid/ 
control in the MDA cell line.  This is the first study to report this finding, although it 
was only significant with CLA-mix, c9,t11 and t10,c12-CLA.  In the A10p10p cell 
line, all fatty acids alone caused an increase in sphingosine levels relative to control.  
Treatments of Dox alone and in combination with each fatty acid resulted in a further 
although not significant increase.  Sweeney and co-workers (1998) established that 
sphingosine also induces apoptosis –independently from ceramide, acting in an 
earlier part of the apoptotic pathway than ceramide. 
 
The p185 c-erbB2/c-neu Calbiochem ELISA was performed on MDA and A10p10p 
cells treated with CLA-mix; c9,t11-CLA; t10,c12-CLA; EPA or DHA.  In untreated 
cells, the A10p10p cell line had significantly higher levels of Her2/neu coded p185 c-
erbB2/c-neu
 oncoprotein present than in MDA cells.  This indicates another potential 
mechanism by which the A10p10p cell line maintains resistance to conventional 
anticancer drugs.  Overexpression of the Her2/neu oncogene has been shown 
previously to confer resistance to chemotherapeutic drugs in breast cancer cells 
(Colomer et al., 2000).  Treatment of both MDA and A10p10p cells with CLA-mix 
resulted in down-regulation of Her2/neu expression.  Also, both EPA and DHA 
resulted in down-regulation in the A10p10p cell line.  Menendez et al. (2005) also 
demonstrated that DHA down-regulated Her2/neu expression in breast cancer cells 
overexpressing the gene.  However, there were opposing results with treatments of 
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the single isomers c9,t11 and t10,c12-CLA.  Both isomers caused significant up-
regulation of Her2/neu expression in A10p10p and c9,t11-CLA also caused 
significant up-regulation in MDA cells.  Since these two studies are the only to date 
to investigate the effects of these fatty acids on Her2/neu expression in melanoma 
cells, further work is necessary to elucidate the mechanisms behind and confirm 
these opposing effects.   
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Chapter 5 
Modulation of lipid profile by conjugated linoleic acid 
(CLA) in drug-resistant and sensitive melanoma cells. 
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5.0 Abstract 
It is widely accepted that human cancer cells have the ability to synthesis their own 
supply of fatty acids, seemingly independent of the regulatory signals that down-
regulate fatty acid synthesis in normal cells.  Also, the development of doxorubicin 
resistance in breast and colon cancer cells has been associated with decreased fluidity 
of lipid bilayers and increased degree of fatty acid saturation of cholesterol esters.  
The previous chapters showed that exogenous fatty acids had a significant inhibitory 
effect on growth in breast cancer cell lines.  One proposed mechanism for this 
anticarcinogenic activity is the alteration of the fatty acid composition of the cell 
membrane phospholipids by CLA isomers resulting in reduced synthesis of 
arachidonic acid (AA) and AA-derived eicosanoids associated with stimulation of 
cancer cell proliferation.  Fatty acid profiles of untreated MDA-MB-435S-F (MDA) 
melanoma cells and a doxorubicin resistant variant MDA-MB435S-F/Adr10p10p 
(A10p10p) were analysed by gas chromatography.  There was a statistically 
significant increase in the proportion of total saturated fatty acids (SFA) and decrease 
in the ratio of unsaturated fatty acids (UFA) to SFA in the resistant A10p10p cell line 
relative to the MDA line, suggesting an up-regulation in fatty acid synthase (FAS) 
activity.  Uptake of CLA by MDA cells was dose dependent; treatment with c9,t11-
CLA and t10,c12-CLA (75 µM) for 72 h resulted in significant uptake into MDA 
cells (29.44 + 3.63 and 26.37 + 5.53 % total fatty acid methyl ester (FAME) 
respectively).  Less uptake by the CLA mixture of isomers into MDA cells was 
observed.  A similar pattern of CLA uptake was observed in drug resistant cells.  
There was a definite trend, although not always significant, of a decrease in the long 
chain saturated fatty acids (LCSFA) and an increase in the unsaturation index of both 
cell lines following all fatty acid treatments, possibly due to FAS inhibition.  With 
the exception of the CLA-mix in the resistant line, all fatty acids in both cell lines 
caused a decrease in the ratio of C18:1/18:0 suggesting the ∆ 9 desaturase enzyme 
stearoyl-CoA desaturase (SCD) as a potential target for inhibition by fatty acid 
treatments.  These data highlight the potential of fatty acids to modulate lipid 
composition of tumour cells and the need for further study to fully elucidate the 
specific interactions with the enzymes involved. 
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5.1 Introduction 
 
Analysis of the fatty acid composition of cellular lipids has indicated an altered 
balance of saturated to monounsaturated fatty acids in tumours relative to normal non 
malignant cells (Fermor et al., 1992).  A study by Merchant et al. (1991) using 31P 
NMR spectroscopy found that levels of the major lipid classes (phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol 
(PI) and sphingomyelin (SM)) were different in normal and transformed breast tissue 
cells.  In particular, there was an elevated level of PI in the malignant breast cells.  In 
a following study, it was found that PC levels in colon cancer cells were significantly 
different when comparing moderately and poorly differentiated tumours (Merchant et 
al., 1995). 
 
Studies have also reported differences in lipid composition between sensitive and 
multidrug resistant cancer cells.  In P388 murine leukaemia cells it was found that 
the sub-line resistant to doxorubicin displayed altered PC/SM ratio caused by the 
decrease in membrane PC and an increase in SM, with the membranes being more 
ordered.  Also in Leukemic T-lymphoblasts, cell membranes from the vinblastine 
resistant line had significantly higher cholesterol and phospholipid levels and raised 
protein/lipid ratio compared to the drug sensitive cells leading to a more ordered and 
therefore less fluid membrane (reviewed in Hendrich and Michalak, 2003).    
 
Cancer cells and indeed all cells have only two options available to source the 
biologically active fatty acids they require: host diet/circulation or de novo synthesis 
(Spector and Burns, 1987).  It is widely accepted that human cancer cells have the 
ability to synthesis their own supply of fatty acids, seemingly independent of the 
regulatory signals that down-regulate fatty acid synthesis in normal cells (Kuhajda, 
2000).  Fatty acid synthase (FAS), previously known as oncogenic antigen 519 (OA-
519), is a key enzyme in the de novo synthesis of fatty acids and has been identified 
as a tumour marker in breast cancer indicating a poor prognosis (Kuhajada et al., 
1989; 1994).  FAS is a multi-enzyme complex comprising an intertwined dimer with 
two lateral semicircular reaction chambers, each containing a full set of catalytic 
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domains required for fatty acid elongation.  De novo synthesis by FAS involves a 
cyclic set of chemical reactions leading to the formation of palmitate (C16:0) from 
acetyl- and malonyl-CoA.  Palmitate is released from the final domain, thioesterase 
(TE) and is then available to be processed by other desaturases or elongase to form 
other fatty acid molecules (Maier et al., 2006).  FAS is down-regulated in normal 
human cells by the intake of small amounts of fat in the diet, but is highly expressed 
in human cancers and is probably one of the most common molecular changes in 
cancer cells (Kuhajda, 2000; Menendez et al., 2005).  Of interest is the recent 
discovery that elevated FAS expression contributes to increased drug resistance in 
breast cancer cells (Liu et al., 2008). 
 
Another important enzyme in de novo fatty acid synthesis is stearoyl-CoA desaturase 
(SCD).  SCD is responsible for catalyzing the formation of monounsaturated fatty 
acids (MUFA), particularly oleic (C18:1) and palmitoleic (C16:1) acid.  The MUFA 
synthesised can then be used in the synthesis of major lipid classes such as 
phospholipids, triglycerides and cholesterol esters (Ntambi et al., 2004).  Hardy et al 
(2000) found that oleic acid stimulated proliferation in breast cancer cell lines, while 
palmitate, a product of FAS, inhibited growth.  It is probable that although 
production of palmitate is upregulated in cancer cells and further up regulated in drug 
resistant cells as described above, it is quickly metabolised by SCD to form oleic 
acid vital for survival and proliferation of cancer cells. 
 
There is a large body of evidence both in vivo and in vitro indicating that tumour cell 
growth can be modulated by individual fatty acids (Burns and Spector, 1993; 
Bougnoux, 1999).  In particular, CLA has been shown to exert a wide range of health 
benefits including anticarcinogenic activity (Belury, 2002; Wahle et al., 2004; Nagao 
et al., 2005).  One proposed mechanism for this anticarcinogenic activity is the 
alteration of the FA composition of the cell membrane phospholipids by CLA 
isomers resulting in reduced synthesis of arachidonic acid (AA) and AA-derived 
eicosanoids associated with stimulation of cancer cell proliferation (Banni et al., 
1999; 2001). 
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It has been suggested that CLA competes with LA for desaturation and elongation 
enzymes involved in the conversion of long chain metabolites (Banni et al., 2004).  
These same enzymes are involved in the metabolism of the n-3 fatty acid α-linolenic 
acid, ALA (Figure 5.1.1).   
 
 
 
Figure 5.1.1.  Schematic of pathways of the metabolism of CLA and LA and the n-3 ALA 
 
 
Elongation and desaturase metabolites of CLA, notable for their conservation of the 
conjugated diene structure, have been detected and identified by Banni and 
coworkers in various tissues including mammary tissue, rat liver and lamb tissue 
(1996, 1999, 2001).  In rat liver and adipose tissue c9,t11-CLA was found to be 
mainly converted into a C20:3 conjugated fatty acid, while the t10,c12-CLA isomer 
EPA 
c5,c8,c11,c14,c17 
C20:5 
 
AA  
c5,c8,c11,c14  
C20:4 
 
c5,c8,c11,c13  
C20:4 
 
c8,c11,c14,c17 
C20:4 
 
 
 
 
∆5-desaturase 
DGLA  
c8,c11,14  
C20:3 
 
c8,c11,c13  
C20:3 
 
c6,c9,c12,c15  
C18:4  
 
 
 
 
elongase 
GLA  
c6,c9,c12 
C18:3  
 
c6,c9,c11 
C18:3 
ALA  
c9,c12,c15 
C18:3 
 
 
 
 
∆6-desaturase 
LA  
c9,c12 
C18:2 
CLA 
c9,t11 
 C18:2 
 
n-3 fatty acids  
 
n-6 fatty acids 
                                  
 161 
was metabolised into a conjugated C18:3 or C16:3 fatty acid (Sebedio et al., 2001).  
The presence of these metabolites in different lipid fractions of tissues (Banni et al., 
2001) may account for some of the differing and sometimes conflicting physiological 
effects of the different CLA isomers. 
 
Examination of the lipid profiles of drug-resistant and sensitive melanoma cells 
following treatment with exogenous fatty acids including CLA may identify a 
potential therapeutic target to modulate the lipid environment and functionality of 
membrane related signalling proteins and drug efflux protein pumps.  The overall 
objective of the work described in this chapter was to determine any differences 
between fatty acid profiles of untreated MDA-MB-435S-F (MDA) melanoma cells 
and a doxorubicin resistant variant MDA-MB435S-F/Adr10p10p (A10p10p) by gas 
chromatography (GC) methods.  In addition, the extent to which CLA mixture of 
isomers (CLA-mix), purified isomers c9,t11 and t10,c12-CLA and omega-3 fatty 
acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), can modulate 
the lipid composition of MDA and A10p10p were determined.   
 
 
5.2 Specific Objectives 
 
 To validate a gas chromatographic (GC) procedure for the analysis of the 
lipid profiles in total lipid extracts of drug sensitive MDA-MB435S-F (MDA) 
and drug resistant MDA-MB435S-F-Adr10p10p (A10p10p) melanoma cells. 
 
 To determine the differences if any between the lipid profiles of untreated 
MDA and A10p10p cells. 
 
 To investigate the effects of a mixture of CLA isomers (CLA-mix), two 
purified single isomers (c9,t11 and t10,c12-CLA) and two omega-3 fatty 
acids (EPA and DHA) on the total cellular lipid fatty acid profiles of both 
MDA and A10p10p cell lines. 
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5.3 Materials & Methods 
5.3.1 Materials 
 
MDA-MB-435-S-F (MDA) human melanoma cell line and its Doxorubicin resistant 
variant MDA-MB-435-S-F/ Adriamycin 10p10p (A10p10p) were developed and 
kindly donated by Dr. Sharon Glynn (NICB, Dublin).  Chemotherapy agent 
Doxorubicin (Dox) was kindly donated by Dr. Glynn (NICB, Dublin).  Conjugated 
Linoleic Acid (CLA) mixture of isomers (99 % pure) (Cat: UC-59A) and single 
preparations (90 % pure) of isomers c9,t11 and t10,c12- CLA (Cat: UC-60A, UC-
61A) as listed previously were from NuChek-Prep, Elysian, MN, USA.  A 7 FAME 
mixture comprising C14:0, C16:0, C16:1, C18:0, C18:1, C18:2 and C18:3 was also 
from NuChek-Prep.  Fatty acid methyl esters (FAME) of single isomers c9,t11; 
t9,t11 and t10,c12- CLA and a mix of 37 FAME were purchased from Matreya Inc., 
Netherlands.  Two FAME mixtures comprising; C8:0, C10:0, C12:0, C14:0 and 
C16:0, and C16:0, C18:0, C18:1 (Oleate), C18:2 (linoleate) and C18:3 (linolenate) 
along with single FAME standards of C20:0 (arachidate), C20:4 (arachidonate), 
C22:6 (docosahexanoate) and internal standard heptadecanoic acid were purchased 
from Sigma-Aldrich (Dublin, Ireland).   
 
All sterile disposable plastic-ware was from Sarstedt Ltd., Wexford, Ireland.  Cell 
culture media, supplements and reagents were purchased from Sigma-Aldrich.  
Boron trifluoride (BF3/meth) (B1252) was also purchased from Sigma, as were all 
other chemicals and solvents listed in this section unless otherwise specified.  All 
solutions were prepared in advance and stored in the solvent press or refrigerator as 
appropriate.  Solvents were HPLC grade or higher.   
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5.3.2 Methods 
5.3.2.1 Cell Culture 
 
Cell lines were grown and maintained as listed previously in a ShelLab, IR2424 
model CO2 humidified Incubator at 37oC.  T-75 flasks were seeded with MDA or 
A10p10p cells at a density of 2x106 cells/flask and cultured for 24 h to allow the 
cells to attach. Flasks were then treated in triplicate with fatty acids (FA) at final 
concentrations of 21 and 75 µM.  FA examined were CLA mixture of isomers 
(CLA), purified isomers c9,t11 and t10,c12-CLA and omega-3 fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  Control flasks were 
treated with media containing ethanol at the same concentration as in experimental 
flasks (<0.01 %).  After 3 days all flasks were harvested.  Floating cells were 
collected by spinning down the media in the flasks and adherent cells were 
trypsinised as listed previously.  These were pooled and a cell count performed using 
the Trypan Blue exclusion method.  Cells were spun down at 1000 rpm for 5 min 
using a Labofuge 400 centrifuge, Heraeus Instruments (Foss Electric, Dublin) and 
the pellets frozen until extraction at a later date. 
 
 
5.3.2.2 Cellular Lipid Extraction 
 
Frozen cell pellets were removed from the freezer, allowed to thaw and total cellular 
lipids were extracted by a method modified from Folch et al, (1957) and Bligh and 
Dyer (1959).  Briefly, 3.75 mL chloroform/methanol solution (2:1 v/v), 10 µL 
internal standard (IS) heptadecanoic acid (50mg/mL), 1.25 mL chloroform and 1.25 
mL ultrapure water were added.  The solution was vortexed well between each 
addition and centrifuged at 2000 rpm for 8 min (Heraeus Labofuge 400 centrifuge, 
Foss Electric, Dublin).  The lower (organic) phase was collected, transferred to an 
extraction tube, dried under nitrogen and stored at -20 oC before methylation at a 
later date. 
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5.3.2.3 Methylation of Lipid Extract 
 
The lipid extract containing free fatty acids was methylated in 14 % BF3/meth 
according to Alonso et al (2004).  To the extract 100 µL methanolic NaOH (1 M) 
was added.  The solution was vortexed and incubated in a water bath at 70 oC.  After 
15 min 200 µL BF3/meth was added and incubated at room temperature for a further 
30 min, following which 200 µL hexane and 100 µL dH20 were added.  This was 
again vortexed and spun at 1000 rpm for 5 min in a centrifuge (Heraeus Labofuge 
400 centrifuge supplied by Foss Electric, Dublin).  The upper (organic) phase was 
transferred to a GC vial, dried under nitrogen and stored at -20 oC for later use.  Prior 
to injection vials are thawed, 100 µL hexane added and vortexed.  Using a Hamilton 
micro-syringe, 1 µL of sample/standard was injected into the gas chromatograph 
(GC). 
 
 
5.3.2.4 Gas Chromatography Analysis 
 
The fatty acid methyl esters (FAME) were analysed using a VARIAN CP-3800 gas 
chromatograph (GC) equipped with a flame ionization detector and a WCOT Fused 
Silica CP-Select CB column- 100 m x 0.25 mm ID, 0.2 µm film thickness 
(Chrompack, Middleburg, The Netherlands).  The injector and the detector 
temperature were maintained at 250 oC.  The column temperature was operated 
isothermally at 190 oC for 60 minutes after injection of samples and then raised from 
190 oC to 225 oC at 4 oC /min with a final hold of 10 min at 225 oC.  Nitrogen was 
used as carrier gas with column flow rate 0.7 mL/min.  Samples were run in split 
(1:20) mode.  
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5.3.2.5 Identification of FAMEs 
 
FAMEs were identified by retention time (RT) with reference to various standard 
FAMEs.  Two FAME mixtures comprising; C8:0, C10:0, C12:0, C14:0 and C16:0, 
and C16:0, C18:0, C18:1 (cis 9), C18:2 (cis 9, cis 12) and C18:3 (cis 9, cis 12, cis 
15) were initially analysed by GC and identified in the order listed (Figure 5.3.2.5.1 a 
& b).  A 7 FAME mixture comprising C14:0, C16:0, C16:1, C18:0, C18:1, C18:2 
and C18:3 was also analysed and cross referenced with the above to confirm 
identities (Figure 5.3.2.5.2).   
 
Individual FAME standards of c9,t11, t9,t11 and t10,c12- CLA, C18:1 (trans 11) 
(vaccenic acid, t-VA), C20:0 (arachidate), C20:4 (arachidonate), C22:6 
(docosahexanoate) and internal standard heptadecanoic acid (C17:0) were run and 
RT’s recorded.  A mixture of 37 FAME was then run and identified according to the 
supplier’s specifications and cross referenced with the above (Figure 5.3.2.5.3 (a)).  
FAME standards of c9,t11, t9,t11 and t10,c12- CLA and t-VA were added to the 37 
FAME mixture and again analysed (Figure 5.3.2.5.3 (b)).  This mixture now contains 
all FAME to be investigated in samples and was injected with every experiment and 
used in the quantification of the various fatty acids present in the cellular lipid 
samples.  As can be seen in Figure 5.3.2.5.3 (b) 18:1 t9, methyl elaidate and 18:1 t11, 
methyl vaccinate eluted together as one peak on the chromatogram.  This combined 
peak also connects at its base with the peak for 18:1 c9, methyl oleate.  Therefore, to 
remove ambiguity all three 18:1’s were measured as one value.  Table 5.3.2.5.1 
contains the chemical name, abbreviation, retention time (RT), quantity present and 
peak area of FAME as detected from a typical injection of the 41 standard fatty acid 
mixture.   
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 (a) 
 
 
 (b) 
 
 
Figure 5.3.2.5.1.  Sample chromatograms of (a) 5 FAME mix C8:0, C10:0, C12:0, C14:0 and 
C16:0, and (b) 5 FAME mix C16:0, C18:0, C18:1 (cis 9), C18:2 (cis 9, cis 12) and C18:3 
(cis 9, cis 12, cis 15) analysed using a 100 m CP-Select CB capillary column.  The solvent 
hexane is the first peak identified in each case eluting at approximately 11.37 min. 
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Figure 5.3.2.5.2.  Sample chromatogram of a 7 FAME mix comprising C14:0, C16:0, C16:1, 
C18:0, C18:1 (cis 9), C18:2 (cis 9, cis 12) and C18:3 (cis 9, cis 12, cis 15) analysed using a 
100 m CP-Select CB capillary column. 
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 (a) 
 
 
 (b) 
 
 
Figure 5.3.2.5.3.  GC chromatogram of the methyl esters of (a) 37 fatty acid standard 
mixture and (b) 41 standard fatty acid mixture analysed using a 100 m CP-Select CB 
capillary column on a Varian CP 3800 GC. 
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Table 5.3.2.5.1.  Notation, Chemical name, quantity present, retention time (RT), and 
peak area of a typical injection of the 41 standard fatty acid mixture analysed using a 
100 m CP-Select CB capillary column on a Varian CP 3800 GC. 
Notation Chemical name 
 
Amount 
mg/mL 
 RT  
Min 
 Peak 
Area 
          
Solvent (Hexane) Hexane   11.36 57484444 
C4:0 Methyl butyrate 1.376  Unidentified 
C6:0 Methyl hexanoate 1.376 11.76 907432 
C8:0 Methyl octanoate 1.376 12.11 1067428 
C10:0 Methyl decanoate 1.376 12.71 1123277 
C11:0 Methyl undecanoate 0.688 13.16 563010 
C12:0 Methyl laurate 1.376 13.76 1174259 
C13:0 Methyl tetradecanoate  0.688 14.54 586533 
C14:0 Methyl myristate 1.376 15.58 1182762 
C14:1 Methyl myristoleate 0.688 16.42 586266 
C15:0 Methyl pentadecanoate 0.688 16.94 591187 
C15:1 Methyl pentadecenoate 0.688 18.04 583906 
C16:0 Methyl palmitate 2.064 18.80 1812848 
C16:1 Methyl palmitoleate 0.688 19.89 587527 
C17:0 Methyl heptadecanoate  9.988 21.11 3767253 
C17:1 Methyl heptadecenoate 0.688 22.79 559917 
C18:0 Methyl stearate 1.376 24.30 1213745 
C18:1 (t9, t11 & c9) 
Methyl elaidate, 
vaccinate (t-VA) & oleate 2.406 25.51 3503790 
C18:2 (t9,t12) Methyl linoelaidate 0.688 27.06 598750 
C18:2 (c9,12) Methyl linoleate (LA) 0.688 28.78 613373 
C18:3 (c6,9,12) 
Methyl gamma-linoleate 
(GLA) 0.688 31.01 588919 
C18:3 (c9,12,15) Methyl linolenate (ALA) 0.688 32.89 590350 
C20:0 Methyl arachidate 1.376 33.79 1235250 
C18:2 (c 9,t11) Methyl c9,t11-CLA  1.03 34.19 365660 
C18:2 (t10,c12) Methyl t10,c12-CLA   1.03 35.02 423112 
C20:1 (c11) Methyl eicosanoate 0.688 36.30 603029 
C18:2 (t9,t11) Methyl t9,t11-CLA  0.52 36.88 255409 
C21:0 Methyl heneicosanoate 0.688 40.70 607104 
C20:2 (c11,14) Methyl eicosadienoate 0.688 41.29 604843 
C20:3 (c8,11,14) 
Methyl dihomo-γ-linoleate 
(DGLA) 0.688 44.94 586727 
C20:4 (c5,8,11,14) Methyl arachidonate (AA) 0.688 47.74 598817 
C20:3 (c11,14,17) Methyl eicosatrienoate 0.688 48.28 624319 
C22:0 Methyl behenate 1.376 49.95 1194218 
C22:1 (c13) Methyl erucate 0.688 54.08 609763 
C23:0 Methyl tricosanoate 0.688 56.20 574299 
C22:2 (c13,16) Methyl docosadienoate 0.688 61.58 630700 
C20:5 (c5,8,11,14,17) 
Methyl eicosapentanoic 
acid (EPA) 0.688 62.22 569050 
C24:0 Methyl lignocerate 1.376 68.98 1270807 
C24:1 (c15) Methyl nervonate 0.688 70.96 636075 
C22:6 (c4,7,10,13,16,19) 
 
Methyl docosahexanoic 
acid (DHA) 
0.688 
 74.04 577297 
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5.3.2.6 Quantification of Cellular Lipid FAME 
 
The first step in calculating quantities of fatty acids in a sample is to correct for 
variations in sample and injection volume and other errors which may occur during 
extraction and methylation.  An internal standard at known concentrations in both 
sample and standard, in this case heptadecanoic acid or C17:0 is used to correct for 
these variations.  A standard mixture of 41 fatty acids was run with each experiment 
and the values obtained were used to calculate levels of individual fatty acids in all 
samples within that experiment.  Table 1 is an example of a typical standard 
injection.  Using the following equation the corrected peak areas were determined for 
each fatty acid identified in a sample. 
 
   AC17:0 Standard          [C17:0 Sample] 
 Acx  =  Ax  x   ------------------    x      ------------------ 
                          AC17:0 Sample            [C17:0 Standard] 
 
Ax denotes the area of the peak for the fatty acid identified in the chromatogram for 
the sample.  Acx denotes the corrected peak area for the fatty acid in question.  AC17:0 
standard and AC17:0 sample denote the internal standard peak areas in the standard 
mixture and the sample, respectively.  [C17:0 standard] and [C17:0 sample] denote 
the internal standard concentration in the standard solution and the sample 
respectively. 
 
From these corrected peak areas (Acx) the concentration in mg/mL of specific fatty 
acid or [x] present in the cellular lipids of each sample can be calculated using the 
following equation. 
      [x Standard]  
 [x]  =  Acx   x    ---------------- 
      Ax Standard 
 
Ax Standard and [x Standard] denote the peak area and concentration of the standard 
of the particular fatty acid in question, x (Table 5.3.2.5.1).   
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5.3.2.7 An example of how [t10,c12-CLA] in a lipid extract may be 
quantified 
 
Concentrations and peak area data from a typical injection of the standard mixture 
are presented in Table 5.3.2.5.1, including the internal standard C17:0 and an 
example of the t10,c12-CLA standard in bold.  From this table the concentration and 
peak area of the internal standard C17:0 in the standard mixture were 9.988 mg/mL 
and 3767253 peak area units respectively.  Corresponding values for t10,c12-CLA in 
the standard were 1.03 mg/mL and 423112 peak area units.  Following analysis of a 
sample of MDA cells treated with the CLA mixture of isomers at 21 µg/mL for three 
days, the peak area for t10,c12-CLA was found to be 1848 peak area units.  
Corresponding values for C17:0 in the sample were 5 mg/mL and 976855 peak area 
units. 
 
Using the first equation: 
 
                  3767253       5 mg/mL 
 Ac t10,c12-CLA  =  1848  x   ---------------    x      ------------------ 
                                          976855   9.988 mg/mL 
 
 Ac t10,c12-CLA  =  3571.0 
 
 
Using the second equation: 
 
               1.03 mg/mL 
 [t10,c12-CLA]  =  3571.0   x     ---------------- 
               423112 
 
 [t10,c12-CLA]  =  0.0087 mg/mL  
      
     =  8.7 µg/mL 
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5.3.2.8 Validation of GC methods 
 
To evaluate the percentage recovery of fatty acids, 21 µg of t10,c12-CLA was spiked 
into 2x106 MDA cells with at least three replicates per experiment.  Lipids were then 
extracted from these samples, methylated and analysed by GC as listed above (Figure 
5.3.2.8 illustrates a typical chromatogram).  Individual lipids were then quantified 
using the above equations.  This calculation results in a concentration in mg/mL, 
therefore the value obtained is multiplied by the sample volume of 0.1 mL to give the 
total amount in mg present in the sample.  Recovery was then calculated and was 
expressed as a percentage of the spiked amount, in this case 21 µg.  Repeatability 
was assessed by calculating the above recoveries of spikes of 21 µg of t10,c12-CLA 
in 2x106 MDA cells on four separate occasions. 
 
 
 
Figure 5.3.2.8.  GC chromatogram of 21 µg of t10,c12-CLA spiked into 2x106 MDA cells 
analysed using a 100 m CP-Select CB capillary column on a Varian CP 3800 GC. 
 
5.3.3 Statistical Analysis 
 
Differences between means were analysed for significance using the Student’s two-
tailed, paired t-test, unless otherwise stated.   
t10,c12-CLA  
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5.4 Results 
5.4.1 Validation of GC methods 
 
To evaluate the percentage recovery of fatty acids, 21 µg of t10,c12-CLA was spiked 
into 2x106 MDA cells with at least three replicates per experiment.  Recovery was 
then calculated and expressed as a percentage of the spiked amount, in this case 21 
µg.  Table 5.4.1.1 lists values obtained over 4 days with at least three replicates per 
experiment.  Intra-assay variation ranged from 4.9 to 41.2 % CV, while the amount 
recovered ranged from 19.7 to 23.1 µg corresponding to percentage recovery of 93.6 
to 110.0 % over the 4 days. 
 
 
Table 5.4.1.1.  Intra-assay variation of recovered t10,c12-CLA spiked into MDA cells 
 t10,c12-CLA  
Recovered (µg) 
Mean  
+ SD 
%   
CV 
% 
Recovery 
 
Day 1 27.5 29.3 12.4 15.0 14.0 19.7 + 8.1 41.2 93.6 
Day 2 20.7 19.3 21.3   20.4 + 1.0 4.9 97.3 
Day 3 22.7 22.6 16.5   20.6 + 3.5 17.1 98.1 
Day 4 23.9 16.0 29.4   23.1 + 6.7 29.0 110.0 
 
 
Repeatability was assessed by calculating the above recoveries of spikes of 21 µg of 
t10,c12-CLA in 2x106 MDA cells on four separate occasions, listed in table 5.4.1.2.  
Average recovery was 20.9 + 1.5 µg of t10,c12-CLA, equating to an average 
percentage recovery of 99.7 %.  Inter-assay variation was calculated to be 7.1 % CV. 
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Table 5.4.1.2.  Inter-assay variation of recovered t10,c12-CLA over 4 days  
t10,c12-
CLA 
 
1 
 
2 
 
3 
 
4 
Mean  
+ SD 
%  
CV 
% 
Recovery 
 
 µg  
+ SD 
 
19.7  
+ 8.1 
 
20.4  
+ 1.0 
 
20.6  
+ 3.5 
 
23.1 
+ 6.7 
 
20.9 
+ 1.5 
 
7.1 
 
99.7 
 
 
5.4.2 Fatty acid profiles of untreated MDA and A10p10p cells 
 
The fatty acid profile of untreated drug sensitive MDA cells was analysed as 
described earlier and compared to that of the drug resistant A10p10p cell line.  
Figure 5.4.2.1 illustrates typical chromatograms of the profiles of both cell lines.  
Table 5.4.2.1 lists the fatty acid composition of untreated MDA and A10p10p cells, 
while table 5.4.2.2 lists the summary of fatty acid composition and various fatty acid 
ratios of both cell lines.  The most abundant fatty acid in both cell lines was the long 
chain saturated fatty acid (LCSFA), C18:0 stearic acid at 34.03 + 0.93 % of total 
cellular FAME in MDA cells and a similar level in A10p10p cells at 34.98 + 4.12 % 
of total.  LCSFA were taken to be any saturated fatty acid (SFA) above a chain 
length of fourteen carbons.   
 
Another predominant LCSFA, C16:0 methyl palmitate, was more abundant in MDA 
cells at 23.13 + 0.26 % total lipid compared to 19.65 + 1.92 % in A10p10p cells 
although this difference was not statistically significant.  This apparent difference in 
methyl palmitate accounts for the overall raised level of LCSFA in the MDA cell 
line, with 61.80 + 1.14 % in MDA cells and 58.25 + 5.36 % of total FAME in 
A10p10p cells.  However, total SFA were significantly higher in A10p10p cells than 
MDA with 73.27 + 1.27 % FAME in MDA and 76.91 + 1.91 % in A10p10p 
suggesting an up-regulation of the FAS enzyme followed by β-oxidation to produce 
short chain SFA (Table 5.4.2.2).   
 
                                  
 175 
Other LCSFA were present in minor amounts in both cell lines including C14:0 
methyl myristate, which was present at a significantly higher level in MDA (3.62 + 
0.13 % FAME) than A10p10p (2.19 + 0.44 % FAME) (Table 5.4.2.1). 
 
The predominant mono-unsaturated fatty acid (MUFA) in MDA cells was the group 
of three C18:1 fatty acids; elaidic (t-9), vaccenic (t-11), and oleic acid (c-9), which 
were indistinguishable from each other and eluted together at approximately 25.51 
min in every run.  Their combined proportion of total cellular lipids was 12.74 + 0.56 
% in MDA cells, whereas this decreased significantly to 7.60 + 1.37 % in the 
resistant A10p10p cells.  The predominant mono-unsaturated fatty acid (MUFA) in 
A10p10p cells was C16:1 methyl palmitoleate (palmitoleic acid) at 8.98 + 2.01 % 
FAME.  The corresponding proportion in MDA cells was 6.46 + 1.31 % total lipid 
(Table 5.4.2.1).   
 
Other UFA were present in both cell lines in minor amounts.  C18:2 (c9,c12) linoleic 
acid (LA) comprised 3.08 + 0.19 % FAME in MDA cells and 1.97 + 0.62 % in 
A10p10p.  C22:6 docosahexanoic acid (DHA) was significantly more abundant in 
MDA cells (1.29 + 0.12 % FAME) than A10p10p cells (0.92 + 0.19 % FAME).  By 
contrast C18:3 α-linolenic acid (ALA), a precursor of DHA, was present in lower 
amounts in MDA control cells at 0.28 + 0.12 % FAME compared to A10p10p cells 
at 0.63 + 0.05 % FAME, possibly due to down-regulation in ∆5/∆6 desaturase and/or 
elongase activities in A10p10p cells (Table 5.4.2.1). 
 
 The reduced level in the group of C18:1 MUFA contributed largely to an apparent 
decrease in overall MUFA from 19.40 + 0.95 % in MDA to 17.30 + 1.66 % of total 
lipid in A10p10p cells and in percentage total unsaturated fatty acids (UFA) from 
26.73 + 1.27 % in MDA cells to 23.09 + 1.91 % in A10p10p (p<0.05) (Table 
5.4.2.2).   
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(a) 
 
 
 
 (b) 
 
 
Figure 5.4.2.1.  Typical chromatograms of fatty acid profiles of untreated (a) MDA  and (b) 
A10p10p cells. 
 
C17:0 
C18:1 (c9, t9 & t11) 
C18:0 
C16:0 
C16:1 
C17:0 
C16:0 
C16:1 
C18:0 
C18:1 (c9, t9 & t11) 
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 These apparent differences in the levels of LCSFA, MUFA and UFA in the MDA 
cell line compared to the A10p10p cell line cancelled each other out when calculated 
as ratios of UFA/LCSFA with similar values obtained in both cell lines, 0.43 + 0.02 
in MDA and 0.40 + 0.02 in A10p10p cells.  Corresponding values for the 
MUFA/LCSFA ratio were 0.31 + 0.01 and 0.30 + 0.02 for the MDA and A10p10p 
cell line respectively.  However, there was a significant decrease in the unsaturation 
index of A10p10p compared to MDA cells when total UFA/SFA were calculated, 
yielding 0.37 + 0.03 in MDA cells and 0.30 + 0.03 in A10p10p (Table 5.4.2.2).   
 
The ratio of C16:1/C16:0 apparently increased from 0.28 + 0.06 in MDA cells to 
0.48 + 0.13 in A10p10p cells and while this difference did not reach statistical 
significance it points to trends in the data.  However in the ratio of C18:1/C18:0 the 
decrease from 0.38 + 0.03 in MDA to 0.22 + 0.04 in A10p10p cells was deemed 
statistically significant.  Since these ratios are thought to be governed by the same 
∆9-desaturase enzyme, which introduces one double bond to the saturated fatty acid, 
they highlight opposing trends in activity of the enzyme (Table 5.4.2.2). 
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Table 5.4.2.1. Fatty acid composition of untreated drug sensitive MDA and drug 
resistant A10p10p cells. 
Fatty Acid MDA A10p10p 
C6:0 0.38 + 0.20 0.38 + 0.03 
C8:0 3.83 + 1.47 8.60 + 4.71 
C10:0 2.76 + 0.27 1.61 + 1.18 
C11:0 3.25 + 0.36 5.43 + 1.60 
C12:0 0.09 + 0.06 0.09 + 0.08 
C13:0 1.16 + 0.10 2.55 + 0.95 
C14:0 3.62 + 0.13 2.19 + 0.44* 
C14:1 0.18 + 0.09 0.38 + 0.29 
C15:0 0.50 + 0.19 0.26 + 0.08 
C15:1 0.02 + 0.02 0.06 + 0.03 
C16:0 23.13 + 0.26 19.65 + 1.92 
C16:1 6.46 + 1.31 8.98 + 2.01 
C18:0 34.03 + 0.93 34.98 + 4.12 
C18:1 (t-9, t-11 & c-9) 12.74 + 0.56 7.60 + 1.37* 
C18:2  LA 3.08 + 0.19 1.97 + 0.62 
C18:3  GLA 0.00 + 0.00 0.10 + 0.10 
C18:3 ALA 0.28 + 0.12 0.63 + 0.05 
C20:0 0.25 + 0.14 0.91 + 0.19 
C18:2 c9,t11-CLA 0.14 + 0.14 0.03 + 0.03 
C18:2 t10,c12-CLA 0.05 + 0.05 0.02 + 0.01 
C20:1 (c11) 0.10 + 0.10 0.02 + 0.02 
C18:2 (t9,t11-CLA) 0.14 + 0.14 0.10 + 0.05 
C20:2 (c11,14) 0.00 + 0.00 0.13 + 0.09 
C20:3  DGLA 0.32 + 0.16 0.16 + 0.02 
C20:4  AA 1.93 + 0.23 1.54 + 0.24 
C22:1 (c13) 0.00 + 0.00 0.10 + 0.10 
C23:0 0.27 + 0.14 0.08 + 0.04 
C20:5  EPA 0.00 + 0.00 0.18 + 0.18 
C24:0 0.00 + 0.00 0.19 + 0.19 
C24:1 (c15) 0.00 + 0.00 0.18 + 0.16 
C22:6  DHA 1.29 + 0.12 0.92 + 0.19* 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to MDA cells as determined by the Student’s t-test (p<0.05) 
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 Table 5.4.2.2. Fatty acid composition and ratios of untreated drug sensitive MDA 
and drug resistant A10p10p cells. 
 
Fatty Acids MDA A10p10p 
SFA 
LCSFA 
73.27 + 1.27 
61.80 + 1.14 
76.91 + 1.91* 
58.25 + 5.36 
UFA 26.73 + 1.27 23.09 + 1.91* 
MUFA 19.40 + 0.95 17.30 + 1.66 
UFA/SFA 
UFA/LCSFA 
0.37 + 0.02 
0.43 + 0.02 
0.30 + 0.03* 
0.40 + 0.02 
MUFA/LCSFA 0.31 + 0.01 0.30 + 0.02 
C16:1/C16:0 0.28 + 0.06 0.48 + 0.13 
C18:1(t9, t11 & c9)/C18:0 0.38 + 0.03 0.22 + 0.04* 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to MDA cells as determined by the Student’s t-test (p<0.05). 
 
 
5.4.3 Fatty acid profiles of MDA cells following treatments 
5.4.3.1 Effects of CLA mixture on Fatty acid profiles of MDA cells 
 
Flasks of 2x106 MDA cells were seeded for 24 h before treatment with 21 and 75 µM 
CLA mixture, incubated for 3 days and extracted and analysed as described earlier.  
Figure 5.4.3.1 illustrates a chromatogram from a typical injection of an MDA sample 
treated with (a) 21 and (b) 75 µM CLA mixture of isomers (CLA-mix).  Table 6 lists 
the fatty acid composition of untreated MDA control and MDA cells treated with 21 
and 75 µM CLA-mix, while table 5.4.3.1.2 lists the summary of fatty acid 
composition and various fatty acid ratios of the above.  The most abundant fatty acid 
in each treatment was the long chain saturated fatty acid (LCSFA) C18:0 stearic acid, 
at similar levels with each treatment, comprising 31.39 + 1.93 % total cellular FAME 
in cells treated with 21 µM CLA-mix and 28.19 + 1.33 % FAME following 75 µM 
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CLA-mix, compared to 34.03 + 0.93 % in control MDA cells.  Another predominant 
LCSFA C16:0 was apparently reduced from 23.13 + 0.26 % FAME in control MDA 
cells to 21.40 + 0.81 and 14.02 + 4.10 % FAME following treatment with 21 and 75 
µM CLA-mix respectively, although these differences were not deemed statistically 
significant.  The decrease in both C16:0 and C18:0 suggests inhibition of FAS by the 
CLA-mix.  Other LCSFA were present in minor amounts including C14:0 methyl 
myristate, which decreased significantly with 21 and 75 µM CLA treatments relative 
to control from 3.62 + 0.13 % FAME to 3.39 + 0.11 and 2.46 + 0.15 % of total 
FAME respectively (Table 5.4.3.1.1).   
 
The predominant MUFA was the group of three C18:1 fatty acids elaidic (t-9), 
vaccenic (t-11), and oleic acid (c-9).  Their combined proportion of total cellular 
lipids of 12.74 + 0.56 % in control MDA cells decreased to 11.31 + 0.31 and 6.48 + 
0.70 % FAME following 21 and 75 µM CLA-mix treatment respectively although 
the difference was only significant following 75 µM CLA-mix treatment (Table 
5.4.3.1.1).  This decrease is possibly due to inhibition of ∆9-desaturase, which 
introduces a double bond into C18:0 stearic acid, producing C18:1 oleic acid.   
 
There was a trend towards an increase in the mono-unsaturated fatty acid (MUFA) 
C16:1 methyl palmitoleate (palmitoleic acid) from 6.46 + 1.31 % total lipid in 
control MDA cells to 6.92 + 2.47 and 9.78 + 5.66 % FAME following 21 and 75 µM 
CLA-mix treatment respectively.  Other UFA were present in minor amounts.  C18:2 
(c9,c12) linoleic acid (LA) comprised 3.08 + 0.19 % FAME in control MDA cells 
and 1.92 + 0.96 and 1.25 + 0.63 % FAME following 21 and 75 µM CLA-mix 
treatment respectively.  C22:6 docosahexanoic acid (DHA) comprised 1.29 + 0.12 % 
FAME in control MDA cells and 0.84 + 0.42 and 0.57 + 0.32 % FAME following 21 
and 75 µM CLA-mix treatment.  There was an apparent drop in C20:4 arachidonic 
acid (AA) levels from 1.93 + 0.23 % FAME in MDA cells to 1.60 + 0.60 and 0.83 + 
0.39 % FAME with 21 and 75 µM CLA-mix, suggesting inhibition of ∆5/∆6 
desaturase and/or elongase activities (Table 5.4.3.1.1). 
 
The level of the c9,t11-CLA isomer was apparently increased from 0.14 + 0.14 % 
FAME in control MDA cells to 0.72 + 0.26 and 3.41 + 2.04 % FAME following 21 
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and 75 µM CLA-mix treatment.  Corresponding levels for the t10,c12-CLA isomer 
were 0.05 + 0.05 % FAME in control MDA cells and 0.95 + 0.56 and 6.08 + 2.59 % 
FAME following 21 and 75 µM CLA-mix treatment.  However, none of these 
differences were found to be statistically significant (Table 5.4.3.1.1). 
 
The apparent reduction in C18:0 stearic acid and C16:0 methyl palmitate levels and 
significant reduction C14:0 methyl myristate levels following 21 and 75 µM CLA-
mix treatment resulted in an apparent overall decreased level of LCSFA from 61.80 
+ 1.14 % FAME in control MDA cells to 57.24 + 2.43 % FAME following 21 µM 
CLA-mix treatment and a significant decrease to 45.93 + 3.62 % FAME following 
75 µM CLA-mix treatment.  This suggests inhibition of FAS activity (Table 
5.4.3.1.2). 
 
The overall UFA level, at 26.73 + 1.27 % FAME in control MDA cells was 28.30 + 
2.47 and 32.86 + 7.52 % FAME following 21 and 75 µM CLA-mix treatment.  
Corresponding MUFA levels were 19.40 + 0.95 % FAME in control MDA cells and 
18.48 + 2.50 and 16.52 + 5.50 % FAME following 21 and 75 µM CLA-mix 
treatment.  The apparent differences in the levels of LCSFA, MUFA and UFA in the 
lipid composition of control MDA cells compared to cells following treatment also 
resulted in a significant increase in the ratio of UFA/LCSFA from 0.43 + 0.02 in 
control MDA cells to 0.49 + 0.03 in cells following treatment with 21 µM CLA-mix 
and an apparent but not significant increase to 0.72 + 0.16 with 75 µM CLA-mix 
treatment.  Corresponding values for the MUFA/LCSFA ratio were 0.31 + 0.01 in 
control MDA cells and 0.32 + 0.03 and 0.36 + 0.12 in cells following treatment with 
21 and 75 µM CLA-mix respectively (Table 5.4.3.1.2).   
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 (a) 
 
 
 (b) 
 
Figure 5.4.3.1.  Typical chromatograms of fatty acid profiles of MDA cells treated with (a) 
21 and (b) 75 µM CLA mixture. 
c9,t11-CLA t10,c12-CLA 
t10,c12-CLA c9,t11-CLA 
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Table 5.4.3.1.1.  Fatty acid composition of MDA cells treated with CLA mix for 72 h. 
Fatty Acid Control CLA 21 µM CLA 75 µM 
C6:0 0.38 + 0.20 0.39 + 0.20 0.55 + 0.55 
C8:0 3.83 + 1.47 4.70 + 2.28 1.55 + 0.84 
C10:0 2.76 + 0.27 2.38 + 0.51 3.04 + 0.80 
C11:0 3.25 + 0.36 4.83 + 1.63 8.46 + 5.26 
C12:0 0.09 + 0.06 0.03 + 0.03 0.29 + 0.19 
C13:0 1.16 + 0.10 1.39 + 0.19 4.88 + 3.14 
C14:0 3.62 + 0.13 3.39 + 0.11* 2.46 + 0.15* 
C14:1 0.18 + 0.09 0.25 + 0.25 0.07 + 0.07 
C15:0 0.50 + 0.19 0.47 + 0.14 0.91 + 0.74 
C15:1 0.02 + 0.02 0.00 + 0.00 0.14 + 0.14 
C16:0 23.13 + 0.26 21.40 + 0.81 14.02 + 4.10 
C16:1 6.46 + 1.31 6.92 + 2.47 9.78 + 5.66 
C18:0 34.03 + 0.93 31.39 + 1.93 28.19 + 1.33 
C18:1 (t-9, t-11 & c-9) 12.74 + 0.56 11.31 + 0.31 6.48 + 0.70* 
C18:2 (c9,12), LA 3.08 + 0.19 1.92 + 0.96 1.25 + 0.63 
C18:3 (c6,9,12), GLA 0.00 + 0.00 0.88 + 0.82 0.56 + 0.50 
C18:3 (c9,12,15) 0.28 + 0.12 0.29 + 0.23 0.67 + 0.62 
C20:0 0.25 + 0.14 0.32 + 0.04 0.25 + 0.03 
C18:2 c9,t11-CLA 0.14 + 0.14 0.72 + 0.26 3.41 + 2.04 
C18:2 t10,c12-CLA 0.05 + 0.05 0.95 + 0.56 6.08 + 2.59 
C20:1 (c11) 0.10 + 0.10 0.41 + 0.30 1.31 + 0.79 
C18:2 (t9,t11-CLA) 0.14 + 0.14 0.31 + 0.05 0.52 + 0.30 
C20:2 (c11,14) 0.00 + 0.00 0.06 + 0.06 0.04 + 0.04 
C20:3  DGLA 0.32 + 0.16 0.32 + 0.16 0.18 + 0.09 
C20:4  AA 1.93 + 0.23 1.60 + 0.60 0.83 + 0.39 
C22:1(c13) 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C23:0 0.27 + 0.14 0.27 + 0.14 0.10 + 0.06 
C22:2 (c13,16) 0.00 + 0.00 0.06 + 0.06 0.04 + 0.04 
C20:5 EPA 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C24:0 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C24:1(c15) 0.00 + 0.00 0.00 + 0.00 0.05 + 0.05 
C22:6 DHA 1.29 + 0.12 0.84 + 0.42 0.57 + 0.32 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05). 
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The ratio of C18:1/C18:0 decreased from 0.38 + 0.03 in control MDA cells to 0.36 + 
0.03 in cells following treatment with 21 µM CLA-mix and decreased significantly 
to 0.23 + 0.03 with 75 µM CLA-mix treatment, suggesting inhibition of oleic acid 
production by ∆9-desaturase in CLA-mix treated cells.  However, the ratio of 
C16:1/C16:0 apparently increased from 0.28 + 0.06 in control MDA cells to 0.32 + 
0.11 and 0.65 + 0.30 in cells treated with 21 and 75 µM CLA-mix respectively, 
indicating that more complex interactions with the enzyme may be at play (Table 
5.4.3.1.2). 
 
 
Table 5.4.3.1.2.  Fatty acid composition and ratios of MDA cells treated with CLA mix 
for 72 h. 
Fatty Acids Control CLA mix 
21 µM 
CLA mix 
75 µM 
LCSFA 61.80 + 1.14 57.24 + 2.43 45.93 + 3.62* 
UFA 26.73 + 1.27 28.30 + 2.47 32.86 + 7.52 
MUFA 19.40 + 0.95 18.48 + 2.50 16.52 + 5.50 
UFA/LCSFA 0.43 + 0.02 0.49 + 0.03* 0.72 + 0.16 
MUFA/LCSFA 0.31 + 0.01 0.32 + 0.03 0.36 + 0.12 
C16:1/C16:0 0.28 + 0.06 0.32 + 0.11 0.65 + 0.30 
C18:1 (t9, t11 & c9)/C18:0 0.38 + 0.03 0.36 + 0.03 0.23 + 0.03* 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05). 
 
 
5.4.3.2  Effects of c9,t11-CLA treatments on Fatty acid profiles of 
MDA cells 
 
Flasks of 2x106 MDA cells were seeded for 24 h before treatment with the c9,t11-
CLA isomer at 21 and 75 µM, incubated for 3 days and extracted and analysed as 
described earlier.  Figure 5.4.3.2 illustrates a chromatogram from a typical injection 
of an MDA sample treated with (a) 21 and (b) 75 µM c9,t11-CLA.   
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 (b) 
 
 
Figure 5.4.3.2.  Typical chromatograms of fatty acid profiles of MDA cells treated with (a) 
21 and (b) 75 µM c9,t11-CLA. 
 
c9,t11-CLA 
c9,t11-CLA 
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Table 5.4.3.2.1 lists the fatty acid composition of untreated MDA control and MDA 
cells treated with 21 and 75 µM c9,t11-CLA, while table 5.4.3.2.2 lists the summary 
of fatty acid composition and various fatty acid ratios of the above.  The most 
abundant fatty acid in each treatment was the long chain saturated fatty acid 
(LCSFA) C18:0 stearic acid.  This was apparently reduced from 34.03 + 0.93 % total 
cellular FAME in control MDA cells to 28.14 + 3.82 % FAME in cells treated with 
21 µM c9,t11-CLA and significantly reduced to 21.09 + 3.34 % FAME following 75 
µM c9,t11-CLA.  A similar trend was observed in another predominant LCSFA, 
C16:0 methyl palmitate.  This was apparently reduced from 23.13 + 0.26 % FAME 
in control MDA cells to 16.66 + 5.53 % FAME in cells treated with 21 µM c9,t11-
CLA and significantly reduced to 15.12 + 1.85 % FAME following treatment with 
75 µM c9,t11-CLA.  These decreases suggest inhibition of FAS by the c9,t11-CLA 
isomer.  Other LCSFA present in minor amounts include C14:0 methyl myristate, 
which decreased relative to control MDA cells from 3.62 + 0.13 % FAME to 3.07 + 
0.40 % FAME with treatment of 21 µM c9,t11-CLA and decreased significantly with 
75 µM c9,t11-CLA to 2.28 + 0.18 % of total FAME (Table 5.4.3.2.1).   
 
The predominant MUFA was the group of three C18:1 fatty acids elaidic (t-9), 
vaccenic (t-11), and oleic acid (c-9).  Their combined proportion of total cellular 
lipids of 12.74 + 0.56 % in control MDA cells decreased to 10.87 + 1.47 % FAME 
with treatment of 21 µM c9,t11-CLA and decreased significantly to 6.79 + 0.67 % 
FAME following 75 µM c9,t11-CLA treatment, suggesting inhibition of ∆9-
desaturase.  There was a trend towards an increase in the mono-unsaturated fatty acid 
(MUFA) C16:1 methyl palmitoleate (palmitoleic acid) from 6.46 + 1.31 % total lipid 
in control MDA cells to 11.24 + 4.75 and 12.15 + 5.15 % FAME following 21 and 
75 µM c9,t11-CLA treatment respectively (Table 5.4.3.2.1).   
 
Other UFA were present in minor amounts.  C18:2 (c9,c12) linoleic acid (LA) 
comprised 3.08 + 0.19 % FAME in control MDA cells and 1.37 + 0.84 % FAME 
following 21 c9,t11-CLA treatment and was significantly reduced to 1.69 + 0.08 % 
FAME following treatment with 75 µM c9,t11-CLA.  C22:6 docosahexanoic acid 
(DHA) comprised 1.29 + 0.12 % FAME in control MDA cells and 2.30 + 1.08 and 
0.87 + 0.08 % FAME following 21 and 75 µM c9,t11-CLA treatment.  There was an 
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apparent drop in C20:4 arachidonic acid (AA) levels from 1.93 + 0.23 % FAME in 
MDA cells to 1.24 + 0.63 and 1.08 + 0.07 % FAME with 21 and 75 µM c9,t11-CLA, 
suggesting inhibition of ∆5/∆6 desaturase and/or elongase activities (Table 
5.4.3.2.1). 
 
The level of the c9,t11-CLA isomer was apparently increased from 0.14 + 0.14 % 
FAME in control MDA cells to 1.55 + 0.87 % FAME following 21 µM c9,t11-CLA 
treatment and increased significantly to 29.44 + 3.63 % FAME with 75 µM c9,t11-
CLA.  Corresponding levels for the t10,c12-CLA isomer remained at trace levels of 
0.05 + 0.05 % FAME in control MDA cells and 0.67 + 0.54 and 0.10 + 0.03 % 
FAME following 21 and 75 µM c9,t11-CLA treatment (Table 5.4.3.2.1). 
 
The reduction in C18:0 methyl stearic acid, C16:0 methyl palmitate and C14:0 
methyl myristate levels following 21 and 75 µM c9,t11-CLA treatment resulted in an 
overall decreased level of LCSFA from 61.80 + 1.14 % FAME in control MDA cells 
to 48.93 + 9.33 % FAME following 21 µM c9,t11-CLA treatment and a significant 
decrease to 39.53 + 5.13 % FAME with 75 µM c9,t11-CLA (Table 9).  The overall 
UFA level, at 26.73 + 1.27 % FAME in control MDA cells, increased to 32.85 + 2.12 
% FAME following 21 µM c9,t11-CLA treatment and increased significantly to 
54.20 + 6.37 % FAME with 75 µM c9,t11-CLA.  Corresponding MUFA levels were 
19.40 + 0.95 % FAME in control MDA cells and 22.27 + 3.64 and 19.05 + 4.85 % 
FAME following 21 and 75 µM c9,t11-CLA treatment (Table 5.4.3.2.2).   
 
The differences in the levels of LCSFA, MUFA and UFA in the lipid composition of 
control MDA cells compared to cells following treatment resulted in an increase in 
the ratio of UFA/LCSFA from 0.43 + 0.02 in control MDA cells to 0.76 + 0.22 and 
1.47 + 0.39 following 21 and 75 µM c9,t11-CLA treatment respectively, although the 
differences were not deemed statistically significant.  Corresponding MUFA/LCSFA 
levels were 0.31 + 0.01 in control MDA cells and 0.53 + 0.21 and 0.52 + 0.18 
following 21 and 75 µM c9,t11-CLA treatment (Table 5.4.3.2.2).   
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Table 5.4.3.2.1.  Fatty acid composition of MDA cells treated with c9,t11-CLA for 72 h. 
Fatty Acid Control c9,t11-CLA  
21 µM 
c9,t11-CLA  
75 µM 
C6:0 0.38 + 0.20 1.19 + 0.70 0.42 + 0.42 
C8:0 3.83 + 1.47 2.27 + 1.20 1.29 + 0.67 
C10:0 2.76 + 0.27 2.10 + 0.49 2.23 + 0.74 
C11:0 3.25 + 0.36 8.22 + 5.30 1.97 + 0.12 
C12:0 0.09 + 0.06 0.08 + 0.08 0.04 + 0.04 
C13:0 1.16 + 0.10 3.93 + 2.75 0.31 + 0.15* 
C14:0 3.62 + 0.13 3.07 + 0.40 2.28 + 0.18* 
C14:1 0.18 + 0.09 0.01 + 0.01  0.00 + 0.00 
C15:0 0.50 + 0.19 0.55 + 0.45 0.40 + 0.22 
C15:1 0.02 + 0.02 0.12 + 0.12 0.00 + 0.00 
C16:0 23.13 + 0.26 16.66 + 5.53 15.12 + 1.85* 
C16:1 6.46 + 1.31 11.24 + 4.75 12.15 + 5.15 
C18:0 34.03 + 0.93 28.14 + 3.82 21.09 + 3.34* 
C18:1 (t9, t11 & c9) 12.74 + 0.56 10.87 + 1.47 6.79 + 0.67* 
C18:2 LA 3.08 + 0.19 1.37 + 0.84 1.69 + 0.08* 
C18:3 GLA 0.00 + 0.00 0.97 + 0.97 0.00 + 0.00 
C18:3(c9,12,15) 0.28 + 0.12 0.38 + 0.29 0.09 + 0.04 
C20:0 0.25 + 0.14 0.36 + 0.07 0.22 + 0.10 
C18:2 c9,t11-CLA 0.14 + 0.14 1.55 + 0.87 29.44 + 3.63* 
C18:2 t10,c12-CLA 0.05 + 0.05 0.67 + 0.54 0.10 + 0.03 
C20:1 (c11) 0.10 + 0.10 0.21 + 0.14 0.78 + 0.37 
C18:2 t9,11-CLA 0.14 + 0.14 0.19 + 0.10 0.88 + 0.88 
C20:2 (c11,14) 0.00 + 0.00 0.00 + 0.00 0.03 + 0.03 
C20:3  DGLA 0.32 + 0.16 0.28 + 0.16 0.18 + 0.10 
C20:4  AA 1.93 + 0.23 1.24 + 0.63 1.08 + 0.07 
C22:1(c13) 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C23:0 0.27 + 0.14 0.15 + 0.12 0.12 + 0.06 
C22:2 (c13,16) 0.00 + 0.00 0.09 + 0.09 0.00 + 0.00  
C20:5 EPA 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C24:0 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00  
C24:1(c15) 0.00 + 0.00 0.03 + 0.03 0.12 + 0.10 
C22:6 DHA 1.29 + 0.12 2.30 + 1.08 0.87 + 0.08 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition. *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05). 
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The ratio of C16:1/C16:0 apparently increased from 0.28 + 0.06 in control MDA 
cells to 1.40 + 1.10 and 0.90 + 0.43 in cells treated with 21 and 75 µM c9,t11-CLA 
treatment.  However in the ratio of C18:1/C18:0 remained relatively similar at 0.38 + 
0.03 in control MDA cells to 0.39 + 0.00 and 0.33 + 0.02 in cells following treatment 
with 21 and 75 µM c9,t11-CLA treatment respectively (Table 5.4.3.2.2). 
 
 
 
Table 5.4.3.2.2.  Fatty acid composition and ratios of MDA cells treated with c9,t11-
CLA for 72 h. 
Fatty Acids Control c9,t11-CLA  
21 µM 
c9,t11-CLA  
75 µM 
LCSFA 61.80 + 1.14 48.93 + 9.33 39.53 + 5.13* 
UFA 26.73 + 1.27 32.85 + 2.12 54.20 + 6.37* 
MUFA 19.40 + 0.95 22.27 + 3.64 19.05 + 4.85 
UFA/LCSFA 0.43 + 0.02 0.76 + 0.22 1.47 + 0.39 
MUFA/LCSFA 0.31 + 0.01 0.53 + 0.21 0.52 + 0.18 
C16:1/C16:0 0.28 + 0.06 1.40 + 1.10 0.90 + 0.43 
C18:1 (t9, t11 & c9)/C18:0 0.38 + 0.03 0.39 + 0.00 0.33 + 0.02 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.01).   
 
 
5.4.3.3 Effects of t10,c12-CLA treatments on Fatty acid profiles of 
MDA cells 
 
Flasks of 2x106 MDA cells were seeded for 24 h before treatment with the t10,c12-
CLA isomer at 21 and 75 µM, incubated for 3 days and extracted and analysed as 
described earlier.  Figure 8 illustrates a chromatogram from a typical injection of an 
MDA sample treated with (a) 21 and (b) 75 µM t10,c12-CLA.  Table 5.4.3.3.1 lists 
the fatty acid composition of untreated MDA control and MDA cells treated with 21 
and 75 µM t10,c12-CLA.  
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Figure 5.4.3.3.  Typical chromatograms of fatty acid profiles of MDA cells treated with (a) 
21 and (b) 75 µM t10,c12-CLA. 
 
 
t10,c12-CLA 
t10,c12-CLA 
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Table 5.4.3.3.2 lists the summary of fatty acid composition and various fatty acid 
ratios of untreated MDA control and MDA cells treated with 21 and 75 µM t10,c12-
CLA.  The most abundant fatty acid in each treatment was the long chain saturated 
fatty acid (LCSFA) C18:0 stearic acid.  This was apparently reduced from 34.03 + 
0.93 % total cellular FAME in control MDA cells to 30.79 + 1.73 % FAME in cells 
treated with 21 µM t10,c12-CLA and 23.32 + 5.06 % FAME following 75 µM 
t10,c12-CLA.  A similar trend was observed in another predominant LCSFA, C16:0 
methyl palmitate.  This was apparently reduced from 23.13 + 0.26 % FAME in 
control MDA cells to 19.99 + 1.12 and 15.65 + 3.33 % FAME in cells treated with 
21 µM and 75 µM t10,c12-CLA respectively.  These decreases suggest inhibition of 
FAS activity by the t10,c12-CLA isomer.  Other LCSFA present in minor amounts 
include C14:0 methyl myristate, which comprised 3.62 + 0.13 % FAME in control 
MDA cells and 3.08 + 0.38 and 2.67 + 0.11 % FAME 21 µM and 75 µM t10,c12-
CLA (Table 5.4.3.3.1).   
 
The predominant MUFA was the group of three C18:1 fatty acids elaidic (t-9), 
vaccenic (t-11), and oleic acid (c-9).  Their combined proportion of total cellular 
lipids of 12.74 + 0.56 % in control MDA cells decreased to 9.58 + 2.77 % FAME 
with treatment of 21 µM t10,c12-CLA and decreased significantly to 6.78 + 0.54 % 
FAME following 75 µM t10,c12-CLA treatment, possibly due to inhibition of ∆9-
desaturase.  The mono-unsaturated fatty acid (MUFA) C16:1 methyl palmitoleate 
(palmitoleic acid) increased from 6.46 + 1.31 % total lipid in control MDA cells to 
16.01 + 6.10 and 8.80 + 3.12 % FAME following 21 and 75 µM t10,c12-CLA 
treatment respectively, although neither increase was significant (Table 5.4.3.3.1).   
 
Other UFA were present in minor amounts.  C18:2 (c9,c12) linoleic acid (LA) 
comprised 3.08 + 0.19 % FAME in control MDA cells and 2.26 + 0.17 % and 2.07 + 
0.14 % FAME following treatment with 21 and 75 µM t10,c12-CLA.  C22:6 
docosahexanoic acid (DHA) comprised 1.29 + 0.12 % FAME in control MDA cells 
and 1.07 + 0.04 % FAME with 21 µM t10,c12-CLA and was significantly reduced to 
1.04 + 0.12 % FAME 75 µM t10,c12-CLA treatment (Table 5.4.3.3.1). 
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Table 5.4.3.3.1.  Fatty acid composition of MDA cells treated with t10,c12-CLA for 72 
h. 
Fatty Acid Control t10,c12-CLA  
21 µM 
t10,c12-CLA  
75 µM 
C6:0 0.38 + 0.20 0.17 + 0.09 0.15 + 0.14 
C8:0 3.83 + 1.47 2.17 + 0.83 1.99 + 0.57 
C10:0 2.76 + 0.27 3.67 + 1.03 2.52 + 0.75 
C11:0 3.25 + 0.36 2.49 + 0.43 1.72 + 0.24 
C12:0 0.09 + 0.06 0.00 + 0.00 0.02 + 0.02 
C13:0 1.16 + 0.10 0.93 + 0.14 0.76 + 0.17 
C14:0 3.62 + 0.13 3.08 + 0.38 2.67 + 0.11 
C14:1 0.18 + 0.09 0.00 + 0.00 0.00 + 0.00 
C15:0 0.50 + 0.19 0.49 + 0.25 0.31 + 0.13 
C15:1 0.02 + 0.02 0.00 + 0.00 0.00 + 0.00 
C16:0 23.13 + 0.26 19.99 + 1.12 15.65 + 3.33 
C16:1 6.46 + 1.31 16.01 + 6.10 8.80 + 3.12 
C18:0 34.03 + 0.93 30.79 + 1.73 23.32 + 5.06 
C18:1 (t9, t11 & c9) 12.74 + 0.56 9.58 + 2.77 6.78 + 0.54* 
C18:2 LA 3.08 + 0.19 2.26 + 0.17 2.07 + 0.14 
C18:3 GLA 0.00 + 0.00 0.07 + 0.04 0.00 + 0.00 
C18:3(c9,12,15) 0.28 + 0.12 0.33 + 0.22 0.29 + 0.16 
C20:0 0.25 + 0.14 0.53 + 0.15 0.66 + 0.07 
C18:2 c9,t11-CLA 0.14 + 0.14 0.28 + 0.10 0.17 + 0.09 
C18:2 t10,c12-CLA 0.05 + 0.05 3.59 + 1.12 26.37 + 5.53* 
C20:1 (c11) 0.10 + 0.10 0.30 + 0.16 0.95 + 0.24 
C18:2 t9,11-CLA 0.14 + 0.14 0.20 + 0.20 0.95 + 0.95 
C20:2 (c11,14) 0.00 + 0.00 0.08 + 0.04 0.09 + 0.05 
C20:3  DGLA 0.32 + 0.16 0.24 + 0.12 0.30 + 0.05 
C20:4  AA 1.93 + 0.23 1.46 + 0.08 1.57 + 0.18 
C22:1(c13) 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C23:0 0.27 + 0.14 0.19 + 0.08 0.12+ 0.05 
C22:2 (c13,16) 0.00 + 0.00 0.00 + 0.00 0.10 + 0.10 
C20:5 EPA 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C24:0 0.00 + 0.00 0.00 + 0.00 0.32 + 0.32 
C24:1(c15) 0.00 + 0.00 0.02 + 0.02 0.13+ 0.13 
C22:6 DHA 1.29 + 0.12 1.07 + 0.04 1.04 + 0.12* 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition. *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05). 
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The level of the t10,c12-CLA isomer was apparently increased from 0.05 + 0.05 % 
FAME in control MDA cells to 3.59 + 1.12 % FAME following 21 µM t10,c12-CLA 
treatment and increased significantly to 26.37 + 5.53 % FAME with 75 µM t10,c12-
CLA.  Corresponding levels for the c9,t11-CLA isomer remained at trace levels of 
0.14 + 0.14 % FAME in control MDA cells and 0.28 + 0.10 and 0.17 + 0.09 % 
FAME following 21 and 75 µM t10,c12-CLA treatment (Table 5.4.3.3.1). 
 
The apparent decreases in C18:0 stearic acid, C16:0 methyl palmitate and C14:0 
methyl myristate levels following 21 and 75 µM t10,c12-CLA treatment resulted in 
an overall decreased level of LCSFA from 61.80 + 1.14 % FAME in control MDA 
cells to 55.08 + 2.79 and 43.24 + 8.05 % FAME following 21 and 75 µM t10,c12-
CLA treatment, although not deemed significant.  The overall UFA level, at 26.73 + 
1.27 % FAME in control MDA cells, apparently increased to 35.48 + 4.45 and 49.60 
+ 9.01 % FAME with 21 and 75 µM t10,c12-CLA.  Corresponding MUFA levels 
were 19.40 + 0.95 % FAME in control MDA cells and 25.61 + 3.68 and 15.71 + 2.72 
% FAME following 21 and 75 µM t10,c12-CLA treatment (Table 5.4.3.3.2).   
 
Resultant ratio of UFA/LCSFA apparently increased from 0.43 + 0.02 in control 
MDA cells to 0.65 + 0.11 and 1.35 + 0.55 following 21 and 75 µM t10,c12-CLA 
treatment respectively, although the differences were not deemed statistically 
significant.  Corresponding MUFA/LCSFA levels were 0.31 + 0.01 in control MDA 
cells and 0.47 + 0.09 and 0.42 + 0.17 following 21 and 75 µM t10,c12-CLA 
treatment (Table 5.4.3.3.2).   
 
The ratio of C16:1/C16:0 apparently increased from 0.28 + 0.06 in control MDA 
cells to 0.84 + 0.33 and 0.74 + 0.42 in cells treated with 21 and 75 µM t10,c12-CLA 
treatment.  However the ratio of C18:1/C18:0 remained relatively similar at 0.38 + 
0.03 in control MDA cells to 0.30 + 0.07 and 0.32 + 0.07 in cells following treatment 
with 21 and 75 µM t10,c12-CLA treatment respectively (Table 5.4.3.3.2). 
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Table 5.4.3.3.2.  Fatty acid composition and ratios of MDA cells treated with t10,c12-
CLA for 72 h. 
Fatty Acids Control t10,c12-CLA  
21 µM 
t10,c12-CLA  
75 µM 
LCSFA 61.80 + 1.14 55.08 + 2.79 43.24 + 8.05 
UFA 26.73 + 1.27 35.48 + 4.45 49.60 + 9.01 
MUFA 19.40 + 0.95 25.61 + 3.68 15.71 + 2.72 
UFA/LCSFA 0.43 + 0.02 0.65 + 0.11 1.35 + 0.55 
MUFA/LCSFA 0.31 + 0.01 0.47 + 0.09 0.42 + 0.17 
C16:1/C16:0 0.28 + 0.06 0.84 + 0.33 0.74 + 0.42 
C18:1 (t9, t11 & c9)/C18:0 0.38 + 0.03 0.30 + 0.07 0.32 + 0.07 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.   
 
 
5.4.3.4 Effects of EPA treatments on Fatty acid profiles of MDA 
cells 
 
Flasks of 2x106 MDA cells were seeded for 24 h before treatment with 
eicosapentanoic acid (EPA) at 21 and 75 µM, incubated for 3 days and extracted and 
analysed as described earlier.  Figure 5.4.3.4 illustrates a chromatogram from a 
typical injection of an MDA sample treated with (a) 21 and (b) 75 µM EPA.  Table 
5.4.3.4.1 lists the fatty acid composition of untreated MDA control and MDA cells 
treated with 21 and 75 µM EPA, while table 5.4.3.4.2 lists the summary of fatty acid 
composition and various fatty acid ratios of the above.  The most abundant fatty acid 
in each treatment was the long chain saturated fatty acid (LCSFA) C18:0 stearic acid.   
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Figure 5.4.3.4.  Typical chromatograms of fatty acid profiles of MDA cells treated with (a) 
21 and (b) 75 µM EPA. 
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C18:0 stearic acid was relatively unchanged from 34.03 + 0.93 % total cellular 
FAME in control MDA cells to 30.28 + 2.37 % FAME in cells treated with 21 µM 
EPA and 34.15 + 0.46 % FAME following 75 µM EPA.  Another predominant 
LCSFA, C16:0 methyl palmitate was significantly reduced from 23.13 + 0.26 % 
FAME in control MDA cells to 19.93 + 0.51 % FAME in cells treated with 21 µM 
EPA and apparently reduced to 20.03 + 0.95 % FAME with 75 µM EPA, perhaps 
due to inhibition of FAS activity by EPA (Table 5.4.3.4.1).   
 
Other LCSFA present in minor amounts include C14:0 methyl myristate, which 
comprised 3.62 + 0.13 % FAME in control MDA cells and decreased to 2.74 + 0.45 
with 21 µM EPA and decreased significantly to 2.07 + 0.21 % FAME with 75 µM 
EPA.  LCSFA C10:0 and C11:0 levels decreased significantly with treatments of 21 
µM EPA relative to control MDA cells from 2.76 + 0.27 to 1.08 + 0.58 % FAME 
and from 3.25 + 0.36 to 1.67 + 0.19 % FAME.  C10:0, C13:0 and C14:0 levels 
decreased significantly with treatments of 75 µM EPA from 2.76 + 0.27 to 0.34 + 
0.29 %, 1.16 + 0.10 to 0.06 + 0.06 % and from 3.62 + 0.13 to 2.07 + 0.21 % FAME 
respectively.  These decreases may be due to a reduced level of β-oxidation of longer 
chain fatty acids.  C20:0 increased significantly from 0.25 + 0.14 % FAME in the 
MDA control cells to 0.84 + 0.06 with treatments of 75 µM EPA.  Also, C24:0 
increased significantly from undetectable levels in the MDA control cells to 0.12 + 
0.01 and 0.30 + 0.07 with 21 and 75 µM EPA respectively (Table 5.4.3.4.1).   
 
The predominant MUFA was the group of three C18:1 fatty acids elaidic (t-9), 
vaccenic (t-11), and oleic acid (c-9).  Their combined proportion of total cellular 
lipids of 12.74 + 0.56 % in control MDA cells decreased to 6.34 + 2.29 % FAME 
with treatment of 21 µM EPA and decreased significantly to 3.15 + 1.44 % FAME 
following 75 µM EPA treatment, suggesting inhibition of the ∆9-desaturase enzyme.  
The mono-unsaturated fatty acid (MUFA) C16:1 methyl palmitoleate (palmitoleic 
acid) increased from 6.46 + 1.31 % total lipid in control MDA cells to 25.20 + 3.95 
and 27.15 + 3.81 % FAME following 21 and 75 µM EPA treatment respectively.  
C20:1 methyl eicosanoate increased significantly from 0.10 + 0.10 to 0.25 + 0.06 
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with 75 µM EPA treatment, possibly formed as an intermediate in the 
oxidation/metabolism of the C20:5 EPA (Table 5.4.3.4.1).   
 
Other UFA were present in minor amounts.  C18:2 (c9,c12) linoleic acid (LA) 
comprised 3.08 + 0.19 % FAME in control MDA cells and 2.05 + 0.69 % following 
treatment with 21 µM EPA and was decreased significantly to 1.09 + 0.34 % FAME 
with 75 µM EPA.  C18:3 α-linolenic acid (ALA), a precursor of EPA, increased 
from 0.28 + 0.12 to 0.51 + 0.07 % FAME with 75 µM EPA, possibly due to negative 
feedback by EPA inhibiting ∆5/∆6 desaturase and/or elongase activities.  There was 
an apparent drop in C20:4 arachidonic acid (AA) levels from 1.93 + 0.23 % FAME 
in MDA cells to 1.62 + 0.51 and 0.88 + 0.32 % FAME with 21 and 75 µM CLA-mix, 
also suggesting inhibition of ∆5/∆6 desaturase and/or elongase activities (Table 
5.4.3.4.1). 
 
C20:2 methyl eicosadienoate, an oxidation intermediate of EPA, increased 
significantly from undetectable to 0.13 + 0.02 % FAME with 75 µM EPA.  C22:6 
docosahexanoic acid (DHA) comprised 1.29 + 0.12 % FAME in control MDA cells 
and 1.02 + 0.28 % FAME with 21 µM EPA and was significantly reduced to 0.40 + 
0.06 % FAME following 75 µM EPA treatment.  This indicates inhibition of ∆4-
desaturase and/or elongase enzymes (Table 5.4.3.4.1). 
 
The level of EPA apparently increased from undetectable in control MDA cells to 
trace levels of 0.14 + 0.13 and 0.46 + 0.43 % FAME following 21 and 75 µM EPA 
treatment (Table 5.4.3.4.1).  This indicates that most of the EPA taken into the cells 
is quickly metabolised to other forms resulting in an apparently low uptake. 
 
There was a significant decrease in the overall level of LCSFA from 61.80 + 1.14 % 
FAME in control MDA cells to 56.76 + 1.58 with 21 µM EPA, whereas the level 
remained relatively unchanged at 60.73 + 1.61 % FAME following 75 µM EPA 
treatment.  The overall UFA level, at 26.73 + 1.27 % FAME in control MDA cells, 
increased significantly to 38.39 + 0.61 and 35.66 + 2.08 % FAME with 21 and 75 
µM EPA.  Corresponding MUFA levels increased significantly from 19.40 + 0.95 % 
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FAME in control MDA cells to 31.70 + 1.74 and 30.73 + 2.43 % FAME following 
21 and 75 µM EPA treatment (Table 5.4.3.4.2).   
 
The ratio of UFA/LCSFA significantly increased from 0.43 + 0.02 in control MDA 
cells to 0.68 + 0.03 with 21 µM EPA, with an apparent but not significant increase to 
0.59 + 0.05 with 75 µM EPA.  The MUFA/LCSFA ratio increased significantly from 
0.31 + 0.01 in control MDA cells to 0.56 + 0.03 following 21 µM EPA treatment, 
with a corresponding level of 0.51 + 0.05 following 75 µM EPA treatment (Table 
5.4.3.4.2).   
 
The ratio of C18:1/C18:0 apparently decreased from 0.38 + 0.03 in control MDA 
cells to 0.22 + 0.09 in cells following treatment with 21 µM EPA and significantly 
decreased to 0.09 + 0.04 in cells with 75 µM EPA, possibly due to inhibition of ∆9-
desaturase.  The ratio of C16:1/C16:0 significantly increased from 0.28 + 0.06 in 
control MDA cells to 1.27 + 0.22 and 1.38 + 0.24 in cells treated with 21 and 75 µM 
EPA (Table 5.4.3.4.2). 
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Table 5.4.3.4.1.  Fatty acid composition of MDA cells treated with EPA for 72 h. 
Fatty Acid Control EPA  21 µM EPA  75 µM 
C6:0 0.38 + 0.20 0.09 + 0.09 0.02 + 0.02 
C8:0 3.83 + 1.47 1.52 + 0.27 1.19 + 0.23 
C10:0 2.76 + 0.27 1.08 + 0.58* 0.34 + 0.29* 
C11:0 3.25 + 0.36 1.67 + 0.19* 2.00 + 0.13 
C12:0 0.09 + 0.06 0.03 + 0.01 0.00 + 0.00  
C13:0 1.16 + 0.10 0.47 + 0.27 0.06 + 0.06* 
C14:0 3.62 + 0.13 2.74 + 0.45 2.07 + 0.21* 
C14:1 0.18 + 0.09 0.00 + 0.00 0.00 + 0.00 
C15:0 0.50 + 0.19 1.07 + 0.29  0.66 + 0.13 
C15:1 0.02 + 0.02 0.00 + 0.00 0.00 + 0.00 
C16:0 23.13 + 0.26 19.93 + 0.51* 20.03 + 0.95 
C16:1 6.46 + 1.31 25.20 + 3.95* 27.15 + 3.81* 
C18:0 34.03 + 0.93 30.28 + 2.37 34.15 + 0.46 
C18:1 (t9, t11 & c9) 12.74 + 0.56 6.34 + 2.29 3.15 + 1.44* 
C18:2 LA 3.08 + 0.19 2.05 + 0.69 1.09 + 0.34* 
C18:3 GLA 0.00 + 0.00 0.06 + 0.02 0.12 + 0.04 
C18:3(c9,12,15) 0.28 + 0.12 0.36 + 0.10 0.51 + 0.07 
C20:0 0.25 + 0.14 0.52 + 0.05 0.84 + 0.06* 
C18:2 c9,t11-CLA 0.14 + 0.14 0.16 + 0.01 0.20 + 0.04 
C18:2 t10,c12-CLA 0.05 + 0.05 0.15 + 0.15 0.00 + 0.00 
C20:1 (c11) 0.10 + 0.10 0.16 + 0.04 0.25 + 0.06* 
C18:2 t9,11-CLA 0.14 + 0.14 0.24 + 0.12 0.19 + 0.05 
C20:2 (c11,14) 0.00 + 0.00 0.14 + 0.07 0.13 + 0.02* 
C20:3 DGLA 0.32 + 0.16 0.32 + 0.11 0.14 + 0.09 
C20:4 AA 1.93 + 0.23 1.62 + 0.51 0.88 + 0.32 
C22:1(c13) 0.00 + 0.00 0.03 + 0.03 0.23 + 0.15 
C23:0 0.27 + 0.14 2.05 + 0.75 2.64 + 0.90 
C22:2 (c13,16) 0.00 + 0.00 0.27 + 0.21 0.55 + 0.19 
C20:5 EPA 0.00 + 0.00 0.14 + 0.13 0.46 + 0.43 
C24:0 0.00 + 0.00 0.12 + 0.01* 0.30 + 0.07* 
C24:1(c15) 0.00 + 0.00 0.13 + 0.02* 0.20 + 0.09 
C22:6 DHA 1.29 + 0.12 1.02 + 0.28 0.40 + 0.06* 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).   
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Table 5.4.3.4.2.  Fatty acid composition and ratios of MDA cells treated with EPA for 
72 h. 
Fatty Acids Control EPA 21 µM EPA 75 µM 
LCSFA 61.80 + 1.14 56.76 + 1.58* 60.73 + 1.61 
UFA 26.73 + 1.27 38.39 + 0.61* 35.66 + 2.08* 
MUFA 19.40 + 0.95 31.70 + 1.74* 30.73 + 2.43* 
UFA/LCSFA 0.43 + 0.02 0.68 + 0.03* 0.59 + 0.05 
MUFA/LCSFA 0.31 + 0.01 0.56 + 0.03* 0.51 + 0.05 
C16:1/C16:0 0.28 + 0.06 1.27 + 0.22* 1.38 + 0.24* 
C18:1 (t9, t11 & c9)/C18:0 0.38 + 0.03 0.22 + 0.09 0.09 + 0.04* 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).   
 
 
 
5.4.3.5 Effects of DHA treatments on Fatty acid profiles of MDA 
cells 
 
Flasks of 2x106 MDA cells were seeded for 24 h before treatment with 
docosahexanoic acid (DHA) at 21 and 75 µM, incubated for 3 days and extracted and 
analysed as described earlier.  Figure 5.4.3.5 illustrates a chromatogram from a 
typical injection of an MDA sample treated with (a) 21 and (b) 75 µM DHA.  Table 
5.4.3.5.1 lists the fatty acid composition of untreated MDA control and MDA cells 
treated with 21 and 75 µM DHA.  Table 5.4.3.5.2 lists the summary of fatty acid 
composition and various fatty acid ratios of untreated MDA control and MDA cells 
treated with 21 and 75 µM DHA.  The most abundant fatty acid in each treatment 
was the long chain saturated fatty acid (LCSFA) C18:0 stearic acid.   
 
C18:0 stearic acid was relatively unchanged from 34.03 + 0.93 % total cellular 
FAME in control MDA cells to 29.97 + 2.19 % FAME in cells treated with 21 µM 
DHA and 30.22 + 1.26 % FAME following 75 µM DHA.  Another predominant 
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LCSFA, C16:0 methyl palmitate was apparently reduced from 23.13 + 0.26 % 
FAME in control MDA cells to 19.39 + 1.77 and 19.35 + 2.06 % FAME in cells 
treated with 21 and 75 µM DHA respectively, although not statistically significant 
(Table 5.4.3.5.1).  This indicates DHA had little or no effect on FAS activity in 
MDA cells.  
 
The predominant MUFA was the group of three C18:1 fatty acids elaidic (t-9), 
vaccenic (t-11), and oleic acid (c-9).  Their combined proportion of total cellular 
lipids of 12.74 + 0.56 % in control MDA cells decreased significantly to 5.93 + 1.80 
% FAME with treatment of 21 µM DHA and resulted in an apparent decrease to 6.41 
+ 1.48 % FAME following 75 µM DHA treatment, suggesting inhibition of ∆9-
desaturase by DHA.  The mono-unsaturated fatty acid (MUFA) C16:1 methyl 
palmitoleate (palmitoleic acid) apparently increased from 6.46 + 1.31 % total lipid in 
control MDA cells to 24.40 + 9.03 and 18.28 + 3.98 % FAME following 21 and 75 
µM DHA treatment respectively (Table 5.4.3.5.1).   
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Figure 5.4.3.5.  Typical chromatograms of fatty acid profiles of MDA cells treated with (a) 
21 and (b) 75 µM DHA. 
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Other UFA were present in minor amounts.  C18:2 (c9,c12) linoleic acid (LA) 
comprised 3.08 + 0.19 % FAME in control MDA cells and 1.31 + 0.78 and 1.92 + 
0.45 % FAME following treatment with 21 and 75 µM DHA.  C18:3 α-linolenic acid 
(ALA) levels comprised 0.28 + 0.12 % FAME in control MDA cells and 0.26 + 0.17 
and 0.20 + 0.10 % FAME with 21 and 75 µM DHA (Table 5.4.3.5.1).   
 
DHA treatment resulted in significant uptake of DHA into the cells with levels rising 
from 1.29 + 0.12 % FAME in control MDA cells to 4.41 + 1.37 and 8.06 + 0.78 % 
FAME following treatment with 21 and 75 µM DHA respectively (Table 5.4.3.5.1). 
 
There was an apparent decrease in the overall level of LCSFA from 61.80 + 1.14 % 
FAME in control MDA cells to 52.78 + 4.21 and 54.24 + 2.53 % FAME following 
21 and 75 µM DHA treatment.  The overall UFA level, at 26.73 + 1.27 % FAME in 
control MDA cells, apparently increased to 38.17 + 7.10 and 36.75 + 1.96 % FAME 
with 21 and 75 µM DHA.  Corresponding MUFA levels apparently increased from 
19.40 + 0.95 % FAME in control MDA cells to 30.67 + 8.46 and 24.99 + 2.27 % 
FAME following 21 and 75 µM EPA treatment (Table 5.4.3.5.2).  The increase in 
overall UFA and MUFA is mainly due to a combination of direct uptake of DHA and 
indirect actions leading to increases in C16:1 palmitoleic acid. 
 
There was an apparent but not significant increase ratio of UFA/LCSFA from 0.43 + 
0.02 in control MDA cells to 0.77 + 0.22 and 0.69 + 0.06 with 21 and 75 µM DHA.  
The corresponding values for the MUFA/LCSFA ratio were 0.31 + 0.01 in control 
MDA cells and 0.64 + 0.23 and 0.47 + 0.06 following 21 and 75 µM DHA treatment 
(Table 5.4.3.5.2).   
 
The ratio of C18:1/C18:0 apparently decreased from 0.38 + 0.03 in control MDA 
cells to 0.21 + 0.04 in cells following treatment with 21 µM DHA and significantly 
decreased to 0.20 + 0.06 in cells with 75 µM DHA, indicating inhibition of ∆9-
desaturase.  The ratio of C16:1/C16:0 apparently increased from 0.28 + 0.06 in 
control MDA cells to 1.41 + 0.60 and 1.05 + 0.28 in cells treated with 21 and 75 µM 
DHA (Table 5.4.3.5.2). 
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Table 5.4.3.5.1.  Fatty acid composition of MDA cells treated with DHA for 72 h. 
Fatty Acid Control DHA  21 µM DHA  75 µM 
C6:0 0.38 + 0.20 0.54 + 0.31 0.19 + 0.14 
C8:0 3.83 + 1.47 2.78 + 1.23 1.94 + 0.49 
C10:0 2.76 + 0.27 3.37 + 1.49 2.95 + 0.79 
C11:0 3.25 + 0.36 1.75 + 0.65 2.96 + 0.65 
C12:0 0.09 + 0.06 0.04 + 0.04 0.02 + 0.02 
C13:0 1.16 + 0.10 0.56 + 0.29 0.96 + 0.41 
C14:0 3.62 + 0.13 2.59 + 0.51 2.76 + 0.44 
C14:1 0.18 + 0.09 0.04 + 0.04 0.09 + 0.06 
C15:0 0.50 + 0.19 0.24 + 0.12 0.68 + 0.42 
C15:1 0.02 + 0.02 0.00 + 0.00 0.01 + 0.01 
C16:0 23.13 + 0.26 19.39 + 1.77 19.35 + 2.06 
C16:1 6.46 + 1.31 24.40 + 9.03 18.28 + 3.98 
C18:0 34.03 + 0.93 29.97 + 2.19 30.22 + 1.26 
C18:1 (t9, t11 & c9) 12.74 + 0.56 5.93 + 1.80* 6.41 + 1.48  
C18:2 LA 3.08 + 0.19 1.31 + 0.78 1.92 + 0.45 
C18:3 GLA 0.00 + 0.00 0.00 + 0.00 0.04 + 0.03 
C18:3(c9,12,15) 0.28 + 0.12 0.26 + 0.17 0.20 + 0.10 
C20:0 0.25 + 0.14 0.45 + 0.16 0.39 + 0.08 
C18:2 c9,t11-CLA 0.14 + 0.14 0.08 + 0.05 0.04 + 0.02 
C18:2 t10,c12-CLA 0.05 + 0.05 0.12 + 0.05 0.11 + 0.08 
C20:1 (c11) 0.10 + 0.10 0.09 + 0.04 0.04 + 0.02 
C18:2 t9,11-CLA 0.14 + 0.14 0.00 + 0.00 0.00 + 0.00 
C20:2 (c11,14) 0.00 + 0.00 0.01 + 0.01 0.02 + 0.02 
C20:3 DGLA 0.32 + 0.16 0.27 + 0.15 0.30 + 0.08 
C20:4 AA 1.93 + 0.23 0.93 + 0.54 1.03 + 0.25 
C22:1(c13) 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C23:0 0.27 + 0.14 0.14 + 0.14 0.76 + 0.22 
C22:2 (c13,16) 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C20:5 EPA 0.00 + 0.00 0.00 + 0.00 0.00 + 0.00 
C24:0 0.00 + 0.00 0.00 + 0.00 0.05 + 0.04 
C24:1(c15) 0.00 + 0.00 0.31 + 0.25 0.20 + 0.11 
C22:6 DHA 1.29 + 0.12 4.41 + 1.37* 8.06 + 0.78* 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).   
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Table 5.4.3.5.2  Fatty acid composition and ratios of MDA cells treated with DHA for 
72 h. 
Fatty Acids Control DHA 21 µM DHA 75 µM 
LCSFA 61.80 + 1.14 52.78 + 4.21 54.24 + 2.53 
UFA 26.73 + 1.27 38.17 + 7.10 36.75 + 1.96 
MUFA 19.40 + 0.95 30.67 + 8.46 24.99 + 2.27 
UFA/LCSFA 0.43 + 0.02 0.77 + 0.22 0.69 + 0.06 
MUFA/LCSFA 0.31 + 0.01 0.64 + 0.23 0.47 + 0.06 
C16:1/C16:0 0.28 + 0.06 1.41 + 0.60 1.05 + 0.28 
C18:1 (t9, t11 & c9)/C18:0 0.38 + 0.03 0.20 + 0.06* 0.21 + 0.04 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).   
 
 
5.4.4 Fatty acid profiles of A10p10p cells following treatments 
5.4.4.1 Effects of CLA mixture treatments on Fatty acid profiles of 
A10p10p cells 
 
Flasks of 2x106 of drug resistant A10p10p cells were seeded for 24 h before 
treatment with 21 and 75 µM CLA mixture, incubated for 3 days and extracted and 
analysed as described earlier.  Figure 5.4.4.1 illustrates a chromatogram from a 
typical injection of an A10p10p sample treated with (a) 21 and (b) 75 µM of the 
CLA mixture of isomers (CLA-mix).  Table 5.4.4.1.1 lists the fatty acid composition 
of untreated A10p10p control cells and A10p10p cells treated with 21 and 75 µM 
CLA-mix, while table 5.4.4.1.2 lists the summary of fatty acid composition and 
various fatty acid ratios of the above.  The most abundant fatty acid in each treatment 
was the long chain saturated fatty acid (LCSFA) C18:0 stearic acid.   
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Figure 5.4.4.1.  Typical chromatograms of fatty acid profiles of A10p10p cells treated with 
(a) 21 and (b) 75 µM CLA-mix. 
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C18:0 stearic acid was relatively unchanged from 34.98 + 4.12 % total cellular 
FAME in control A10p10p cells to 37.53 + 0.51 % FAME in cells treated with 21 
µM CLA-mix and an apparent but not significant decrease to 24.69 + 6.70 % FAME 
following 75 µM CLA-mix.  Another predominant LCSFA, C16:0 methyl palmitate 
was apparently reduced from 19.65 + 1.92 % FAME in control A10p10p cells to 
18.94 + 1.15 and 14.58 + 2.75 % FAME in cells treated with 21 and 75 µM CLA-
mix respectively, although not statistically significant (Table 5.4.4.1.1).  These 
decreases suggest inhibition of FAS activity. 
 
The predominant mono-unsaturated fatty acid (MUFA), C16:1 methyl palmitoleate 
(palmitoleic acid), apparently increased from 8.98 + 2.01 % total lipid in control 
A10p10p cells to 10.25 + 1.16 and 21.11 + 12.32 % FAME following 21 and 75 µM 
CLA-mix treatment respectively, indicating a possible increase in ∆9-desaturase 
activity by CLA-mix.  Another abundant MUFA was the group of three C18:1 fatty 
acids elaidic (t-9), vaccenic (t-11), and oleic acid (c-9).  Their combined proportion 
of total cellular lipids of 7.60 + 1.37 % in control A10p10p cells remained relatively 
unchanged with treatments of 21 and 75 µM CLA-mix, with levels of 7.83 + 1.78 
and 6.38 + 1.89 % FAME respectively (Table 5.4.4.1.1).   
 
Other UFA were present in minor amounts.  C18:2 (c9,c12) linoleic acid (LA) 
comprised 1.97 + 0.62 % FAME in control A10p10p cells and 2.15 + 0.68 and 1.92 
+ 0.95 % FAME following treatment with 21 and 75 µM CLA-mix.  C18:3 α-
linolenic acid (ALA) levels comprised 0.63 + 0.05 % FAME in control A10p10p 
cells and 0.81 + 0.26 and 0.58 + 0.20 % FAME with 21 and 75 µM CLA-mix.  Also, 
there was relatively no change in C20:4 arachidonic acid (AA) levels from 1.54 + 
0.24 % FAME in control A10p10p cells to 1.31 + 0.34 and 1.32 + 0.07 % FAME 
with 21 and 75 µM CLA-mix (Table 5.4.4.1.1).   
 
While there was an apparent increase in c9,t11-CLA levels with both concentrations 
of CLA-mix from 0.03 + 0.03 % FAME in control A10p10p cells to 0.66 + 0.48 and 
4.87 + 3.62 % FAME, and in t10,c12-CLA levels from 0.02 + 0.01 % FAME in 
control A10p10p cells to 0.41 + 0.66 and 3.66 + 6.06 % FAME following treatment 
with 21 and 75 µM CLA-mix, the differences were not found to be statistically 
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significant relative to control cells (Table 5.4.4.1.1).  These low levels indicate that a 
higher proportion of both isomers are metabolised to other forms when delivered 
together in the CLA-mix than as single isomers. 
 
There was relatively no change in the overall level of LCSFA from 58.25 + 5.36 % 
FAME in control A10p10p cells to 60.32 + 1.03 % FAME following 21 µM CLA-
mix treatment and an apparent but not significant decrease to 45.37 + 7.66 % FAME 
with 75 µM CLA-mix.  The overall UFA level, at 23.09 + 1.91 % FAME in control 
A10p10p cells, apparently increased to 26.66 + 1.30 and 44.38 + 11.06 % FAME 
with 21 and 75 µM CLA-mix.  Corresponding MUFA levels apparently increased 
from 17.30 + 1.66 % FAME in control A10p10p cells to 19.16 + 0.21 and 28.18 + 
11.29 % FAME following 21 and 75 µM CLA-mix treatment (Table 5.4.4.1.2).  The 
increases in both UFA and MUFA levels are mainly due to direct uptake of the CLA 
isomers, c9,t11 and t10,c12-CLA,  and the increase in C16:1, palmitoleic acid. 
 
There was a significant increase in the ratio of UFA/LCSFA from 0.40 + 0.02 in 
control A10p10p cells to 0.44 + 0.01 following treatment with 21 µM CLA-mix and 
an apparent but not significant increase in the ratio to 1.10 + 0.37 with 75 µM CLA-
mix.  The corresponding values for the MUFA/LCSFA ratio were 0.30 + 0.02 in 
control A10p10p cells and 0.32 + 0.01 and 0.71 + 0.35 following 21 and 75 µM 
CLA-mix treatment (Table 5.4.4.1.2).   
 
The ratio of C16:1/C16:0 apparently increased from 0.48 + 0.13 in control A10p10p 
cells to 0.54 + 0.04 and 2.00 + 1.48 in cells treated with 21 and 75 µM CLA-mix, 
suggesting up-regulation of the ∆9-desaturase enzyme.  The ratio of C18:1/C18:0 
remained relatively unchanged following CLA-mix treatment, with a value of 0.22 + 
0.04 in control A10p10p cells and 0.21 + 0.05 and 0.26 + 0.01 in cells treated with 
21 and 75 µM CLA-mix (Table 5.4.4.1.2). 
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Table 5.4.4.1.1.  Fatty acid composition of A10p10p cells treated with CLA-mix for 72 
h. 
Fatty Acid Control CLA  21 µM CLA  75 µM 
C6:0 0.38 + 0.03 1.15 + 0.76 0.39 + 0.27 
C8:0 8.60 + 4.71 1.73 + 1.00 2.08 + 1.18 
C10:0 1.61 + 1.18 0.92 + 0.72  1.26 + 1.16 
C11:0 5.43 + 1.60 6.14 + 1.39 4.42 + 0.43 
C12:0 0.09 + 0.08 0.08 + 0.05 0.10 + 0.07 
C13:0 2.55 + 0.95 3.00 + 1.02 2.00 + 0.63 
C14:0 2.19 + 0.44 2.08 + 0.68 2.34 + 0.56 
C14:1 0.38 + 0.29 0.48 + 0.44 0.04 + 0.02 
C15:0 0.26 + 0.08 0.28 + 0.10 0.27 + 0.10 
C15:1 0.06 + 0.03 0.14 + 0.08 0.03 + 0.03 
C16:0 19.65 + 1.92 18.94 + 1.15 14.58 + 2.75 
C16:1 8.98 + 2.01 10.25 + 1.16 21.11 + 12.32 
C18:0 34.98 + 4.12 37.53 + 0.51 24.69 + 6.70 
C18:1 (t9, t11 & c9) 7.60 + 1.37 7.83 + 1.78  6.38 + 1.89 
C18:2 LA 1.97 + 0.62 2.15 + 0.68 1.92 + 0.95 
C18:3 GLA 0.10 + 0.10 0.36 + 0.23 0.13 + 0.07 
C18:3(c9,12,15) 0.63 + 0.05 0.81 + 0.26 0.58 + 0.20 
C20:0 0.91 + 0.19 0.84 + 0.28 0.72 + 0.22 
C18:2 c9,t11-CLA 0.03 + 0.03 0.66 + 0.48 4.87 + 3.62 
C18:2 t10,c12-CLA 0.02 + 0.01 0.42 + 0.39 4.96 + 2.97 
C20:1 (c11) 0.02 + 0.02 0.08 + 0.04 0.08 + 0.05 
C18:2 t9,11-CLA 0.10 + 0.05 0.32 + 0.20 0.99 + 0.80 
C20:2 (c11,14) 0.13 + 0.09 0.23 + 0.12 0.17 + 0.13 
C20:3  DGLA 0.16 + 0.02 0.17 + 0.12 0.25 + 0.14 
C20:4  AA 1.54 + 0.24 1.31 + 0.34 1.32 + 0.07 
C22:1(c13) 0.10 + 0.10 0.37 + 0.19 0.52 + 0.34 
C23:0 0.08 + 0.04 0.13 + 0.08 0.51 + 0.44 
C22:2 (c13,16) 0.00 + 0.00 0.03 + 0.02 0.00 + 0.00 
C20:5 EPA 0.18 + 0.18 0.15 + 0.15 0.28 + 0.27 
C24:0 0.19 + 0.19 0.51 + 0.38 1.83 + 1.71 
C24:1(c15) 0.18 + 0.16 0.08 + 0.07 0.11 + 0.00 
C22:6 DHA 0.92 + 0.19 0.80 + 0.16 0.65 + 0.26 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.005).   
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Table 5.4.4.1.2.  Fatty acid composition and ratios of A10p10p cells treated with CLA 
mix for 72 h. 
Fatty Acids Control CLA mix 
21 µM 
CLA mix 
75 µM 
LCSFA 58.25 + 5.36 60.32 + 1.03 45.37 + 7.66 
UFA 23.09 + 1.91 26.66 + 1.30 44.38 + 11.06 
MUFA 17.30 + 1.66 19.16 + 0.21 28.18 + 11.29 
UFA/LCSFA 0.40 + 0.02 0.44 + 0.01* 1.10 + 0.37 
MUFA/LCSFA 0.30 + 0.02 0.32 + 0.01 0.71 + 0.35 
C16:1/C16:0 0.48 + 0.13 0.54 + 0.04 2.00 + 1.48 
C18:1 (t9, t11 & c9)/C18:0 0.22 + 0.04 0.21 + 0.05 0.26 + 0.01 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).   
 
 
5.4.4.2 Effects of c9,t11-CLA on Fatty acid profiles of A10p10p 
cells 
 
Flasks of 2x106 of drug resistant A10p10p cells were seeded for 24 h before 
treatment with 21 and 75 µM c9,t11-CLA, incubated for 3 days and extracted and 
analysed as described earlier.  Figure 5.4.4.2 illustrates a chromatogram from a 
typical injection of an A10p10p sample treated with (a) 21 and (b) 75 µM of the 
c9,t11-CLA isomer.   
 
Table 5.4.4.2.1 lists the fatty acid composition of untreated A10p10p control cells 
and A10p10p cells treated with 21 and 75 µM c9,t11-CLA, while table 19 lists the 
summary of fatty acid composition and various fatty acid ratios of the above.  The 
most abundant fatty acid in each treatment was the long chain saturated fatty acid 
(LCSFA) C18:0 stearic acid.   
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 (a) 
 
 
 (b) 
 
 
 
Figure 5.4.4.2.  Typical chromatograms of fatty acid profiles of A10p10p cells treated with 
(a) 21 and (b) 75 µM c9,t11-CLA. 
 
c9,t11-CLA 
c9,t11-CLA 
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 C18:0 stearic acid was relatively unchanged from 34.98 + 4.12 % total cellular 
FAME in control A10p10p cells to 37.51 + 4.25 % and 30.88 + 3.20 % FAME in 
cells treated with 21 and 75 µM c9,t11-CLA.  Another predominant LCSFA, C16:0 
methyl palmitate was also relatively unchanged comprising 19.65 + 1.92 % FAME in 
control A10p10p cells and 22.05 + 0.84 and 18.14 + 0.36 % FAME in cells treated 
with 21 and 75 µM c9,t11-CLA respectively.  This indicates that the c9,t11-CLA 
isomer had little or no effect on FAS activity in A10p10p cells.  Other LCSFA were 
present in minor amounts, including C14:0 methyl myristate at 2.19 + 0.44 % FAME 
in control A10p10p cells and 2.20 + 0.52 and 1.71 + 0.31 % FAME following 
treatment with 21 and 75 µM c9,t11-CLA (Table 5.4.4.2.1).   
 
The predominant mono-unsaturated fatty acid (MUFA), C16:1 methyl palmitoleate 
(palmitoleic acid), apparently increased from 8.98 + 2.01 % total lipid in control 
A10p10p cells to 10.25 + 1.16 % FAME following 21 µM c9,t11-CLA treatment, 
although reverting to 8.58 + 3.50 % FAME with 75 µM c9,t11-CLA.  Another 
abundant MUFA was the group of three C18:1 fatty acids elaidic (t-9), vaccenic (t-
11), and oleic acid (c-9).  Their combined proportion of total cellular lipids of 7.60 + 
1.37 % in control A10p10p cells remained relatively unchanged with treatments of 
21 and 75 µM c9,t11-CLA, with levels of 7.52 + 1.55 and 5.15 + 0.64 % FAME 
respectively (Table 5.4.4.2.1).   
 
Other UFA were present in minor amounts.  C18:2 (c9,c12) linoleic acid (LA) 
comprised 1.97 + 0.62 % FAME in control A10p10p cells and 2.02 + 0.62 and 1.34 
+ 0.17 % FAME following treatment with 21 and 75 µM c9,t11-CLA.  At 75 µM 
c9,t11-CLA, there was a significant reduction in C20:3 dihomo-γ-linolenic acid 
(DGLA) from 0.16 + 0.02 % in control A10p10p cells to 0.07 + 0.04 % FAME.  
There was an apparent drop in C20:4 arachidonic acid (AA) levels from 1.54 + 0.24 
% FAME in A10p10p control cells to 1.11 + 0.43 and 0.85 + 0.47 % FAME with 21 
and 75 µM c9,t11-CLA (Table 5.4.4.2.1).  The decreases in both DGLA and AA 
levels suggest inhibition of ∆5/∆6 desaturase and/or elongase activities.  C18:3 α-
linolenic acid (ALA) levels comprised 0.63 + 0.05 % FAME in control A10p10p 
cells and 0.52 + 0.26 and 0.40 + 0.20 % FAME with 21 and 75 µM c9,t11-CLA 
(Table 5.4.4.2.1).   
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Following treatment with 21 and 75 µM c9,t11-CLA, there was an apparent but 
again not significant increase in c9,t11-CLA levels from 0.03 + 0.03 % FAME in 
control A10p10p cells to 3.12 + 0.94 and 20.19 + 6.86 % of total cellular FAME 
respectively.   There was also an apparent increase in t9,t11-CLA levels following 
treatment with 21 and 75 µM c9,t11-CLA, from 0.10 + 0.05 % FAME in control 
A10p10p cells to 0.37 + 0.20 and 1.00 + 0.44 % FAME respectively (Table 
5.4.4.2.1).  This isomer is present in minor amounts in the c9,t11-CLA treatments. 
 
There was relatively no change in the overall level of LCSFA from 58.25 + 5.36 % 
FAME in control A10p10p cells to 63.09 + 4.00 and 51.89 + 3.51  % FAME 
following 21 and 75 µM c9,t11-CLA treatment.  The overall UFA level, at 23.09 + 
1.91 % FAME in control A10p10p cells, apparently increased to 27.19 + 3.24 and 
39.51 + 2.45 % FAME with 21 and 75 µM c9,t11-CLA.  Corresponding MUFA 
levels were 17.30 + 1.66 % FAME in control A10p10p cells and 18.30 + 3.00 and 
14.30 + 3.76 % FAME following 21 and 75 µM c9,t11-CLA treatment (Table 
5.4.4.2.2).  The increases in both UFA and MUFA levels were due to direct uptake of 
the c9,t11-CLA isomer. 
 
There was an apparent but not significant increase in the ratio of UFA/LCSFA from 
0.40 + 0.02 in control A10p10p cells to 0.44 + 0.07 and 0.77 + 0.09 with 21 and 75 
µM c9,t11-CLA.  The corresponding values for the MUFA/LCSFA ratio were 0.30 + 
0.02 in control A10p10p cells and 0.30 + 0.06 and 0.27 + 0.06 following 21 and 75 
µM c9,t11-CLA treatment (Table 5.4.4.2.2).   
 
The ratio of C16:1/C16:0 remained relatively unchanged following c9,t11-CLA 
treatment, with a value of 0.48 + 0.13 in control A10p10p cells and 0.48 + 0.20 and 
0.48 + 0.20 in cells treated with 21 and 75 µM c9,t11-CLA.  The ratio of 
C18:1/C18:0 was also unchanged following c9,t11-CLA treatment, with a value of 
0.22 + 0.04 in control A10p10p cells and 0.21 + 0.06 and 0.17 + 0.02 in cells treated 
with 21 and 75 µM c9,t11-CLA (Table 5.4.4.2.2).  Both ratios remaining unchanged 
indicates that the c9,t11-CLA isomer had no effect on the activity of the ∆9-
desaturase enzyme in A10p10p cells. 
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Table 5.4.4.2.1.  Fatty acid composition of A10p10p cells treated with c9,t11-CLA for 72 
h. 
Fatty Acid Control c9,t11-CLA  21 µM c9,t11-CLA  75 µM 
C6:0 0.38 + 0.03 0.20 + 0.15 0.22 + 0.08 
C8:0 8.60 + 4.71 2.87 + 1.52 2.97 + 1.03 
C10:0 1.61 + 1.18 1.38 + 1.07 1.24 + 0.97 
C11:0 5.43 + 1.60 3.25 + 1.64 2.49 + 0.90 
C12:0 0.09 + 0.08 0.03 + 0.02 0.13 + 0.12 
C13:0 2.55 + 0.95 2.00 + 0.55 1.55 + 0.43 
C14:0 2.19 + 0.44 2.20 + 0.52 1.71 + 0.31 
C14:1 0.38 + 0.29 0.05 + 0.05 0.13 + 0.11 
C15:0 0.26 + 0.08 0.23 + 0.05 0.13 + 0.04 
C15:1 0.06 + 0.03 0.02 + 0.02 0.02 + 0.02 
C16:0 19.65 + 1.92 22.05 + 0.84 18.14 + 0.36 
C16:1 8.98 + 2.01 10.36 + 3.89 8.58 + 3.50 
C18:0 34.98 + 4.12 37.51 + 4.25 30.88 + 3.20 
C18:1 (t9, t11 & c9) 7.60 + 1.37 7.52 + 1.55 5.15 + 0.64 
C18:2 LA 1.97 + 0.62 2.02 + 0.62 1.34 + 0.17 
C18:3 GLA 0.10 + 0.10 0.16 + 0.08 0.22 + 0.13 
C18:3 ALA 0.63 + 0.05 0.52 + 0.26 0.40 + 0.20 
C20:0 0.91 + 0.19 0.71 + 0.35 0.58 + 0.20 
C18:2 c9,t11-CLA 0.03 + 0.03 3.12 + 0.94 20.19 + 6.86 
C18:2 t10,c12-CLA 0.02 + 0.01 0.00 + 0.00 0.02 + 0.02 
C20:1 (c11) 0.02 + 0.02 0.07 + 0.04 0.08 + 0.04 
C18:2 t9,11-CLA 0.10 + 0.05 0.37 + 0.20 1.00 + 0.44  
C20:2 (c11,14) 0.13 + 0.09 0.26 + 0.15 0.26 + 0.13 
C20:3  DGLA 0.16 + 0.02 0.14 + 0.08 0.07 + 0.04* 
C20:4  AA 1.54 + 0.24 1.11 + 0.43 0.85 + 0.47 
C22:1(c13) 0.10 + 0.10 0.31 + 0.17 0.33 + 0.19 
C23:0 0.08 + 0.04 0.06 + 0.03 0.03 + 0.01 
C22:2 (c13,16) 0.00 + 0.00 0.09 + 0.09 0.11+ 0.11 
C20:5 EPA 0.18 + 0.18 0.17 + 0.17 0.18 + 0.18 
C24:0 0.19 + 0.19 0.30 + 0.23 0.34 + 0.23 
C24:1(c15) 0.18 + 0.16 0.03 + 0.02 0.10 + 0.08 
C22:6 DHA 0.92 + 0.19 0.86 + 0.23 0.51 + 0.18 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).   
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Table 5.4.4.2.2.  Fatty acid composition and ratios of A10p10p cells treated with c9,t11-
CLA mix for 72 h. 
Fatty Acids Control c9,t11-CLA  
21 µM 
c9,t11-CLA  
75 µM 
LCSFA 58.25 + 5.36 63.09 + 4.00 51.89 + 3.51 
UFA 23.09 + 1.91 27.19 + 3.24 39.51 + 2.45 
MUFA 17.30 + 1.66 18.30 + 3.00 14.30 + 3.76 
UFA/LCSFA 0.40 + 0.02 0.44 + 0.07 0.77 + 0.09 
MUFA/LCSFA 0.30 + 0.02 0.30 + 0.06 0.27 + 0.06 
C16:1/C16:0 0.48 + 0.13 0.48 + 0.20 0.48 + 0.20 
C18:1 (t9, t11 & c9)/C18:0 0.22 + 0.04 0.21 + 0.06 0.17 + 0.02 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).   
 
 
5.4.4.3 Effects of t10,c12-CLA on Fatty acid profiles of A10p10p 
cells 
 
Flasks of 2x106 of drug resistant A10p10p cells were seeded for 24 h before 
treatment with 21 and 75 µM t10,c12-CLA, incubated for 3 days and extracted and 
analysed as described earlier.  Figure 5.4.4.3 illustrates a chromatogram from a 
typical injection of an A10p10p sample treated with (a) 21 and (b) 75 µM of the 
t10,c12-CLA isomer.  Table 5.4.4.3.1 lists the fatty acid composition of untreated 
A10p10p control cells and A10p10p cells treated with 21 and 75 µM t10,c12-CLA, 
while table 21 lists the summary of fatty acid composition and various fatty acid 
ratios of the above.  The most abundant fatty acid in each treatment was the long 
chain saturated fatty acid (LCSFA) C18:0 stearic acid.   
 
C18:0 stearic acid was relatively unchanged from 34.98 + 4.12 % total cellular 
FAME in control A10p10p cells to 40.28 + 0.23 % and 30.55 + 2.83 % FAME in 
cells treated with 21 and 75 µM t10,c12-CLA respectively (Table 5.4.4.3.1).   
                                  
 216 
 
 
 (a) 
 
 
 (b) 
 
 
 
Figure 5.4.4.3.  Typical chromatograms of fatty acid profiles of A10p10p cells treated with 
(a) 21 and (b) 75 µM t10,c12-CLA. 
 
 
 
t10,c12-CLA 
t10,c12-CLA 
CCCLA 
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Another predominant LCSFA, C16:0 methyl palmitate was also relatively unchanged 
comprising 19.65 + 1.92 % FAME in control A10p10p cells and 22.64 + 0.83 and 
18.05 + 0.68 % FAME in cells treated with 21 and 75 µM t10,c12-CLA.  This 
indicates t10,c12-CLA had little or no effect on FAS activity in A10p10p cells.  
Other LCSFA were present in minor amounts, including C6:0 methyl hexanoate at 
0.38 + 0.03 % FAME in control A10p10p cells, was significantly reduced to 0.10 + 
0.05 % FAME following treatment with 75 µM t10,c12-CLA (Table 5.4.4.3.1).   
 
The predominant mono-unsaturated fatty acid (MUFA), C16:1 methyl palmitoleate 
(palmitoleic acid), remained relatively unchanged from 8.98 + 2.01 % total lipid in 
control A10p10p cells to 10.28 + 4.06 and 9.19 + 4.04 % FAME following 21 and 75 
µM t10,c12-CLA treatment respectively.  Another abundant MUFA was the group of 
three C18:1 fatty acids elaidic (t-9), vaccenic (t-11), and oleic acid (c-9).  Their 
combined proportion of total cellular lipids of 7.60 + 1.37 % in control A10p10p 
cells was apparently reduced with 21 and 75 µM t10,c12-CLA to 5.37 + 0.52 and 
4.87 + 0.49 % FAME respectively, suggesting inhibition of ∆9-desaturase by 
t10,c12-CLA (Table 5.4.4.3.1).   
 
Other UFA were present in minor amounts.  C18:2 (c9,c12) linoleic acid (LA) 
comprised 1.97 + 0.62 % FAME in control A10p10p cells and 1.57 + 0.13 and 1.46 
+ 0.08 % FAME following treatment with 21 and 75 µM t10,c12-CLA.  C18:3 α-
linolenic acid (ALA) levels comprised 0.63 + 0.05 % FAME in control A10p10p 
cells and 0.49 + 0.25 and 0.42 + 0.21 % FAME with 21 and 75 µM t10,c12-CLA 
(Table 5.4.4.3.1).   
 
Treatments with 21 µM t10,c12-CLA resulted in direct uptake and significant 
increase in t10,c12-CLA levels from 0.02 + 0.01 % in control cells to 1.96 + 0.26 % 
of total cellular FAME and while not significant there was an apparent increase 
following 75 µM t10,c12-CLA treatment to 20.12 + 6.48 % FAME.  This indicates a 
lower rate of metabolism of the t10,c12-CLA isomer than when delivered as part of a 
CLA mixture of isomers and the lack of statistical significance is possibly due to this 
changeable rate of metabolism.  There was a significant increase in levels of t9,t11-
CLA following 75 µM t10,c12-CLA treatment from 0.10 + 0.05 % to 2.04 + 0.28 % 
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FAME (Table 5.4.4.3.1).  The t9,t11-CLA isomer was present in minor amounts in 
the t10,c12-CLA treatment and clearly is not metabolised readily. 
 
There was an apparent increase in the overall level of LCSFA from 58.25 + 5.36 % 
FAME in control A10p10p cells to 66.89 + 1.22 % FAME following treatment with 
21 µM t10,c12-CLA and an apparent decrease with 75 µM t10,c12-CLA to 51.53 + 
3.69 % FAME.  The overall UFA level, at 23.09 + 1.91 % FAME in control 
A10p10p cells, remained unchanged at 23.18 + 5.95 % FAME with 21 µM t10,c12-
CLA and was increased significantly to 41.62 + 1.34 % FAME with 75 µM t10,c12-
CLA, due to direct uptake of t10,c12-CLA.  Corresponding MUFA levels were 17.30 
+ 1.66 % FAME in control A10p10p cells and 16.16 + 4.78 and 14.50 + 4.55 % 
FAME following 21 and 75 µM t10,c12-CLA treatment (Table 5.4.4.3.2).  
 
While the ratio of UFA/LCSFA appeared to decrease from 0.40 + 0.02 in control 
A10p10p cells to 0.35 + 0.09 with 21 µM t10,c12-CLA treatment, the value 
increased significantly with 75 µM t10,c12-CLA to 0.82 + 0.08, again due to direct 
t10,c12-CLA uptake.  The corresponding values for the MUFA/LCSFA ratio were 
0.30 + 0.02 in control A10p10p cells and 0.24 + 0.08 and 0.27 + 0.07 following 21 
and 75 µM t10,c12-CLA treatment (Table 5.4.4.3.2).   
 
The ratio of C16:1/C16:0 remained relatively unchanged following t10,c12-CLA 
treatment, with a value of 0.48 + 0.13 in control A10p10p cells and 0.47 + 0.19 and 
0.49 + 0.21 in cells treated with 21 and 75 µM t10,c12-CLA.  The ratio of 
C18:1/C18:0 apparently decreased following t10,c12-CLA treatment, with a value of 
0.22 + 0.04 in control A10p10p cells and 0.13 + 0.01 and 0.16 + 0.01 in cells treated 
with 21 and 75 µM t10,c12-CLA, suggesting possible inhibition of oleic acid 
production by ∆9-desaturase in cells treated with the t10,c12-CLA isomer (Table 
5.4.4.3.2). 
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Table 5.4.4.3.1  Fatty acid composition of A10p10p cells treated with t10,c12-CLA for 
72 h. 
Fatty Acid Control t10,c12-CLA  21 µM t10,c12-CLA  75 µM 
C6:0 0.38 + 0.03 0.66 + 0.28 0.10 + 0.05* 
C8:0 8.60 + 4.71 3.37 + 1.33 1.20 + 1.20 
C10:0 1.61 + 1.18 2.51 + 2.10 1.71 + 1.50 
C11:0 5.43 + 1.60 2.08 + 1.45 2.38 + 0.61 
C12:0 0.09 + 0.08 0.06 + 0.05 0.04 + 0.03 
C13:0 2.55 + 0.95 1.25 + 0.32 1.44 + 0.43 
C14:0 2.19 + 0.44 1.79 + 0.11 1.84 + 0.19 
C14:1 0.38 + 0.29 0.00 + 0.00 0.01 + 0.01 
C15:0 0.26 + 0.08 0.24 + 0.11 0.20 + 0.03 
C15:1 0.06 + 0.03 0.03 + 0.03 0.08 + 0.06 
C16:0 19.65 + 1.92 22.64 + 0.83 18.05 + 0.68 
C16:1 8.98 + 2.01 10.28 + 4.06 9.19 + 4.04 
C18:0 34.98 + 4.12 40.28 + 0.23 30.55 + 2.83 
C18:1 (t9, t11 & c9) 7.60 + 1.37 5.37 + 0.52 4.87 + 0.49 
C18:2 LA 1.97 + 0.62 1.57 + 0.13 1.46 + 0.08 
C18:3 GLA 0.10 + 0.10 0.22 + 0.11 0.21 + 0.13 
C18:3  ALA 0.63 + 0.05 0.49 + 0.25 0.42 + 0.21 
C20:0 0.91 + 0.19 0.85 + 0.29 0.63 + 0.26 
C18:2 c9,t11-CLA 0.03 + 0.03 0.16 + 0.08 0.64 + 0.32 
C18:2 t10,c12-CLA 0.02 + 0.01 1.96 + 0.26* 20.12 + 6.48+ 
C20:1 (c11) 0.02 + 0.02 0.04 + 0.02  0.03 + 0.03 
C18:2 t9,11-CLA 0.10 + 0.05 0.29 + 0.16 2.04 + 0.28* 
C20:2 (c11,14) 0.13 + 0.09 0.22 + 0.12 0.07 + 0.05 
C20:3  DGLA 0.16 + 0.02 0.14 + 0.08 0.13 + 0.07 
C20:4  AA 1.54 + 0.24 1.08 + 0.55 1.06 + 0.43 
C22:1(c13) 0.10 + 0.10 0.32 + 0.17 0.29 + 0.15 
C23:0 0.08 + 0.04 0.12 + 0.06 0.09 + 0.04 
C22:2 (c13,16) 0.00 + 0.00 0.03 + 0.02 0.06 + 0.06 
C20:5 EPA 0.18 + 0.18 0.16 + 0.16 0.18 + 0.18 
C24:0 0.19 + 0.19 0.97 + 0.53 0.18 + 0.11 
C24:1(c15) 0.18 + 0.16 0.15 + 0.14 0.05 + 0.04 
C22:6 DHA 0.92 + 0.19 0.65 + 0.11 0.68 + 0.03 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).  +Denotes 
p=0.088 
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Table 5.4.4.3.2.  Fatty acid composition and ratios of A10p10p cells treated with 
t10,c12-CLA for 72 h. 
Fatty Acids Control t10,c12-CLA  
21 µM 
t10,c12-CLA  
75 µM 
LCSFA 58.25 + 5.36 66.89 + 1.22 51.53 + 3.69 
UFA 23.09 + 1.91 23.18 + 5.95 41.62 + 1.34* 
MUFA 17.30 + 1.66 16.16 + 4.78 14.50 + 4.55 
UFA/LCSFA 0.40 + 0.02 0.35 + 0.09 0.82 + 0.08* 
MUFA/LCSFA 0.30 + 0.02 0.24 + 0.08 0.27 + 0.07 
C16:1/C16:0 0.48 + 0.13 0.47 + 0.19 0.49 + 0.21 
C18:1 (t9, t11 & c9)/C18:0 0.22 + 0.04 0.13 + 0.01 0.16 + 0.01 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).   
 
 
5.4.4.4 Effects of EPA on Fatty acid profiles of A10p10p cells 
 
Flasks of 2x106 of drug resistant A10p10p cells were seeded for 24 h before 
treatment with 21 and 75 µM eicosapentanoic acid (EPA), incubated for 3 days and 
extracted and analysed as described earlier.  Figure 5.4.4.4 illustrates a 
chromatogram from a typical injection of an A10p10p sample treated with (a) 21 and 
(b) 75 µM of EPA.   
 
Table 5.4.4.4.1 lists the fatty acid composition of untreated A10p10p control cells 
and A10p10p cells treated with 21 and 75 µM EPA, while table 23 lists the summary 
of fatty acid composition and various fatty acid ratios of the above.  The most 
abundant fatty acid in each treatment was the long chain saturated fatty acid 
(LCSFA) C18:0 stearic acid.   
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 (a) 
 
 
 (b) 
 
 
Figure 5.4.4.4.  Typical chromatograms of fatty acid profiles of A10p10p cells treated with 
(a) 21 and (b) 75 µM EPA. 
EPA 
20:5 
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20:5 
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 C18:0 stearic acid was relatively unchanged from 34.98 + 4.12 % total cellular 
FAME in control A10p10p cells to 39.96 + 0.92 % and 38.90 + 3.39 % FAME in 
cells treated with 21 and 75 µM EPA respectively.  Another predominant LCSFA, 
C16:0 methyl palmitate was significantly increased following 21 µM EPA 
comprising 19.65 + 1.92 % FAME in control A10p10p cells and 23.19 + 1.43 % 
FAME in cells treated with 21 µM EPA.  However, the level was relatively 
unchanged following treatment with 75 µM EPA at 19.80 + 1.58 % FAME (Table 
5.4.4.4.1).  This indicates EPA had little or no effect on FAS activity in A10p10p 
cells.  
 
Other LCSFA were present in minor amounts.  C6:0 methyl hexanoate at 0.38 + 0.03 
% FAME in control A10p10p cells, was significantly reduced to 0.07 + 0.07 % 
FAME following treatment with 75 µM EPA.  C14:0 methyl myristate levels were 
significantly reduced from 2.19 + 0.44 % FAME in control A10p10p cells to 1.39 + 
0.43 % FAME with 75 µM EPA (Table 5.4.4.4.1).   
 
The predominant mono-unsaturated fatty acid (MUFA), C16:1 methyl palmitoleate 
(palmitoleic acid), apparently increased from 8.98 + 2.01 % total lipid in control 
A10p10p cells to 14.37 + 4.10 and 18.64 + 2.55 % FAME following 21 and 75 µM 
EPA treatment respectively.  Another abundant MUFA was the group of three C18:1 
fatty acids elaidic (t-9), vaccenic (t-11), and oleic acid (c-9).  Their combined 
proportion of total cellular lipids of 7.60 + 1.37 % in control A10p10p cells was 
apparently reduced to 5.53 + 1.02 with 21 µM EPA and significantly reduced to 2.19 
+ 0.49 % FAME following treatment with 75 µM EPA (Table 5.4.4.4.1).  The 
increase in C16:1 and decrease in C18:1 suggests different substrate specificity of the 
∆9-desaturase enzyme in A10p10p cells and diversion of monounsaturated fatty acid 
synthesis away from oleic acid towards palmitoleic acid.  
 
Other UFA were present in minor amounts.  C18:2 (c9,c12) linoleic acid (LA) 
comprised 1.97 + 0.62 % FAME in control A10p10p cells and was apparently 
reduced to 1.66 + 0.55 and 0.64 + 0.29 % FAME following treatment with 21 and 75 
µM EPA.  C20:4 arachidonic acid (AA) levels were significantly reduced from 1.54 
+ 0.24 % FAME in control A10p10p cells to 0.54 + 0.15 % FAME with 75 µM EPA.   
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Table 5.4.4.4.1.   Fatty acid composition of A10p10p cells treated with EPA for 72 h. 
Fatty Acid Control EPA  21 µM EPA  75 µM 
C6:0 0.38 + 0.03 0.06 + 0.06 0.07 + 0.07* 
C8:0 8.60 + 4.71 0.85 + 0.69 0.51 + 0.26 
C10:0 1.61 + 1.18 0.79 + 0.79 0.00 + 0.00 
C11:0 5.43 + 1.60 4.37 + 0.22 4.33 + 0.43 
C12:0 0.09 + 0.08 0.00 + 0.00  0.00 + 0.00 
C13:0 2.55 + 0.95 0.50 + 0.24 0.56 + 0.31 
C14:0 2.19 + 0.44 2.34 + 0.50 1.39 + 0.43* 
C14:1 0.38 + 0.29 0.13 + 0.13 0.55 + 0.55 
C15:0 0.26 + 0.08 0.15 + 0.04 0.11 + 0.06 
C15:1 0.06 + 0.03 0.00 + 0.00 0.00 + 0.00 
C16:0 19.65 + 1.92 23.19 + 1.43* 19.80 + 1.58 
C16:1 8.98 + 2.01 14.37 + 4.10 18.64 + 2.55 
C18:0 34.98 + 4.12 39.96 + 0.92 38.90 + 3.39 
C18:1 (t9, t11 & c9) 7.60 + 1.37 5.53 + 1.02 2.19 + 0.49* 
C18:2 LA 1.97 + 0.62 1.66 + 0.55 0.64 + 0.29 
C18:3 GLA 0.10 + 0.10 0.27 + 0.16 0.38 + 0.17 
C18:3(c9,12,15) 0.63 + 0.05 0.52 + 0.19 0.71 + 0.17 
C20:0 0.91 + 0.19 0.73 + 0.25 0.96 + 0.15 
C18:2 c9,t11-CLA 0.03 + 0.03 0.16 + 0.10 0.11 + 0.08 
C18:2 t10,c12-CLA 0.02 + 0.01 0.10 + 0.06 0.09 + 0.06 
C20:1 (c11) 0.02 + 0.02 0.03 + 0.02 0.04 + 0.01 
C18:2 t9,11-CLA 0.10 + 0.05 0.06 + 0.03 0.13+ 0.06 
C20:2 (c11,14) 0.13 + 0.09 0.24 + 0.14 0.23 + 0.15 
C20:3  DGLA 0.16 + 0.02 0.18 + 0.08 0.08 + 0.06 
C20:4  AA 1.54 + 0.24 0.84 + 0.29 0.54 + 0.15* 
C22:1(c13) 0.10 + 0.10 0.16 + 0.08 0.17 + 0.11 
C23:0 0.08 + 0.04 1.18 + 0.41 2.66 + 0.75 
C22:2 (c13,16) 0.00 + 0.00 0.22 + 0.16 0.27 + 0.17 
C20:5 EPA 0.18 + 0.18 0.33 + 0.19 0.29 + 0.26 
C24:0 0.19 + 0.19 0.34 + 0.18 0.52 + 0.21 
C24:1(c15) 0.18 + 0.16 0.04 + 0.03 0.04 + 0.02 
C22:6 DHA 0.92 + 0.19 0.69 + 0.14 5.07 + 4.89 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).  
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C18:3 γ-linolenic acid (GLA) was apparently increased from 0.10 + 0.10 % FAME 
in control A10p10p cells to 0.27 + 0.16 and 0.38 + 0.17 % FAME with 21 and 75 
µM EPA (Table 5.4.4.4.1).  These changes indicate inhibition of ∆5 desaturase 
and/or elongase enzyme activities by EPA or its metabolites. 
 
C18:3 α-linolenic acid (ALA) levels comprised 0.63 + 0.05 % FAME in control 
A10p10p cells and 0.52 + 0.19 and 0.71 + 0.17 % FAME with 21 and 75 µM EPA.  
Treatments with EPA did not result in direct uptake and EPA levels remained 
relatively unchanged from 0.18 + 0.18 % in control A10p10p cells to 0.33 + 0.19 and 
0.29 + 0.26 % of total cellular FAME with 21 and 75 µM EPA, indicating rapid 
metabolism following uptake (Table 5.4.4.4.1).   
 
There was an apparent increase in the overall level of LCSFA from 58.25 + 5.36 % 
FAME in control A10p10p cells to 67.89 + 1.50 % FAME following treatment with 
21 µM EPA and a significant increase with 75 µM EPA to 64.35 + 5.05 % FAME.  
This increase was due to a combination of minor changes over a range of fatty acids.  
The overall UFA level, at 23.09 + 1.91 % FAME in control A10p10p cells was 
apparently increased to 25.52 + 3.25 and 30.19 + 5.35 % FAME 21 and 75 µM EPA 
respectively.  Total MUFA levels were apparently increased from 17.30 + 1.66 % 
FAME in control A10p10p cells to 20.23 + 3.13 and 21.58 + 2.82 % FAME 
following 21 and 75 µM EPA treatment (Table 5.4.4.4.2).  The increases in overall 
UFA and MUFA level were due to a combination of changes including the increase 
in C16:1 palmitoleic acid and not due to direct uptake of EPA. 
 
While the ratio of UFA/LCSFA was relatively unchanged from 0.40 + 0.02 in 
control A10p10p cells to 0.38 + 0.05 with 21 µM EPA treatment, the value 
apparently increased with 75 µM EPA to 0.49 + 0.12.  The corresponding values for 
the MUFA/LCSFA ratio were 0.30 + 0.02 in control A10p10p cells and 0.30 + 0.05 
and 0.34 + 0.05 following 21 and 75 µM EPA treatment (Table 5.4.4.4.2).   
 
The ratio of C16:1/C16:0 apparently increased following EPA treatment, with a 
value of 0.48 + 0.13 in control A10p10p cells and 0.65 + 0.19 and 0.95 + 0.11 in 
cells treated with 21 and 75 µM EPA.  The ratio of C18:1/C18:0 was significantly 
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reduced with EPA treatment, with a value of 0.22 + 0.04 in control A10p10p cells 
and 0.14 + 0.02 and 0.06 + 0.01 in cells treated with 21 and 75 µM EPA (Table 
5.4.4.4.2).  The increase in the C16:1/C16:0 ratio and decrease in C18:1/C18:0 
suggests different substrate specificity of ∆9-desaturase and inhibition of oleic acid 
modulation in favour of palmitoleic acid in EPA treated cells. 
 
 
Table 5.4.4.4.2.  Fatty acid composition and ratios of A10p10p cells treated with EPA 
for 72 h. 
Fatty Acids Control EPA 21 µM EPA 75 µM 
LCSFA 58.25 + 5.36 67.89 + 1.50  64.35 + 5.05* 
UFA 23.09 + 1.91 25.52 + 3.25 30.19 + 5.35 
MUFA 17.30 + 1.66 20.23 + 3.13 21.58 + 2.82 
UFA/LCSFA 0.40 + 0.02 0.38 + 0.05 0.49 + 0.12 
MUFA/LCSFA 0.30 + 0.02 0.30 + 0.05 0.34 + 0.05 
C16:1/C16:0 0.48 + 0.13 0.65 + 0.19 0.95 + 0.11 
C18:1 (t9, t11 & c9)/C18:0 0.22 + 0.04 0.14 + 0.02* 0.06 + 0.01* 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).  
 
 
5.4.4.5 Effects of DHA on Fatty acid profiles of A10p10p cells 
 
Flasks of 2x106 of drug resistant A10p10p cells were seeded for 24 h before 
treatment with 21 and 75 µM docosahexanoic acid (DHA), incubated for 3 days and 
extracted and analysed as described earlier.  Figure 5.4.4.5 illustrates a 
chromatogram from a typical injection of an A10p10p sample treated with (a) 21 and 
(b) 75 µM of DHA.  Table 5.4.4.5.1 lists the fatty acid composition of untreated 
A10p10p control cells and A10p10p cells treated with 21 and 75 µM DHA, while 
table 5.4.4.5.2 lists the summary of fatty acid composition and various fatty acid 
ratios of the above.  The most abundant fatty acid in each treatment was the long 
chain saturated fatty acid (LCSFA) C18:0 stearic acid.   
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(a) 
 
 
 (b) 
 
 
Figure 5.4.4.5.  Typical chromatograms of fatty acid profiles of A10p10p cells treated with 
(a) 21 and (b) 75 µM DHA. 
 
DHA 
22:6 
DHA 
22:6 
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Table 5.4.4.5.1.  Fatty acid composition of A10p10p cells treated with DHA for 72 h. 
Fatty Acid  Control DHA  21 µM DHA  75 µM 
C6:0 0.38 + 0.03 0.17 + 0.10 0.47 + 0.47 
C8:0 8.60 + 4.71 1.78 + 0.89 0.56 + 0.56 
C10:0 1.61 + 1.18 0.00 + 0.00 0.17 + 0.09 
C11:0 5.43 + 1.60 4.60 + 1.18 5.38 + 1.05 
C12:0 0.09 + 0.08 0.00 + 0.00 0.00 + 0.00 
C13:0 2.55 + 0.95 1.11 + 0.51 1.74 + 0.85 
C14:0 2.19 + 0.44 1.45 + 0.06 0.86 + 0.36 
C14:1 0.38 + 0.29 0.32 + 0.32 0.28 + 0.21 
C15:0 0.26 + 0.08 0.16 + 0.03 0.10 + 0.02 
C15:1 0.06 + 0.03 0.08 + 0.05 0.08 + 0.08 
C16:0 19.65 + 1.92 20.35 + 1.56 19.73 + 2.40 
C16:1 8.98 + 2.01 18.86 + 5.37 19.55 + 6.97 
C18:0 34.98 + 4.12 36.73 + 3.62 40.79 + 4.26 
C18:1 (t9, t11 & c9) 7.60 + 1.37 4.12 + 0.87 1.87 + 0.67 
C18:2 LA 1.97 + 0.62 1.07 + 0.20 0.40 + 0.19 
C18:3 GLA 0.10 + 0.10 0.30 + 0.16 0.42 + 0.17 
C18:3  AA 0.63 + 0.05 0.86 + 0.04 1.02 + 0.05* 
C20:0 0.91 + 0.19 1.02 + 0.09 1.06 + 0.19 
C18:2 c9,t11-CLA 0.03 + 0.03 0.05 + 0.03 0.11 + 0.11 
C18:2 t10,c12-CLA 0.02 + 0.01 0.10 + 0.10 0.03 + 0.01 
C20:1 (c11) 0.02 + 0.02 0.00 + 0.00 0.03 + 0.02 
C18:2 t9,11-CLA 0.10 + 0.05 0.11 + 0.09 0.03 + 0.03 
C20:2 (c11,14) 0.13 + 0.09 0.20 + 0.07 0.19 + 0.10 
C20:3 DGLA 0.16 + 0.02 0.19 + 0.06 0.13 + 0.05 
C20:4  AA 1.54 + 0.24 1.26 + 0.18 0.06 + 0.07 
C22:1(c13) 0.10 + 0.10 0.52 + 0.15 0.57 + 0.18 
C23:0 0.08 + 0.04 0.31 + 0.05 0.08 + 0.07 
C22:2 (c13,16) 0.00 + 0.00 0.02 + 0.02 0.05 + 0.05 
C20:5 EPA 0.18 + 0.18 0.29 + 0.17 0.23 + 0.22 
C24:0 0.19 + 0.19 0.44 + 0.09 0.64 + 0.13 
C24:1(c15) 0.18 + 0.16 0.07 + 0.04 0.04 + 0.02 
C22:6 DHA 0.92 + 0.19 3.42 + 0.69 3.02 + 1.22 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.  *Denotes results which are significantly 
different to untreated/control cells as determined by the Student’s t-test (p<0.05).  
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C18:0 stearic acid was relatively unchanged from 34.98 + 4.12 % total cellular 
FAME in control A10p10p cells to 36.73 + 3.62 % and 40.79 + 4.26 % FAME in 
cells treated with 21 and 75 µM DHA respectively.  Another predominant LCSFA, 
C16:0 methyl palmitate was also relatively unchanged following treatment, 
comprising 19.65 + 1.92 % FAME in control A10p10p cells and 20.35 + 1.56 and 
19.73 + 2.40 % FAME in cells treated with 21 and 75 µM DHA (Table 5.4.4.5.1).  
This indicates DHA had little or no effect on FAS activity in A10p10p cells.  
 
Other saturated fatty acids were present in minor amounts.  C13:0 methyl 
tetradecanoate at 2.55 + 0.95 % FAME in control A10p10p cells, was apparently 
reduced to 1.11 + 0.51 and 1.74 + 0.85 % FAME following treatment with 21 and 75 
µM DHA.  C14:0 methyl myristate levels were apparently reduced from 2.19 + 0.44 
% FAME in control A10p10p cells to 1.45 + 0.06 and 0.86 + 0.36 % FAME with 21 
and 75 µM DHA (Table 5.4.4.5.1).   
 
The predominant mono-unsaturated fatty acid (MUFA), C16:1 methyl palmitoleate 
(palmitoleic acid), apparently increased from 8.98 + 2.01 % total lipid in control 
A10p10p cells to 18.86 + 5.37 and 19.55 + 6.97 % FAME following 21 and 75 µM 
DHA treatment respectively (Table 5.4.4.5.1).   
 
Another abundant MUFA was the group of three C18:1 fatty acids elaidic (t-9), 
vaccenic (t-11), and oleic acid (c-9).  Their combined proportion of total cellular 
lipids of 7.60 + 1.37 % in control A10p10p cells was apparently reduced to 4.12 + 
0.87 and 1.87 + 0.67 % FAME following 21 and 75 µM DHA treatment (Table 
5.4.4.5.1).  The increase in C16:1 and decrease in C18:1 represent a decreased level 
of oleic acid production in favour of palmitoleic acid in DHA treated A10p10p cells. 
 
Other UFA were present in minor amounts.  C18:2 (c9,c12) linoleic acid (LA) 
comprised 1.97 + 0.62 % FAME in control A10p10p cells and was apparently 
reduced to 1.07 + 0.20 and 0.40 + 0.19 % FAME following treatment with 21 and 75 
µM DHA.  C20:4 arachidonic acid (AA) levels were apparently reduced from 1.54 + 
0.24 % FAME in control A10p10p cells to 1.26 + 0.18 and 0.06 + 0.07 % FAME 
with 21 and 75 µM DHA, suggesting inhibition of ∆5/∆6 desaturase and/or elongase 
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activities by DHA (Table 24).  C18:3 α-linolenic acid (ALA) levels comprised 0.63 
+ 0.05 % FAME in control A10p10p cells and was apparently increased to 0.86 + 
0.04 % FAME with 21 µM DHA and significantly increased to 1.02 + 0.05 % FAME 
with 75 µM DHA treatment (Table 5.4.4.5.1).  This also suggests inhibition of ∆5/∆6 
desaturase and/or elongase activities by DHA, possibly due to negative feedback, 
preventing conversion of ALA to more unsaturated longer chain metabolites 
including EPA and DHA. 
 
Treatments with DHA did not result in significant direct uptake, although there was 
an apparent increase in DHA levels from 0.92 + 0.19 % in control A10p10p cells to 
3.42 + 0.69 and 3.02 + 1.22 % of total cellular FAME with 21 and 75 µM DHA 
treatments (Table 5.4.4.5.1).  These levels indicate rapid metabolism of DHA in 
A10p10p cells. 
 
There was an apparent increase in the overall level of LCSFA from 58.25 + 5.36 % 
FAME in control A10p10p cells to 60.49 + 5.32 following treatment with 21 µM 
DHA and an increase to 63.32 + 6.80 % with 75 µM DHA.  The overall UFA level, 
at 23.09 + 1.91 % FAME in control A10p10p cells, was apparently increased to 
31.85 + 5.65 and 28.37 + 8.02 % FAME following 21 and 75 µM DHA treatment 
respectively.  Total MUFA levels were apparently increased from 17.30 + 1.66 % 
FAME in control A10p10p cells to 23.97 + 5.01 and 22.39 + 6.83 % FAME 
following 21 and 75 µM DHA treatment (Table 5.4.4.5.2).  These increases in UFA 
and MUFA levels were due to a combination of direct DHA uptake and range of 
minor changes in individual fatty acid levels. 
 
The ratio of UFA/LCSFA was apparently increased from 0.40 + 0.02 in control 
A10p10p cells to 0.55 + 0.16 and 0.49 + 0.20 with 21 and 75 µM DHA treatments.  
The corresponding values for the MUFA/LCSFA ratio were 0.30 + 0.02 in control 
A10p10p cells and 0.42 + 0.13 and 0.39 + 0.17 following 21 and 75 µM DHA 
treatment (Table 5.4.4.5.2).   
 
The ratio of C16:1/C16:0 apparently increased following DHA treatment, with a 
value of 0.48 + 0.13 in control A10p10p cells and 0.98 + 0.36 and 1.13 +
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cells treated with 21 and 75 µM DHA.  The ratio of C18:1/C18:0 was appartently 
reduced with DHA treatment, with a value of 0.22 + 0.04 in control A10p10p cells 
and 0.11 + 0.02 and 0.05 + 0.02 in cells treated with 21 and 75 µM DHA (Table 
5.4.4.5.2).   
 
The increase in the C16:1/C16:0 ratio and decrease in C18:1/C18:0 suggests different 
substrate specificity of ∆9-desaturase and inhibition of oleic acid modulation in 
favour of palmitoleic acid in DHA-treated A10p10p cells (Table 5.4.4.5.2). 
 
 
Table 5.4.4.5.2.  Fatty acid composition and ratios of A10p10p cells treated with DHA 
for 72 h. 
Fatty Acids Control DHA 21 µM DHA 75 µM 
LCSFA 58.25 + 5.36 60.49 + 5.32 63.32 + 6.80 
UFA 23.09 + 1.91 31.85 + 5.65 28.37 + 8.02 
MUFA 17.30 + 1.66 23.97 + 5.01 22.39 + 6.83 
UFA/LCSFA 0.40 + 0.02 0.55 + 0.16 0.49 + 0.20 
MUFA/LCSFA 0.30 + 0.02 0.42 + 0.13 0.39 + 0.17 
C16:1/C16:0 0.48 + 0.13 0.98 + 0.36 1.13 + 0.56 
C18:1 (t9, t11 & c9)/C18:0 0.22 + 0.04 0.11 + 0.02 0.05 + 0.02 
Data represent Mean + SEM of at least three experiments in triplicate expressed as a 
percentage of total cellular lipid composition.   
 
 
 
Discussion 
 
The hypothesis being tested in this work is that uptake and incorporation of fatty 
acids including CLA into cells can alter their lipid composition such that cellular 
processes controlling cancer cell growth are modulated.  One proposed mechanism 
for the anticarcinogenic activity of these fatty acids is that alteration of the fatty acid 
composition of the cell membrane phospholipids by CLA isomers results in reduced 
synthesis of arachidonic acid (AA) and AA-derived eicosanoids associated with 
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stimulation of cancer cell proliferation (Banni et al., 1999; 2001).  The overall 
objective of the work described in this chapter was to determine the extent to which 
CLA mixture of isomers (CLA-mix), purified isomers c9,t11 and t10,c12-CLA and 
omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
can modulate the lipid composition of MDA-MB-435S-F (MDA) melanoma cells 
and a doxorubicin resistant variant MDA-MB-435S-F/Adr10p10p (A10p10p).   
 
The Gas chromatography (GC) technique employed used a long (100 m) capillary 
column to separate fatty acids as fatty acid methyl esters (FAME).  The method 
separated FAME including CLA cis/trans, trans/cis and trans/trans isomers with 
good resolution on the basis of chain length, geometric configuration and numbers of 
double bonds.  However, 18:1 (t9) methyl elaidate and 18:1 (t11) methyl vaccinate 
eluted together as one peak on the chromatogram.  This combined peak also 
connected at its base with the peak for 18:1 (c9) methyl oleate.  Therefore, to remove 
ambiguity all three 18:1’s were measured as one value.   
 
All FAMEs were quantitated by reference to an internal standard heptadecanoic acid 
(C17:0) which was added to cell pellets before lipid extraction.  Methylation was a 
two stage procedure involving alkali-catalysed hydrolysis in methanol for 
derivatising bound fatty acids in lipid extracts and BF3 /methanol for methylation of 
free fatty acids.  This procedure was previously shown to suppress artificial 
isomerisation of cis/trans CLA and trans/cis CLA to trans/trans CLA (Igarashi et 
al., 2004; Koritala and Rohwedder 1972; Kramer et al., 1997).   
 
As presented above, the recovery of CLA was in the range 93.6-110.0 % with intra-
assay variation ranging between 4.9-41.2 % CV.  A possible reason for the high 
variation in some of the runs was degradation of the GC column due to age and the 
extent to which it had been used prior to this project.  This was further confirmed by 
the finding that peaks for the three C18:1’s were blending together at the base and 
had to be measured as one.  In previous work in the lab these had eluted separately.   
 
Overall reproducibility was 99.7 % and inter-assay variation was 7.1 % CV.  The 
data reported here is consistent with those reported in the literature when NaOH-BF3 
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reagent was used for methylation (Kim et al., 2000; Jiang et al., 1996; Alonso et al., 
2004).  The former reported 83 % recovery of CLA and 6.6 % CV for repeatability 
using capillary GC analysis while the latter reported 89.4 % recovery with 3.6 % CV.  
The method was therefore considered advantageous for analysis of CLA isomers in 
MDA cells.  
 
The first hypothesis being tested was whether there were any differences between the 
lipid profiles of the drug-sensitive MDA cells and the drug-resistant A10p10p cell 
line.  The fatty acid profile of untreated MDA and A10p10p cells was analysed as 
described in earlier sections.  Both cell lines were characterised by higher 
proportions of long chain saturated fatty acids (LCSFA) such as C18:0 stearic acid 
and C16:0 methyl palmitate compared with unsaturated fatty acids (LCSFA>UFA), 
suggesting that these cells were capable of synthesising their own supply of fatty 
acids via fatty acid synthase (FAS).  While these long chain saturated fatty acids 
(LCSFA) were slightly reduced in the drug resistant A10p10p cell line compared to 
drug sensitive MDA cells; the total saturated fatty acids (SFA) were significantly 
higher in A10p10p cells than in MDA cells.  This is suggestive of an up-regulation of 
the fatty acid synthase (FAS) enzyme followed by β-oxidation resulting in 
production of short chain saturated FA.  As described above, FAS is a key enzyme in 
the de novo synthesis of fatty acids which has been identified as a tumour marker in 
breast cancer indicating a poor prognosis (Kuhajda, 2000) and recently discovered to 
contribute to increased drug resistance in breast cancer cells (Liu et al., 2008).   
 
C16:1 palmitoleic acid and the group of three C18:1 fatty acids; elaidic (t-9), 
vaccenic (t-11), and oleic acid (c-9) represent the major monounsaturated fatty acids 
(MUFA) of both cell lines.  C16:1 palmitoleic acid was the predominant MUFA in 
A10p10p cells, while the C18:1 group was predominant in MDA cells.  This increase 
in C16:1 and decrease in C18:1 in A10p10p cells relative to MDA cells represent 
conflicting evidence on the activity of the ∆9-desaturase enzyme, stearoyl-CoA 
desaturase (SCD).  This enzyme introduces one double bond to the corresponding 
saturated fatty acid.  Originally, C18:0 stearic acid was thought be the sole substrate, 
but more recently C16:0 was also found to be a substrate for the enzyme (Ntambi, 
1999).  Attie et al. (2002) recently described the desaturation index or ratio of 
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C18:1/C18:0 as a marker of SCD activity in plasma, seemingly ignoring the 
C16:1/C16:0 ratio.  Further, Miyasaki et al (2002) identified C18:0 as the preferred 
substrate for the SCD1 isoform of the enzyme in mouse models.  Following this 
model the reduced C18:1/C18:0 ratio indicates downregulation of SCD activity in the 
A10p10p cell line.  Alternatively, it could be that the enzyme shows an altered 
specificity in A10p10p cells, favouring production of C16:1. 
 
The polyunsaturated fatty acid (PUFA) C22:6 docosahexanoic acid (DHA) was 
significantly more abundant in MDA cells than A10p10p cells, while C18:3 α-
linolenic acid (ALA), a precursor of DHA, was less abundant in MDA control cells 
compared to A10p10p cells.  This suggest a possible down-regulation in ∆5/∆6 
desaturase and/or elongase activities in A10p10p cells. 
 
The second hypothesis being tested was whether there was an alteration of the fatty 
acid composition of the cell membrane phospholipids by the exogenous fatty acids 
evidenced by reduced synthesis of arachidonic acid (AA) and AA-derived 
eicosanoids (prostaglandin E2 (PGE2)) associated with stimulation of cancer cell 
proliferation.  The data presented above shows that although only significant with 
treatments of EPA at 75 µM in the A10p10p cell line, all treatments reduced the 
levels of AA to a similar extent relative to control in both cell lines.  This points to a 
clear trend and suggests these fatty acids inhibit ∆5, ∆6 desaturase and/or elongase 
activities through competition for the same pathways in both MDA and A10p10p 
cells.  Also, in MDA cells only, the CLA-mix, c9,t11 and t10,c12-CLA and EPA 
treatments caused a reduction in the cellular levels of DHA, which is consistent with 
the theory that these fatty acids inhibit ∆5, ∆6 desaturase and/or elongase activities.  
The fact that EPA caused a reduction in DHA also points to inhibition in MDA cells 
of ∆6 desaturase, the enzyme responsible for one of the steps in converting EPA to 
DHA.  Other possible markers of inhibition of these enzymes would be increased 
levels of alpha linolenic acid (ALA), dihomo-gamma-linolenic acid (DGLA), 
gamma-linolenic acid (GLA) and linoleic acid (LA) relative to control (Figure 5.1.1).  
DGLA and GLA were present in very low amounts, just above trace levels and 
therefore not reliable predictors of enzyme activity.  LA however, was reduced with 
all fatty acid treatments in both cell lines suggesting a contradiction to this 
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hypothesis.  It is possible that in addition to competing for the same metabolic 
enzymes, these fatty acid treatments also compete with LA for uptake from the 
medium and incorporation into the cells resulting in reduced cellular levels of LA 
and subsequent production of AA (and AA derived eicosanoids). 
 
The CLA-mix, c9,t11 and t10,c12-CLA treatments all reduced the levels of LCSFA, 
particularly C16:0 palmitate and C18:0 stearic acid in the MDA cell line suggesting 
inhibition of FAS, although only the CLA-mix was effective in this regard in 
A10p10p cells.  Consistent with these observations Belury and co-workers found that 
CLA reduced FAS expression in wistar rats (Purushotham et al., 2007).  Also, 
Menendez et al. (2005b) concluded that the selective anticancer action of gamma-
linolenic acid (GLA), a plant derived n-6 PUFA, in human breast cancer cells was 
due in part to the inhibition of FAS activity.  EPA and DHA treatments by 
comparison caused minimal reduction of LCSFA in MDA and both actually resulted 
in an increase in LCSFA levels in A10p10p cells suggesting that while these fatty 
acids may result in some degree of inhibition, they are not as effective lowering 
saturated fatty acid levels as the CLA preparations.  As with CLA, there are some 
animal studies which show the EPA and DHA in the diet causes a reduction in FAS 
expression/activity (Kim et al., 2004), however this is the first study to include both 
CLA preparations and omega-3 fatty acids allowing a direct comparison. 
 
Using the C18:1/C18:0 ratio as an indicator of SCD ∆9 desaturase activity, all fatty 
acid treatments in the MDA cell line and t10,c12-CLA, EPA and DHA caused 
inhibition of SCD in A10p10p cells.  However, all fatty acid treatments in both cell 
lines caused an increase in C16:1 levels and in the C16:1/C16:0 ratio, highlighting 
the need for further investigation into the interaction of these fatty acids and the SCD 
enzyme.  CLA was found previously to reduce both C18:1/C18:0 and C16:1/C16:0 
ratios in the study mentioned above in Wistar rats (Purushotham et al., 2007).   
 
In terms of direct uptake measurement, EPA treatments resulted in the lowest level 
of  uptake of the five fatty acids in both cell lines.  However, there were significant 
changes in a range of individual fatty acid levels, including increases in derivatives 
of EPA, suggesting that EPA may be very susceptible to oxidation and that the 
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enhancement of the cytotoxic effect of doxorubicin observed in chapter 3 was 
perhaps due to a combination of the action of these derivates, the increase in 
membrane fluidity and competition with LA leading to reduced production of AA.   
 
DHA treatment also resulted in low cellular uptake relative to the CLA preparations, 
although there was some significant DHA uptake detected in the MDA cell line.  
DHA in general was the least effective fatty acid at modulating the lipid profiles in 
both cell lines, suggesting that the enhancement of the cytotoxic effect of 
doxorubicin observed above was due to a more direct cytotoxic mechanism.  It was 
noted in chapter 3 that DHA was more cytotoxic as a single treatment than the other 
fatty acids tested.  Recently, the sensitisation of breast cancer cells to doxorubicin by 
DHA was found to be due to a loss of glutathione peroxidase response, a crucial 
enzyme for protection against hydrogen and lipid peroxides (Vibet et al., 2008).   
 
Both c9,t11 and t10,c12-CLA treatments resulted in significantly higher cellular 
uptake levels than the other fatty acids including the CLA-mix, even taking into 
account the lower concentrations of each contained in the mixture of isomers 
compared to pure isomer treatments.  This lower direct uptake in the CLA mixture 
may be due to a lower level of incorporation into the cells, or a higher rate of 
metabolism of the isomers once incorporated leading to a lower detection.  
Considering the range of effects on individual and overall fatty acid levels in both 
cell lines and the fact that the CLA-mix was the only treatment found to have an 
effect on a measure of FAS activity in the A10p10p cell line, the latter is more likely.  
Banni et al., (2004) described different patterns of incorporation into cellular lipids 
and rates of metabolism of the c9,t11 and t10,c12-CLA isomers, perhaps when 
delivered as a mixture there is some interaction allowing one to facilitate the other 
yielding more positive results than the single isomers alone. 
 
Finally, one question remains, why are the combinations of fatty acid and drug more 
effective, both in terms of enhanced drug efficacy and total cell kill, in the drug 
resistant A10p10p cells than in the parental drug sensitive MDA cell line?  First, 
looking at the observations of enzyme activity through alterations in lipid profiles, 
both cell lines contained reduced cellular levels of LA and AA (and AA derived 
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eicosanoids) by the fatty acid treatments.  The A10p10p cell line was more resistant 
to alterations of markers of FAS activity by the fatty acid treatments than the MDA 
cell line.  While all fatty acid treatments in the MDA cell line caused inhibition of 
SCD evidenced by a reduction in the C18:1/C18:0 ratio, only t10,c12-CLA, EPA and 
DHA caused inhibition of SCD in A10p10p cells.  It would appear that from this 
point of view that the drug-resistant cell line A10p10p is more resistant to 
modification of its lipid metabolic pathways than the MDA cell line.  Also, taking a 
more fundamental approach, with the exception of the CLA-mix, each fatty acid 
treatment caused an increase in the fluidity of cell membranes, by reduced LCSFA 
and/or increased UFA levels, to a similar or lesser degree in A10p10p cells than the 
corresponding treatment in MDA cells.   
 
To conclude, while these data may explain some of the mechanisms by which these 
fatty acids enhance chemotherapy in melanoma cells (reduction in markers of FAS 
activity, reduced AA and AA derived eicosanoid formation (PGE2) and increased 
fluidity of cell membranes by increasing the UFA/LCSFA ratio), the mechanism(s) 
by which they result in a greater cytotoxic effect in drug-resistant cells remains 
elusive.  Santini et al. (2001) found drug resistant breast cancer cells contained more 
neutral lipids than their drug sensitive counterparts and a range of differences in 
individual fatty acid levels of the various lipid fractions, perhaps further study is 
required focusing on the effects and incorporation of fatty acid treatments on and into 
these lipid fractions within the cells.  Also, it has been known for quite some time 
that the function of the ABC-transporter, P-glycoprotein (P-gp), a trans-membrane 
drug transport pump overexpressed in multidrug resistant cancer cells, is dependent 
on the surrounding lipid in the membrane.  Delipidated P-gp loses ATP-ase activity, 
which can be restored after reconstitution of P-gp into liposomes (Doige et al., 
1993).  It seems likely that alterations in the lipid domains of membranes by 
exogenous fatty acids could also alter the function of these and other transporter 
proteins such as MRP1, thus explaining how these treatments can render multidrug-
resistant cells more sensitive to chemotherapy drugs than their drug-sensitive 
counterparts and represents another potential target area for further research. 
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Chapter 6  
Final Discussion and Conclusions 
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Final Discussion and Conclusions 
 
Cancer is a group of diseases characterised by uncontrolled growth, impaired cell 
death and spread of abnormal cells.  If the spread is not controlled it can result in 
patient death.  It has been estimated by Lopez et al. (2006) that there were 
approximately 12 million new cases of cancer worldwide in 2007.  Of this number 
1.3 million were breast cancer, with just under 0.5 million deaths associated with 
breast cancer, making it the leading cause of cancer death among women worldwide.  
The five-year survival of women with breast cancer is 89 % in the United States, but 
76 % in Europe, perhaps due to a lack of an established mammography screening 
program in some countries.  The stage at diagnosis is the most important prognostic 
variable, and while the overall prognosis for breast cancer is relatively favourable in 
the US, five-year survival drops to 26 % for patients presenting with advanced 
disease (American Cancer Society, 2007).  This highlights tremendous scope for 
improving current and developing new treatment regimes outlined in Chapter 1. 
 
Several isomers of CLA both in pure form and as a mixture have been shown to be 
cytotoxic at micromolar concentrations for a variety of breast, colon, prostate and 
skin tumour cell lines (Belury, 2002a; Miller et al., 2001; 2003; O’Shea et al., 2000).  
Following method development described in chapter 2 (including an evaluation of 
the cytotoxic effects of PUFA including CLA and doxorubicin (Dox) as single 
agents), the overall objective of this project was to characterise the effects of co-
administering PUFA including CLA with the anticancer drug Dox in a human 
melanoma cellular model of multi-drug resistance and to determine mechanisms by 
which fatty acids may modulate drug resistance or sensitivity.   
 
In the first set of single treatments, MCF-7 and MCF-7/cis cells were treated with the 
fatty acids; CLA mixture of isomers (CLA-mix), LA, c9,t11 and t10,c12-CLA 
delivered as sodium salts in medium containing BSA in a 2:1 w/w ratio FA:BSA 
(473:1 molar ratio).  BSA, or bovine serum albumin, is a carrier protein in the blood 
stream designed to bind to and transport molecules such as fatty acids, facilitating the 
transport of large quantities of these relatively insoluble molecules throughout the 
body (Spector, 1975).  Therefore, delivery of the above fatty acids as sodium salts in 
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medium containing BSA in a 2:1 w/w ratio was designed to mimic the biologic 
situation (Ip, et al., 1999).  Cytotoxic effects of CLA-mix, c9,t11 and t10,c12-CLA 
were time and dose-dependent in both MCF-7 and MCF-7/cis cell lines.  
Cytotoxicity of CLA was found to be dependent on isomer composition, 
concentration and duration of exposure.  This was consistent with findings by 
O’Shea et al. (2000) that the cytotoxic effects of CLA were concentration dependant 
in the MCF-7 cell line.  However little is known about the action of CLA on a drug-
resistant cell line.  Here the MCF-7 cisplatin resistant cells were found to be more 
sensitive to inhibition by t10,c12-CLA and the CLA mixture than parental MCF-7 
cells.   
 
Following this, it was decided to test the cytotoxic action of PUFA including CLA on 
multi-drug resistant cell lines in which the resistance was better characterised.  
MDA-MB435S-F (MDA) human melanoma cell line and taxol resistant variants 
MDA-MB435S-F/Taxol 10p (Tax10p) and MDA-MB435S-F/Taxol 10p4p 
(Tax10p4p) were developed and kindly donated by Dr. Sharon Glynn (NICB, 
Dublin) (Glynn et al., 2004).  In light of reports indicating a 2:1 molar ratio of fatty 
acids to BSA represented a better delivery solution to mimic the biological situation 
more closely (Evans et al., 2001; 2002; Iwakiri et al., 2002) stock solutions of CLA-
mix, c9,t11 and t10,c12-CLA, LA and GLA were prepared in RPMI medium 
containing BSA in a 2:1 molar ratio.  This ratio is based on evidence indicating BSA 
contains two strong binding sites for long chain fatty acids (Reed, 1986). 
 
Of the fatty acid treatments, CLA-mix and t10,c12-CLA were similarly effective at 
inhibiting growth in all three cell lines.  c9,t11-CLA however, at the higher 
concentrations (36 & 40 µg/mL) appeared to be more effective at inhibiting cell 
growth in Tax10p cells than in the MDA or Tax10p4p cell lines.  LA showed no 
significant inhibition in any cell line at the concentrations used (0-50 µg/mL).  GLA 
(0-50 µg/mL) on the other hand, while the resulting inhibition was significant 
relative to control, the inhibition observed was much lower than that of all three CLA 
preparations.   
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One of the problems encountered when using BSA as the vehicle for delivery was 
that it introduced considerable variation to the system which was made manifest in 
high standard deviations (SD).  Also, there was an apparent lack of consensus among 
those using BSA as the delivery vehicle for fatty acid treatments, with molar ratios 
ranging from approximately 667:1 to 2:1 and many in between (Moya-Camarena et 
al., 1999; Brown et al., 2003; Kim et al., 2003; Evans et al., 2001; 2002; Iwakiri et 
al., 2002).  Increasingly, other authors opted to omit BSA altogether from the 
experimental design and deliver the fatty acids as free fatty acids (FFA) in a media 
solution (Chamras et al., 2002; Tanmahasamut et al., 2004; Maheo et al., 2005; Wu 
et al., 2005).  Also Richieri (1993) demonstrated that not all serum fatty acids are 
bound to albumin in solution, some remain as FFA.  These fluctuations in the level of 
fatty acid binding to albumin in solution could account for the high SD observed in 
the cytotoxicity assays described above.  For these reasons, it was decided to repeat 
the fatty acid assays using FFA instead of that complexed with BSA.   
 
Delivery of the fatty acids as FFA solutions eliminated one source of variation in the 
experiments, resulting in statistically significant inhibition at lower concentrations –
including with LA, which was showing negligible effects complexed with BSA.  The 
IC50 values of all fatty acid treatments were reduced compared to the treatments 
containing BSA in a 2:1 molar ratio, suggesting that BSA conferred a protective 
effect on the cells.  The MDA cell line appeared to be more susceptible to inhibition 
by the three CLA preparations; CLA-mix, c9,t11 and t10,c12-CLA followed by 
Tax10p4p and least susceptible, Tax10p although these differences were not 
statistically significant. 
 
The outcomes of these experiments are: that multidrug resistant cell lines are more 
(MCF-7/cis) or similarly (Tax10p and Tax10p4p) susceptible to the cytotoxic action 
of CLA as their drug sensitive counterparts.  This is the first report to demonstrate 
this phenomenon and represents an attractive new approach to developing more 
effective treatment regimes to counteract multi-drug resistance in tumours.  Other 
outcomes relate to experimental design; that long term exposures (7 day) and free 
fatty acid treatments yield more consistent results with lower SD and better statistical 
significance than shorter term assays or fatty acids complexed with BSA. 
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The chemotherapeutic agents doxorubicin (Dox), taxotere (Tax) and 5-fluorouracil 
(5-FU) were also tested on MDA, Tax10p and Tax10p4p cells in a 7 day exposure.  
No significant difference was observed in the sensitivity of the three cell lines to Tax, 
Dox or 5-FU –suggesting that resistance of the Tax10p and Tax10p4p lines to Tax 
and other drugs might be better observed in short term assays.  To this end it was 
decided to run the drug assays as 4 h exposure followed by 7 day recovery, in place 
of long term (7 day) exposure.  This is also with a view to mimicking the clinical 
situation more closely (Glynn et al., 2004).   
 
With Dox, Tax and 5-FU, the change in design from treatments from a 7 day 
exposure to the 4 h exposure, 7 day recovery resulted in a dramatic increase in IC50 
values as expected.  Differences emerged between the cell lines in terms of drug 
sensitivities.  When comparing IC50 values, Tax10p and Tax10p4p cells were 1.6 and 
1.7 fold more resistant to 5-FU treatment than MDA cells respectively.  Similarly, 
Tax10p and Tax10p4p were 1.2 and 1.5 fold more resistant to Dox treatment and 1.7 
and 2.5 fold more resistant to Tax treatment than the MDA cell line.  Not 
surprisingly, of the two cell lines that had previously been taxol pulsed; Tax10p4p, 
which had four extra rounds of pulses of Tax, displayed higher resistance to each of 
the three drugs than Tax10p.  This finding supports data from the original 
characterisation of these cell lines (Glynn et al., 2004).   
 
IC50 values of both fatty acid and drugs obtained above were used in the design of an 
experiment using sub-optimal concentrations (below IC50) of both fatty acids and 
drugs to investigate synergistic interactions in melanoma cells.  The MDA drug 
sensitive cell line and a Dox pulsed variant MDA-MB-435S-F/Adr-10p10p 
(A10p10p) were used in this experiment.  A10p10p was shown previously to have 
increased levels of Pgp and MRP1 drug efflux proteins and while the parental MDA 
line was shown to be highly invasive, the pulsed A10p10p variant displayed a more 
aggressively invasive phenotype, termed “superinvasive” (Glynn et al., 2004).   
 
At this point the potential of five free fatty acids (CLA-mix, c9,t11 and t10,c12-CLA, 
EPA and DHA) to enhance the cytotoxicity of doxorubicin in the above melanoma 
                                  
 242 
model was investigated.  The three preparations of CLA used (CLA-mix, c9,t11 and 
t10,c12-CLA) were similarly effective to the omega-3 fatty acids, EPA and DHA at 
enhancing the cytotoxicity of doxorubicin in MDA-MB435S-F (MDA) melanoma 
cells.  Data show that CLA enhanced cytotoxicity of Dox on the MDA cell line in a 
dose dependant manner in each of the three treatment groups with significant 
enhancement (p<0.05) seen with as low as 1 µg/mL (21 µM) of each of the fatty 
acids in combination with Dox.  The most effective regime over all was found to be 
pre-exposure to fatty acid followed by concurrent treatment with Dox and a 7 day 
fatty acid exposure in the [pre-treat] group.  The report by Fite et al. (2007) that CLA 
isomers (40 µM) can significantly potentiate the cytotoxicity of docetaxel in breast 
cancer cells is the only other report to demonstrate the effect of CLA on the efficacy 
of chemotherapeutic drugs in cancer cell lines. 
 
All fatty acids enhanced the efficacy of Dox in the multi-drug resistant cell line 
A10p10p to a greater extent than the corresponding treatments in the MDA cell line.  
Further, all five fatty acids in combination with Dox rendered the A10p10p cells 
more sensitive to the drug than the parental drug sensitive MDA cells with higher 
levels of percentage inhibition for corresponding combination treatments.  The fatty 
acids are therefore in effect reversing the Dox-resistance in the A10p10p cells.   This 
is the first study to report the effects of CLA on the efficacy of chemotherapeutic 
drugs in multi-drug resistant cancer cell lines. 
 
The c9,t11-CLA isomer was found to enhance the uptake of Dox into the cells in 
both cell lines possibly by increasing the fluidity of the membrane allowing more 
passive diffusion and/or flip flop of the drug across the membrane (Hendrich and 
Michalak, 2003).  Also, the CLA mixture of isomers enhanced drug retention after 
treatment in the A10p10p line, while c9,t11-CLA enhanced retention in both cell 
lines. 
 
The ability to enhance chemosensitivity of drug resistant tumour cells by 
administering CLA prior to or simultaneously with chemotherapeutics is of potential 
benefit for treatment of cancer.  The mechanism of action of CLA may be through a 
combination of many different pathways.  Studies in breast cancer (Wu et al., 2005) 
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and leukaemic (Siddiqui et al., 2003) cells have shown that omega-3 polyunsaturated 
fatty acids attenuated cancer growth through activation of a neutral 
sphingomyelinase-mediated pathway leading to increased ceramide production.  
However, data in the literature is not conclusive; others have reported decreases in 
ceramide levels in response to n-3 PUFA treatment (Jolly et al., 1997; McMurray et 
al., 2000).   
 
Ceramide and basal sphingosine levels were analysed and compared in untreated 
MDA and A10p10p cells.  Ceramide levels were found to be higher in A10p10p cells 
than in the MDA cell line, which points to one mechanism by which the drug 
resistant A10p10p cells protect themselves from anticancer drugs.  It has been shown 
that decreased levels of endogenous ceramide by over-expression of 
glucosylceramide synthase results in the development of a multidrug resistant 
phenotype in cancer cells.  Glucosylceramide synthase clears ceramide levels by 
incorporating it into less toxic glucosylceramide (Ogretmen and Hannun, 2001). 
 
MDA and A10p10p cells were treated in the presence or absence of Dox, with CLA-
mix; c9,t11-CLA; t10,c12-CLA; EPA or DHA.  EPA single treatments caused a 
significant reduction in ceramide levels in both cell lines, suggesting that the 
cytotoxic action of EPA is not through a pathway initiated by ceramide production.  
In contrast, all fatty acids plus Dox resulted in an increase in ceramide levels relative 
to Dox alone in both cell lines although this was only significant in the case of 
c9,t11- and t10,c12-CLA in A10p10p cells.  This points to a trend indicating that 
perhaps ceramide production is one of many pathways by which these fatty acids 
enhance the cytotoxic action of anticancer drugs. 
 
Interestingly, Dox treatments alone and in combination with fatty acids caused an 
increase in sphingosine levels relative to respective single treatments of fatty 
acid/control in the MDA cell line, although this was only significant with CLA-mix, 
c9,t11 and t10,c12-CLA.  In the A10p10p cell line, all fatty acids alone caused an 
increase in sphingosine levels relative to control.  Treatments of Dox alone and in 
combination with each fatty acid resulted in a further although not significant 
increase.  While evidence in the literature is lacking to support this finding, Sweeney 
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and co-workers (1998) established that sphingosine also induces apoptosis –
independently from ceramide, acting in an earlier part of the apoptotic pathway than 
ceramide. 
 
CLA has been shown to alter a wide array of targets (outlined in chapter 1).  
Relatively recently, DHA was found by Menendez and colleagues (2005c) to 
downregulate c-erbB2 (Her2/neu) oncogene expression in Her2/neu over-expressing 
human breast cancer cells.  Her2/neu normally encodes a transmembrane tyrosine 
kinase glycoprotein which if overexpressed, is part of a signalling cascade that 
involves the activation of PI3K/Akt and MAPK pathways and the promotion of cell 
survival.  It was postulated that perhaps the cytotoxic action of CLA may relate to an 
effect on the expression of Her2/neu in MDA &/or A10p10p cells.  In untreated 
cells, the A10p10p cell line had significantly higher levels of Her2/neu coded p185 c-
erbB2/c-neu
 oncoprotein present than in MDA cells.  This indicates another mechanism 
by which the A10p10p cell line maintains resistance to conventional anticancer 
drugs.  Overexpression of the Her2/neu oncogene has been shown previously to 
confer resistance to chemotherapeutic drugs in breast cancer cells (Colomer et al., 
2000).   
 
Treatment of both MDA and A10p10p cells with CLA-mix resulted in down-
regulation of Her2/neu expression.  Also, both EPA and DHA resulted in down-
regulation in the A10p10p cell line.  This supports the finding by Menendez et al. 
(2005) that DHA down-regulated Her2/neu expression in breast cancer cells 
overexpressing the gene.  However, there were opposing results with treatments of 
the purified single isomers c9,t11 and t10,c12-CLA.  Both isomers caused significant 
up-regulation of Her2/neu expression in A10p10p and c9,t11-CLA also caused 
significant up-regulation in MDA cells.  Since this study is the only to date to 
demonstrate Her2/neu in melanoma cells and the first to investigate the effects of 
these fatty acids on Her2/neu expression in melanoma cells, further work is 
necessary to elucidate the mechanisms behind and confirm these unexpected and 
opposing effects.   
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Previous studies in the lab have shown that CLA isomers and its precursor t-VA are 
rapidly taken up into cancer cells (O’Shea et al., 2000; Miller et al., 2003b).  Further, 
Agatha et al. (2004) reported that CLA modulated membrane FA composition and 
PUFA metabolism (FA desaturation and elongation), in four cultured human 
leukemia cell lines representing a profile of possible variations of leukemic tumor 
differentiation.   
 
Fatty acid profiles of untreated MDA and A10p10p were analysed by gas 
chromatography in chapter 5.   Both MDA and A10p10p cell lines were 
characterised by higher proportions of long chain saturated fatty acids (LCSFA) such 
as C18:0 methyl stearate and C16:0 methyl palmitate compared with unsaturated 
fatty acids, suggesting that these cells were capable of synthesising their own supply 
of fatty acids via fatty acid synthase (FAS).  Furthermore, the level of total saturated 
fatty acids (SFA) was significantly higher in A10p10p cells than in MDA cells, 
suggestive of an up-regulation of the fatty acid synthase (FAS) enzyme followed by 
β-oxidation resulting in production of shorter chain saturated FA.   
 
As described above, FAS is a key enzyme in the de novo synthesis of fatty acids but 
is downregulated in most normal human tissues because of the fat in human diet.  In 
contrast, FAS is often highly expressed in human cancers; has been identified as a 
tumour marker in breast cancer indicating a poor prognosis (Kuhajda, 2000) and 
recently discovered to contribute to increased drug resistance in breast cancer cells 
(Liu et al., 2008).  
  
The CLA-mix, c9,t11 and t10,c12-CLA treatments all resulted in reduction in 
saturated fatty acids (LCSFA), a marker of FAS activity, although only the CLA-mix 
was effective in this regard in A10p10p cells.  Consistent with these observations 
Belury and co-workers found that CLA reduced FAS expression in Wistar rats 
(Purushotham et al., 2008).  Also, Menendez et al. (2005b) concluded that the 
selective anticancer action of gamma-linolenic acid (GLA), a plant derived n-6 
PUFA, in human breast cancer cells was due in part to the inhibition of FAS activity.  
EPA and DHA treatments by comparison caused minimal reduction in LCSFA in 
MDA and both actually resulted in an increase in LCSFA in A10p10p cells 
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suggesting that while these fatty acids may result in growth inhibition, they are not as 
effective at inhibiting FAS as the CLA preparations.  However, there are some 
animal studies which show that EPA and DHA in the diet of rats caused a reduction 
in FAS expression/activity (Kim et al., 2004).   
 
This is the first study to demonstrate the effect of CLA on a marker of FAS activity 
in drug-resistant cancer cells and to compare its effects with omega-3 fatty acids.  
Inhibition of fatty-acid synthesis by CLA could be a means to enhance cytotoxic 
effects of chemotherapeutic agents in proliferating cells with high levels of FAS.  
This strategy would likely target cancer cells and leave the normal proliferating cells 
in the human body intact.  It would be interesting to confirm data obtained here by 
examining the direct effect of these fatty acids on the activity of FAS, by 
measurement of incorporation of [14C] malonyl-CoA into cellular fatty acids as 
described by Knowles et al. (2007), and effects on FAS protein expression by 
Western-blot analysis (Vazquez-Martin et al., 2008). 
 
C16:1 palmitoleic acid and the group of three C18:1 fatty acids; elaidic (t-9), 
vaccenic (t-11), and oleic acid (c-9) represent the major monounsaturated fatty acids 
(MUFA) of both cell lines.  C16:1 palmitoleic acid was the predominant MUFA in 
A10p10p cells, while the C18:1 group was predominant in MDA cells.  The reduced 
C18:1/C18:0 ratio indicates downregulation of stearoyl-CoA desaturase (SCD) 
activity towards stearate in the A10p10p cell line.   Using the C18:1/C18:0 ratio as 
an indicator of SCD ∆9 desaturase activity, all fatty acid treatments in the MDA cell 
line and t10,c12-CLA, EPA and DHA caused inhibition of SCD in A10p10p cells.  
CLA was found previously to reduce both C18:1/C18:0 and C16:1/C16:0 ratios in 
the study mentioned above in Wistar rats (Purushotham et al., 2008).  However, the 
results presented here are anomalous when combined with data demonstrating that all 
fatty acid treatments in both cell lines caused an increase in C16:1 levels and in the 
C16:1/C16:0 ratio, highlighting the need for further investigation into the interaction 
of these fatty acids and the SCD enzyme.  A direct measurement of SCD activity 
would be benefical, in which cells are incubated with 3 µM (0.25 microcurie Ci/dish) 
[14C] stearic acid as described by Scaglia et al. (2005).  The ∆9 desaturating activity 
of SCD can then be estimated by conversion of [14C] stearic acid to [14C] oleic acid.  
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This combined with a measurement of SCD protein expression by immunoblot 
analysis (Scaglia et al., 2005) would shed more light on the altered function of SCD 
in drug-resistant cell lines and the effect of these fatty acids on drug-sensitive and 
resistant cell lines. 
 
Another mechanism proposed for the anticarcinogenic activity of these fatty acids 
was the alteration of the fatty acid composition of the cell membrane phospholipids 
by CLA isomers resulting in reduced synthesis of arachidonic acid (AA) in turn 
leading to reduced synthesis of AA-derived eicosanoids associated with stimulation 
of cancer cell proliferation (Banni et al., 1999; 2001).  Although only significant 
with treatments of EPA at 75 µM in the A10p10p cell line, all treatments reduced the 
levels of AA to a similar extent relative to control in both cell lines.  This points to a 
clear trend and suggests these fatty acids inhibit ∆5, ∆6 desaturase and/or elongase 
activities through competition for the same pathways in both MDA and A10p10p 
cells.  Also, in MDA cells only, the CLA-mix, c9,t11 and t10,c12-CLA and EPA 
treatments caused a reduction in the cellular levels of DHA, which is consistent with 
the theory that these fatty acids inhibit ∆5, ∆6 desaturase and/or elongase activities.  
The fact that EPA caused a reduction in DHA also points to inhibition in MDA cells 
of ∆6 desaturase, the enzyme responsible for one of the steps in converting EPA to 
DHA.  It is possible that in addition to competing for the same metabolic enzymes, 
these fatty acid treatments also compete with LA for uptake from the medium and 
incorporation into the cells resulting in reduced cellular levels of LA and subsequent 
production of AA (and AA derived eicosanoids such as PGE2). 
 
In terms of direct uptake measurement, EPA treatments resulted in the lowest level 
of  uptake of the five fatty acids in both cell lines.  However, there were significant 
changes in a range of individual fatty acid levels, including increases in derivatives 
of EPA, suggesting that EPA is very susceptible to oxidation and that the 
enhancement of the cytotoxic effect of doxorubicin observed in chapter 3 was due to 
a combination of the action of these derivatives, the increase in membrane fluidity 
through greater unsaturation of membrane fatty acids and the competition with LA 
leading to reduced production of AA.   
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DHA treatment also resulted in low cellular uptake relative to the CLA preparations, 
although there was some significant DHA uptake detected in the MDA cell line.  
DHA in general was the least effective fatty acid at modulating the lipid profiles in 
both cell lines, suggesting that the enhancement of the cytotoxic effect of 
doxorubicin observed above was due to a more direct cytotoxic mechanism.  It was 
noted in chapter 3 that DHA was more cytotoxic as a single treatment than the other 
fatty acids tested.  Recently, the sensitisation of breast cancer cells to doxorubicin by 
DHA was found to be due to a loss of glutathione peroxidase response, a crucial 
enzyme for protection against hydrogen and lipid peroxides (Vibet et al., 2008).   
 
Both c9,t11 and t10,c12-CLA treatments resulted in significantly higher cellular 
uptake levels than the other fatty acids including the CLA-mix, even taking into 
account the lower concentrations of each contained in the mixture of isomers 
compared to pure isomer treatments.  This may be due to a lower level of 
incorporation into the cells, or a higher rate of metabolism of the isomers once 
incorporated leading to a lower detection rate.  Considering the range of effects on 
individual and overall fatty acid levels in both cell lines and the fact that the CLA-
mix was the only treatment found to have an effect on markers of FAS activity in the 
A10p10p cell line, the latter is more likely.  Banni et al., (2004) described different 
patterns of incorporation into cellular lipids and rates of metabolism of the c9,t11 and 
t10,c12-CLA isomers, perhaps when delivered as a mixture there is some interaction 
allowing one to facilitate the other yielding more positive results than the single 
isomers alone.  The increased membrane unsaturation index as a result of CLA 
incorporation would likely provide more abundant targets for reactive oxygen 
species (ROS) generated by Dox metabolism.  Products of lipid peroxidation such as 
hydroperoxides, hydroxynonenal, malondialdehyde and other aldehydes interfere 
with intracellular signalling cascades involved in cell replication and cell death and 
thus may account for increased drug efficacy.  The degree of lipid peroxidation 
induced by the combination of CLA and doxorubicin could be determined by 
measurement of the production of hydroperoxides, hydroxynonenal and 
malondialdehyde according to methods described by Requena et al. (1997).   
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Another issue to address at this point is regarding the MDA cell line.  Although 
originally derived from a 31 year old female with metastatic, ductal adenocarcinoma 
of the breast it is now accepted that the cell line is in fact a melanoma derived cell 
line (Ellison et al., 2002; Rae et al., 2007).  This in no way invalidates the research 
described in these chapters, but rather what is lost from the breast cancer research 
arena is gained by the melanoma research arena.  Further, it is probable that since the 
action of the fatty acids described here is focused on cellular processes common to 
many diverse cancer cell lines, the combination of CLA and chemotherapeutic drugs 
may be similarly efficacious in many different cancer cell lines and perhaps many 
types of tumours in vivo. 
 
In summary, this study has identified many mechanisms by which a multi-drug 
resistant cancer cell line maintains its resistance to chemotherapeutic drugs.  The first 
characteristic of a multidrug resistant phenotype in cancer cells observed was that 
ceramide levels were lower in A10p10p cells than in the parental MDA cell line.  
The A10p10p cell line had significantly higher levels of Her2/neu coded p185 c-
erbB2/c-neu
 oncoprotein present than in MDA cells.  Also, metabolic markers of β-
oxidation and FAS were shown to be elevated in A10p10p relative to MDA cells and 
there were alterations in markers for SCD which remain to be fully elucidated. 
 
These differences between the cell lines represent attractive therapeutic targets by 
which to selectively kill multi-drug resistant tumour cells while causing minimal 
damage to surrounding normal proliferating cells.  While single treatments of the 
fatty acids failed to cause an alteration in ceramide levels, all fatty acids in 
combination with Dox resulted in an increase in ceramide levels in both cell lines, 
indicating that ceramide production is one of many pathways by which these fatty 
acids enhance the cytotoxic action of anticancer drugs.  Interestingly, all fatty acids 
in combination with Dox resulted in an increase in sphingosine levels in both cell 
lines, with a more marked effect in the A10p10p cells line.  Effects of CLA on 
Her2/neu expression were not as conclusive.  CLA-mix treatment in both MDA and 
A10p10p cells and EPA and DHA in A10p10p cells resulted in down-regulation of 
Her2/neu expression.  There were however, opposing results with treatments of the 
single isomers c9,t11 and t10,c12-CLA.  Both isomers caused significant up-
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regulation of Her2/neu expression in A10p10p and c9,t11-CLA also caused 
significant up-regulation in MDA cells.  The CLA-mix, c9,t11 and t10,c12-CLA 
treatments all resulted in reduction of markers of FAS activity, although only the 
CLA-mix was effective in A10p10p cells.  Finally, all treatments reduced the level of 
arachidonic acid (AA) to a similar extent in both cell lines suggesting these fatty 
acids inhibit ∆5, ∆6 desaturase and/or elongase activities through competition for the 
same pathways in both MDA and A10p10p cells.   
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6.1 Future Work 
 
The obvious area to explore following this work is to determine whether CLA can 
also potentiate the cytotoxic effect of Dox and other chemotherapeutic drugs in other 
types of cancer cell lines.   
 
Also, it would be interesting to elucidate whether these effects are due in part to an 
alteration in the activity of the function of the ABC-transporter, P-glycoprotein (P-
gp), a trans-membrane drug transport pump overexpressed in multidrug resistant 
cancer cells.  These and other transporter proteins such as breast cancer resistance 
protein (BCRP) in breast cancer cells are localised to specific cholesterol-rich 
domains termed membrane rafts and their function is dependent on the surrounding 
lipid in the membrane rafts (Dos Santos et al., 2007; Storch et al., 2007).  By 
isolating membrane rafts from cancer cells using Brij-96 as described by Radeva et 
al., (2005) and extracting the lipids as in chapter 5, the local effects of CLA 
treatments can be determined in these rafts.  In combination with this approach, the 
direct effects of CLA on protein expression of P-gp, MRP1 and caveolin-1 (a 
signalling protein associated with specialised rafts called caveolae (Liu et al., 2002)) 
can be determined by western blot techniques (Gouaze et al., 2005; Storch et al., 
2007).     
 
Immunoblot analysis can be used to determine fatty acid synthase (FAS) protein 
expression and activity.  Cells for this experiment would be lysed in SDS sample 
buffer, separated by SDS-PAGE and transferred to nitrocellulose as described by 
Vazquez-Martin et al. (2008).  FAS activity may be determined by measurement of 
incorporation of [14C] malonyl-CoA into cellular fatty acids as described by 
Knowles et al. (2007).    
 
A direct measurement of SCD activity would be benefical in light of conflicting 
evidence for the effect of CLA treatment on the markers of SCD activity 
(C18:1/C18:0 and C16:1/C16:0 ratios).  The ∆9 desaturating activity of SCD may be 
estimated by conversion of [14C] stearic acid to [14C] oleic acid.  Effects on SCD 
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protein expression can be assessed by immunoblot analysis according to Scaglia et 
al. (2005).   
 
The degree of lipid peroxidation induced by the combination of CLA and 
doxorubicin could be determined by measurement of the production of 
hydroperoxides, hydroxynonenal, malondialdehyde according to methods described 
by Requena et al. (1997).  Alternatively, a direct measurement of lipid hydroperoxide 
levels is possible by utilising redox reactions with ferrous ions as in the Calbiochem 
Lipid Hydroperoxide (LPO) Assay kit.  The resulting ferric ions can then be detected 
by spectrophotometry  using thiocyanate ion as the chromogen (Morrow and 
Roberts, 1997). 
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